

Tuesday, 12. November 2024*Opening Session*

09:00 - 10:00

MG

OS01 - Opening session**Welcome**

Nadine Tereza (United Kingdom)

09:00 - 09:02

Keynote Speech

Guy Marks (Sydney, Australia)

09:02 - 09:18

Chief guest from the Government of Indonesia

Budi G. Sadikin (Indonesia)

09:18 - 09:23

Updates from CCSA on the selection of abstracts, number of submissions received, etc

Carrie Tudor (United States)

09:23 - 09:27

Parliamentarian Perspective

Hon. Warren Entsch (Australia)

09:27 - 09:30

Affected Community Speaks

Ani Herna Sari (Indonesia)

09:30 - 09:34

Community Voices / Activists take the stage

09:34 - 09:41

Vote of Thanks

Cassandra Kelly-Cirino (Switzerland)

09:41 - 09:47

Photo of Opening Session Speakers

09:47 - 09:50

Opening Session

09:00 - 10:00

AU

OS03 - Overflow for Opening Session*Opening Session*

09:00 - 10:00

EG2

OS04 - Overflow of opening session*Union Live Session*

09:00 - 10:00

UL

ULOS - Opening session*Symposium*

10:30 - 17:00

MG

SY01 - WHO Global #EndTB Symposium 2024

Hannah Monica Dias (Switzerland)

Opening session

10:30 - 10:30

Welcome remarks

Tereza Kasaeva (Switzerland)

10:30 - 10:35

Rising Above TB: Inspiring the next generation to champion change

Farahdiba Zalika Fatah (Indonesia)

10:35 - 10:40

Breaking new ground: Progress in the TB response

10:40 - 11:40

Global Status Update: Exploring new frontiers and advancing high-level end TB commitments into action

Tereza Kasaeva (Switzerland)	11:40 - 11:40
Interactive Q&A	11:40 - 11:40
High level panel From Ambitious Commitments to Bold Action: The Path Forward	11:40 - 11:40
Yudhi Pramono Mars (Indonesia) Senyor Narciso Fernandes (East Timor) Hon. Warren Entsch (Australia) Hon. Nawabzada Jamal Khan Raisani (Pakistan)	
Estimates of TB burden: recent updates, ongoing work, and future directions	11:40 - 13:10
Nimalan Arinaminpathy (Switzerland)	
Burden estimates of TB incidence and mortality, and targets assessment	13:10 - 13:10
Mathieu Bastard (Geneva, Switzerland)	
Uganda community-wide screening experiences and lessons for TB burden estimates	13:10 - 13:10
Stavia Turyahabwe (Uganda)	
Indonesia's inventory study	13:10 - 13:10
Tiffany Tiara Pakasi (South Jakarta, Indonesia)	
New developments in TB burden estimation: Overview of recent meeting of the Global WHO Task Force on TB Impact Measurement	13:10 - 13:10
Nimalan Arinaminpathy (Switzerland)	
WHO's new definitions for asymptomatic TB and programmatic implications	13:10 - 13:10
Dennis Falzon (Geneva, Switzerland)	
Q&A	13:10 - 13:10
Lunch	13:10 - 14:40
FIRESIDE CHAT	14:40 - 15:30
Multisectoral engagement and accountability in action: Addressing the drivers and challenges of the TB epidemic	
Scene setter: Joining forces across sectors on the road to end TB	15:30 - 15:30
Hannah Monica Dias (Switzerland)	
Ending TB together: The critical role of civil society in driving multisectoral action and accountability	15:30 - 15:30
Yuliia Kalancha (Kyiv, Ukraine)	
Transforming Kerala's TB Response: Harnessing Multisectoral Collaboration and Innovation	15:30 - 15:30
Rajan Khobragade (India)	
Making social protection a reality for people with tuberculosis	15:30 - 15:30
Tom Wingfield (United Kingdom)	
Tackling the dual burden of TB and migration: Key priorities	15:30 - 15:30
Patrick Duigan (Thailand)	
Addressing undernutrition and food insecurity: A critical focus in the TB response	15:30 - 15:30
Annabel Baddeley (Geneva, Switzerland)	
Q&A	15:30 - 15:30
New frontiers in TB research and innovation	15:30 - 16:25

Matteo Zignol (Switzerland)	
Point-of-care tests for the diagnosis of TB	16:25 - 16:25
Addithya Cattamanchi (United States)	
The promise of long-acting injectables for TB prevention	16:25 - 16:25
Eric Nuermberger (United States)	
TB vaccines research and development: progress and potential	16:25 - 16:25
Ann Ginsberg (United States)	
Closing remarks	16:25 - 16:30
<i>Post-Graduate Course</i>	
10:30 - 18:00	HB
PGC01 - An introduction to tuberculosis modelling	
Finn McQuaid (London, United Kingdom)	
Sandip Mandal (New Delhi, India)	
Katherine Horton (London, United Kingdom)	
Introduction	10:30 - 10:40
David Dowdy (United States)	
Lecture 1: An introduction to Tuberculosis modelling	10:40 - 11:20
David Dowdy (United States)	
Practical 1: Setting up a model of Mtb	11:20 - 13:00
Lara Goscé (London, United Kingdom)	
Alvaro Schwalb (London, United Kingdom)	
Martin Harker (United Kingdom)	
Katherine Horton (London, United Kingdom)	
Finn McQuaid (London, United Kingdom)	
Mphatso D. Phiri (Blantyre, Malawi)	
Sun Kim (Boston, United States)	
Yuli Lily Hsieh (Boston, United States)	
Kate LeGrand (London, United Kingdom)	
Paper Discussion 1: How to critically review a modelling paper?	13:00 - 13:30
Rebecca Clark (London, United Kingdom)	
Lunch break	13:30 - 15:00
Paper discussion 2: how to critically review a modelling paper	15:00 - 15:30
Rebecca Clark (London, United Kingdom)	
Lecture 2 a&b: Tuberculosis modelling - Interventions and cost effectiveness	15:30 - 16:30
Sandip Mandal (New Delhi, India)	
Nick Menzies (United States)	
Practical 2: Modelling the impact and cost-effectiveness of TB interventions	16:30 - 17:50
Martin Harker (United Kingdom)	
Nick Menzies (United States)	
Lara Goscé (London, United Kingdom)	
Alvaro Schwalb (London, United Kingdom)	
Katherine Horton (London, United Kingdom)	
Finn McQuaid (London, United Kingdom)	
Mphatso D. Phiri (Blantyre, Malawi)	
Kate LeGrand (London, United Kingdom)	
Sun Kim (Boston, United States)	
Yuli Lily Hsieh (Boston, United States)	
Summary of the day	17:50 - 18:00

Katherine Horton (London, United Kingdom)

Post-Graduate Course

10:30 - 13:30

FR

PGC03 - Therapeutic drug monitoring; roadmap to person centred drug dosing in the community

Jan-Willem Alffenaar (Sydney, Australia)

Simon Tiberi (London, United Kingdom)

Heda Melinda Nataprawira (Bandung, Indonesia)

Welcome & Introductions

10:30 - 10:35

Simon Tiberi (London, United Kingdom)

Heda Melinda Nataprawira (Bandung, Indonesia)

Drug exposure: Efficacy/toxicity relationship explained and rational for TDM

10:35 - 11:02

Fajri Gafar (Montreal, Canada)

Identifying people with TB who may benefit from TDM

11:02 - 11:29

Sean Wasserman (London, United Kingdom)

How to decide which assay is suitable for your setting?

11:29 - 11:55

Thi Nguyen (Australia)

Coffee Break

11:55 - 12:05

Developing a TDM program that works with programmatic care

12:05 - 12:32

Stellah Mpagama (Tanzania)

What can we expect in the next 5 years?

12:32 - 12:54

Rovina Ruslami (Bandung, Indonesia)

Panel discussion and take-home messages

12:54 - 13:24

Simon Tiberi (London, United Kingdom)

Heda Melinda Nataprawira (Bandung, Indonesia)

Wrap-up and closing remarks

13:24 - 13:30

Workshop

10:30 - 13:30

BG

WS05 - TB drug regimens development school: Advanced preclinical and translational tools within the public-private ERA4TB consortium hub

Ainhoa Lucía Quintana (Spain)

Diana Angelica Aguilar Ayala (Spain)

Alfonso Mendoza Losana (Spain)

Khisimuza Mdluli (United States)

Brief introduction to the ERA4TB consortium

10:30 - 10:40

Alfonso Mendoza Losana (Spain)

Khisimuza Mdluli (United States)

Advancements in preclinical profiling techniques within ERA4TB: *in vitro*, *in vivo*, imaging

10:40 - 10:40

Novel *in vitro* tools to inform pre-clinical and clinical progression of TB combination therapy

10:40 - 10:55

Santiago Ramón-García (Zaragoza, Spain)

Advanced animal models and biomarker analysis to better predict the efficacy of new anti-mycobacterial compounds

10:55 - 11:10

Christoph Hölscher (Germany)

PET-CT imaging and immune monitoring to predict disease progression: Pathogenesis of TB in cynomolgus macaque

11:10 - 11:25

Candie Joly (France)

Translational power of ERA4TB strategies	11:25 - 11:25
Preclinical development and FTIH platform to optimise clinical trials Irene García García (Spain)	11:25 - 11:40
Model-informed drug development for new drugs for the treatment of tuberculosis Oscar Della Pasqua (United Kingdom)	11:40 - 11:55
Break	11:55 - 12:10
From theory to practice. Let's progress a molecule within a combination regimen to fight TB, through a series of hands-on exercises.	12:10 - 13:05
Group discussion and closing remarks	13:05 - 13:30
<i>Post-Graduate Course</i> 10:30 - 18:00	OC
PGC04 - Planning and implementing social protection programmes for people affected by TB: An introduction Delia Boccia (Italy) Farai Mavhunga (Switzerland) Tauhid Islam (Switzerland)	
Welcome Tauhid Islam (Switzerland)	10:30 - 10:40
Introduction to the course: learning objectives and rationale Farai Mavhunga (Switzerland)	10:40 - 10:50
What is social protection and why it matters for TB Tom Wingfield (United Kingdom)	10:50 - 11:20
Planning social protection programmes for people affected by TB: a generic approach Delia Boccia (Italy)	11:20 - 11:40
Planning social protection programmes for people affected by TB: the role of National TB Programmes Tauhid Islam (Switzerland)	11:40 - 12:00
Q&A	12:00 - 12:10
Coffee break	12:10 - 12:30
First practical session on the planning of social protection for people affected by TB Tauhid Islam (Switzerland) Delia Boccia (Italy)	12:30 - 13:30
Lunch Break	13:30 - 15:00
Implementing and evaluating social protection programmes for people affected by TB Priya Shete (United States)	15:00 - 15:30
Second practical session on the implementation of social protection programmes for people affected by TB Priya Shete (United States) Tom Wingfield (United Kingdom)	15:30 - 16:30
Tea break	16:30 - 16:40

Models of multisectoral collaborations between TB and social protection sector: lessons from a scoping review	16:40 - 17:00
Lieve Vanleeuw (Tampere, Finland)	
Third practical session on the establishment of multisectoral collaborations	17:00 - 17:50
Tom Wingfield (United Kingdom)	
Priya Shete (United States)	
Delia Boccia (Italy)	
Farai Mavhunga (Switzerland)	
Tauhid Islam (Switzerland)	
Wrap - up and closing remarks	17:50 - 18:00

Post-Graduate Course

10:30 - 18:00

JKA

PGC05 - Updates on the latest TB guidance from the World Health Organization: Translating research evidence into policy and practice to end TB

Linh Nguyen (Switzerland)

Fuad Mirzayev (Geneva, Switzerland)

Matteo Zignol (Switzerland)

Tiffany Tiara Pakasi (South Jakarta, Indonesia)

Introduction of the session	10:30 - 10:35
Matteo Zignol (Switzerland)	
Tiffany Tiara Pakasi (South Jakarta, Indonesia)	
Linh Nguyen (Switzerland)	
Fuad Mirzayev (Geneva, Switzerland)	
TB prevention, diagnosis and treatment	10:35 - 10:35
Why and how of the WHO guidelines development process	10:35 - 10:50
Matteo Zignol (Switzerland)	
Updated WHO guidelines on TB preventive treatment	10:50 - 11:10
Dennis Falzon (Geneva, Switzerland)	
Q&A	11:10 - 11:20
Updated WHO recommendations and guidance on TB diagnostics	11:20 - 11:40
Nazir Ismail (Johannesburg, South Africa)	
Q&A	11:40 - 11:50
Updated WHO recommendations and guidance on treatment of drug-resistant TB	11:50 - 12:10
Fuad Mirzayev (Geneva, Switzerland)	
Q&A	12:10 - 12:20
Coffee-break	12:20 - 12:35
Perspective of national TB programme and civil society in Indonesia on the development, adoption and uptake of WHO TB recommendations and guidance	12:35 - 12:55
Tiffany Tiara Pakasi (South Jakarta, Indonesia)	
Paran Sarimita Winarni (East Jakarta, Indonesia)	
Panel discussion	12:55 - 13:30
Tiffany Tiara Pakasi (South Jakarta, Indonesia)	
Matteo Zignol (Switzerland)	
Norbert Ndjeka (South Africa)	
Kobto Ghislain Koura (PARIS, France)	
Agnes Gebhard (Netherlands)	
Vineet Bhatia (India)	

Lunch break	13:30 - 15:00
Introduction to the afternoon session: WHO guidance to foster comprehensive people-centred care Tiffany Tiara Pakasi (South Jakarta, Indonesia) Farai Mavhunga (Switzerland)	15:00 - 15:05
WHO guidance on social protection for people affected by TB Delia Boccia (Italy)	15:05 - 15:25
Q&A	15:25 - 15:35
WHO guidance on TB-associated disability Marzia Calvi (Geneva, Switzerland)	15:35 - 15:55
Q&A	15:55 - 16:05
WHO guidance on TB and comorbidities Annabel Baddeley (Geneva, Switzerland)	16:05 - 16:25
Q&A	16:25 - 16:35
Coffee-break	16:35 - 16:45
WHO guidance on conducting reviews of TB programmes Lana Syed (Geneva, Switzerland)	16:45 - 17:05
Q&A	17:05 - 17:15
Panel discussion Obioma Chijioke-Akaniro (Abuja, Nigeria) Kyung Oh (Philippines) Urvashi B. Singh (New Delhi, India) Victoria James (Zimbabwe) Farai Mavhunga (Switzerland)	17:15 - 17:55
Wrap - up and closing remarks	17:55 - 18:00
<i>Post-Graduate Course</i> 10:30 - 13:30	JKB
PGC02 - Shifting perspectives: Strategies for scaling up the BPALM regimen Medea Gegia (Switzerland) Linh Nguyen (Switzerland) Fuad Mirzayev (Geneva, Switzerland) Ignacio Monedero-Recuero (Paris, France)	
Intro	10:30 - 10:35
Overview of WHO consolidated guidelines on DR- TB treatment Fuad Mirzayev (Geneva, Switzerland)	10:35 - 10:55
Q&A	10:55 - 11:05
Rationale for DR-TB Treatment regimen selection Chen-Yuan Chiang (France)	11:05 - 11:25
Q&A	11:25 - 11:35
Understanding BPALM Regimen: Patient Characteristics and Treatment Monitoring Gisele Badoum (Ouagadougou, Burkina Faso)	11:35 - 11:55
Q&A	11:55 - 12:05

Break	12:05 - 12:15
Management of adverse events in BPaLM regimen for MDR/RR-TB treatment	12:15 - 12:35
Ignacio Monedero-Recuero (Paris, France)	
Q&A	12:35 - 12:45
Engaging stakeholders in the programmatic scale up of BPaLM in the Philippines	12:45 - 13:05
Maria Imelda Quelapio (Philippines)	
Q&A	13:05 - 13:15
Conclusion	13:15 - 13:30
<i>Workshop</i>	
10:30 - 13:30	MD
WS04 - Sharing experiences and practical lessons in scale-up, introduction and innovation of stool-based testing to diagnose TB, zooming in on Asia	
Eveline Klinkenberg (Netherlands)	
Erik Post (Jakarta, Indonesia)	
Petra de Haas (Netherlands)	
Sayera Banu (Bangladesh)	
Intro	10:30 - 10:45
Charlotte Colvin (United States)	
Erik Post (Jakarta, Indonesia)	
Clinical diagnosis of pediatric TB in the era of stool-based diagnosis	10:45 - 11:10
Lisa Adams (United States)	
Charlotte Colvin (United States)	
Performance of molecular tests for stool-based TB testing: experiences with use of Truenat, Xpert XDR cartridge, tNGS	11:10 - 11:35
Alaine Umubyeyi Nyaruhirira (Pretoria, South Africa)	
Joel Kabugo (Kampala, Uganda)	
Jamiu Olabamiji (Lagos, Nigeria)	
Tara Ness (Houston, United States)	
Wethusonkhe Khumalo (Mbabane, Eswatini)	
Use of tongue swabs for TB diagnosis in children: Are we close to routine implementation?	11:35 - 12:00
Jaganath Devan (United States)	
Implementation of stool-based TB testing, zooming in on Asia - Country experiences	12:00 - 12:25
Leveriza Coprada (Makati City, Philippines)	
Vijayashree Yellappa (Delhi, India)	
Nastiti Kaswandani (Jakarta, Indonesia)	
Syed Mohammad Mazidur Rahman (Bangladesh)	
Mai Thu Hien (Vietnam)	
Scale up of stool-based testing: Current status and experiences in SubSaharan Africa	12:25 - 12:50
Eveline Klinkenberg (Netherlands)	
Nkiru Nwokoye (Nigeria)	
Birru Shigut Gondol (Malawi)	
Panel discussion: Key lessons learned and optimization of stool-based TB testing	12:50 - 13:15
Erik Post (Jakarta, Indonesia)	
Gunta Dravniece (Ukraine)	

Conclusion	13:15 - 13:30
<i>Workshop</i> 10:30 - 18:00	NS1
WS03 - Airborne IPC in focus: implementation of feasible measures for eliminating TB transmission risk and staying prepared for the next pandemic	
Grigory Volchenkov (Russian Federation) Varvara Vauhkonen (Finland) Edward Nardell (United States) Matsie Mphahlele (South Africa)	
Welcome	10:30 - 10:35
Varvara Vauhkonen (Finland) Grigory Volchenkov (Russian Federation)	
Introductions	10:35 - 10:40
Edward Nardell (United States) Matsie Mphahlele (South Africa)	
Basics of airborne infection: What we know and what we don't	10:40 - 11:00
Edward Nardell (United States)	
Q&A	11:00 - 11:05
Importance of administrative controls in mitigating airborne infectious disease transmission	11:05 - 11:25
Matsie Mphahlele (South Africa)	
Q&A	11:25 - 11:30
Choosing the right environmental controls in resource-limited settings: Are room air cleaners a good option for high-risk areas?	11:30 - 11:50
Paul Jensen (United States)	
Q&A	11:50 - 11:55
Break	11:55 - 12:10
Architectural design for airborne IPC in resource limited settings	12:10 - 12:30
Jako-Albert Nice (South Africa)	
Q&A	12:30 - 12:35
Making personal respiratory protection program effective and feasible	12:35 - 12:55
Grigory Volchenkov (Russian Federation)	
Q&A	12:55 - 13:00
Safeguarding indoor spaces from airborne pathogens through application of TB IPC measures	13:00 - 13:20
Martie van der Walt (South Africa)	
Q&A	13:20 - 13:30
Lunch break	13:30 - 15:00
Rotating Group Practical Sessions: 6 Stations, 25 Minutes Each	15:00 - 18:00
Practical 1: TB IPC plan development based on risk assessment	18:00 - 18:00
Matsie Mphahlele (South Africa) Martie van der Walt (South Africa)	
Practical 2: Room air cleaner performance evaluation	18:00 - 18:00

Paul Jensen (United States) Sevim Ahmedov (Vienna, United States)	
Practical 3: Architectural design brief development considering key IPC design factors	18:00 - 18:00
Jako-Albert Nice (South Africa) Isabel Ochoa Delgado (Peru)	
Practical 4: Respirator donning, fit testing, seal checking and safe disposal	18:00 - 18:00
Anita Kansal (India) Grigory Volchenkov (Russian Federation)	
Practical 5: Upper room GUV: fixture design, maintenance, effectiveness and safety assessment	18:00 - 18:00
Richard Vincent (United States) Edward Nardell (United States)	
Practical 6: Ventilation performance assessment	18:00 - 18:00
Varvara Vauhkonen (Finland) Aldo Daniel Vilchez Burga (Peru)	
Practical Q&A and Summary	18:00 - 18:00
Conclusion	18:00 - 18:00
<i>Workshop</i> 10:30 - 13:30	NS2
WS02 - Using TB active case-finding data to estimate local TB burden	
Mirjam Bakker (Netherlands) Christina Mergenthaler (Amsterdam, Netherlands) Nimalan Arinaminpathy (Switzerland)	
Welcome and Introductions	10:30 - 10:40
Applying the MATCH framework to make sense of active case-finding and health systems data	10:40 - 11:00
Mirjam Bakker (Netherlands)	
Exercise	11:00 - 11:10
Estimating local TB prevalence in Punjab, Pakistan using active case-finding data and sociodemographic characteristics	11:10 - 11:20
Abdullah Latif (Islamabad, Pakistan)	
Exercise	11:20 - 11:50
Break	11:50 - 12:10
Comparing 2017-2018 national prevalence estimates with ACF data to estimate subnational TB burden in Viet Nam	12:10 - 12:30
Andrew James Codlin (Ha Noi, Vietnam)	
Exercise	12:30 - 12:50
Opportunities, new ideas and challenges to optimize the information value of TB active case-finding data	12:50 - 13:05
Nimalan Arinaminpathy (Switzerland)	
Conclusion	13:05 - 13:20

Workshop

10:30 - 13:30

NS3

WS08 - Decoding TB drug resistance: A deep dive into the updated WHO TB mutation catalogue

Anita Suresh (Singapore, Singapore)

Swapna Uplekar (Geneva, Switzerland)

Nazir Ismail (Johannesburg, South Africa)

Welcome & Introductions

10:30 - 10:40

Swapna Uplekar (Geneva, Switzerland)

Anita Suresh (Singapore, Singapore)

Nazir Ismail (Johannesburg, South Africa)

Overview of the data and methodology used for the second edition of the WHO Mutation Catalogue

10:40 - 11:10

Paolo Miotto (Milan, Italy)

Unlocking the power of the WHO Mutation Catalogue 2nd Edition: A deep dive into the tables and results of the Catalogue

11:10 - 11:40

Claudio Köser (Cambridge, United Kingdom)

Interactive exercise 1

11:40 - 11:55

Paolo Miotto (Milan, Italy)

Claudio Köser (Cambridge, United Kingdom)

Break

11:55 - 12:10

Implementing the WHO TB Mutation Catalogue: Current applications and future directions

12:10 - 12:40

Timothy Walker (Oxford, United Kingdom)

Turning sequencing results into clinical decisions: A clinician's perspective of the WHO Mutation Catalogue

12:40 - 13:10

Maha Farhat (Boston, United States)

Interactive exercise 2

13:10 - 13:25

Timothy Walker (Oxford, United Kingdom)

Maha Farhat (Boston, United States)

Wrap-up and closing remarks

13:25 - 13:30

Anita Suresh (Singapore, Singapore)

Nazir Ismail (Johannesburg, South Africa)

Community Connect

10:30 - 11:15

SG

CCSS001 - From awareness to action: Community-based approaches to TB stigma

Vlada Rabinova (Ukraine)

Zahedul Islam (Ukraine)

Introduction

10:30 - 10:33

Making the TB response rights-based, equitable, and stigma free: Results from the community, rights and gender assessment in Cambodia

10:33 - 10:42

Sok Chamreun Choub (Cambodia)

Unveiling stigma: Employment challenges for people with TB

10:42 - 10:51

Olha Tsvilii (Ukraine)

Enhancing community resilience: CRG assessment impact through Côte d'Ivoire's experiences

10:51 - 11:00

Edouard Sansan (ABIDJAN, Cote D'Ivoire)

Question & answer

11:00 - 11:15

Community Connect

11:00 - 12:00

AU

CCSA001 - Empowering people: Transforming TB care through person-centred approaches

Usman Lodhi (Pakistan)

Jacob Creswell (Switzerland)

Introduction	11:00 - 11:05
Overview of person-centred care in TB: PCC tool by Stop TB Partnership	11:05 - 11:13
Beatrice Wangari Kirubi (Geneva, Sweden)	
Implementation of PCC tool in Pakistan: Insights and outcomes	11:13 - 11:21
Usman Lodhi (Pakistan)	
Combating TB stigma and promoting person-centred care: Lessons from Nigeria	11:21 - 11:29
Stephen John (Yola, Nigeria)	
Effective communication strategies for TB stigma reduction and PCC enhancement	11:29 - 11:37
Kinz Ul Eman (Islamabad, Pakistan)	
Comparative insights on PCC and stigma reduction: Perspectives from developed countries	11:37 - 11:45
Robyn Waite (Ottawa, Canada)	
Question and answer	11:45 - 12:00

Community Connect

11:30 - 12:15

SG

CCSS002 - Survivor-led networks as a catalyst for ending TB in high burden countries: A case study of Touched by TB, the national coalition of TB-affected communities in India

Raghavan Gopa Kumar (New Delhi, India)

Raghavan Gopa Kumar (New Delhi, India)

Introduction	11:30 - 11:36
TB survivor engagement with programme division in Delhi: Challenges and opportunities	11:36 - 11:42
Gulshana Verma (India)	
TB survivor engagement in Nagaland to end TB: Challenges and opportunities	11:42 - 11:48
Monica Subba (India)	
Formation and programme implementation of survivor-led network in Sikkim: Experience of hard-to-reach areas in North East India	11:48 - 11:54
Tshering Samdup Bhutia (India)	
Challenges of formation of survivor-led network in Meghalaya, India	11:54 - 12:00
Ridalin Shullai (India)	
Question and answer	12:00 - 12:15

Community Connect

12:15 - 13:15

AU

CCSA002 - Capacitating communities to engage with research through responsive and interactive online curriculum

Erin McConnell (United States)

Rekha Radhakrishnan (United States)

Introduction	12:15 - 12:20
---------------------	---------------

CABLab: An interactive, asynchronous TB curriculum for all	12:20 - 12:30
Erin McConnell (United States)	
Importance of innovative educational tools and overcoming language barriers in outreach to communities and education	12:30 - 12:40
Daria Mikulich (Russian Federation)	
Community engagement, rights, and gender in CABLab: The Asia-Pacific experience	12:40 - 12:50
Pattariya Maleehom (Thailand)	
Impact on the ground: Tangible impact of community-driven learning in TB advocacy and accountability	12:50 - 13:00
Jacqueline Wambui (Kenya)	
Question and answer	13:00 - 13:15
<i>Community Connect</i>	
12:30 - 13:30	SG
CCSS015 - Carrying TB innovations to new heights: The adventures and learnings from donating portable X-ray technology combined with artificial intelligence to a remote mountainous community in Nepal	
Jacob Creswell (Switzerland)	
Kinz Ul Eman (Islamabad, Pakistan)	
Jeanne Walter (United States)	
Introduction	12:30 - 12:35
From Mount Everest and beyond: How TB REACH helps find people with TB and bring TB innovations to scale	12:35 - 12:45
Jacob Creswell (Switzerland)	
From Mount Everest and beyond: How MinXray portable machines reach and empower communities to diagnose TB where they are	12:45 - 12:55
Michael Cairnie (United States)	
From Mount Everest and Beyond: How Qure.ai removes barriers to diagnosing TB with fast and accurate X-ray reporting	12:55 - 13:05
Jai Bassi (India)	
From Mount Everest and Beyond: How Project Data Sphere is accelerating healthcare access by developing innovative AI solutions	13:05 - 13:15
Asba (AT) Tasneem (United States)	
Question and answer	13:15 - 13:30
<i>Satellite Session</i>	
13:30 - 15:00	AU
SS01 - Strategic Health Purchasing (SHP) for TB Programme under Indonesia's National Social Health Insurance	
Pandu Harimurti (Indonesia)	
Anastasia Susanto (Indonesia)	
Opening	13:30 - 13:35
Assuring Quality for TB Response from the Lense of National Health Insurance	13:35 - 13:45
Current Status of TB and Innovative Approaches to Address Remaining Challenges in Indonesia's TB Program	13:45 - 13:55
Tiffany Tiara Pakasi (South Jakarta, Indonesia)	
The TB Innovative Financing Pilot: Providers Payment Mechanisms to Incentivize Providers' Behavior to Support TB Program	13:55 - 14:05

Ahmad Irsan Moeis (Indonesia)	
Role of the National Health Insurance to Strengthen Indonesia's TB Response	14:05 - 14:15
Global Experiences and Indonesia's Leapfrogging Ambitions	14:15 - 14:25
Ronald Mutasa (Indonesia)	
TB Financial Reform in Other Countries	14:25 - 14:35
William Wells (United States)	
Key Enabling Factors to Empower Providers' Behavior Changes	14:35 - 14:45
Guy Stallworthy (United States)	
Q&A	14:45 - 14:55
Closing	14:55 - 15:00
<i>Community Connect</i>	
14:00 - 15:30	EG2
CCOS001 - Opening session of community connect	
<i>Post-Graduate Course</i>	
15:00 - 18:00	BG
PGC06 - The power of advocacy in advancing global health	
Madison Featherstone (United States)	
Leigh Raithby (Canada)	
Welcome and Introductions	15:00 - 15:10
Leigh Raithby (Canada)	
The role of advocacy in global health	15:10 - 15:25
Jennifer Peake (Australia)	
Q&A + Activities	15:25 - 15:40
Building an advocacy strategy	15:40 - 15:55
Priyanka Aiyer (India)	
Q&A	15:55 - 16:10
Communicating effectively	16:10 - 16:25
Negaya Chorley (Australia)	
Q&A	16:25 - 16:40
Coffee Break	16:40 - 16:55
Case study - ACTION's 20-Year History of Global Fund Advocacy	16:55 - 17:10
Leigh Raithby (Canada)	
Q&A	17:10 - 17:20
Activities: Role-playing + Create an Action Plan	17:20 - 17:50
Leigh Raithby (Canada)	
Negaya Chorley (Australia)	
Jennifer Peake (Australia)	
Conclusion	17:50 - 18:00

Workshop

15:00 - 18:00

MD

WS01 - The role of advancing molecular technologies in BPaLM expansion and clinical management of people with TB: Are we ready?

Medea Gegia (Switzerland)

Carl-Michael Nathanson (Geneva, Switzerland)

Xiaolin Wei (Canada)

Patricia Hall-Eidson (Atlanta, United States)

Welcome & Introduction

15:00 - 15:10

Patricia Hall-Eidson (Atlanta, United States)

Xiaolin Wei (Canada)

State of the art on the expanded access to BPaLM

15:10 - 15:25

Hoang Thanh Thuy (Vietnam)

Q&A

15:25 - 15:35

Advancing technologies for TB drug resistance detection in the BPaLM era

15:35 - 15:50

Claudio Köser (Cambridge, United Kingdom)

Q&A

15:50 - 16:00

Laboratory capacity to support BPaLM roll-out

16:00 - 16:15

Leen Rigouts (Antwerpen, Belgium)

Q&A

16:15 - 16:25

Coffee break

16:25 - 16:40

Molecular technologies in managing resistance and TB elimination: Is the HIV model applicable to TB?

16:40 - 16:55

Ignacio Monedero-Recuero (Paris, France)

Q&A

16:55 - 17:05

Country experience of implementing new drug susceptibility tests and challenges: an example of the way forward

17:05 - 17:20

Shaheed Vally Omar (Johannesburg, South Africa)

Q&A

17:20 - 17:30

Discussion and debrief

17:30 - 17:55

Conclusion

17:55 - 18:00

Workshop

15:00 - 18:00

NS2

WS07 - Building capacity for real-time operational research: Experiences from Asia and Africa

Selma Dar Berger (Portugal)

Divya Nair (India)

Anthony D Harries (United Kingdom)

Ya Diul Mukadi (Washington, DC, United States)

Welcome

15:00 - 15:05

Selma Dar Berger (Portugal)

Divya Nair (India)

Introductions

15:05 - 15:10

Anthony D Harries (United Kingdom)

Ya Diul Mukadi (Washington, DC, United States)

Real-time operational research: What, Why, How

15:10 - 15:30

Ajay Kumar Madhugiri Venkatachalaiah (India)

Q&A	15:30 - 15:40
Real-time OR experience 1- Assessing the Real-Time Impact of COVID-19 on TB and HIV Services in Kenya Jeremiah Chakaya (Nairobi, Kenya)	15:40 - 16:00
Q&A	16:00 - 16:10
Real-time OR experience 3- Disability, comorbidities and risk determinants at end of TB treatment in Kenya, Uganda, Zambia and Zimbabwe Rony Zachariah (Luxembourg)	16:10 - 16:30
The WHO policy brief on TB disability and perspectives Sabine Verkuijl (Geneva, Switzerland)	16:30 - 16:35
Q&A	16:35 - 16:40
Coffee-break	16:40 - 16:50
Real-time OR experience 2- Applying timeliness metrics for management of household contact persons of persons with TB in India Ramya Ananthakrishnan (Chennai, India)	16:50 - 17:10
Q&A	17:10 - 17:20
Quality assured mobile based data capture for conducting real-time operational research Pruthu Thekkur (India)	17:20 - 17:40
Q&A	17:40 - 17:50
Wrap - up and closing remarks Ya Diul Mukadi (Washington, DC, United States) Anthony D Harries (United Kingdom)	17:50 - 18:00
<i>Community Connect</i> 15:00 - 16:00	SG
CCSS013 - The vital role of communities and civil society organisations in implementing the ten key actions of the 2023 Roadmap towards ending TB in children and adolescents Cosette Audi (United States) Gloriah Moses (Kenya) Moorine Penninah Sekadde (Kampala, Uganda)	
Introduction	15:00 - 15:05
Toward ending TB in children and adolescents: What is needed to implement the ten key actions? Sabine Verkuijl (Geneva, Switzerland)	15:05 - 15:13
How investing in TB community-led programmes can contribute to strengthening the response to ending TB in children and adolescents Nicholas Farcy (Switzerland)	15:13 - 15:21
Community engagement to support TB case finding and TB preventive treatment provision for children and adolescents in Indonesia Betty Nababan (Jakarta, Indonesia)	15:21 - 15:29
Community-driven accountability in the TB response: Addressing the specific needs of children and adolescents Gloriah Moses (Kenya)	15:29 - 15:37

<p>Fostering collaboration between national TB programmes, the Ministry of Education and learning institutions: Key contributions from members of civil society</p> <p>Evaline Kibuchi (Kenya)</p> <p>Question and answer</p>	<p>15:37 - 15:45</p> <p>15:45 - 16:00</p>
<p><i>Community Connect</i> 15:15 - 16:00</p>	
AU	
<p>CCSA003 - Harmonising health: AI, acoustics, and innovations in TB diagnosis</p> <p>Kinz Ul Eman (Islamabad, Pakistan) Zhi Zhen Qin (Dubai, United Arab Emirates) Kinz Ul Eman (Islamabad, Pakistan)</p>	
<p>Introduction</p> <p>Potential of artificial intelligence-powered cough classification for TB: A mini review</p> <p>Zhi Zhen Qin (Dubai, United Arab Emirates)</p> <p>HeAR: Unlocking the power of acoustic biomarkers for global health</p> <p>Sujay Kakarmath (United States)</p> <p>Transformative tech: Real-world successes in AI and digital health innovations for community well-being</p> <p>Kinz Ul Eman (Islamabad, Pakistan)</p> <p>Revolutionising rural healthcare with AI-powered telemedicine and smart diagnostics</p> <p>Shuai Guo (China)</p> <p>Question and answer</p>	<p>15:15 - 15:21</p> <p>15:21 - 15:27</p> <p>15:27 - 15:33</p> <p>15:33 - 15:39</p> <p>15:39 - 15:45</p> <p>15:45 - 16:00</p>
<p><i>Community Connect</i> 16:15 - 17:15</p>	
AU	
<p>CCSA004 - From data to action: Mapping diversities in TB key and vulnerable populations</p> <p>Kinz Ul Eman (Islamabad, Pakistan) James Malar (Geneva, Switzerland)</p>	
<p>Introduction</p> <p>Unveiling challenges and pathways: TB impact on key and vulnerable population, and the quest for equity</p> <p>Caomihe Smyth (Geneva, Switzerland)</p> <p>Empowering change: Leveraging the KVP size estimation tool to identify and support key and vulnerable populations in TB elimination</p> <p>Stephen John (Yola, Nigeria)</p> <p>TB KVP size estimation in Moldova: Results, lessons learned and data for use</p> <p>Cristina Celan (Chisinau, Moldova)</p> <p>Tailoring TB services: Aligning care with the unique needs of key and vulnerable populations for enhanced accessibility, availability, acceptability, and quality</p> <p>Kinz Ul Eman (Islamabad, Pakistan)</p> <p>Enhancing TB care with one impact CLM: Insights and field experiences for key and vulnerable populations</p> <p>Viplove Dutta (India)</p>	<p>16:15 - 16:20</p> <p>16:20 - 16:28</p> <p>16:28 - 16:36</p> <p>16:36 - 16:44</p> <p>16:44 - 16:52</p> <p>16:52 - 17:00</p>

Question and answer	17:00 - 17:15
<i>Opening Session</i> 18:30 - 20:00	MG
OS02 - Welcome gathering	
Welcome David Jackson (United Kingdom)	18:30 - 18:34
Chief Guest Speech Budi G. Sadikin (Indonesia)	18:34 - 18:49
Conversation with The Union's Executive Director Cassandra Kelly-Cirino (Switzerland)	18:49 - 18:53
Union Medal Winners - Announcement Guy Marks (Sydney, Australia)	18:53 - 18:57
Affected Community Perspective Joegene V. Mangilaya (Indonesia)	18:57 - 19:01
Balinese dancing	19:01 - 19:08

Wednesday, 13. November 2024*TBScience Session*

08:00 - 09:00

AU

TBS1A - Implications of pathogen heterogeneity for intervention - How pathogen diversity relates to type of manifestation

Willem Hanekom (South Africa)

TBS1A-05 **TBScience Chair Introduction** 08:00 - 08:05TBS1A-15 **Discovering new lipid classes in M. tuberculosis** 08:05 - 08:20

Yashodhan Nair (United States)

TBS1A-20 **Combining host and pathogen diversity for the host-pathogen interactions underlying TB disease** 08:20 - 08:35

Clare Smith (United States)

TBS1A-25 **Transcriptional plasticity underlying stress adaptation in M. tuberculosis** 08:35 - 08:50

Cheng Bei (China)

TBS1A-30 **Q&A** 08:50 - 09:00*Side Meeting*

08:00 - 09:00

HB

SM01 - Africa region*Side Meeting*

08:00 - 09:00

FR

SM02 - NAR region*Side Meeting*

08:00 - 09:00

OC

SM03 - SEA region*Satellite Session*

08:00 - 09:00

JKB

SS02 - Shaping the future of TB infection management: From lessons learned to the screening implementation in high TB burden countries

Erlina Burhan (Jakarta, Indonesia)

Opening remarks 08:00 - 08:05**Programmatic management of TB infection: Past, present, future** 08:05 - 08:20

Masae Kawamura (United States)

Lessons Learned and Future Strategies: Evolving National TB Program for Enhanced Management and Control 08:20 - 08:35

Tiffany Tiara Pakasi (South Jakarta, Indonesia)

Feasibility and Usability Analysis of QFT-Plus Implementation in Indonesia's Primary Healthcare System 08:35 - 08:50

Raden Rara Diah Handayani (Indonesia)

Q&A and closing remarks 08:50 - 09:00

Side Meeting

08:00 - 09:00

NS2

SM04 - Asia Pacific region*Union Live Session*

08:30 - 09:30

UL

UL01 - Messages from our event sponsors*Community Connect*

09:00 - 10:00

SG

CCSS006 - Advancing pregnancy inclusion in TB research: A model for engaging communities to set the agenda

Cosette Audi (United States)

Cosette Audi (United States)

Erin McConnell (United States)

Introduction

09:00 - 09:05

Requiring consensus: A survivor's firsthand experience of TB during pregnancy and the need for improved research inclusion

09:05 - 09:13

Ani Hernasari (Indonesia)

Reaching consensus: Community stakeholder experience generating a community consensus for pregnancy and TB

09:13 - 09:21

Maurine Murenga (Kenya)

Harmonising consensus: Centering and elevating community voices in advocacy

09:21 - 09:29

Oxana Rucsineanu (Moldova)

Advancing consensus: TB Representative Studies Rubric (TB RSR) to assess and advocate for equity and representation in research

09:29 - 09:37

Mike Frick (New York City, United States)

Responding to consensus: A researcher's experience incorporating community feedback

09:37 - 09:45

Nicole Salazar-Austin (Baltimore, United States)

Question and answer

09:45 - 10:00

TBScience Session

09:05 - 09:50

AU

TBS1B - Implications of pathogen heterogeneity for intervention - Oral Abstracts

Timothy Walker (Oxford, United Kingdom)

TBS1B-05

Session introduction

09:05 - 09:07

TBS1B-10

Novel approaches leveraging on genome mining of identical multi-repeat sequences for developing a highly sensitive molecular assay for the diagnosis of TB

09:07 - 09:14

Clement Likhovole (Thika, Kenya)

TBS1B-15

Spatial detection of *M. tuberculosis* mRNA and secreted antigens in Ziehl-Neelsen negative human tissues using RNAscope and immunohistochemistry

09:14 - 09:21

Kievershen Nargan (Durban, South Africa)

TBS1B-20

Differential rates of *M. tuberculosis* transmission associate with host-pathogen sympatry

09:21 - 09:28

Matthias Groeschel (Boston, United States)

TBS1B-25

Dissecting the dominance of *M. tuberculosis* lineage 2: Phylogenomics, mutation rates, association studies and the rise of

09:28 - 09:35

	multi-drug resistance Thierry Wirth (Paris, France)	
TBS1B-30	Q&A	09:35 - 09:50
<i>Oral Abstract Session</i>		
09:20 - 10:50		HB
OA01 - TB prevention and care capacity building		
Yacine Mar Diop (Dakar, Senegal) Mohammed Yassin (Geneva, Switzerland)		
	Introduction	09:20 - 09:25
OA01-100-13	Strengthening capacity for TB Services: Institutionalising an education and training unit at the National Tuberculosis Control Program in Bangladesh Khandoker Abu Jafor Md. Saleh (Dhaka, Bangladesh)	09:25 - 09:34
OA01-101-13	Building capacity of community health officers (CHOs) through an innovative digital learning pedagogy for achieving a "TB-free India" Kritika Upadhyay (Chandigarh, India)	09:34 - 09:43
OA01-102-13	From TB to beyond: Envisioning disease-specific databases modeled after TB portals Andrei Gabrielian (Rockville, United States)	09:43 - 09:52
OA01-103-13	From knowledge nodes to cadre-specific courses: A system approach to TB training content development Abhimanyu Singh (New Delhi, India)	09:52 - 10:01
OA01-104-13	Competitive targeted patent medical vendors (PMV) training can enhance TB case finding: The Benue experience Eze Chukwu (Abuja, Nigeria)	10:01 - 10:10
OA01-105-13	Meaningful engagement of TB survivors within the TB programme: An innovative initiative in Mumbai, India Shweta Bajaj (Mumbai, India)	10:10 - 10:19
OA01-106-13	Enhancing directly observed treatment short-course (DOTs) initiatives via a robust monitoring and evaluation framework: Lessons from Plateau State TB Program Gift Maren (Jos, Nigeria)	10:19 - 10:28
OA01-107-13	Assessment of facility-based mentorship by professional nurse mentors to determine clinical proficiencies of healthcare workers in KwaZulu-Natal, South Africa Munira Khan (Durban, South Africa)	10:28 - 10:37
	Q&A	10:37 - 10:50
<i>Oral Abstract Session</i>		
09:20 - 10:50		FR
OA02 - Digital technologies for TB treatment adherence		
Jeremiah Chakaya (Nairobi, Kenya) Dennis Falzon (Geneva, Switzerland)		
	Introduction	09:20 - 09:25
OA02-108-13	Impact of SMS reminders on TB medication adherence: An analysis of adherence levels of people with TB pre and post 99DOTS Pilot Implementation in Nigeria Iboro Gordon (Abuja, Nigeria)	09:25 - 09:34
OA02-109-13	Exploring engagement and adherence to the TB Treatment Support	09:34 - 09:43

	Tools intervention to support individuals with active TB Sarah Iribarren (Seattle, United States)	
OA02-110-13	Findings from a pragmatic multisite randomised controlled trial of the Tuberculosis Treatment Support Tools in public health hospitals in Argentina Sarah Iribarren (Seattle, United States)	09:43 - 09:52
OA02-111-13	Enhancing TB care in Nigeria: The Impact of digital platforms on information accessibility and peer group support for persons on treatment Stanley Chinkata (Umuahia, Nigeria)	09:52 - 10:01
OA02-112-13	Automated adherence system integrated with public health action improves TB treatment adherence (98%): Scope for usage in TB-DM Shruthi Basavaradhya Sahukar (Chennai, India)	10:01 - 10:10
OA02-113-13	Intervention fidelity of digital adherence technologies for TB treatment support: A mixed methods process evaluation of pragmatic cluster randomised trials in five countries Degu Jerene (The Hague, Netherlands)	10:10 - 10:19
OA02-114-13	Equity and cost-effectiveness of digital adherence technologies to support TB treatment adherence in Ethiopia Nicola Foster (London, United Kingdom)	10:19 - 10:28
OA02-115-13	Effectiveness of a mobile health application on treatment outcomes among people with TB in Shanghai, China: A multicenter randomised controlled trial Nan Qin (Shanghai, China)	10:28 - 10:37
	Q&A	10:37 - 10:50
 <i>Symposium</i>		
	09:20 - 10:50	BG
	SP01 - Fast tracking the cure: Lessons from coordinating cross country community-based advocacy to accelerate uptake and implementation of 6-month drug-resistant TB treatments Blessina Kumar (New Delhi, India) Sandeep Juneja (New York, United States)	
SP01-400-13	Introduction	09:20 - 09:25
SP01-404-13	Outcomes and lessons from funding and project managing a multi-partner and country community-led advocacy initiative to drive access to anti-TB treatments Robyn Waite (Ottawa, Canada)	09:25 - 09:39
SP01-401-13	Fast-tracking access to BPAL-based regimens in Indonesia: Challenges and success stories Yeremia Runtu (Jakarta, Indonesia)	09:39 - 09:53
SP01-402-13	How people affected by TB can help speed access to new treatments like BPAL: The story of TBPeople Philippines Ma. Eloisa Zepeda-Teng (Las Piñas City, Philippines)	09:53 - 10:07
SP01-405-13	Experiences From SCDI's activities to support BPAL/M rollout Anh Cao (Hanoi, Vietnam)	10:07 - 10:21
SP01-403-13	Supporting demand creation for new TB treatments through the Challenge Facility for Civil Society James Malar (Geneva, Switzerland)	10:21 - 10:35
SP01-406-13	Q&A	10:35 - 10:50

Oral Abstract Session

09:20 - 10:50

OC

OA03 - Immunosuppressive states and TB: The role of the undernutrition and beyond

Rebecca Clark (London, United Kingdom)

Anurag Bhargava (Mangalore, India)

	Introduction	09:20 - 09:25
OA03-141-13	Undernutrition assessment, nutrient intake of people with TB, and feasibility of NACS in outpatient TB clinics in the Philippines Glyzelle Anne Lagason (Dasmariñas, Philippines)	09:25 - 09:33
OA03-142-13	Feasibility study for operationalisation of BMI-based field charts for nutritional assessment of adults with TB in South India Madhavi Bhargava (Mangalore, India)	09:33 - 09:41
OA03-143-13	Direct benefit transfer for nutritional support of people with TB and its association with treatment outcomes in India: Analysis of routine programmatic data of 2022 Sanjay Kumar Mattoo (New Delhi, India)	09:41 - 09:49
OA03-144-13	Estimating the epidemiological impact of scaling up a nutritional intervention for TB-affected households across India Finn McQuaid (London, United Kingdom)	09:49 - 09:57
OA03-145-13	Addressing the dual burden of malnutrition and TB in affected paediatric populations: Lessons from Katsina State Pead TB Surge Project Implementation Hauwa Usman Garba (Katsina, Nigeria)	09:57 - 10:05
OA03-146-13	Vitamin A and D deficiency and their predictors in a subset of participants in the RATIONS trial (India) Anurag Bhargava (Mangalore, India)	10:05 - 10:13
OA03-147-13	The interplay between nutrition and helminth infection correlates with microbiota associated with negative immune responses in individuals with M. tuberculosis Arthur VanValkenburg (Newark, United States)	10:13 - 10:21
OA03-148-13	The effect of steroid therapy on IFN-γ level after M. tuberculosis stimulation in systemic lupus erythematosus Laniyati Hamijoyo (Bandung, Indonesia)	10:21 - 10:29
OA03-149-13	The global incidence of TB in people with chronic kidney disease: A systematic review and meta-analysis based on data collected from 1,548,774 people Ayinalem Alemu (Addis Ababa, Ethiopia)	10:29 - 10:37
	Q&A	10:37 - 10:50

Oral Abstract Session

09:20 - 10:50

JKA

OA04 - Strategies for detecting TB in children

Madolyn Dauphinais (Boston, United States)

Nastiti Kaswandani (Jakarta, Indonesia)

	Introduction	09:20 - 09:25
OA04-124-13	A country's drive to improve childhood TB case notification: KNCV Nigeria experience from national childhood TB testing week Ogoamaka Chukwuogo (Abuja, Nigeria)	09:25 - 09:34
OA04-125-13	Leveraging district-led capacity-building initiatives to improve childhood TB case-finding in Western Uganda Raymond Kamara (Kampala, Uganda)	09:34 - 09:43

OA04-126-13	TB case detection in children and adolescents in high-load health facilities in Ethiopia: Lessons from health facility intervention Eshetu Abdissa (Addis Ababa, Ethiopia)	09:43 - 09:52
OA04-127-13	Overcoming barriers to detecting paediatric TB in health facilities and community settings in Vietnam: Results and lessons Huyen Thu Hoang (Hanoi, Vietnam)	09:52 - 10:01
OA04-128-13	Pre-adoption pilot Implementation of stool-based GeneXpert Testing for paediatric TB diagnosis in Mozambique Criménia Mbate-Mutemba (Maputo, Mozambique)	10:01 - 10:10
OA04-129-13	Enhancing paediatric TB specimen collection and diagnosis: Insights from a multi-state intervention in India Aakshi Kalra (Delhi, India)	10:10 - 10:19
OA04-130-13	Accelerating TB case finding among children: A novel intervention involving hub and spoke model in Punjab, India Abhinav Trikha (Chandigarh, India)	10:19 - 10:28
OA04-131-13	Evaluating the missing TB cases in children: A programmatic review of the implementation of a treatment decision-making algorithm Lilungwe Mutti (Lusaka, Zambia)	10:28 - 10:37
	Q&A	10:37 - 10:50

Symposium

09:20 - 10:50

JKB

SP02 - The journey is as important as the destination: Country perspectives on implementation of next-generation sequencing for drug-resistant TB

Andrea Cabibbe (Milano, Italy)

Patricia Hall-Eidson (Atlanta, United States)

SP02-407-13	Introduction	09:20 - 09:25
SP02-408-13	Application of NGS strengthens continuous and district-based surveillance of drug-resistant TB in South Africa Shaheed Vally Omar (Johannesburg, South Africa)	09:25 - 09:39
SP02-409-13	Establishment of WGS-based surveillance of drug-resistant TB within the National Laboratory Network of India Siva Kumar Shanmugam (Chennai, India)	09:39 - 09:53
SP02-410-13	First implementation of sequencing-based surveillance for drug-resistant TB in Nigeria	09:53 - 10:07
SP02-411-13	Incorporation of sequencing into Eswatini's diagnostic algorithm to enhance drug-resistant TB treatment success: An evidence-informed approach Gugu Maphalala (Mbabane, Eswatini)	10:07 - 10:21
SP02-412-13	WHO guidelines and resources supporting implementation of next-generation sequencing for drug-resistant TB Carl-Michael Nathanson (Geneva, Switzerland)	10:21 - 10:35
SP02-413-13	Q&A	10:35 - 10:50

Short Oral Abstract Session

09:20 - 10:50

MD

SOA01 - Active case finding: Experiences from different countries

Kevin Schwartzman (Montreal, Canada)

Manu Easow Mathew (New Delhi, India)

	Introduction	09:20 - 09:25
SOA01-600-13	Analysing the impact of active TB screening on health systems enhancement: Insights from KNCV Nigeria's experience Patience Opara (Lafia, Nigeria)	09:25 - 09:33
SOA01-601-13	TB Club as a tool for improving TB detection in Niger State, North Central Nigeria Isah Ibrahim (Minna, Nigeria)	09:33 - 09:41
SOA01-602-13	Enhancing TB detection in correctional settings: A comprehensive screening approach Folashade Idowu (Abuja, Nigeria)	09:41 - 09:49
SOA01-603-13	Improving childhood TB diagnosis through community-based approach: Engaging Traditional Child Clinic in Nigeria Chidimma Okoye (Abakaliki, Nigeria)	09:49 - 09:57
SOA01-604-13	Strengthening active case finding in Indonesia: Investigating non-compliance among referred contact persons Diah Ayu Puspandari (Sleman, Indonesia)	09:57 - 10:05
SOA01-605-13	Are neighbourhoods of TB cases a high-risk population for active intervention? Sue McAllister (Dunedin, New Zealand)	10:05 - 10:13
SOA01-606-13	Development of TB active case-finding approach for general hospital settings to improve detection of TB Dinagul Otorbaeva (Bishkek, Kyrgyzstan)	10:13 - 10:21
SOA01-608-13	Reaching the unreached: Active TB case finding in police stations in Nairobi City County, Kenya Simon Gundi (Nairobi, Kenya)	10:21 - 10:29
SOA01-609-13	Strategising case-finding approaches to reach targets with limited resources: Community volunteer engagement in Eswatini Joyce Sibanda (Manzini, Eswatini)	10:29 - 10:37
	Q&A	10:37 - 10:50
<i>Symposium</i>		
09:20 - 10:50		NS1
SP03 - Validation of treatment decision algorithms for the diagnosis of pulmonary TB in children: Early research experience		
Chishala Chabala (Lusaka, Zambia) Corinne Merle (Geneva, Switzerland)		
SP03-414-13	Introduction	09:20 - 09:25
SP03-415-13	External validation of integrated treatment decision algorithms: Global needs and processes Sabine Verkuijl (Geneva, Switzerland)	09:25 - 09:39
SP03-416-13	Evaluation of treatment decision algorithms in children with presumptive TB: The experience of Nigeria Ochuko Urhioke (Abuja, Nigeria)	09:39 - 09:53
SP03-417-13	Evaluating the performance, feasibility, acceptability and impact of treatment-decision algorithms for pulmonary TB in children in Burkina Faso Adama Diallo (Ouagadougou, Burkina Faso)	09:53 - 10:07
SP03-418-13	How accurate are new diagnostic TB algorithms in children? Interim results from a Médecins Sans Frontières study in 5 countries	10:07 - 10:21

	Helena Huerga (Brussels, Belgium)	
SP03-419-13	TDA validation using data from established cohorts: The Decide-TB experience Marieke van der Zalm (Cape Town, South Africa)	10:21 - 10:35
SP03-420-13	Q&A	10:35 - 10:50
<i>Symposium</i>		
09:20 - 10:50		NS2
SP04 - Breaking the silence: Unveiling the hidden impact of TB-associated disability		
Anthony D Harries (United Kingdom) Denise Evans (Johannesburg, South Africa)		
SP04-421-13	Introduction	09:20 - 09:25
SP04-422-13	Break the silence: Voices from TB survivors Anh Phuong Nguyen (Hanoi, Vietnam)	09:25 - 09:39
SP04-423-13	Addressing TB-associated disability: WHO guidance Farai Mavhunga (Switzerland)	09:39 - 09:53
SP04-424-13	Evidence and ongoing research on biomedical interventions for TB-associated disability Brian Allwood (Cape Town, South Africa)	09:53 - 10:07
SP04-425-13	The impact of social protection on TB-associated disability: A systematic review of the evidence Marzia Calvi (Geneva, Switzerland)	10:07 - 10:21
SP04-426-13	Voices from country experiences Lieve Vanleeuw (Tampere, Finland)	10:21 - 10:35
SP04-427-13	Q&A	10:35 - 10:50
<i>Late Breaker Oral Abstract Session</i>		
09:20 - 10:50		NS3
LB01 - The Union-WHO HIV and other comorbidities late-breaker session		
Palwasha Yousafzai Khan (London, United Kingdom) Elena Vovc (Switzerland)		
	Introduction	09:20 - 09:25
LB01-1200-13	Does TB alter cardiometabolic profiles of TB survivors? A cross-sectional study among people living with HIV in Uganda Joseph Baluku (Kampala, Uganda)	09:25 - 09:36
LB01-1201-13	Multimorbidity and health-related quality of life after TB treatment in Zimbabwe: A pilot feasibility assessment and comparison to household controls Claire Calderwood (London, United Kingdom)	09:36 - 09:47
LB01-1202-13	Impact of HIV on recurrent TB after successful first-line TB treatment in the Western Cape Province, South Africa Nesbert Zinyakatira (Cape Town, South Africa)	09:47 - 09:58
LB01-1203-13	Time to hepatotoxicity among people in prison in Malaysia receiving 26H vs. 3HP Sheela Sheno (New Haven, United States)	09:58 - 10:09
LB01-1204-13	Feasibility and acceptability of a TB survivor-led peer support intervention using motivational interviewing to address TB/HIV intersectional stigma in South Africa Ruvandhi Nathavitharana (United States)	10:09 - 10:20

LB01-1205-13	Alveolar macrophages from persons with HIV undergoing antiretroviral therapy mount impaired TNF signaling networks and ineffective immune responses against <i>M. tuberculosis</i> infection Jyothi Rengarajan (Atlanta, United States)	10:20 - 10:31
	Q&A	10:31 - 10:50
<i>Union Live Session</i>		
09:30 - 10:00		UL
UL02 - Interviews with Nicola James and Dr Jane Carter		
<i>TBScience Session</i>		
10:00 - 11:00		AU
TBS1C - Pathogen heterogeneity and implications for intervention		
Timothy Walker (Oxford, United Kingdom)		
TBS1C-05	Session introduction	10:00 - 10:03
TBS1C-10	Effect of compensatory evolution in the emergence and transmission of rifampicin-resistant <i>M. tuberculosis</i> in Cape Town, South Africa: A genomic epidemiology study Helen Cox (Cape Town, South Africa)	10:03 - 10:18
TBS1C-15	Indian catalogue of drug resistance Uma Devi Ramalingam (Chennai, India)	10:18 - 10:33
TBS1C-20	Bacterial determinants of TB meningitis Nhat Le (Vietnam)	10:33 - 10:48
TBS1C-25	Q&A	10:48 - 11:00
<i>Union Live Session</i>		
10:00 - 10:30		UL
UL03 - Interview with Dr Mukuhwa Tanaka, Board Member, Stop TB Partnership and messages from our event sponsors		
<i>Union Live Session</i>		
10:30 - 11:00		UL
UL04 - Interviews with Lara Garrido, Katharina Kranzer and Prof Rovina Ruslami		
<i>Union Live Session</i>		
11:00 - 11:10		UL
UL05 - Interviews with Dr Cassandra Kelly-Cirino and Ana Maria Cardenas		
<i>Plenary Session</i>		
11:10 - 12:10		MG
PL-01 - Access to medicines and diagnostics		
Guy Marks (Sydney, Australia)		
	Session introduction	11:10 - 11:12
	Why is access and equity important? Soumya Swaminathan (India)	11:12 - 11:30
	Access to lifesaving medicines for lung health Christophe Perrin (France)	11:30 - 11:45
	What access means for those affected by TB and lung health conditions	11:45 - 11:58

	Zahedul Islam (Ukraine)	
	Experience from a TB survivor	11:58 - 12:03
	Rezil Novaldican (Indonesia)	
	Panel discussion	12:03 - 12:10
<i>Plenary Session</i>		
	11:10 - 12:10	EG2
	PL001 - Access to medicines and diagnostics (Broadcasted)	
<i>Union Live Session</i>		
	11:10 - 12:10	UL
	ULPL01 - Access to medicines and diagnostics	
<i>Union Live Session</i>		
	12:10 - 13:00	UL
	UL06 - Messages from our event sponsors	
<i>E-Posters</i>		
	12:15 - 13:15	M EP1
	EP01 - Era of molecular diagnosis	
	Madolyn Dauphinais (Boston, United States)	
EP01-600-13	Real-world accuracy and impact of Xpert® MTB/XDR in people with confirmed rifampicin-resistant TB in Georgia	12:15 - 12:22
	Theresa Pfurtscheller (Heidelberg, Germany)	
EP01-601-13	Contribution of molecular XDR-TB testing to drug-resistant TB notification in Lilongwe and Chikwawa districts, Malawi	12:22 - 12:29
	Chifundo A. Chipungu (Lilongwe, Malawi)	
EP01-602-13	Drug resistance profiles of rifampicin-resistant TB in Vietnam	12:29 - 12:36
	Han Thi Nguyen (Ha Noi, Vietnam)	
EP01-603-13	Quantitative signature of small non-coding RNAs (sncRNAs) as a biomarker for pulmonary TB diagnosis	12:36 - 12:43
	Sheetal Kaul (New Delhi, India)	
EP01-604-13	Epidemic and endemic M. tuberculosis strains: How pathobiology is shaping their spread	12:43 - 12:50
	Igor Mokrousov (St. Petersburg, Russian Federation)	
EP01-605-13	Initiating the profiling of common mutations in M. tuberculosis genome associated with bedaquiline resistance in Kyrgyzstan: Preliminary data	12:50 - 12:57
	Gulmira Kalmambetova (Bishkek, Kyrgyzstan)	
	Q&A	12:57 - 13:15
<i>E-Posters</i>		
	12:15 - 13:15	M EP2
	EP02 - Strategies to improve TB surveillance systems	
	Mohammed F. Dogo (Lomé, Togo)	
EP02-607-13	Improving utilisation of the TB electronic case-based surveillance in Uganda using simple metrics: Achievements and future direction	12:15 - 12:20
	Mabel Nakawooya (Kampala, Uganda)	
EP02-608-13	National roll-out of an electronic reporting system for TB in Papua New Guinea	12:20 - 12:25

	Herolyn Nindal (Port Moresby, Papua New Guinea)	
EP02-609-13	Use of patient-level line list surveillance dashboard and DHIS 2 system by project enrollment task force on improving patient enrollment: USAID TB-LON 3 Project experience Micheal Pedro (Lagos, Nigeria)	12:25 - 12:30
EP02-610-13	Enhanced data quality assessment efficiency through integrated digitised TBDQR application into the DHIS2-ETL system Galus Sililo (Dodoma, Tanzania)	12:30 - 12:35
EP02-611-13	Utilisation of web-based tools for integrated program performance monitoring Judith Mzyece (Lusaka, Zambia)	12:35 - 12:40
EP02-612-13	Leveraging the use of Applications Programming Interface (API) in TB diagnostics and reporting Johnstone Kithara (Nairobi, Kenya)	12:40 - 12:45
EP02-613-13	The role of enhanced monitoring and supervision in effective public-private mix (PPM) implementation Adeel Tahir (Islamabad, Pakistan)	12:45 - 12:50
EP02-614-13	Improving scale up the national electronic case-based surveillance in Uganda using simple metrics: Achievements and future direction Vincent Kamara (Kampala, Uganda)	12:50 - 12:55
EP02-615-13	TB vulnerability assessment demonstration initiative through application of digital innovation, Timor-Leste Debashish Kundu (Dili, East Timor)	12:55 - 13:00
EP02-616-13	The talking TB performance monitoring wall chart: Madiany sub-county hospital experience Dennis Oira (Nairobi, Kenya)	13:00 - 13:05
EP02-617-13	Data collection on the benchmarks from the WHO standard on universal access to rapid TB diagnostics: The experience from Nigeria Omoniyi Amos Fadare (Abuja, Nigeria)	13:05 - 13:10
	Q&A	13:10 - 13:15
<i>E-Posters</i>		
12:15 - 13:15		M EP3
EP03 - TB diagnostic markers		
Nicole de Souza (Brasília, Brazil)		
EP03-618-13	Unexpected positivity rate with VIDAS® TB-IGRA and validation of the corrective solution Keertan Dheda (Cape Town, South Africa)	12:15 - 12:20
EP03-619-13	Polystyrene nanoparticles impact the course of infection of Staphylococcus aureus on a 2D minilung model José Domínguez-Benítez (Badalona, Spain)	12:20 - 12:25
EP03-620-13	Cytokine responses in a Phase IIB trial of adjunctive rosuvastatin for rifampicin-susceptible TB treatment Gail Cross (Sydney, Australia)	12:25 - 12:30
EP03-621-13	Host-directed therapies for Tuberculosis; what does data from clinical trials and meta-analyses tell us? Gail Cross (Sydney, Australia)	12:30 - 12:35
EP03-622-13	Impact of isoniazid preventive therapy on M. tuberculosis-specific T-cell responses in comorbid TB and Type 2 diabetes mellitus	12:35 - 12:40

	Phillip Ssekamatte (Kampala, Uganda)	
EP03-623-13	A composite peptide vaccine targeting <i>M. tuberculosis</i> and gram-positive and gram-negative bacteria may provide useful strategies to combat TB and sepsis, and mitigate antimicrobial resistance Clara J. Sei (Gaithersburg, United States)	12:40 - 12:45
EP03-624-13	Evaluation of novel host serum biomarker-based tools as diagnostic candidates for active TB and monitoring of the response to TB treatment Lesego Rantho (Cape Town, South Africa)	12:45 - 12:50
EP03-625-13	Sensitivity and specificity of LF-LAM among outpatients with advanced HIV disease: Preliminary results of a multi-center study Lise Denoeud-Ndam (Geneva, Switzerland)	12:50 - 12:55
EP03-626-13	MPT70: A new virulence factor of the <i>M. tuberculosis</i> complex Saniya Kapoor (Montreal, Canada)	12:55 - 13:00
	Q&A	13:00 - 13:10
<i>E-Posters</i>		
12:15 - 13:15		M EP4
EP04 - Innovations in TB diagnosis		
Dakshina Bisht (Ghaziabad, India)		
EP04-627-13	Evaluation of self-collected dry oral swab sample for the early diagnosis of <i>M. tuberculosis</i> in Karu Timan Eliya (Karu, Nigeria)	12:15 - 12:20
EP04-628-13	Multi-gene plasma cell-free <i>M. tuberculosis</i> assay: An innovative approach for enhanced TB detection Sosina Ayalew (Addis Ababa, Ethiopia)	12:20 - 12:25
EP04-629-13	Genomic analysis of drug resistance in <i>M. tuberculosis</i> isolates from Almaty, Kazakhstan Nurlan Takenov (Almaty, Kazakhstan)	12:25 - 12:30
EP04-630-13	Surveillance of multidrug-resistant TB in Taiwan Wan-Hsuan Lin (Taipei, Taiwan)	12:30 - 12:35
EP04-631-13	Prediction of individual unfavorable TB treatment outcomes in Brazil and India using machine learning Claire Vania (Baltimore, United States)	12:35 - 12:40
EP04-632-13	High accuracy RIF and INH resistance detection of <i>M. tuberculosis</i> based on open-system real-time PCR in Indonesia Dilafitria Fauza (Jakarta, Indonesia)	12:40 - 12:45
EP04-633-13	Utilisation and performance of GeneXpert MTB/RIF Ultra Assay for TB diagnosis and rifampicin resistance detection in people with presumptive TB in Mombasa, Kenya (2024) Thani Suleiman (Mombasa, Kenya)	12:45 - 12:50
EP04-634-13	Feasibility of stool-based testing for TB and contribution to childhood TB notification: Case study from Karonga district, Malawi Samson Chitsulo (Lilongwe, Malawi)	12:50 - 12:55
EP04-635-13	Analysing the TB positivity rate from stool sample referral in children: A data analysis of 2023 trends in Imo State, Nigeria Chukwuemekaa Nwekwo (Owerri, Nigeria)	12:55 - 13:00
EP04-636-13	Identification of recent <i>M. tuberculosis</i> exposure using plasma proteome profiling: A pilot study	13:00 - 13:05

	Yutong Han (Shanghai, China)	
	Q&A	13:05 - 13:15
<i>E-Posters</i>		
12:15 - 13:15		M EP5
EP05 - Progressing towards TB elimination		
K. Pewezo Khalo (Dimapur, India)		
EP05-637-13	Enhanced TB notifications and positivity rates with AI-based screening in remote Mon District of Nagaland, India: A post-deployment study Justy Antony Chiramal (Atlanta, United States)	12:15 - 12:20
EP05-638-13	Machine learning models for pleural TB diagnosis Eric Walter Pefura-Yone (Yaoundé, Cameroon)	12:20 - 12:25
EP05-639-13	Analysis of the health system delay among people with pulmonary TB in Namibia: A cross-sectional preliminary study Victor Haimbala (Windhoek, Namibia)	12:25 - 12:30
EP05-640-13	Use of the Lung Flute ECO to assist in sputum collection for TB detection among people attending health facilities: A randomised crossover trial Cyrille Mbuli (Bamenda, Cameroon)	12:30 - 12:35
EP05-642-13	Performance of a stool quantitative polymerase chain reaction assay for pediatric TB detection Anca Vasiliu (Houston, United States)	12:35 - 12:40
EP05-643-13	Bridging clinical TB diagnosis gaps with XMAP platform and portable digital X-ray machines: The KNCV Nigeria perspective Kenneth Ekpen (Abuja, Nigeria)	12:40 - 12:45
EP05-644-13	Low Xpert Ultra specificity for rifampicin resistance in a nationwide diagnostic confirmation study benefits from isoniazid resistance testing Isabel Cuella-Martin (Antwerp, Belgium)	12:45 - 12:50
EP05-645-13	Two-tier ensemble transfer learning method for pulmonary TB detection based on chest radiograph Seng Hansun (Sydney, Australia)	12:50 - 12:55
EP05-646-13	AI-supported screening for pulmonary TB using cough sounds and symptoms: Initial findings from India under National TB Elimination Program Prasaanth Balraj (New Delhi, India)	12:55 - 13:00
	Q&A	13:00 - 13:15
<i>E-Posters</i>		
12:15 - 13:15		M EP6
EP06 - Active case finding: Experiences from across the world		
Betty Nababan (Jakarta, Indonesia)		
EP06-647-13	Evaluating the yield and impact of an active case finding intervention for TB in ethnic minority and remote communities in Vietnam Thuc Doan Ngo (Ha Noi, Vietnam)	12:15 - 12:20
EP06-648-13	Augmenting TB contact investigation in the Kulob region of Tajikistan with engagement of civil society Huriya Hisomova (Dushanbe, Tajikistan)	12:20 - 12:25

EP06-649-13	Cough syrup surveillance: An innovative intensified TB case finding intervention in Himachal Pradesh, India Aatmika Gopimohan Nair (Delhi, India)	12:25 - 12:30
EP06-650-13	Contribution of community health workers in strengthening community system to recover the significant gap through enhancing case finding with the support of C19RM funding Nawrin Kabir (Dhaka, Bangladesh)	12:30 - 12:35
EP06-651-13	Reaching the unreached through social media CareConnect Chatbot: Experiences from Myanmar Nandi U (Yangon, Myanmar)	12:35 - 12:40
EP06-652-13	Who are the missing people with TB in Cambodia? Monyrath Chry (Phnom Penh, Cambodia)	12:40 - 12:45
EP06-653-13	Impact of an innovative community-based active case finding intervention on TB screening and diagnosis: A practical experience for Malawi Madalitso Mmanga (Lilongwe, Malawi)	12:45 - 12:50
EP06-654-13	Community health workers are instrumental in access to quality TB care and services: Active case finding in community TB hotspots in Amref Tanzania Godwin Munuo (Dar Es Salaam, Tanzania)	12:50 - 12:55
EP06-655-13	Exploring existing potential to improve TB case finding amongst Nomadic populations in security-challenged areas of Bauchi State Gideon Zephaniah (Kano, Nigeria)	12:55 - 13:00
EP06-656-13	Improving TB case finding in primary health care setting: Experience from the TB Surge initiative in Nigeria Chidubem Ogbudebe (Abuja, Nigeria)	13:00 - 13:05
	Q&A	13:05 - 13:15
<i>TBScience E-Poster Session</i>		
12:15 - 14:15		M EP7
TBS-EP01 - Implications of pathogen heterogeneity for intervention Part 1		
Helen Cox (Cape Town, South Africa)		
TBS-EP-05	Identification of chemical scaffolds that inhibit the M. tuberculosis respiratory complex succinate dehydrogenase Cara Adolph (Dunedin, New Zealand)	12:15 - 12:20
TBS-EP-07	Diagnostic performance of 6-mRNA loop mediated isothermal amplification assay for rapid diagnosis of childhood TB disease Giselle R. D'Souza (London, United Kingdom)	12:20 - 12:25
TBS-EP-08	Evaluation of novel compact rapid PCR system for the detection of M. tuberculosis Akiko Takaki (Tokyo, Japan)	12:25 - 12:30
TBS-EP-10	Uncovering mycobacterial genotypic diversity using culture-omics and differentially culturable states Bhavnaben Gordhan (Johannesburg, South Africa)	12:30 - 12:35
TBS-EP-11	Evaluating genetic resistance to fluoroquinolones and bedaquiline in model mycobacteria using CRISPR knockdown and complementation Camus Nimmo (London, United Kingdom)	12:35 - 12:40
TBS-EP-12	Diagnostic accuracy of a revised consensus protocol for tongue swab Xpert Ultra in 4 high-burden settings Bukola Ajide (Karu, Nigeria)	12:40 - 12:45

TBS-EP-13	Estimating the global burden of viable <i>M. tuberculosis</i> infection Alvaro Schwalb (London, United Kingdom)	12:45 - 12:50
TBS-EP-14	Differential culturability of <i>M. tuberculosis</i> uncovers transmission links within households which are missed by standard diagnostic tests Astika Sewcharran (Johannesburg, South Africa)	12:50 - 12:55
TBS-EP-15	Detection of emerging drug resistance to new anti-TB drugs using TM4::GeNL reporter mycobacteriophage Senamile L. Ngema (Durban, South Africa)	12:55 - 13:00
TBS-EP-17	Identifying key transmission nodes in TB community surveillance through genetic and network analysis Reiko Miyahara (Tokyo, Japan)	13:00 - 13:05
TBS-EP-18	Differences in the infectiousness of pulmonary TB by HIV status and sex in the ART era: A potential bio-social interaction? Palwasha Yousafzai Khan (London, United Kingdom)	13:05 - 13:10
TBS-EP-19	Cepheid Xpert TB/LTBI shows promising accuracy as a triage test for TB Hoang Nguyen (Hanoi, Vietnam)	13:10 - 13:15
TBS-EP-20	Genomic evidence for transmission of subclinical TB identified through active case finding Kesia Esther da Silva (Stanford, United States)	13:15 - 13:20
TBS-EP-21	Spatio-temporal tolerance analysis of bio-resilience caused by hetero-population of <i>M. tuberculosis</i> Shiomi Yoshida (Sakai, Japan)	13:20 - 13:25
TBS-EP-22	Genomic characteristics of prospectively sequenced <i>M. tuberculosis</i> from respiratory and non-respiratory sources in a low-incidence setting Xiaomei Zhang (Sydney, Australia)	13:25 - 13:30
TBS-EP-23	Differentially expressed coding and non-coding RNAs reveal the mechanisms of transcriptome regulation and RNA signatures in clinical strains of <i>M. tuberculosis</i> Nontobeko Mvubu (Durban, South Africa)	13:30 - 13:35
TBS-EP-24	Identifying resistance modifying mutations using a set of 44,710 uniformly processed <i>M. tuberculosis</i> genomes Lachlan Coin (Melbourne, Australia)	13:35 - 13:40
TBS-EP-25	Detection of genomic markers of drug resistance in <i>M. tuberculosis</i> populations utilising both culture-based whole genome sequencing and culture-independent targeted next-generation sequencing Xiaomei Zhang (Sydney, Australia)	13:40 - 13:45
TBS-EP-26	A multicenter study to improve procedures to target the EUCAST inoculum range for <i>M. tuberculosis</i> Diana Angelica Aguilar Ayala (Spain)	13:45 - 13:50
TBS-EP-27	Micro-variant detection in <i>M. tuberculosis</i> whole genome sequencing data: Pipeline benchmarking and investigation of bedaquiline-associated micro-variants and resistance Shandukani Mulaudzi (Boston, United States)	13:50 - 13:55
TBS-EP01	Q&A	13:55 - 14:10

Community Connect

12:30 - 13:30

AU

CCF001 - Films and documentaries

Urip Iku Urup by USAID Mentari TB	12:30 - 12:40
Resilience by Humana People to People India	12:40 - 12:50
Ending TB In Ghana: The Role of TB Champions by TB Voice Network	12:50 - 13:06
Unbreakable against TB by Alliance for Public Health	13:06 - 13:30

Satellite Session

12:30 - 14:00

HB

SS03 - Finding the missing millions with TB: Mobilising youth to improve health care seeking behaviour'

Ari Probandari (Surakarta, Indonesia)

Ingrid Eshun-Wilsonova (South Africa)

Welcome and introduction	12:30 - 12:40
Mobilizing Youth for TB Health care seeking in India Deepak Balasubramanian (India)	12:40 - 12:52
Barriers and facilitators to youth TB health care seeking. Siva Anggita (Indonesia)	12:52 - 13:04
Key lessons learnt from TB youth activation programs Henry Diatmo (Indonesia)	13:04 - 13:16
Panel discussion: Addressing the TB health equity challenge for Urban poor youth	13:16 - 13:56
Conclusions	13:56 - 14:00

Side Meeting

12:30 - 13:30

FR

SM05 - TB in Prisons WG*Side Meeting*

12:30 - 13:30

BG

SM06 - Maternal and Child TB WG*Side Meeting*

12:30 - 13:30

OC

SM07 - WG TB and ethics*Union Live Session*

13:00 - 13:30

UL

UL07 - Interviews with Niesje Jansen and Maruschka Sebek*Paper Posters*

13:20 - 14:20

M PPA

PP01 - Multipronged approach for TB prevention and care

Ajoy Kumar Verma (New Delhi, India)

PP01-800-13

Efficacy of TB symptom screening and added yield of chest X-ray and universal Xpert MTB/RIF in Uganda prisons George Tumusinze (Kampala, Uganda)	13:20 - 13:25
--	---------------

PP01-801-13	Routine evaluation of stool-based testing to diagnose TB using the Truenat platform in comparison to Xpert (Ultra) on stool in Nigeria: Results and lessons learned Jamiu Olabamiji (Lagos, Nigeria)	13:25 - 13:30
PP01-802-13	Prevalence and features of TB among people with sputum trace Xpert Ultra results in two African healthcare settings Emily A. Kendall (Baltimore, United States)	13:30 - 13:35
PP01-803-13	Proportion of Xpert MTB/RIF Ultra “trace” result varies widely between different populations with presumptive TB: A systematic review Kudakwashe Chani (Canberra, Australia)	13:35 - 13:40
PP01-804-13	Impact of refresher training on stool GeneXpert technique and boost on childhood TB detection in Osun State, Nigeria: Implementation results and lesson learned Jamiu Olabamiji (Lagos, Nigeria)	13:40 - 13:45
PP01-805-13	15,000 samples in less than seven days: Laboratory experiences and strategies during a National TB campaign in Kampala Metropolitan, Uganda Mona Muhammad (Kampala, Uganda)	13:45 - 13:50
PP01-806-13	Seeking to combat TB in Ethiopia: A successful optimisation plan led to increased utilisation of GeneXpert testing and higher case notification rates Endale Mengesha (Addis Ababa, Ethiopia)	13:50 - 13:55
PP01-807-13	Scaling up the stool sample-based testing to diagnose childhood TB: Bangladesh experience Umme Tasnim Maliha (Dhaka, Bangladesh)	13:55 - 14:00
PP11-903-14	Tube-ovarian masses and menstrual dysfunction in adolescent girls with pulmonary TB Sangeeta Sharma (New Delhi, India)	14:00 - 14:05
	Q&A	14:05 - 14:20
<i>Paper Posters</i>		
13:20 - 14:20		M PPB
PP10 - Align cases demand under cost perspective		
Sonia Menon (Brussels, Belgium)		
PP10-884-13	Socioeconomic status of households containing children exposed to multi-drug-resistant TB in South Africa Thomas Wilkinson (Cape Town, South Africa)	13:20 - 13:25
PP10-885-13	Namibia’s catastrophic costs: A situational analysis and recommendations Tjatja Kavari (Windhoek, Namibia)	13:25 - 13:30
PP10-886-13	The burden of pre-diagnosis costs: Association between catastrophic health expenditure and diagnostic delay for TB in Cambodia Sothearith Eng (Tsukuba, Japan)	13:30 - 13:35
PP10-887-13	A study to reduce financial burden of TB by social PROTECTION in Timor-Leste (TB-PROTECT): A cluster randomised trial Hongjo Choi (Seoul, Korea, Republic of)	13:35 - 13:40
PP10-888-13	Estimation of the burden of catastrophic cost among TB-affected families of West Bengal, India: A secondary analysis of the sub-national certification survey data Abhijit Dey (New Delhi, India)	13:40 - 13:45

PP10-889-13	Assessment of Body Mass Index and nutritional supplementation are important for preventing incidence amongst contacts of people with TB, especially in high underweight prevalence areas Pranati Das (Patna, India)	13:45 - 13:50
PP10-890-13	Determinants of TB treatment completion in an inpatient setting among people with TB in Texas Quratulain Kizilbash (San Antonio, United States)	13:50 - 13:55
PP10-891-13	Impact of integration of TB active case finding, bidirectional TB/COVID-19 surveillance, and COVID-19 vaccination in Benue State, North Central Nigeria Israel Popoola (Ibadan, Nigeria)	13:55 - 14:00
PP10-892-13	Challenges and opportunities in integrated TB and diabetes screening: Insights from Indonesia Hardini Utami (Jakarta, Indonesia)	14:00 - 14:05
PP10-893-13	Evolution of direct benefit transfer under National TB Elimination Programme: Innovations enhancing efficiency and programme impact Ca Rahul Sharma (New Delhi, India)	14:05 - 14:10
	Q&A	14:10 - 14:15
<i>Paper Posters</i>		
13:20 - 14:20		M PPC
PP03 - Lab and sample transport		
Regina Loprang (Jakarta city (DKI), Indonesia)		
PP03-819-13	Expanding the laboratory hub systems for enhanced drug-resistant TB surveillance in Karamoja region Simon Ojore (Kampala, Uganda)	13:20 - 13:25
PP03-820-13	Enhancing TB diagnosis accessibility utilising community volunteers in Rajasthan, India Priyanka Sharma (Jaipur, India)	13:25 - 13:30
PP03-821-13	Promoting universal health coverage through integrated specimen referral systems in arid and semi-arid regions of Kenya James Marcomic (Nairobi, Kenya)	13:30 - 13:35
PP03-822-13	Improved specimen referral system and increased access to quality TB laboratory services in Zambia: The role of integrated system Judith Mzyece (Lusaka, Zambia)	13:35 - 13:40
PP03-823-13	External quality assurance for molecular WHO-recommended diagnostics (mWRDs): Its significance for clinical interpretation of results Michael Umoren (Uyo, Nigeria)	13:40 - 13:45
PP03-824-13	Improving sputum collection and transportation in Madhya Pradesh, India by linking peripheral health centres with TB diagnostic centres through private-sector engagement Varsha Rai (Bhopal, India)	13:45 - 13:50
PP03-825-13	Enhancing TB diagnosis: Implementing laboratory quality management systems in Kenya - A case study of five laboratories accredited John Gituma (Nairobi, Kenya)	13:50 - 13:55
PP03-826-13	A regional approach to strengthening TB laboratory systems Miriam Urasa (Arusha, Tanzania)	13:55 - 14:00
PP03-827-13	Using digital tools for streamlining TB specimen transport tracking	14:00 - 14:05

	and timely result communication in Tamil Nadu, India Pirabu Ramanan (New Delhi, India)	
PP03-828-13	Optimised specimen referral system plus: Leveraging local capacities for sustainable solutions in health systems strengthening in Cebu City, the Philippines Leveriza Coprada (Makati City, Philippines)	14:05 - 14:10
	Q&A	14:10 - 14:20
<i>Paper Posters</i>		
13:20 - 14:20		M PPD
PP04 - Community-led monitoring programming		
James Malar (Geneva, Switzerland)		
PP04-829-13	OneImpact Community-led Monitoring: Using actionable data to break down barriers and provide better services for people with TB Helen Hallström (Matola, Mozambique)	13:20 - 13:25
PP04-830-13	TB MukT Vahini: Impact of TB survivors-led network in India Sudeshwar Kumar Singh (Patna, India)	13:25 - 13:30
PP04-831-13	Improving TB treatment outcomes through food enablers and livelihood to reduce catastrophic costs Alex Oddama (Kampala, Uganda)	13:30 - 13:35
PP04-832-13	Improving community outreach through contextually-relevant art-based health promotion in rural Sindh, Pakistan Shiza Kamil (Karachi, Pakistan)	13:35 - 13:40
PP04-833-13	Why condition cash transfers? A multi-method pilot study evaluating the conditioning of cash transfers for TB treatment Rachel Forse (Ha Noi, Vietnam)	13:40 - 13:45
PP04-834-13	Evaluating the role of lawyers in stigma and human rights violations in TB prevention and care programme: The Lagos experience, Nigeria Rommy Mom (Abuja, Nigeria)	13:45 - 13:50
PP04-835-13	Navigating towards a TB-free India: An interim assessment of Pradhan Mantri TB MukT Bharat Abhiyaa - Unveiling barriers and enablers Harsh Shah (Gandhinagar, India)	13:50 - 13:55
PP04-836-13	School-based contact tracing: Addressing TB in a community Masingita Lambane (Johannesburg, South Africa)	13:55 - 14:00
PP04-837-13	Measuring the knowledge attitude and practice of TB preventive treatment uptake among the high-risk groups in Indonesia: Cross-sectional study Dwi Rahmadini (Dki Jakarta, Indonesia)	14:00 - 14:05
PP04-838-13	Mapping private sale of TB medicines as an avenue to closing the notification gap: A case study involving private pharmacies in Punjab province, Pakistan Beatrice Wangari Kirubi (Geneva, Sweden)	14:05 - 14:10
	Q&A	14:10 - 14:20
<i>Paper Posters</i>		
13:20 - 14:20		M PPE
PP05 - Dynamic to penetrate TB barriers		
Wim Vanderveelde (Cape Town, South Africa)		

PP05-839-13	Establishing the KwaZulu Natal Province TB Caucus: A collaborative endeavor between an NGO and the KZN Provincial Council on AIDS Masingita Lambane (Johannesburg, South Africa)	13:20 - 13:26
PP05-840-13	Assessing the impact of community-driven nutritional support campaign on treatment outcome of persons with TB in Haryana, India Shiv Hireen Joshi (New Delhi, India)	13:26 - 13:32
PP05-841-13	Driving change: Community engagement for improved TB testing - Nagpur rural district's advocacy, communication, and social mobilisation efforts Swarna Ramteke (New Delhi, India)	13:32 - 13:38
PP05-842-13	Improving advocacy and political participation for TB in Eswatini Talkmore Taurai Mazorodze (Mankayane, Eswatini)	13:38 - 13:44
PP05-843-13	Extending quality TB service delivery to underserved populations: Lessons from engaging civil society organisations in central Uganda Ignatius Senteza (Kampala, Uganda)	13:44 - 13:50
PP05-844-13	Catalysing self-help groups (SHG) and Mahila Mandals (women groups) to support a community-level fight against TB in Himachal Pradesh, India Sunil Savita (Shimla, India)	13:50 - 13:56
PP05-845-13	Leveraging the potential of multi-sectoral collaboration towards ending TB in Himachal Pradesh, India Sunil Savita (Shimla, India)	13:56 - 14:02
PP05-846-13	Strengthening leadership and governance: A pathway to quality and sustainable health interventions in TB - A case study of Kiambu County in Kenya (2022-2024) Damiana Kimuyu (Nairobi, Kenya)	14:02 - 14:08
	Q&A	14:08 - 14:20
<i>Paper Posters</i> 13:20 - 14:20		M PPF
PP06 - Surviving TB and its aftermath		
Reinout van Crevel (Nijmegen, Netherlands)		
PP06-848-13	Persistence of respiratory impairment six months after completion of TB treatment in Gambian children and adolescents Esin Nkereuwem (Fajara, Gambia)	13:20 - 13:25
PP06-849-13	Paediatric post-TB lung disease in Kenya: Longitudinal insights and health implications Joy Githua (Nairobi, Kenya)	13:25 - 13:30
PP06-850-13	Baseline C-reactive protein is associated with neurological disability in TB meningitis Sarah Kimuda (Kampala, Uganda)	13:30 - 13:35
PP06-851-13	Persistent respiratory symptoms and residual lung disability in people post-TB: A pilot study in Bandung, West Java, Indonesia Intan Mauli Dewi (Bandung, Indonesia)	13:35 - 13:40
PP06-852-13	Microbial cross-talk of the gut-lung axis in people with pulmonary TB in South Korea Hyejin Kim (Cheongju, Korea, Republic of)	13:40 - 13:45
PP06-853-13	Beyond the illness: A qualitative exploration of the burden of caring	13:45 - 13:50

	for people with TB on caregivers and their households in South Africa	
	Lieve Vanleeuw (Tampere, Finland)	
PP06-854-13	TB incidence in people living with HIV attending routine settings post-TB preventive treatment initiation in Ethiopia, South Africa, and Zimbabwe	13:50 - 13:55
	Lucy Chimoyi (Johannesburg, South Africa)	
PP06-855-13	Linking whole genome sequencing of M. tuberculosis isolates to epidemiological and social network data from passive and active community case finding in Bandung, Indonesia	13:55 - 14:00
	Hanif Ahmad Kautsar Djunaedy (Bandung, Indonesia)	
	Q&A	14:00 - 14:15
<i>Paper Posters</i>		
13:20 - 14:20		M PPG
	PP07 - Implementing strategies for drug-resistant TB assistance: Time for strengthening person-centred care	
	Jason Farley (Baltimore, United States)	
PP07-856-13	Decentralising drug-resistant TB care in South Africa: The trade-off between service coverage and quality of care	13:20 - 13:25
	Waasila Jassat (Johannesburg, South Africa)	
PP07-858-13	Drug-resistant TB: Biosocial approach with attention to food security in Sao Paulo State (2021 to 2024)	13:25 - 13:30
	Valdir De Souza Pinto (Sao Paulo, Brazil)	
PP07-859-13	Treatment outcomes from implementation of the modified short treatment regimen among people with multi-drug-resistant TB in Uganda	13:30 - 13:35
	Enock Kizito (Kampala, Uganda)	
PP07-860-13	Improving access to multi-drug-resistant TB care: Lessons from implementing a satellite clinic at a primary care facility in Eastern Uganda	13:35 - 13:40
	Damalie Namuyodi (Mbale, Uganda)	
PP07-861-13	Continuity of drug-resistant TB care during complex emergencies: The successful experience of the Poland-Ukraine collaboration	13:40 - 13:45
	Gabriella Ferlazzo (Rome, Italy)	
PP07-862-13	Identifying the steps that contribute to delays with drug-resistant TB contact diagnosis and treatment in Vietnam	13:45 - 13:50
	Quy Thi Lam (Ho Chi Minh City, Vietnam)	
PP07-863-13	Strengthening drug-resistant TB care institutions by creating structures for diffusing expertise through a Center of Excellence (CoE) program: Experiences from India	13:50 - 13:55
	Meera Bhatia (New Delhi, India)	
PP07-864-13	Differentiating TB service delivery in an urban setting: Lessons from a community drug delivery program in Central Uganda	13:55 - 14:00
	Ignatius Senteza (Kampala, Uganda)	
PP07-865-13	Comparison of treatment outcomes between people with MDR/RR-TB receiving a shorter treatment regimen with injectable drugs and the 9-month all-oral regimen in Cambodia	14:00 - 14:05
	Sam Sophan (Phnom Penh, Cambodia)	
	Q&A	14:05 - 14:20

Paper Posters

13:20 - 14:20

M PPH

PP08 - Finding the missing people with TB

Gisele Badoum (Ouagadougou, Burkina Faso)

PP08-866-13	Active case finding for TB in special populations: Assessing the effectiveness of routine screening in correctional centers in Lagos, Nigeria Oluwatimilehin Rotimi-Ojo (Lagos, Nigeria)	13:20 - 13:25
PP08-867-13	Smartphone-based cough frequency monitoring among people screened for TB in an urban African community setting Patrick Biche (Baltimore, United States)	13:25 - 13:30
PP08-868-13	Is drug-resistant TB transmitted as drug-resistant TB? Insights from a drug-resistant TB contact investigation initiative in Vietnam Khanh Hoai Le (Ha Noi, Vietnam)	13:30 - 13:35
PP08-869-13	Yield from implementing targeted universal testing for TB among household contacts of individuals with TB disease using TB support officers in South Africa Ndavheleseni Elias Ramarumo (Pretoria, South Africa)	13:35 - 13:40
PP08-870-13	Active case finding efforts among homeless population in Delhi: A paragon partnership engaging Mobile Medical Vans Lakshmi Aravindakshan (New Delhi, India)	13:40 - 13:45
PP08-871-13	Who do we target for TB case-finding strategies? Assessing TB positivity rates among at-risk-populations aged 15-24years using GeneXpert technology: Review of diagnostic surveillance data, Kenya Rhoda Pola (Nairobi, Kenya)	13:45 - 13:50
PP08-872-13	Finding the missing people with TB through targeted active TB screening in slum and hard-to-reach areas using peer-network strategy in Nigeria Chidubem Ogbudebe (Abuja, Nigeria)	13:50 - 13:55
PP08-873-13	Enhancing TB screening in resource-limited high workload facilities: The role of auxiliary linkage assistants in improving active case finding in Machakos county, Kenya Hilary Ngeso (Machakos, Kenya)	13:55 - 14:00
PP08-874-13	The TEMU TPT initiative: A case study on the uptake of TB preventive therapy through health worker-led education and contact invitation in Indonesia Roviliana Trishanty Rondonuwu (Jakarta Selatan, Indonesia)	14:00 - 14:05
PP08-875-13	Increasing childhood TB notification rates in Nigeria: The impact of a collaborative childhood testing week Bolatito Aiyenigba (Abuja, Nigeria)	14:05 - 14:10
	Q&A	14:10 - 14:20

Paper Posters

13:20 - 14:20

M PPI

PP09 - Capacity building for TB prevention, care and management

Mohammed Yassin (Geneva, Switzerland)

PP09-876-13	Demonstration and cross learning forums contributed to the transformed TB programme in Ethiopia Zewdu Gashu Dememew (Addis Ababa, Ethiopia)	13:20 - 13:26
PP09-877-13	Extending capacity for pediatric stool processing: The Uganda Supranational Reference Laboratory's (SRL) program for multi-	13:26 - 13:32

	country training and capacity building	
	Joanita Namutebi (Kampala, Uganda)	
PP09-878-13	Reducing diagnostic delays: The 2RF model of review, reorientation and feedback for culture & DST Labs (C&DST) in Andhra Pradesh, India	13:32 - 13:38
	G. Mahesh (Hyderabad, India)	
PP09-879-13	Evaluation of PrimeEQA® Xpert MTB proficiency panels at WHO TB Supranational Reference Laboratories in South Africa, Uganda and Benin	13:38 - 13:44
	Barry Kosloff (Bethesda, United States)	
PP09-881-13	Results of community approach to improving access to mental health services in Nigeria TB programme	13:44 - 13:50
	Chinwe Eze (Enugu, Nigeria)	
PP09-882-13	The impact of sustained advocacies to clinicians in strengthening childhood TB surveillance and GeneXpert stool assay optimisation: Lessons from the TB-LON project in Nigeria	13:50 - 13:56
	Lotanna Ugochukwu (Abuja, Nigeria)	
PP09-883-13	Enhancing Truenat sample processing accuracy through continuous supportive supervision and refresher training: Implementation approach	13:56 - 14:02
	Jamiu Olabamiji (Lagos, Nigeria)	
	Q&A	14:02 - 14:14
<i>Paper Posters</i>		
13:20 - 14:20		M PPJ
PP02 - Mixed methods and quality		
Amrita Daftary (Toronto, Canada)		
PP02-808-13	How do Indonesian doctors value the different features of a TB case notification system? Answers from a discrete-choice experiment	13:20 - 13:25
	Panji Fortuna Hadisoemarto (Bandung, Indonesia)	
PP02-809-13	Psychosocial experiences of adolescents with TB in Cape Town	13:25 - 13:30
	Dillon Wademan (Cape Town, South Africa)	
PP02-810-13	The dynamics of motherhood and fatherhood and the TB experience in South Africa	13:30 - 13:35
	Kelly Rutt (Wake Forest, United States)	
PP02-811-13	Relating the 'fourth space' to improving respiratory illness outpatient access for people aged ≥5yrs in Fiji from 2013 to 2020	13:35 - 13:40
	Sainimere Boladuadua (Auckland, New Zealand)	
PP02-812-13	Migrants healthcare seeking behaviour and willingness to use tongue swabs for TB screening: A qualitative study	13:40 - 13:45
	Francesca Saluzzo (Italy)	
PP02-813-13	'Apart from being sick it's torturing giving them that everyday': Qualitative analysis - Lived experiences providing drug-resistant TB medicine to children, in KwaZulu-Natal, South Africa	13:45 - 13:50
	Shriya Misra (Durban, South Africa)	
PP02-814-13	A multi-country evaluation of patient preferences for future TB diagnostic tests using a discrete choice experiment	13:50 - 13:55
	Talemwa Nalugwa (Kampala, Uganda)	
PP02-815-13	Contribution of 3rd Party Logistic (3PL) support services in anti-TB drugs and logistics supply chain management in West Bengal, India	13:55 - 14:00
	Abhijit Dey (New Delhi, India)	

PP02-816-13	Perspectives from people with TB on quality-of-life transitions during and after TB treatment in South Africa Nancy Bedingfield (Montreal, Canada)	14:00 - 14:05
PP02-817-13	Exploring the rising trends of deaths in persons with TB: A mixed-methods study from Kashmir, India Praveen Kumar Yadav (Delhi, India)	14:05 - 14:10
PP02-818-13	“Six months is a lot of time to lie”: Anticipated stigma, disclosure and treatment preferences among participants in a TB therapeutic trial Faith Mugodhi (Milton Park, Zimbabwe)	14:10 - 14:15
	Q&A	14:15 - 14:20
<i>Union Live Session</i>		
13:30 - 14:00		UL
UL08 - Interview with Dr Razia, Technical Consultant for TB strategic planning and Global Fund applications at the UN Office for Project Services, and Chair of the TB section and Vice-Chair of the Ethics Advisory Group at The Union		
<i>Union Live Session</i>		
14:00 - 14:30		UL
UL09 - Union LIVE - Content from across the WCLH 2024		
<i>Community Connect</i>		
14:15 - 15:00		AU
CCSA005 - The power of storytelling in TB care: Empowering key and vulnerable populations Dozia Joseph (New Delhi, India) Blessina Kumar (New Delhi, India)		
	Introduction	14:15 - 14:20
	Personal journey with TB and strategies to make TB care more inclusive for sex workers Vika Yaroshenko (Poland)	14:20 - 14:25
	Personal journey with TB and strategies to make TB care more inclusive for PLHIV Carol Nawina Nyirenda (Zambia)	14:25 - 14:30
	Personal journey with TB and strategies to make TB care more inclusive for people who use drugs Bello Abdussalam (Nigeria)	14:30 - 14:35
	Personal journey with TB and strategies to make TB care more inclusive for women Meera Yadav (India)	14:35 - 14:40
	Personal journey with TB and strategies to make TB care more inclusive for people who use drugs Iman Setiawan (Indonesia)	14:40 - 14:45
	Question and answer	14:45 - 15:00
<i>Community Connect</i>		
14:15 - 15:00		SG
CCSS008 - Empowering communities in public-private mix models for ending TB in India Mohanambe Lingappa (India) Meena Putturaj (India) Mohanambe Lingappa (India)		

	Introduction	14:15 - 14:21
	REACH Nakshatra: A private health sector engagement initiative Ramya Ananthakrishnan (Chennai, India)	14:21 - 14:27
	Engaging community health workers in increasing TB notifications and TPT coverage in rural India Manish Kumar (India)	14:27 - 14:33
	TB careline by the Karnataka Health Promotion Trust (KHPT) Rehana Begum (Bengaluru, India)	14:33 - 14:39
	Roping Informal Private Providers for Enhanced TB Detection (RIPEND) Vikas Panibatla (India)	14:39 - 14:45
	Question and answer	14:45 - 15:00
<i>Special Session</i>		
14:20 - 15:50		HB
	SPS01 - The fever rises: Climate change and the TB pandemic Finn McQuaid (London, United Kingdom) Dennis Falzon (Geneva, Switzerland)	
	Session introduction	14:20 - 14:25
	Climate change and TB: Policy and research perspective Matteo Zignol (Switzerland)	14:25 - 14:40
	Climate change and social justice: a TB implementer's perspective Uzma Khan (Montreal, Canada)	14:40 - 14:55
	How climate-driven hunger will affect the TB pandemic Rebecca Clark (London, United Kingdom)	14:55 - 15:10
	The impact of TB on climate change (Experience from India) Palanivel Chinnakali (Puducherry, India)	15:10 - 15:25
	Panel discussion with Q&A from the audience Mohammed Yassin (Geneva, Switzerland)	15:25 - 15:50
<i>Oral Abstract Session</i>		
14:20 - 15:50		FR
	OA05 - From stigma to support: Addressing mental health for better outcomes Alanna Bergman (Charlottesville, United States) Imran Pambudi (Jakarta, Indonesia)	
	Introduction	14:20 - 14:25
OA05-132-13	Mental health condition (MHC) among Diagnosed TB (DTB): Cross-sectional study 2018 Indonesian National Health Survey (NHS) Siti Isfandari (Jakarta, Indonesia)	14:25 - 14:33
OA05-133-13	Prevalence and predictors of depression among people with TB in Ghana: Implications for integrated care and stigma reduction Jacob Idan (Winneba, Ghana)	14:33 - 14:41
OA05-134-13	Mental health support for people with TB during wartime: Experience of Ukraine Evgenia Geliukh (Kyiv, Ukraine)	14:41 - 14:49
OA05-135-13	Evaluating depression intensity with the PHQ-9 scale among people with drug-resistant TB in Vietnam	14:49 - 14:57

	Huy Le Ngoc (Hanoi, Vietnam)	
OA05-136-13	Co-design for peer-led mental health and TB services integration in Pune, India: A qualitative study Manvi Poddar (Baltimore, United States)	14:57 - 15:05
OA05-137-13	Breaking barriers: Combining DOTS integration and TB screening for improved case detection in mental health settings Folashade Idowu (Abuja, Nigeria)	15:05 - 15:13
OA05-138-13	Integrated mental health and TB services in Montserrado County, Liberia Mike Mulbah (Monrovia, Liberia)	15:13 - 15:21
OA05-139-13	Prevalence of mental health issues at different stages of TB treatment: Insight from rural India Reena Marbate (Samastipur, India)	15:21 - 15:29
OA05-140-13	Integrated harm reduction strategies for TB in conflict-affected regions of Myanmar Ye Htet Kyaw (Yangon, Myanmar)	15:29 - 15:37
	Q&A	15:37 - 15:50
 <i>Oral Abstract Session</i>		
	14:20 - 15:50	BG
	OA06 - Transmission dynamics of M. tuberculosis: Insights and challenges	
	Mikaela Coleman (Bordeaux; Sydney, Australia) Rein Houben (London, United Kingdom)	
	Introduction	14:20 - 14:25
OA06-116-13	Transmission networks with whole-genome sequencing data Caroline Colijn (Vancouver, Canada)	14:25 - 14:34
OA06-117-13	Predictive factors for co-membership in a transmission network among individuals with TB in Blantyre, Malawi Melanie H. Chitwood (New Haven, United States)	14:34 - 14:43
OA06-118-13	Longitudinal transmission of multi-drug-resistant TB in China: A population-based genomic epidemiology analysis Lu Xiaoyu (Guangdong, China)	14:43 - 14:52
OA06-119-13	Quantifying subclinical transmission of TB using whole genome sequencing and Bayesian inference: A population-based study in Taiwan Chieh-Yin Wu (Taipei, Taiwan)	14:52 - 15:01
OA06-120-13	Implementing a community transmission study in a TB-endemic setting: Lessons learned from TARGET-TB (Targeting TB transmission hotspots to find undiagnosed TB in South Africa) Kegaugetswe Motsomi (Durban, South Africa)	15:01 - 15:10
OA06-121-13	Comparison of the transmissibility of isoniazid-resistant TB and drug-susceptible TB Hao-Hsuan Lin (Taipei, Taiwan)	15:10 - 15:19
OA06-122-13	The impact of diabetes mellitus on transmission dynamics of TB Chuan-Chin Huang (Boston, United States)	15:19 - 15:28
OA06-123-13	Risk of within-household M. tuberculosis transmission by HIV/ART and symptom status of people starting treatment for pulmonary TB in rural KwaZulu-Natal, South Africa Palwasha Yousafzai Khan (London, United Kingdom)	15:28 - 15:37

	Q&A	15:37 - 15:50
<i>Oral Abstract Session</i>		
14:20 - 15:50		OC
OA07 - Identifying and managing TB infection		
Razia Kaniz Fatima (Islamabad, Pakistan)		
Norbert Heinrich (Munich, Germany)		
	Introduction	14:20 - 14:25
OA07-151-13	Can preceding symptoms predict the occurrence of hypersensitivity reaction with 3HP? Sayontonee Ghosh (Sydney, Australia)	14:25 - 14:34
OA07-152-13	Treatment adherence to an adult levofloxacin formulation in children on multi-drug-resistant TB preventive treatment within the TB-CHAMP trial Trinh Duong (London, United Kingdom)	14:34 - 14:43
OA07-153-13	High prevalence of fluoroquinolone resistance and <i>katG</i> mutations in adult index patients in a multinational multi-drug-resistant TB prevention trial Soyeon Kim (Brookline, United States)	14:43 - 14:52
OA07-154-13	Safety profile of levofloxacin preventive treatment for multi-drug-resistant TB: A meta-analysis of the VQUIN and TB-CHAMP trials Trinh Duong (London, United Kingdom)	14:52 - 15:01
OA07-155-13	Bedaquiline or linezolid resistance without co-occurring fluoroquinolone resistance in the Western Cape, South Africa Janre Steyn (Cape Town, South Africa)	15:01 - 15:10
OA07-156-13	Treatment discontinuation patterns and reasons in individuals receiving TB preventive treatment with standard and high-dose rifampin: Post hoc analysis of the 2R2 randomised controlled trial Lika Apriani (Bandung, Indonesia)	15:10 - 15:19
OA07-157-13	Managing TB infection among household contacts of people with TB under JEET project, India, 2021-2024 Aakshi Kalra (Delhi, India)	15:19 - 15:28
OA07-158-13	TB Vaccine Readiness Repository: An interactive inventory of past, present, and future work to share the state of vaccine readiness Joeri Sumina Buis (The Hague, Netherlands)	15:28 - 15:37
	Q&A	15:37 - 15:50
<i>Symposium</i>		
14:20 - 15:50		JKA
SP05 - TB preventive treatment for children: Where are we and what's next?		
Ben Marais (Australia)		
Cecily Miller (Geneva, Switzerland)		
SP05-428-13	Introduction	14:20 - 14:25
SP05-429-13	WHO updates on TB preventive treatment for children: Recommendations and dosing guidance Tiziana Masini (Geneva, Italy)	14:25 - 14:39
SP05-430-13	Protecting our young: enabling implementation of 3HP in children with age-appropriate formulations Makaita Gombe (Harare, Zimbabwe)	14:39 - 14:53
SP05-431-13	Acceptability of dispersible and non-dispersible tablet levofloxacin	14:53 - 15:07

	formulations in children	
	Dillon Wademan (Cape Town, South Africa)	
SP05-432-13	Accelerating uptake of TB preventive treatment among children and adolescents in Uganda: experience from the National TB and Leprosy Program	15:07 - 15:21
	Moorine Penninah Sekadde (Kampala, Uganda)	
SP05-433-13	What's next in TB prevention for children?	15:21 - 15:35
	Nicole Salazar-Austin (Baltimore, United States)	
SP05-434-13	Q&A	15:35 - 15:50
<i>Short Oral Abstract Session</i>		
14:20 - 15:50		
		JKB
SOA02 - Burden of smoking and impact of tobacco control measures		
Les Hagen (Edmonton, Canada)		
Gea Melinda (Central Jakarta, Indonesia)		
	Introduction	14:20 - 14:25
SOA02-611-13	Electronic cigarette and heated tobacco product use and their association with tobacco control factors among adults in Indonesia, Kazakhstan, and the Philippines	14:25 - 14:34
	Chandrashekhar T. Sreeramareddy (Kuala LUMPUR, Malaysia)	
SOA02-612-13	Tobacco smoking-attributable mortality in Kenya: 2012-2021	14:34 - 14:43
	Lazarus Odeny (Nairobi, Kenya)	
SOA02-613-13	How the tobacco industry normalise its CSR activities to bypass TAPS ban in Vietnam: A media narrative analysis	14:43 - 14:52
	Huong Nguyen (Ha Noi, Vietnam)	
SOA02-614-13	Increase in anti-tobacco media campaigns over last 5 years: Case study of West Bengal, India	14:52 - 15:01
	Amitrajit Ukil (Kolkata, India)	
SOA02-615-13	Programme evaluation of tobacco-free secondary municipal schools in Pimpri-Chinchwad, Pune district, Maharashtra, India: Quasi-experimental study	15:01 - 15:09
	Sahana Hegde -Shetiya (Pune, India)	
SOA02-616-13	Comparative analysis of e-cigarette regulation impact on retail marketing strategies: An observational study in China	15:09 - 15:18
	Chenyu Qian (Shanghai, China)	
SOA02-618-13	Assessing impact of tobacco control measures on tobacco-related diseases in the state of Himachal Pradesh in India	15:18 - 15:26
	Gopal Chauhan (Shimla, India)	
SOA02-619-13	Outcome of brief tobacco smoking cessation intervention among people with TB in Myanmar	15:26 - 15:35
	Pyae Phyo Oo (Yangon, Myanmar)	
	Q&A	15:35 - 15:50
<i>Symposium</i>		
14:20 - 15:50		
		MD
SP06 - Scaling up collaborative action on TB and diabetes: Making commitments a reality		
Lin Yan (Beijing, China)		
SP06-435-13	Introduction	14:20 - 14:25
	Living with diabetes and having TB: a survivor's perspective	14:25 - 14:39

	Chanra Mustamin (Makassar, Indonesia)	
SP06-436-13	Overview of the global joint burden and WHO guidance on TB and diabetes Annabel Baddeley (Geneva, Switzerland)	14:39 - 14:53
SP06-437-13	Review of evidence on collaborative action to address TB and diabetes Julia Critchley (London, United Kingdom)	14:53 - 15:07
SP06-438-13	Active TB screening among people with diabetes mellitus in Indonesia: Progress and integration efforts Tiffany Tiara Pakasi (South Jakarta, Indonesia)	15:07 - 15:21
SP06-439-13	Challenges and opportunities in scaling up TB and diabetes in China Xiaoqiu Liu (Beijing, China)	15:21 - 15:35
	Q&A	15:35 - 15:50
<i>Symposium</i>		
14:20 - 15:50		NS1
	SP07 - One dose fits many, but not all: Personalised dosing for those who need it Jan-Willem Alffenaar (Sydney, Australia) Payam Nahid (United States)	
SP07-442-13	Introduction	14:20 - 14:25
SP07-443-13	Why does drug exposure, pathogen susceptibility in TB treatment matter. Fajri Gafar (Montreal, Canada)	14:25 - 14:39
SP07-444-13	Identifying patients who may benefit from personalised treatment. Christopher Cousins (London, United Kingdom)	14:39 - 14:53
SP07-445-13	Personalised treatment within programmatic care; the best of both worlds Rovina Ruslami (Bandung, Indonesia)	14:53 - 15:07
SP07-446-13	Personalised or stratified medicine feasibility and challenges for adoption in TB treatment guidelines? Fuad Mirzayev (Geneva, Switzerland)	15:07 - 15:21
SP07-447-13	Panel discussion	15:21 - 15:35
SP07-448-13	Q&A	15:35 - 15:50
<i>Symposium</i>		
14:20 - 15:50		NS2
	SP08 - Addressing a blind spot in the TB response: The need for adolescent-friendly TB services Leonid Lecca (Lima, Peru) Martina Casenghi (Geneva, Switzerland)	
SP08-449-13	Introduction	14:20 - 14:30
SP08-450-13	The need for differentiated care to address TB in adolescents Silvia Chiang (Providence, United States)	14:30 - 14:45
SP08-451-13	Implementing and evaluating adolescent-friendly interventions in the context of HIV: experiences from Lima, Peru Molly Franke (Boston, United States)	14:45 - 15:00
SP08-452-13	TB screening and diagnosis amongst adolescents: experiences from an integrated service delivery approach in rural Sindh, Pakistan	15:00 - 15:15

	Annum Aftab (Karachi, Pakistan)	
SP08-453-13	Integrated and patient-centered services for adolescents: experiences from the “Adolescents Clinic” in Zimbabwe Regina Fungayi Magore (Harare, Zimbabwe)	15:15 - 15:30
SP08-454-13	Q&A	15:30 - 15:50
<i>Oral Abstract Session</i>		
14:20 - 15:50		NS3
OA08 - Digital Chest X-Ray + AI for TB Detection		
Pranay Sinha (Boston, United States) Chelsie Cintron (Providence, United States)		
	Introduction	14:20 - 14:25
OA08-160-13	Experiences with chest X-ray screening and artificial intelligence software in TB screening and diagnosis at health facility level in Malawi George Talama (Lilongwe, Malawi)	14:25 - 14:35
OA08-161-13	Enhancing TB detection through the integration of computer-aided detection (CAD) software in chest radiography: Findings from targeted outreach programs in Kenya Rhoda Karisa (Nairobi, Kenya)	14:35 - 14:45
OA08-162-13	Automated interpretation of chest X-rays predicts incident TB risk in a prospective cohort in prisons Argita D. Salindri (Stanford, United States)	14:45 - 14:55
OA08-163-13	Triage or no triage: Use of CXR-CAD in community-wide TB-screening in an urban community in Zambia Albertus Schaap (London, Zambia)	14:55 - 15:05
OA08-164-13	Bridging the gap: Enhanced TB detection using mobile digital X-ray and AI as screening tool surpasses W4S-based screening in community-based intervention - Insights from Malawi Birru Shigut Gondol (Malawi)	15:05 - 15:15
OA08-165-13	Upscaling diagnosis of pulmonary TB through routine GeneXpert testing of stool from hospitalised children with severe acute malnutrition: Experience from Sokoto State, Nigeria Ochuko Urhioke (Abuja, Nigeria)	15:15 - 15:25
OA08-166-13	Can AI-driven computer-aided detection optimise Xpert-orientated community-based active case finding for TB? An interim trial progress report Alex John Scott (Cape Town, South Africa)	15:25 - 15:35
	Q&A	15:35 - 15:50
<i>TBScience E-Poster Session</i>		
14:20 - 16:20		M EP7
TBS-EP02 - Implications of pathogen heterogeneity for intervention Part 2		
Charissa Naidoo (Cape Town, South Africa)		
TBS-EP-28	Investigating the mechanisms of Mtb dormancy using novel trehalose-based probes	14:20 - 14:25
TBS-EP-29	A Nanopore-based long-read sequencing panel to detect drug-resistant TB Parthasarathy Ponnusamy (Bengaluru, India)	14:25 - 14:30
TBS-EP-31	CD4⁺ T cell profiles during TB/HIV co-infection and their	14:30 - 14:35

	associations with TB treatment response and cavitary disease Santhuri Rambaran (Durban, South Africa)	
TBS-EP-32	First report of whole-genome analysis of an extensively drug-resistant <i>M. tuberculosis</i> clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda Jupiter Marina Kabahita (Kampala, Uganda)	14:35 - 14:40
TBS-EP-33	Pre-analytical sampling and processing of tongue swabs for <i>Mycobacterium tuberculosis complex (Mtb)</i> impacts diagnostic yield Helen Savage (Liverpool, United Kingdom)	14:40 - 14:45
TBS-EP-34	Leveraging digital health technology for real-time disease surveillance through diagnostic connectivity in Uganda: A case of Kampala District Arnold Kennedy Tumuhairwe (Kampala, Uganda)	14:45 - 14:50
TBS-EP-35	A scoping review on molecular diagnostic testing for isoniazid-resistant TB: Current status and gaps Thi Mai Nguyen (Sydney, New South Wales, Australia)	14:50 - 14:55
TBS-EP-36	Understanding TB transmission dynamics in urban and rural Nepal using genomics, to optimally target interventions (TARGET TB) Sarah Dunstan (Melbourne, Australia)	14:55 - 15:00
TBS-EP-37	Drug resistance and genotypic profiling of <i>M. tuberculosis</i> strains in Uganda Dennis Mujuni (Kampala, Uganda)	15:00 - 15:05
TBS-EP-38	Classification of unsequenced <i>M. tuberculosis</i> strains in a high-burden setting using a pairwise logistic regression approach Isabel Rancu (New Haven, United States)	15:05 - 15:10
TBS-EP-40	Analysis of <i>M. tuberculosis</i> genomes from TB Portals database identifies genomic variants associated with efflux pumps involved in bedaquiline resistance Andrei Gabrielian (Rockville, United States)	15:10 - 15:15
TBS-EP-41	Enhanced extrapulmonary TB diagnosis in body fluids using nanoplate digital PCR S. D. Tasneem Fatima (Hyderabad, India)	15:15 - 15:20
TBS-EP-42	Multicenter prospective clinical trial to evaluate the diagnostic accuracy of Truenat MTB Plus in people with presumed pulmonary TB in Brazil	15:20 - 15:25
TBS-EP-43	Improved treatment outcomes for people with multi-drug-resistant TB without prior anti-TB treatment: A nine-year cohort study in Shanghai Liu Yidian (Shanghai, China)	15:25 - 15:30
TBS-EP-44	Whole-genome sequence data and TB transmission: Understanding transmission paths Jennifer McNichol (Vancouver, Canada)	15:30 - 15:35
TBS-EP-45	Navigating dual mycobacterial infections in a kidney transplant recipient: A case of therapeutic adaptation and management challenges Oldi Dedy (Jogjakarta, Indonesia)	15:35 - 15:40
TBS-EP02	Q&A	15:40 - 16:15

<i>Union Live Session</i>		
14:30 - 15:00		UL
UL10 - Interviews with Professor Guy Marks and Mukul Jerath		
<i>Community Connect</i>		
15:00 - 16:30		EG2
CCWS003 - We are KVPs!		
Austin Obiefuna (Ghana)		
	Engaging young people and LGBTIQA community in the TB response	15:00 - 15:00
	Aman Shukla (India)	
	Engagement of key and vulnerable populations in the TB response in Eastern Europe and Central Asia	15:00 - 15:00
	Svetlana Doltu (Moldova)	
	The role of community-led monitoring and research in closing knowledge gaps on TB	15:00 - 15:00
	Omar Kora (Ghana)	
	Stop TB Partnership KVP delegation as an effective platform for amplifying the voice of key and vulnerable populations in TB response	15:00 - 15:00
	Lusiana Aprilawati (Indonesia)	
<i>Union Live Session</i>		
15:00 - 17:00		UL
UL11 - Messages from our event sponsors		
<i>Community Connect</i>		
15:15 - 16:15		AU
CCSA006 - Unlocking the power of community advisory groups: Navigating who, what, where, when, and how		
Nicola James (United Kingdom)		
Madhava Sai Sivapuram (India)		
Nicola James (United Kingdom)		
	Introduction	15:15 - 15:20
	Sharing the experiences of CABs - CAB member UNITE4TB, benefit kids and co-chair national CAB, ICMR, India.	15:20 - 15:30
	Blessina Kumar (New Delhi, India)	
	Sharing the experiences of facilitating a CAG in Vitenam	15:30 - 15:40
	Duy Trinh-Hoang (Ha Noi, Vietnam)	
	Community leaders taking action to increase accountability for TB policy implementation in South Africa	15:40 - 15:50
	Goodman Makanda (South Africa)	
	Sharing the experiences of a CAG member from a war torn country, Ukraine	15:50 - 16:00
	Zahedul Islam (Ukraine)	
	Question and answer	16:00 - 16:15

Community Connect

15:15 - 16:15

SG

CCSS009 - Working with TB champions to mobilise domestic resources for TB

Mayowa Joel (Nigeria)

Mayowa Joel (Nigeria)

Queen Ogbuji-Ladipo (Nigeria)

Introduction

15:15 - 15:20

Stop TB Partnership Nigeria: The paradigm shift in advocacy for domestic resource mobilisation for TB in Nigeria

15:20 - 15:28

Mayowa Joel (Nigeria)

Comparative advantage of advocacy organisations in complementing the role of the national TB programme

15:28 - 15:36

Labaran Shehu (Nigeria)

Support for TB advocacy and need for national stop TB partnerships

15:36 - 15:44

Lucica Ditiu (Switzerland)

Role of women leaders in ending TB: Case study of first ladies in Nigeria

15:44 - 15:52

Queen Ogbuji-Ladipo (Nigeria)

Critical role of advocacy in supporting the work of partners and other stakeholders in providing effective and sustainable TB services

15:52 - 16:00

Bethrand Odume (Abuja, Nigeria)

Question and answer

16:00 - 16:15

Late Breaker Oral Abstract Session

16:10 - 17:40

MG

LB02 - The Union-CDC late-breaker session (treatment and clinical trials)

Rovina Ruslami (Bandung, Indonesia)

Ali Hammad (United States)

Introduction

16:10 - 16:15

LB02-1206-13

Pharmacokinetics and safety of 12-weeks rifapentine and isoniazid in children for TB prevention

16:15 - 16:24

Louvina van der Laan (Stellenbosch, South Africa)

LB02-1207-13

Bedaquiline and clofazimine resistance following an interruption in treatment for rifampicin-resistant TB

16:24 - 16:33

Rina Liang (Bronx, NY, United States)

LB02-1208-13

Association between daily linezolid dose and BPAL regimen safety in a multi-country operational research study

16:33 - 16:42

Veriko Mirtskhulava (The Hague, Netherlands)

LB02-1209-13

High efficacy of BPAL regimen among people with TB in the Philippines with *M. tuberculosis* lineage 1

16:42 - 16:51

LB02-1210-13

One vs. three months of rifapentine and isoniazid to prevent TB in people exposed in the household or workplace in Brazil: The Ultra-Curto Trial (NCT04703075)

16:51 - 17:00

Betina Durovni (Rio de Janeiro, Brazil)

LB02-1211-13

Acquisition of resistance to bedaquiline, delamanid, clofazimine, linezolid, and fluoroquinolones during treatment in the endTB trial

17:00 - 17:09

Elisa Ardizzoni (Antwerp, Belgium)

LB02-1212-13

WX-081, a novel compound against *M. tuberculosis*

17:09 - 17:18

	Xiaojing Sang (Shanghai, China)	
LB02-1213-13	endTB-Q: Interim results of a randomised controlled trial testing a shorter treatment strategy for pre-XDR TB Lorenzo Guglielmetti (Paris, France)	17:18 - 17:27
	Q&A	17:27 - 17:40
<i>Short Oral Abstract Session</i>		
16:10 - 17:40		HB
SOA03 - Mapping TB: Integrating molecular and spatial approaches		
Helen Jenkins (Boston, United States)		
	Introduction	16:10 - 16:15
SOA03-620-13	Phylogeography and transmission of M. tuberculosis in an emerging city, China: A 9-year prospective population-based genomic epidemiological study Xi Zhu (Shenzhen, China)	16:15 - 16:22
SOA03-621-13	Internal migrants as drivers of long-distance cross-regional transmission of TB in China Meng Li (Shanghai, China)	16:22 - 16:29
SOA03-622-13	Predicting TB prevalence and transmission hotspots in urban areas: A genomic epidemiology approach with machine learning models Yixiao Lu (Shenzhen, China)	16:29 - 16:36
SOA03-623-13	Mapping TB prevalence in Africa using a geospatial meta-analysis Kefyalew Alene (Perth, Australia)	16:36 - 16:43
SOA03-624-13	Spatio-temporal patterns of TB in Makassar, South Sulawesi Indonesia Indra Dwinata (Makassar, Indonesia)	16:43 - 16:50
SOA03-625-13	Risk spatial clusters and mapping of attention to drug-resistant TB in the state of São Paulo (2013-2020) Yan Alves (Ribeirão Preto, Brazil)	16:50 - 16:57
SOA03-626-13	Identifying emerging high burden clusters of TB in Uttar Pradesh, India: A comprehensive geospatial analysis Preeti PS (New Delhi, 110011, India)	16:57 - 17:04
SOA03-627-13	A geospatial analysis of TPT treatment outcomes among PLHIV in Ethiopia, South Africa, and Zimbabwe Joeri Sumina Buis (The Hague, Netherlands)	17:04 - 17:11
SOA03-628-13	Whole genome sequencing reveals M. tuberculosis lineages and drug resistance distribution in Northeastern Thailand Waritta Sawaengdee (Nonthaburi, Thailand)	17:11 - 17:18
SOA03-629-13	Integrating genomic and spatial analyses to understand TB transmission: A scoping review Yu Lan (New Haven, United States)	17:18 - 17:25
	Q&A	17:25 - 17:40
<i>Symposium</i>		
16:10 - 17:40		FR
SP09 - Asymptomatic TB: How important is it?		
Guy Marks (Sydney, Australia)		
Mike Frick (New York City, United States)		

SP09-455-13	Introduction	16:10 - 16:15
SP09-456-13	What is known about asymptomatic TB? Hanif Esmail (London, United Kingdom)	16:15 - 16:29
SP09-457-13	Public health significance of asymptomatic TB: Global policy Cecily Miller (Geneva, Switzerland)	16:29 - 16:43
SP09-458-13	Public health significance of asymptomatic TB: Country perspective Lindiwe Mvusi (Pretoria, South Africa)	16:43 - 16:57
SP09-459-13	How to resource the management of asymptomatic TB? Grania Brigden (Switzerland)	16:57 - 17:11
SP09-460-13	Key research needs for programmatic action on asymptomatic TB Anna Coussens (Parkville, Australia)	17:11 - 17:25
SP09-461-13	Q&A	17:25 - 17:40
<i>Oral Abstract Session</i>		
16:10 - 17:40		BG
OA09 - Resisting resistance: Challenge of drug-resistant TB		
Fuad Mirzayev (Geneva, Switzerland)		
Erlina Burhan (Jakarta, Indonesia)		
	Introduction	16:10 - 16:15
OA09-167-13	Bedaquiline resistance and treatment outcomes among people with TB previously exposed to bedaquiline in India Rupak Singla (New Delhi, India)	16:15 - 16:23
OA09-168-13	Comparative effectiveness of bedaquiline in reducing mortality in MDR/RR-TB: A target trial emulation Miriam Ngarega (Antwerp, Belgium)	16:23 - 16:31
OA09-169-13	Overcoming barriers to access: Strategies for improving drug-resistant TB care delivery in underserved communities Hauwa Usman Garba (Katsina, Nigeria)	16:31 - 16:39
OA09-170-13	Linezolid interruption and rechallenge in rifampicin-resistant TB: A review of South African programmatic data from 2018 to 2020 Keertan Dheda (Cape Town, South Africa)	16:39 - 16:47
OA09-171-13	Treatment outcomes for drug-resistant TB contacts diagnosed with drug-sensitive TB Han Thi Nguyen (Ha Noi, Vietnam)	16:47 - 16:55
OA09-172-13	Understanding the reasons for pre-treatment lost to follow-up of people with drug-resistant TB in Bihar Shruthi Basavaradhya Sahukar (Chennai, India)	16:55 - 17:03
OA09-173-13	Indonesia's journey to roll out the 6-month drug-resistant TB treatment regimen Imran Pambudi (Jakarta, Indonesia)	17:03 - 17:11
OA09-174-13	Home-based screening of persons exposed to drug-resistant TB, Dharavi, India, 2020-2022 Rajesh Deshmukh (Mumbai, India)	17:11 - 17:19
OA09-175-13	Point-of-care integration of XDR assay for enhanced drug-resistant TB management in Punjab, Pakistan Kinz Ul Eman (Islamabad, Pakistan)	17:19 - 17:27
	Q&A	17:27 - 17:40

Oral Abstract Session

16:10 - 17:40

OC

OA10 - Solutions for TB elimination

Julio Croda (Campo Grande, Brazil)

Kristin Nelson (Atlanta, United States)

	Introduction	16:10 - 16:15
OA10-177-13	Genomic and clinical evidence of <i>M. tuberculosis</i> strains harboring <i>rpoB</i> mutations outside the rifampicin resistance-determining region associated with misdiagnosis of rifampicin resistance in Myanmar Zaw Myint (Yangon, Myanmar)	16:15 - 16:25
OA10-178-13	Prevalence of bedaquiline-resistant TB in three provinces of South Africa Harry Moultrie (Johannesburg, South Africa)	16:25 - 16:35
OA10-179-13	Facility-based screening for TB in pregnant and post-partum women in Papua New Guinea Anca Vasiliu (Houston, United States)	16:35 - 16:45
OA10-181-13	Report on oral second-line drug resistance rate of MDR/RR pulmonary TB in South Korea from 2018 to 2023 Seungmo Kim (Chungju, Korea, Republic of)	16:45 - 16:55
OA10-182-13	TB and associated factors in refugee camps in Ethiopia Abyot Meaza Dasho (Adiss Ababa, Ethiopia)	16:55 - 17:05
OA10-183-13	Enhancing TB case detection in Malawi: Non-monetary public-private mix engagement yields promising results Birru Shigut Gondol (Malawi)	17:05 - 17:15
OA10-184-13	UNMASK-TB: Face mask sampling for <i>M. tuberculosis</i> detection in children with pulmonary TB Lennard Meiwes (Borstel, Germany)	17:15 - 17:25
	Q&A	17:25 - 17:40

Symposium

16:10 - 17:40

JKA

SP10 - TB and the climate crisis: Why we need to wake up

Palwasha Yousafzai Khan (London, United Kingdom)

Finn McQuaid (London, United Kingdom)

SP10-462-13	Introduction	16:10 - 16:15
SP10-463-13	How can climate displacement increase vulnerability? Uzma Khan (Montreal, Canada)	16:15 - 16:29
SP10-464-13	How can worsening air quality drive risk of disease? Stephan Schwander (Piscataway NJ, 07052, United States)	16:29 - 16:43
SP10-465-13	How can climate-driven nutritional stress affect burden? Rebecca Clark (London, United Kingdom)	16:43 - 16:57
SP10-466-13	How can climate events disrupt services? Siti Rofiqah Nuriyah (Bogor, Indonesia)	16:57 - 17:11
SP10-467-13	What do we need to do to climate-proof TB prevention and care? Jeremiah Chakaya (Nairobi, Kenya)	17:11 - 17:25
SP10-468-13	Q&A	17:25 - 17:40

Symposium

16:10 - 17:40

JKB

SP11 - Standards for training content creation

Amar Shah (India)

Shibu Balakrishnan (India)

SP11-469-13	Introduction	16:10 - 16:15
SP11-470-13	Modernized Training of HCW in Netherlands Niesje Jansen (The Hague, Netherlands)	16:15 - 16:29
SP11-471-13	Training Content Development in NTP Indonesia Wayan Gede Artawan Eka Putra (Denpasar, Indonesia)	16:29 - 16:43
SP11-472-13	The Union Courses Caroline Bennett (France)	16:43 - 16:57
SP11-473-13	Training content development systems and processes in South Africa Munira Khan (Durban, South Africa)	16:57 - 17:11
SP11-474-13	Digital Content Development System for NTEP, India Manu Easow Mathew (New Delhi, India)	17:11 - 17:25
SP11-475-13	Q&A	17:25 - 17:40

Symposium

16:10 - 17:40

MD

SP12 - TB and mental health integration is urgent and possible: Lessons from WHO feasibility pilots in Ghana, Kenya, and Pakistan

Annabel Baddeley (Geneva, Switzerland)

Mohammed Yassin (Geneva, Switzerland)

SP12-476-13	Introduction	16:10 - 16:15
SP12-477-13	TB and mental health: What do we know? Annika Sweetland (New York, United States)	16:15 - 16:30
SP12-478-13	TB and mental health integration: lessons from Ghana Kafui Senya (Accra, Ghana)	16:30 - 16:45
SP12-479-13	TB and mental health integration: lessons from Kenya Immaculate Kathure (Kenya)	16:45 - 17:00
SP12-480-13	TB and mental health integration: lessons from Pakistan Khawaja Laeeq Ahmad (Islamabad, Pakistan)	17:00 - 17:15
SP12-481-13	Q&A	17:15 - 17:30

Oral Abstract Session

16:10 - 17:40

NS1

OA11 - Innovative strategies for TB care: Co-creation, community engagement, closing the treatment

Weibing Wang (Shanghai, China)

	Introduction	16:10 - 16:15
OA11-186-13	Learning and innovation can adapt care to population needs: A decentralised model of TB prevention and care in highly populated urban areas of Manila, Philippines Mary Ruth Roxas (Manila, Philippines)	16:15 - 16:24
OA11-187-13	Co-creating an innovation intervention through a people-centered design process for re-imagining TB care: Reflections from Uganda	16:24 - 16:33

	Achilles Katamba (Kampala, Uganda)	
OA11-188-13	Project 'PAR CARIOCA': Aligning quality TB care into extremely vulnerable population Fernando Augusto Dias e Sanches (Rio de Janeiro, Brazil)	16:33 - 16:42
OA11-189-13	Closing the gap of finding the missing people with TB through intensified community-based intervention: Experience from Ogun state, Nigeria Musibau Akande Tijani (Abeokuta, Nigeria)	16:42 - 16:51
OA11-190-13	Systematic triaging of severely ill: Addressing the predictors of early deaths among persons with TB in Delhi, India Lakshmi Aravindakshan (New Delhi, India)	16:51 - 17:00
OA11-191-13	Addressing high rates of loss to follow-up: Implementation of the person-centered care model for people with TB at Kalingalinga clinic in Lusaka, Zambia Gillian Kabeba (Lusaka, Zambia)	17:00 - 17:09
OA11-192-13	Closing the gap in TB treatment success rates (TSR) in the Ankole region, Uganda: The role of the TB/HIV Root Cause Analysis (RCA) tool Atlang Mompe (Washington DC, United States)	17:09 - 17:18
OA11-193-13	Contribution of alternative courier specimen referral to enhance access to TB diagnostic in Ethiopia Gudeta Tibesso (Addis Ababa, Ethiopia)	17:18 - 17:27
	Q&A	17:27 - 17:40
 <i>Symposium</i>		
	16:10 - 17:40	NS2
	SP13 - Going beyond Xpert and Truenat towards a new class of low complexity molecular technologies: WHO TB diagnostic guidelines update Nazir Ismail (Johannesburg, South Africa) Marguerite Massinga Loembe (Libreville, Gabon)	
SP13-482-13	Q&A	16:10 - 16:15
SP13-483-13	Update of WHO TB diagnostic guidelines: new classes of diagnostic technologies Alexei Korobitsyn (Geneva, Switzerland)	16:15 - 16:29
SP13-484-13	Systematic reviews informing the policy update Yemisi Takwoingi (Birmingham, United Kingdom)	16:29 - 16:43
SP13-485-13	Economic evidence informing WHO policy update Alice Zwerling (Ottawa, Canada)	16:43 - 16:57
SP13-486-13	WHO prequalification process for new TB molecular products for the diagnosis of TB and drug resistance Irena Prat (Geneva, Switzerland)	16:57 - 17:11
SP13-487-13	The emerging diagnostic landscape of new low-complexity molecular technologies: A lens into Asia Sarabjit Chandha (Delhi, India)	17:11 - 17:25
SP13-488-13	Q&A	17:25 - 17:40

Special Session

16:10 - 17:40

NS3

SPS02 - Combatting Big Tobacco: Uniting against industry influence on public health

Allen Gallagher (United Kingdom)

Tara Singh Bam (Singapore)

Session introduction

16:10 - 16:15

Monitoring Tobacco Industry Interference Index: Findings, challenges, opportunities

16:15 - 16:30

Yodhim Dela Rosa (Thailand)

Flagging Tobacco Online Marketing: The Challenges and Solutions

16:30 - 16:45

Enrico Aditjondro (Indonesia)

Protecting Public Health: Mobilizing Communities Against Tobacco Industry Influence

16:45 - 16:55

Sonu Goel (Chandigarh, India)

The Tobacco Industry Interference in Policy Development and E-cigarette marketing in Indonesia

16:55 - 17:10

Putu Ayu Swandewi Astuti (Indonesia)

Panel discussion with Q&A

17:10 - 17:40

Community Connect

16:30 - 17:30

AU

CCSA007 - Driving innovation in TB vaccine advocacy, policy, and access to End TB: An interactive community and civil society discussion

Shaun Palmer (Netherlands)

Priyanka Aiyer (India)

Shaun Palmer (Netherlands)

Introduction

16:30 - 16:35

Realising the role of middle-income high burden countries

16:35 - 16:43

Fernanda Dockhorn (Brasília, Brazil)

Consensus statement on the inclusion of pregnant and lactating women in TB vaccine research

16:43 - 16:51

Nomathamsanqa Majozi (South Africa)

Stakeholder voices in the WHO TB vaccine accelerator council

16:51 - 16:59

Birgitte Giersing (Switzerland)

TB vaccine development: Research institute perspective

16:59 - 17:07

Alexander Schmidt (United States)

TB vaccine development: Non-profit perspective

17:07 - 17:15

Shelly Malhotra (United States)

Question and answer

17:15 - 17:30

Community Connect

16:30 - 17:30

SG

CCSS010 - Breaking the silence: TB survivors share their mental health journeys

Vashita Madan (India)

Chapal Mehra (India)

Introduction

16:30 - 16:36

The hidden cost of TB: The psychological journey of TB diagnosis and treatment

16:36 - 16:42

Sachin Atre (India)	
Affected community perspectives: How social isolation and stigma impact TB care	16:42 - 16:48
Akshata Acharya (India)	
Integrating mental healthcare into TB treatment programmes	16:48 - 16:54
Ashna Ashesh (India)	
Healthcare professionals' perspectives on mental health support for people with TB	16:54 - 17:00
Divya Sojan (India)	
Question and answer	17:00 - 17:15
<i>Community Connect</i>	
17:00 - 17:30	EG2
CCLP001 - "Small Steps, Big Hopes" by Yayasan Rekat Peduli Indonesia	
<i>Union Live Session</i>	
17:00 - 17:30	UL
UL12 - A panel of students discuss their work in the fight against TB and lung disease and Wednesday highlights from the conference floor	
<i>Side Meeting</i>	
18:00 - 19:30	HB
SM08 - Childhood Pneumonia WG	
<i>Satellite Session</i>	
18:00 - 19:30	FR
SS05 - The evolution of adherence support through digital tools: Insights on engagement, sustainable integrations, actionable data, and the future with AI	
Rachel Powers (Netherlands)	
Inez de Kruijf-Carter (Netherlands)	
Introduction	18:00 - 18:10
Engagement with Digital Adherence Technologies: A Multi-Country Analysis for Enhanced Patient Care	18:10 - 18:25
Tofik Abdurhman (Ethiopia)	
Integrating Digital Adherence Technologies into National Programs: Overcoming Barriers and Achieving Sustainability	18:25 - 18:40
Baraka Onajre (Tanzania)	
Data-Driven Care: Unlocking the Power of Digital Adherence	18:40 - 18:55
Norma Madden (The Hague, Netherlands)	
Gamechangers in the provision of TB care: How AI and user-empowering solutions will improve digital treatment support	18:55 - 19:10
Kristian van Kalmthout (Netherlands)	
Q&A	19:10 - 19:30
<i>Satellite Session</i>	
18:00 - 19:30	BG
SS04 - China's innovations contribute to End TB targets	
Liang Li (China)	
Yu Pang (China)	
Opening remarks	18:00 - 18:05

Overall introduction of Innovation Alliance on Tuberculosis Diagnosis and Treatment	18:05 - 18:15
Yuhong Liu (China)	
The Achievements of Tuberculosis Infection Screening in China by Using TB-IGRA	18:15 - 18:25
Lingna Lyu (China)	
Progress towards more equitable access to diagnosis of TB	18:25 - 18:35
Adam Penn-Nicholson (Switzerland)	
Innovative tuberculosis diagnostic technologies for TB high-burden countries	18:35 - 18:45
Jianrong Lou (China)	
Development of rapid and highly sensitive molecular POCT diagnostic technology for tuberculosis	18:45 - 18:55
Xiang Li (Beijing, China)	
Artificial intelligence imaging products and system solutions for active screening for pulmonary tuberculosis	18:55 - 19:05
Wei Liu (China)	
From screening and drug-resistance testing to non-tuberculosis mycobacterium identification	19:05 - 19:15
Qingge Li (China)	
Q&A	19:15 - 19:30
<i>Side Meeting</i> 18:00 - 19:30	OC
SM09 - Asia Pacific region 1	
<i>Side Meeting</i> 18:00 - 19:00	JKA
SM10 - TB and Migration WG	
<i>Satellite Session</i> 18:00 - 19:30	JKB
SS06 - What will it take to meet the needs of people with TB wherever they seek care? Exploring private sector engagement	
Mohammed Yassin (Geneva, Switzerland) Robert Makombe (South Africa)	
Introduction	18:00 - 18:05
Global overview: Progress in advancing public-private sector engagement and accountability	18:05 - 18:16
Hannah Monica Dias (Switzerland)	
Engagement of all care providers in TB care and prevention: what lessons have we learned in Kenya?	18:16 - 18:27
Jeremiah Chakaya (Nairobi, Kenya)	
Contracting for private sector engagement	18:27 - 18:38
William Wells (United States)	
Lessons from Big Chain Hospital TB public-private mix engagement in Indonesia	18:38 - 18:49
Lia Gardenia Partakusuma (Indonesia)	
Private-for-Profit Engagement models and strategies	18:49 - 19:00

Syed Imran Farooq (Indonesia)

Panel discussion

19:00 - 19:15

Q&A

19:15 - 19:30

Side Meeting

18:00 - 19:00

MD

SM11 - TB and mental health WG

Thursday, 14. November 2024*TBScience Session*

08:00 - 09:00

AU

TBS2A - Fundamental advances in understanding pathogenesis

Willem Hanekom (South Africa)

TBS2A-10	Session welcome	08:00 - 08:03
TBS2A-15	M. tuberculosis strategies for restricting activation of innate immune pathways Amy Barczak (United States)	08:03 - 08:18
TBS2A-20	Effect of BCG vaccination in cattle Abebe Fromsa Merga (Ethiopia)	08:18 - 08:33
TBS2A-25	Lessons learned from IV BCG vaccination of NHPs Charles Scanga (United States)	08:33 - 08:48
TBS2A-30	Q&A	08:48 - 09:00

Side Meeting

08:00 - 09:00

BG

SM12 - TB infection control WG*Satellite Session*

08:00 - 09:00

JKA

SS07 - New advances in TB diagnosis: From diagnosing latent TB with IGRA testing to implementing targeted sequencing for drug-resistant TB

Debkishore Gupta (India)

	Introduction	08:00 - 08:05
	VIDAS® TB-IGRA analytical and clinical performances with a focus on specific patients populations Keertan Dheda (Cape Town, South Africa)	08:05 - 08:25
	Q&A	08:25 - 08:30
	Targeted next-generation sequencing for drug-resistant tuberculosis detection Swapna Uplekar (Switzerland)	08:30 - 08:50
	Q&A	08:50 - 09:00

Satellite Session

08:00 - 09:00

JKB

SS08 - From insights to action: Bolstering National TB Programmes and results through improved data and information systems

Sabrina Eagan (United States)

Anastasia Susanto (Indonesia)

	Welcome/Introduction	08:00 - 08:03
	Presenting Mr Hadi	08:03 - 08:04
	Improving TB Screening, Prevention, Case Management, and Linkage Through Digital Innovations: Lessons from Pakistan Syed Hussain Hadi (Pakistan)	08:04 - 08:10
	Presenting Dr Anis	08:10 - 08:11

	Supporting Health Workers Through Interoperability: Reducing Data Entry Burden and Improving Access to Quality Data in Indonesia	08:11 - 08:17
	Anis Hariri (Indonesia)	
	Presenting Dr. Mugomeri	08:17 - 08:18
	Subnational Roll-Out of Making Sense of TB Data in Zimbabwe	08:18 - 08:24
	Eltony Mugomeri (Zimbabwe)	
	Presenting Nikki	08:24 - 08:25
	Data to Action Assessments: Cross-Country Look at Findings and Proposed Actions to Strengthen Country TB Data Use	08:25 - 08:31
	Nikki Davis (United States)	
	Transition	08:31 - 08:32
	Panel discussion	08:32 - 09:00
<i>Union Live Session</i>		
	08:30 - 09:30	UL
UL13 - Messages from our event sponsors		
<i>Community Connect</i>		
	09:00 - 10:00	SG
CCSS011 - Innovative models to bring new TB tools from the clinic to communities: The role of Product Development Partnerships		
Shaun Palmer (Netherlands)		
Robyn Waite (Ottawa, Canada)		
Ganendra Kristandya (Indonesia)		
	Introduction	09:00 - 09:05
	Advancing TB vaccines through licensure	09:05 - 09:15
	Saif ul Hadi (India)	
	Innovating TB treatments to tackle drug resistance	09:15 - 09:25
	Pietro Turilli (United States)	
	Next-generation diagnostics to find the missing millions	09:25 - 09:35
	Kavindhran Velen (Switzerland)	
	Community action for new TB tools	09:35 - 09:45
	Ani Hernasari (Indonesia)	
	Question and answer	09:45 - 10:00
<i>TBScience Session</i>		
	09:05 - 09:50	AU
TBS2B - Fundamental advances in understanding pathogenesis - Oral Abstracts		
Henry Mwandumba (United Kingdom)		
TBS2B-05	Session introduction	09:05 - 09:07
TBS2B-10	Evaluation of tongue swab and sputum-dipped swab molecular testing for TB on the novel Pluslife platform	09:07 - 09:14
	Job Mukwatamundu (Kampala, Uganda)	
TBS2B-15	A controlled human infection/antigenic challenge model using pulmonary delivery of live BCG and PPD to gain insights into TB immunopathogenesis	09:14 - 09:21

TBS2B-20	A 4-metabolite signature to diagnose pulmonary TB in adults and monitor treatment response Jeffrey Collins (Atlanta, United States)	09:21 - 09:28
TBS2B-25	Platelets drive neutrophil-mediated neuroinflammation in TB meningitis Keira Skolimowska (London, United Kingdom)	09:28 - 09:35
TBS2B-30	Q&A	09:35 - 09:50
<i>Oral Abstract Session</i>		
09:20 - 10:50		HB
OA12 - Innovative approaches for TB prevention and care		
Fuad Mirzayev (Geneva, Switzerland) Ari Probandari (Surakarta, Indonesia)		
	Introduction	09:20 - 09:25
OA12-194-14	Pixels to predictions: How use of artificial intelligence at radiology centres enhanced TB detection in Chikkaballapur, Karnataka, India Shazia Anjum (New Delhi, 110011, India)	09:25 - 09:35
OA12-195-14	Responsible AI framework for TB screening: Enhancing transparency and trust in AI integration Richa Pant (Pune, India)	09:35 - 09:45
OA12-196-14	Impact of predictive AI and NTEP interventions on adverse TB outcomes in India: Early multi-state learnings from India Aparna Chaudhary (New Delhi, India)	09:45 - 09:55
OA12-198-14	Redesigning Uganda's health system to achieve and sustain high-quality TB patient outcomes Abel Nkolo (Kampala, Uganda)	09:55 - 10:05
OA12-199-14	Incentivising care: Transformative approach under NTEP in Rajasthan, India Kanishtha Arora (Jaipur, India)	10:05 - 10:15
OA12-200-14	Impact of electronic stock cards on circumventing stock out of TB commodities in USAID TB LON 3 supported states (Ogun, Oyo, Osun, and Lagos), Nigeria Vivian Okafor (Lagos, Nigeria)	10:15 - 10:25
OA12-552-14	Expanding the availability of TB laboratory trainings to the private sector: augmentation of certified Xpert MTB/RIF Ultra trainers in the Philippines Ma. Cecilia Vanessa Serrano (Makati, Philippines)	10:25 - 10:35
	Q&A	10:35 - 10:50
<i>Oral Abstract Session</i>		
09:20 - 10:50		FR
OA13 - Airborne infection control and safety		
Martie van der Walt (South Africa) Sevim Ahmedov (Vienna, United States)		
	Introduction	09:20 - 09:25
OA13-201-14	Parameters for optimal ventilation beyond air changes per hour (ACPH) for planning interventions to reduce air-borne infection risk: Experiences from India's drug-resistant TB centres Tarak Shah (New Delhi, India)	09:25 - 09:35
OA13-202-14	TB infection prevention and control practices at healthcare	09:35 - 09:45

	settings in high HIV/TB burden Indian states Sumalata Chittiboyina (Hyderabad, India)	
OA13-203-14	Impact of mentorship and support practices on strengthening infection prevention and control in healthcare settings in Zimbabwe during COVID-19 pandemic Mildred Pepukai (Harare, Zimbabwe)	09:45 - 09:55
OA13-204-14	Effectiveness of workplace TB program in managing TB in global operations at an oil and gas company Gabriel Chia (Singapore, Singapore)	09:55 - 10:05
OA13-205-14	The heterogeneous evolution of the L2 major lineage MTB in urban agglomerations along the Yangtze River Basin in China Junhong Chen (Shenzhen, China)	10:05 - 10:15
OA13-206-14	Neonatal BCG vaccination does not prevent M. tuberculosis transmission within households Kristin Nelson (Atlanta, United States)	10:15 - 10:25
OA13-207-14	Strengthening TB infection control among healthcare workers during the COVID-19 pandemic in Zimbabwe Julia Ershova (Atlanta, United States)	10:25 - 10:35
	Q&A	10:35 - 10:50
 <i>Oral Abstract Session</i>		
	09:20 - 10:50	BG
	OA14 - Signature mapping for TB Chandramathi Samudi (Kuala Lumpur, Malaysia) Frederick Quinn (Athens, United States)	
	Introduction	09:20 - 09:25
OA14-208-14	A urinary biomarker study of TB immunopathology in ART naïve PLWHA Andrea B. Doltrario (New York, United States)	09:25 - 09:35
OA14-209-14	Self-powered rapid antigen-specific T cell response assay for M. tuberculosis infections Bo Ning (New Orleans, United States)	09:35 - 09:45
OA14-210-14	Delineating host-pathogen interactions along the TB spectrum in human tissues Carly Young (Cape Town, South Africa)	09:45 - 09:55
OA14-211-14	Validation of host protein signatures dually associated with TB pathogenesis in blood and lung Pumla Majozi (Durban, South Africa)	09:55 - 10:05
OA14-212-14	Overlooked inborn errors of IFN-γ immunity in adults with recurrent and/or disseminated mycobacterial infections: A retrospective study in a tertiary hospital in China Jingyu Zhou (Shanghai, China)	10:05 - 10:15
OA14-213-14	Blood transcriptomic signatures predict treatment outcomes in persons with drug-susceptible pulmonary TB Thomas Scriba (Cape Town, South Africa)	10:15 - 10:25
OA14-214-14	Novel subunit TB vaccine delivered by flagellin elicits protective humoral and cellular immunological responses in vivo Nkanyenzi Masondo (Durban, South Africa)	10:25 - 10:35
	Q&A	10:35 - 10:50

Oral Abstract Session

09:20 - 10:50

OC

OA15 - How could we improve TB services?

Lin Yan (Beijing, China)

Antonia Saktiawati (Yogyakarta, Indonesia)

	Introduction	09:20 - 09:25
OA15-216-14	Evaluating targeted strategies for declining TB burden in Kashmir, India Praveen Kumar Yadav (Delhi, India)	09:25 - 09:34
OA15-217-14	Evaluating the yield from TB diagnostic referrals from private pharmacies in Vietnam Tien Thi Hoai Pham (Ha Noi, Vietnam)	09:34 - 09:43
OA15-218-14	Linking non-TB diagnostic to TB-diagnostic health facilities leads to improved TB cure rate in rural settings: Case study of Karamoja Region-Uganda Etwom Alfred (Kampala, Uganda)	09:43 - 09:52
OA15-219-14	Understanding the TB-disability linkages: Preliminary findings from a pilot in India Ramya Ananthakrishnan (Chennai, India)	09:52 - 10:01
OA15-220-14	Factors associated with TB treatment initiation among bacteriologically negative individuals evaluated for TB: An individual patient data meta-analysis Sun Kim (Boston, United States)	10:01 - 10:10
OA15-221-14	Boosting TB detection in Cambodia: A quality improvement collaborative approach Kunthea Soch (Phnom Penh, Cambodia)	10:10 - 10:19
OA15-222-14	Implementing differentiated service delivery models for TB care to inform national policy in Uganda Odile Ferroussier-Davis (Atlanta, United States)	10:19 - 10:28
OA15-223-14	Perception of community stakeholders and healthcare providers with using drones for TB diagnosis in Nepal: An exploratory qualitative study Kritika Dixit (Kathmandu, Nepal)	10:28 - 10:37
	Q&A	10:37 - 10:50

Short Oral Abstract Session

09:20 - 10:50

JKA

SOA04 - The sleeper must not awaken: Detecting and preventing TB

Hanif Esmail (London, United Kingdom)

Shamala Devi Sekaran (Port Dickson, Malaysia)

	Introduction	09:20 - 09:25
SOA04-630-14	TPT for PLHIV in Mozambique: Eligibility, coverage, completion, April 2021-September 2023 Durval Respeito (Maputo, Mozambique)	09:25 - 09:32
SOA04-631-14	Impact of repeat courses of TB preventive treatment among people living with HIV in Nairobi, Kenya 2012-2021 Abraham Katana (Nairobi, Kenya)	09:32 - 09:39
SOA04-632-14	Coverage of TB preventive treatment cascade among people living with HIV in two districts in Yogyakarta Special Region, Indonesia Yanri Wijayanti Subronto (Yogyakarta, Indonesia)	09:39 - 09:46

SOA04-633-14	Sex differences in M. tuberculosis immunoreactivity risk in Blantyre, Malawi: A community-based prevalence survey Mphatso D. Phiri (Blantyre, Malawi)	09:46 - 09:53
SOA04-634-14	Enhancing asymptomatic TB detection through mobile active case finding initiatives Yu Yu Lwin (Yangon, Myanmar)	09:53 - 10:00
SOA04-635-14	Prevalence of subclinical pulmonary TB in Mozambique: Implications for TB screening Ivan Manhica (Maputo, Mozambique)	10:00 - 10:07
SOA04-636-14	Sub-clinical TB in participants of a national prevalence survey in Timor-Leste Lesy Atok (Dili, East Timor)	10:07 - 10:14
SOA04-637-14	Lung structure and function are relatively well-preserved, post-treatment, in subclinical pulmonary TB Angela Lau (Edmonton, Canada)	10:14 - 10:21
SOA04-638-14	The prevalence of asymptomatic TB among participants of community-based case-finding activities and common risk factors in 3 provinces in the Philippines Marianne Calnan (Chevy Chase, United States)	10:21 - 10:28
SOA04-639-14	Are diabetics at very high risk for TB infection? Learnings from B.E.S.T. undertaking, Mumbai, India Anilkumar Singal (Mumbai, India)	10:28 - 10:35
	Q&A	10:35 - 10:50
<i>Symposium</i>		
09:20 - 10:50		JKB
SP14 - Ending TB disparities in prisons through evidence-based, community-engaged approaches		
Salome Charalambous (Johannesburg, South Africa) Jason Andrews (Stanford, United States)		
SP14-489-14	Introduction	09:20 - 09:25
SP14-490-14	Active Tuberculosis case finding in Indonesian prisons (the ACTION study) Argita Salindri (Bandung, Indonesia)	09:25 - 09:39
SP14-491-14	From Innovation to Intervention: Advancing TB Control in Prisons as a Public Health Priority Julio Croda (Campo Grande, Brazil)	09:39 - 09:53
SP14-492-14	Isoniazid vs. 3HP: treatment completion and adverse events in a RCT conducted in the largest prison in Malaysia Sheela Sheno (New Haven, United States)	09:53 - 10:07
SP14-493-14	Spillover of excess TB risk from prisons to the community: evidence from Paraguay Guillermo Sequera (Paraguay)	10:07 - 10:21
SP14-494-14	Experience of retention in care interventions for formerly incarcerated people re-entering community settings in South Africa Nasiphi Ntombela (Johannesburg, South Africa)	10:21 - 10:35
SP14-495-14	Q&A	10:35 - 10:50

Short Oral Abstract Session

09:20 - 10:50

MD

SOA05 - Looking through the lens on drug-resistant TB: Operational research perspective

Alberto Garcia Basteiro (Manhiça, Mozambique)

Nicolas Veziris (Paris, France)

	Introduction	09:20 - 09:25
SOA05-640-14	Adverse event-free time while on short oral treatment for rifampicin-resistant TB Anita Mesic (Amsterdam, Netherlands)	09:25 - 09:32
SOA05-641-14	Efficacy and safety of BDL/M regimens for multi-drug-resistant and pre-extensively drug-resistant TB: Preliminary results from a multi-centre dual single-arm study Liang Fu (Shenzhen, China)	09:32 - 09:39
SOA05-642-14	Safety of new second-line drug-resistant TB medicine in children diagnosed with drug-resistant TB in KwaZulu Natal, South Africa Nirupa Misra (Durban, South Africa)	09:39 - 09:46
SOA05-643-14	Differentiated service delivery model in the treatment of people with drug-susceptible TB: Results from a prospective cohort study in Ethiopia Zenebe Melaku (Addis Ababa, Ethiopia)	09:46 - 09:53
SOA05-644-14	Integrated TB and leprosy screening among key populations in Northeast Nigeria Suraj Abdulkarim (Gombe, Nigeria)	09:53 - 10:00
SOA05-645-14	It is not only the duration of DR-TB treatment that counts but also the pill burden: Insights of people with DR-TB In Zambia Uchizi Chirwa (Lusaka, Zambia)	10:00 - 10:07
SOA05-646-14	Drug-resistant TB in Morobe Province, Papua New Guinea, 2012-2021 Lingayam Bumbu (Lae, Papua New Guinea)	10:07 - 10:14
SOA05-647-14	Determinants of unsuccessful treatment outcomes among people with TB in West Java 2020 - 2022 Nurmalita Hartiyana Kusuma Wardani (Depok, Indonesia)	10:14 - 10:21
SOA05-648-14	The treatment success rate of BPAL/M regimen among the first cohort of people with rifampicin-resistant TB in Pakistan Sobia Faisal (Islamabad, Pakistan)	10:21 - 10:28
	Q&A	10:28 - 10:43

Oral Abstract Session

09:20 - 10:50

NS1

OA16 - Pregnancy and reproductive health and TB

Jyoti Mathad (New York, United States)

Heda Melinda Nataprawira (Bandung, Indonesia)

	Introduction	09:20 - 09:25
OA16-224-14	M. tuberculosis infection in pregnancy: A systematic review Alison Abboud (Melbourne, Australia)	09:25 - 09:34
OA16-225-14	Burden and outcomes of TB in pregnant women: Insights from Mozambique Criménia Mbate-Mutemba (Maputo, Mozambique)	09:34 - 09:43
OA16-226-14	TB in vulnerable populations: A case study of pregnant women across nine secondary facilities in Kano, Nigeria	09:43 - 09:52

	Husna Baffa (Kano, Nigeria)	
OA16-227-14	TB infection in infertile women: A multi-center study in China (TB-PRIME study) Qiaoling Ruan (Shanghai, China)	09:52 - 10:01
OA16-228-14	Perinatal outcomes of TB in pregnant women with in vitro fertilisation: A retrospective multi-centered cohort study Xuhui Liu (Shanghai, China)	10:01 - 10:10
OA16-229-14	TB treatment outcomes among pregnant women living with HIV with presumably drug-susceptible TB Natalia Hernandez Morfin (Baltimore, United States)	10:10 - 10:19
OA16-230-14	TB infection conversion among pregnant women living with HIV: A sentinel screening study at three Ugandan health facilities Irene Andia-Biraro (Kampala, Uganda)	10:19 - 10:28
OA16-231-14	TB preventive treatment for pregnant women with HIV in South Africa: A modeling analysis of clinical benefits and risks Krishna Reddy (Boston, United States)	10:28 - 10:37
	Q&A	10:37 - 10:50
<i>Oral Abstract Session</i>		
	09:20 - 10:50	NS2
	OA17 - TB preventative therapy, impediments, challenges and successes	
	Dick Menzies (Montreal, Canada) Finny Fitry Yani (Padang, West Sumatera, Indonesia)	
	Introduction	09:20 - 09:25
OA17-232-14	Comprehensive evaluation of TB preventive treatment for household contacts in Andhra Pradesh, India Danie franklin Ravikumar (Kurnool, India)	09:25 - 09:34
OA17-233-14	Acceptability of a hypothetical TB preventive therapy regimen among contact persons of multi-drug-resistant TB in high burden countries: A qualitative study Harsimren Sidhu (Montreal, Canada)	09:34 - 09:43
OA17-234-14	Leveraging tele-consultation (E-Sanjeevani) for initiating TB preventive therapy among contacts of people with TB at the community level: A case-study from Manipur, India Priya Kotwani (New Delhi, India)	09:43 - 09:52
OA17-235-14	Improving TB preventive cascade of care in hard-to-reach populations Grigory Volchenkov (Russian Federation)	09:52 - 10:01
OA17-236-14	Adverse drug reactions to isoniazid and rifapentine had no association with discontinuation/missed doses of treatment during the programmatic rollout of TB preventive treatment in Uganda Christine Sekaggya-Wiltshire (Kampala, Uganda)	10:01 - 10:10
OA17-237-14	Correlation between TB preventive treatment uptake and proportion of women who initiated ART during pregnancy Stephanie O'Connor (Atlanta, United States)	10:10 - 10:19
OA17-238-14	Incentives as a driver for improved TB preventive treatment uptake: Findings from Kaduna State Victor George (Kaduna, Nigeria)	10:19 - 10:28
OA17-239-14	Can community mobilisation and efficient local networks improve TB preventive treatment uptake? The Kano State experience	10:28 - 10:37

	Iboro Gordon (Abuja, Nigeria)	
	Q&A	10:37 - 10:50
	<i>Oral Abstract Session</i>	
	09:20 - 10:50	NS3
	OA18 - TB trends in distressed masses	
	Eduard Kambou Sansan (Abidjan, Cote D'Ivoire)	
	Anthony D Harries (United Kingdom)	
	Introduction	09:20 - 09:25
OA18-240-14	Implementation approach of integrated CAST-TB campaigns in Uganda: Community awareness, screening, testing, prevention and treatment of TB	09:25 - 09:34
	Seyoum Dejene Balcha (Kampala, Uganda)	
OA18-241-14	Examining the influence of insurgency-driven internally displaced persons (IDP) camps and refugee camps on TB transmission: A case study from Benue State, Nigeria	09:34 - 09:43
	Uduak Bassey (Makurdi, Nigeria)	
OA18-242-14	Could this be an epidemic of TB in Guma Internally Displaced Persons Camp, Benue State? Wellness on wheels truck story from World TB Day Week	09:43 - 09:52
	Bethrand Odume (Abuja, Nigeria)	
OA18-243-14	Challenges for provision of TB services for internally displaced people at the Resettlement Center in Cabo Delgado, Mozambique	09:52 - 10:01
	Julia Honwana (Maputo, Mozambique)	
OA18-244-14	TB treatment seeking patterns and needs of refugees in North-East Nigeria	10:01 - 10:10
	Stephen John (Yola, Nigeria)	
OA18-245-14	Innovative interventions to accelerate detection of TB in the urban-based, key and vulnerable population in four metropolitan cities of India	10:10 - 10:19
	Sugata Mukhopadhyay (New Delhi, India)	
OA18-247-14	The engagement of the TB-affected street activist (or TASA) in the fight against TB in India	10:19 - 10:28
	Sugata Mukhopadhyay (New Delhi, India)	
	Q&A	10:28 - 10:41
	<i>Community Connect</i>	
	09:30 - 10:30	EG2
	CCSE001 - United for TB elimination: Collaborative strategies for broadening impact and mobilizing multi stakeholder	
	Nurliyanti Nurliyanti (South Jakarta, Indonesia)	
	Henry Diatmo (Indonesia)	
	Broadening the impact: Investing in civil society for effective TB elimination	09:30 - 09:30
	Yaser Panigoro (Indonesia)	
	Mobilizing multi-stakeholders in ending TB in Indonesia	09:30 - 09:30
	Nurul Luntungan (Indonesia)	
	Dual approach: Harnessing community and clinical strengths to end TB	09:30 - 09:30
	Dyah Erti Mustikawati (Indonesia)	

Union Live Session

09:30 - 10:00

UL

UL14 - Messages from our event sponsors and a Youth 4 Lung Health panel discussion*TBScience Session*

10:00 - 11:00

AU

TBS2C - What role do B cells have in protection against TB? What do we have to learn?

Sarah Fortune (United States)

TBS2C-05	Session introduction	10:00 - 10:03
TBS2C-10	B-cell responses in the human lung Al Leslie (South Africa)	10:03 - 10:13
TBS2C-15	TB-specific antibodies can stimulate inflammasome assembly to protect against experimental infection Babak Javid (United Kingdom)	10:13 - 10:23
TBS2C-20	Setting the stage for protective immunity to Mtb: antibodies as adjuvants Sarah Fortune (United States)	10:23 - 10:33
TBS2C-25	Q&A	10:33 - 11:00

Union Live Session

10:00 - 10:30

UL

UL15 - Interviews with Florent Geerts, Takuma Otsuka and Sok Chamreun Choub*Community Connect*

10:15 - 11:00

SG

CCSS012 - Increasing accountability for TB policy implementation in South Africa

Michelle Galloway (South Africa)

Erika Mohr-Holland (Cape Town, South Africa)

	Introduction	10:15 - 10:21
	Securing political commitments for TB policy implementation at a TB Imbizo in the Western Cape province of South Africa Janet Giddy (South Africa)	10:21 - 10:27
	Community leader mentorship: A grassroots approach to TB advocacy and accountability Renier Coetzee (South Africa)	10:27 - 10:33
	Strengthening accountability for implementation of national TB strategies Russell Rensburg (South Africa)	10:33 - 10:39
	Implementing the OneImpact South Africa approach: Early success stories from community-led accountability Harry Hausler (South Africa)	10:39 - 10:45
	Question and answer	10:45 - 11:00

Union Live Session

10:30 - 11:00

UL

UL16 - Interviews with Dr. Yuhong Liu, Prof. Yu Pang and Dr. Jacob Creswell

Union Live Session

11:00 - 11:10

UL

UL17 - Messages from our event sponsors*Plenary Session*

11:10 - 12:10

MG

PL-02 - Child pneumonia diagnosis and management in low-and middle-income countries: Working towards 2030

Rebecca Nantanda (Uganda)

Session introduction

11:10 - 11:15

Tools for frontline healthcare workers to manage children with pneumonia - global perspective

11:15 - 11:30

Yasir Bin Nisar (Switzerland)

Implementation research on increasing the treatment coverage of child pneumonia in Malawi - lessons learned and way forward

11:30 - 11:45

Humphreys Nsona (Malawi)

Improving access to pulse oximetry and oxygen therapy for severe childhood pneumonia in low-resource settings

11:45 - 12:00

Stephen Howie (New Zealand)

Panel discussion

12:00 - 12:10

Plenary Session

11:10 - 12:10

EG2

PL002 - Child pneumonia diagnosis and management in low-and middle-income countries: Working towards 2030 (Broadcasted)*Union Live Session*

11:10 - 12:10

UL

ULPL02 - Child pneumonia diagnosis and management in low-and middle-income countries: Working towards 2030*E-Posters*

12:15 - 13:15

M EP1

EP07 - TB Elimination through accessibility

Chandramathi Samudi (Kuala Lumpur, Malaysia)

EP07-657-14

Improving diagnostic accuracy of TB in adults through the use of stool specimens for the diagnosis of pulmonary TB in adults

12:15 - 12:20

Judith Mzyece (Lusaka, Zambia)

EP07-658-14

Implementation of *N-acetyltransferase 2 (NAT2)* genotype testing services for people with TB in a provincial hospital in northeastern Thailand

12:20 - 12:25

Thamarerk Sangngan (Roi Et, Thailand)

EP07-659-14

Diagnostic yield of Xpert Ultra in stool specimens from children attending the private health sector in Pakistan

12:25 - 12:30

Azadar Gillani (Islamabad, Pakistan)

EP07-660-14

Genome sequencing of *M. tuberculosis* complex strain from Lesotho

12:30 - 12:35

Mooko Matobo (Maseru, Lesotho)

EP07-661-14

Revitalising access to diagnostics after conflict in Tigray region, Ethiopia

12:35 - 12:40

Gudeta Tibesso (Addis Ababa, Ethiopia)

EP07-662-14	Improving GeneXpert machines uptime in Ethiopia: Overcoming maintenance hurdles Endale Mengesha (Addis Ababa, Ethiopia)	12:40 - 12:45
EP07-663-14	Performance of TB diagnostic network in its ability to meet the needs of the Country's National Strategic Plan: Kenya's experience Nellie Mukiri (Nairobi, Kenya)	12:45 - 12:50
EP07-664-14	A novel 3-gene host response blood-based test for treatment monitoring in rifampicin-resistant TB: Interim results Yilin Zhang (Shanghai, China)	12:50 - 12:55
EP07-665-14	Olink proteomic analysis of immune proteins from the serum of people with non-tuberculous mycobacteria and M. tuberculosis Li Wang (Shanghai, China)	12:55 - 13:00
	Q&A	13:00 - 13:10
<i>E-Posters</i>		
12:15 - 13:15		M EP2
EP08 - Community participation: Treasure for TB		
Esty Febriani (Jakarta Selatan, Indonesia)		
EP08-666-14	Treatment adherence of people with drug-resistant TB in taking medication based on peer educator characteristic Nur Widayati (Yogyakarta, Indonesia)	12:15 - 12:21
EP08-667-14	Empowerment of local self-governing bodies to accelerate TB elimination efforts in Himachal Pradesh, India Aatmika Gopimohan Nair (Delhi, India)	12:21 - 12:27
EP08-668-14	The value of community engagement prioritising a multi-sectoral holistic approach when conducting TB clinical trials in the Matlosana sub-district of South Africa Blossom Makhubalo (Klerksdorp, South Africa)	12:27 - 12:33
EP08-669-14	Survivor-led networks as a catalyst to end TB in high-burden countries: A case study of Indian networks Raghavan Gopa Kumar (New Delhi, India)	12:33 - 12:39
EP08-670-14	Fostering women's health and community bonding: Designing health camps for integrated testing and social interactions Aheli Basu (Delhi, India)	12:39 - 12:45
EP08-672-14	Empowering local leaders: A catalyst for social mobilisation for TPT education in West Java Oetari Cinthya Bramanty (Jakarta, Indonesia)	12:45 - 12:51
EP08-673-14	Finding the missing people with TB in Nigeria: Has community active case finding helped in childhood TB diagnosis? Insights from Kano State Sani Useni (Abuja, Nigeria)	12:51 - 12:57
EP08-674-14	Jeelo Dobara: Community-led, co-created social media campaigns to boost COVID-19 vaccine confidence and uptake in Karachi, Pakistan Kainat Khurshid (Karachi, Pakistan)	12:57 - 13:03
	Q&A	13:03 - 13:15

E-Posters

12:15 - 13:15

M EP3

EP09 - Managing TB

Andrea Cabibbe (Milano, Italy)

EP09-675-14	Avoidable hospitalisations from TB meningitis in Karachi, Pakistan Sadia Shakoor (Karachi, Pakistan)	12:15 - 12:20
EP09-676-14	Clinical significance of hyponatremia in TB meningitis: A prospective cohort in Indonesia Arjan Van Laarhoven (Nijmegen, Netherlands)	12:20 - 12:25
EP09-677-14	An evaluation of the TB infection treatment care cascade among pregnant women in a low-burden setting Meredith Brooks (Boston, United States)	12:25 - 12:30
EP09-678-14	Experience working with private laboratories for QuantiFERON®-TB Gold testing to scale up LTBI diagnosis in Ukraine Liudmyla Skoklyuk (Kyiv, Ukraine)	12:30 - 12:35
EP09-679-14	Limited availability of TBI diagnostic testing in 24 USAID high TB burden countries Peter R. Kerndt (Washington, United States)	12:35 - 12:40
EP09-680-14	Resistance to 1st-line treatment in people with pulmonary tuberculosis enrolled the IeDEA TB-SRN cohort in Abidjan, Côte d'Ivoire Olivier Marcy (Bordeaux, France)	12:40 - 12:45
EP09-681-14	Diagnosis of TB infection among household contacts using tuberculin skin test and QuantiFERON®-TB Gold Plus in 9 high TB burden provinces in Vietnam, 2023 Ha Thi Thuy Nguyen (Hanoi, Vietnam)	12:45 - 12:50
EP09-682-14	The prevalence and determinants of TB infection among households and close contacts of persons with TB in Cambodia Sovanvorleak Tep (Phnom Penh, Cambodia)	12:50 - 12:55
EP09-683-14	Differentiated care for TB: What works, how it works and for whom does it work? An experience from three Indian States Puja Ambule (New Delhi, India)	12:55 - 13:00
	Q&A	13:00 - 13:15

E-Posters

12:15 - 13:15

M EP4

EP10 - Gender and TB

Priyanka Aiyer (India)

EP10-684-14	Healthcare seeking behavior and gender differences among people with presumptive TB: Preliminary results from the 3rd national TB prevalence survey in Cambodia Kim Eam Khun (Phnom Penh, Cambodia)	12:15 - 12:20
EP10-685-14	Gendered barriers in TB care in Indonesia: Insights and recommendations for equity Dini Andriani (Jakarta, Indonesia)	12:20 - 12:25
EP10-686-14	Providing gender balanced TB services in the Philippines: What does it take? Marianne Calnan (Chevy Chase, United States)	12:25 - 12:30
EP10-687-14	Exploring gender-nuanced TB risk factors to design person-centred TB services	12:30 - 12:35

	Marianne Calnan (Chevy Chase, United States)	
EP10-688-14	Gender differences of TB risk factors: Preliminary results from 52 clusters of the 3rd national TB prevalence survey in Cambodia Yom An (Phnom Penh, Cambodia)	12:35 - 12:40
EP10-689-14	Engaging LGBTQAI+ TB champions in India's TB elimination efforts Anupama Srinivasan (Chennai, India)	12:40 - 12:45
EP10-690-14	Exploring health needs and TB services access of LGBTQIA+ individuals in two cities in the Philippines Marianne Calnan (Chevy Chase, United States)	12:45 - 12:50
EP10-691-14	Community, rights, and gender issues at the heart of the TB response in Zimbabwe Kudzaishe Mutungamiri (Gweru, Zimbabwe)	12:50 - 12:55
EP10-692-14	Reciprocal dynamics: Gender-based violence and TB care in Bangladesh Tasnia Alam (Dhaka, Bangladesh)	12:55 - 13:00
	Q&A	13:00 - 13:15
<i>E-Posters</i>		
12:15 - 13:15		M EP5
EP11 - Improving treatment adherence		
Limakatso Lebina (South Africa, South Africa)		
EP11-693-14	Treatment adherence and cost-effectiveness of 6H and 3HP regimens for TB infection in Himachal Pradesh, India: A comparative study Aashul Heda (Shimla, India)	12:15 - 12:20
EP11-694-14	Increasing TPT uptake through continued healthcare worker sensitisation: The Kano State experience Gideon Zephaniah (Kano, Nigeria)	12:20 - 12:25
EP11-695-14	Optimising TPT uptake as a component of contact investigation strategy to mitigate spread of the TB scourge: The KNCV Nigeria TIFA experience Saidat Ibrahim (Kano, Nigeria)	12:25 - 12:30
EP11-696-14	Assessing India's TPT scale-up in the global context: Achievements, challenges, and insights for global strategies Hardik Solanki (New Delhi, India)	12:30 - 12:35
EP11-697-14	Implementing TB preventive therapy within differentiated HIV service delivery models: Experiences from a pilot study in North East Nigeria Suraj Abdulkarim (Gombe, Nigeria)	12:35 - 12:40
EP11-698-14	Acceptability of the 28-day TB preventive therapy regimen: Health workers perspective in Nigeria Stanley Chinkata (Umuahia, Nigeria)	12:40 - 12:45
EP11-699-14	Optimising TB preventive treatment eligibility using QuantiFERON-Plus (QFT-Plus) TB infection test amongst household contacts in Lesotho, 2022 Manthomeng Matete (Maseru, Lesotho)	12:45 - 12:50
EP11-700-14	Low enrolment of TB preventive treatment among childhood contacts and limited availability of the drugs at public health centers in North Sumatera, Indonesia Khairina Ulfa (Medan City, Indonesia)	12:50 - 12:55

EP11-701-14	Enhancing TB preventive therapy uptake through active contact investigation: Insights from Nigeria's private health sector Kelechi Nzeadibe (Abuja, Nigeria)	12:55 - 13:00
EP11-702-14	Implementation and effectiveness of a person-centered model of household contact investigation for TB preventive therapy in Uganda: A before and after study Muhammad Musoke (Kampala, Uganda)	13:00 - 13:05
	Q&A	13:05 - 13:15
<i>E-Posters</i>		
12:15 - 13:15		M EP6
EP12 - Education and training for optimal TB care and prevention		
Niesje Jansen (The Hague, Netherlands)		
EP12-703-14	Impact of TB-centred training on baseline knowledge in nurses offering HAST services in KwaZulu-Natal province, South Africa Munira Khan (Durban, South Africa)	12:15 - 12:20
EP12-704-14	Health education and training about TB in children and adolescents: Assessing skills and knowledge among healthcare workers in Lesotho Matlotliso Khesa (Maseru, Lesotho)	12:20 - 12:25
EP12-705-14	TB portals assist in training the next generation of doctors by integrating artificial intelligence into person-centric clinical resource Andrei Gabrielian (Rockville, United States)	12:25 - 12:30
EP12-706-14	Enhancing TB training for private healthcare providers through e-learning in Indonesia Rini Palupy (Jakarta, Indonesia)	12:30 - 12:35
EP12-707-14	Building sustainable competency-based training systems for community health workers: Insights from the TIFA-STOM project Iboro Gordon (Abuja, Nigeria)	12:35 - 12:40
EP12-708-14	Empowering mid-level healthcare providers: Strengthening community-level outreach of TB services through training and sustained skill building in Telangana, India Gone Srigana (Hyderabad, India)	12:40 - 12:45
EP12-709-14	Strengthening TB response at the grassroots: Capacity building of local self-government structures through Grama Arogya Initiative in Karnataka, India Elizabeth Joy (India, India)	12:45 - 12:50
EP12-710-14	Building nursing capacity in the Pacific through the pathway to the elimination of antibiotic-resistant and latent TB (and leprosy) in the Pacific (PEARL) project Amanda Christensen (Sydney, Australia)	12:50 - 12:55
EP12-711-14	Innovative cost-effective approaches to TB programme capacity building among healthcare workers in Katsina Hauwa Usman Garba (Katsina, Nigeria)	12:55 - 13:00
EP12-712-14	Standardising evaluation tools for innovative LTBI education: Insights from two LTBI ECHO programs in the US Erik Bratland (Worcester, United States)	13:00 - 13:05
	Q&A	13:05 - 13:15

TBScience E-Poster Session

12:15 - 14:15

M EP7

TBS-EP03 - Fundamental advances in understanding pathogenesis | Part 1

Al Leslie (South Africa)

TBS-EP-67	Systemic MMP-8 RNA expression upregulated in children with TB meningitis and associated with infarcts and hydrocephalus Julie Huynh (Ho Chi Minh City, Vietnam)	12:15 - 12:20
TBS-EP-53	M. tuberculosis-specific CFP-10/ESAT-6 CD4 and CD8 T cell non-IFN-γ responses are common in young Kenyan children despite low reported TB exposure Sylvia LaCourse (Seattle, United States)	12:20 - 12:25
TBS-EP-55	Utility of Xpert® MTB/RIF assay on formalin-fixed paraffin-embedded (FFPE) tissues in the diagnosis of extrapulmonary TB Neelima Sudharshan (Hyderabad, India)	12:25 - 12:30
TBS-EP-56	Increased innate immune and neutrophil blood transcriptomic signatures associate with poor outcome in HIV-1 TB meningitis James R. Barnacle (London, United Kingdom)	12:30 - 12:35
TBS-EP-54	Cerebrospinal fluid proteins and mortality of people with TB meningitis using unsupervised network analysis Arjan Van Laarhoven (Nijmegen, Netherlands)	12:35 - 12:40
TBS-EP-57	Integrating clinical trial data to validate the efficacy and safety profile of Cy-Tb, a new TB skin test Rakesh Lothe (Pune, India)	12:40 - 12:45
TBS-EP-58	Exploitation of ALOX5 signalling pathway improves therapeutic treatment of TB induced lung damage Thabo Mpotje (Durban, South Africa)	12:45 - 12:50
TBS-EP-59	Dysfunctional effector memory CD8 T cells in the bronchoalveolar compartment of people with uncontrolled HIV in the setting of latent TB infection Maphe Mthembu (Durban, South Africa)	12:50 - 13:00
TBS-EP-60	Blood and urine early treatment response biomarkers in HIV-associated TB: A prospective cohort study Linda Boloko (Cape Town, South Africa)	13:00 - 13:05
TBS-EP-51	Immunogenicity of H56:IC31 vaccination for prevention of TB recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary TB Anele Gela (Cape Town, South Africa)	13:05 - 13:10
TBS-EP-61	Granuloma Like Structure, a new model for evaluating the efficacy of anti-TB drugs as an alternative to macrophage monolayers Enrico Mastrostefano (Rome, Italy)	13:10 - 13:15
TBS-EP-62	Unravelling the pathogenesis of post-TB lung function impairment through serum proteomics Kathrin Held (Munich, Germany)	13:15 - 13:20
TBS-EP-63	Single-cell immunometabolic profiling of peripheral blood from people with M. tuberculosis and M. abscessus Wei Sha (Shanghai, China)	13:20 - 13:25
TBS-EP-64	Age-related impairment in host-response and compensatory mechanisms in HIV-associated M. tuberculosis sepsis Linda Boloko (Cape Town, South Africa)	13:25 - 13:30
TBS-EP-65	The altered differential genome-wide DNA methylation profile of peripheral blood mononuclear cells in pulmonary TB	13:30 - 13:35

	Ankit Kumar (Chandigarh, India)	
TBS-EP-66	Optimal processing of tongue swab samples for M. tuberculosis detection by the Xpert MTB/RIF Ultra assay David Alland (Newark, United States)	13:35 - 13:40
TBS-EP-68	Efficacy of energy-dense nutritional supplement in improving treatment outcomes in malnourished adults with drug-sensitive pulmonary TB: An open-label randomised controlled trial in India Rakesh Kumar (New Delhi, India)	13:40 - 13:45
TBS-EP-69	Intracellular and secreted cytokine profile of a TB and TB/HIV co-infected cohort in Kenya Asiko Ongaya (Nairobi, Kenya)	13:45 - 13:50
TBS-EP-70	Infection and disease caused by M. tuberculosis are associated with systemic depletion of long chain fatty acids in humans and primates Jeffrey Collins (Atlanta, United States)	13:50 - 13:55
TBS-EP03	Q&A	13:55 - 14:15
<i>Community Connect</i>		
12:30 - 13:30		AU
CCF002 - Films and documentaries		
	Devotion to Treatment by Caritas Tajikistan	12:30 - 12:40
	#MeriTBKiKahaani: Normalizing TB Conversations Breaking by The Union - South East Asia	12:40 - 12:58
	DR-TB Treatment: Fast Track the Cure by Yayasan KNCV Indonesia	12:58 - 13:03
	A New Hope: A Teacher's Story by Yayasan KNCV Indonesia	13:03 - 13:10
	Game Changer: Healing Minds to Cure TB by Annika Sweetland and Nacho Guevera	13:10 - 13:26
	Changing Lives by Dopasi Foundation	13:26 - 13:30
<i>Side Meeting</i>		
12:30 - 13:30		HB
SM13 - TB Undernutrition WG		
<i>Side Meeting</i>		
12:30 - 13:30		FR
SM14 - Gender Equity in TB WG		
<i>Side Meeting</i>		
12:30 - 13:30		OC
SM15 - Asthma management WG		
<i>Satellite Session</i>		
12:30 - 14:00		JKA
SS09 - Closing the gaps in testing for drug-resistant TB		
	Ana Maria Cárdenas (United States) Imran Pambudi (Jakarta, Indonesia)	
	Welcome and introductions	12:30 - 12:35

	Guidelines and common implementation gaps for the diagnosis of drug-resistant tuberculosis (DR-TB)	12:35 - 12:50
	Ana Maria Cárdenas (United States)	
	Closing the gap in the diagnosis of rifampicin-sensitive, isoniazid resistant tuberculosis (Hr-TB): Implementation experience with rapid molecular testing. Includes Q&A	12:50 - 13:15
	Budi Haryanto (Indonesia) Erlina Burhan (Jakarta, Indonesia)	
	Closing the gap in multi-drug resistant tuberculosis (MDR-TB): The critical role of phenotypic drug susceptibility testing in the era of tNGS. Includes Q&A	13:15 - 13:35
	Anita Suresh (Singapore, Singapore)	
	Looking beyond the laboratory: closing the gap between diagnosis, management, and transmission prevention in drug-resistant tuberculosis. Includes Q&A	13:35 - 13:55
	Melissa Richard-Greenblatt (Canada)	
	Final Q&A, closing	13:55 - 14:00
<i>Side Meeting</i>		
12:30 - 13:30		JKB
SM16 - MPOWER Research WG Side mtg		
<i>Union Live Session</i>		
13:00 - 13:30		UL
UL18 - Interview with Enla Fees, Director of Global Health - Stakeholder Engagement, Qure.ai		
<i>Paper Posters</i>		
13:20 - 14:20		M PPA
PP19 - Finding the missing people with TB		
Ya Diul Mukadi (Washington, DC, United States)		
PP19-971-14	Addressing TB pretreatment LTFU associated with outreach activities in congregate settings in Nigeria	13:20 - 13:25
	Chidimma Okoye (Abakaliki, Nigeria)	
PP19-972-14	Bridging gaps in child TB detection through innovative testing week in Nigeria	13:25 - 13:30
	Ochuko Urhioke (Abuja, Nigeria)	
PP19-973-14	Re-engineering the role of accredited social health activists: A community-based mixed-methods intervention study from Chandauli, Uttar Pradesh, India	13:30 - 13:35
	Vinod Kumar V.G. (New Delhi, 110011, India)	
PP19-974-14	Improving TB detection through targeted facility-based screening of hospital attendees in twenty-five health facilities in Kaduna state, North-West Nigeria	13:35 - 13:40
	Habiba Jummai (Kaduna, Nigeria)	
PP19-975-14	A tale of two cities: Comparing the yield of three active case finding strategies in the Erase TB project	13:40 - 13:45
	Lan Phuong Nguyen (Ho Chi Minh City, Vietnam)	
PP19-976-14	Quantifying sputum production challenges as a barrier to community-based TB screening: Experiences from Uganda	13:45 - 13:50
	Peter James Kitonsa (Kampala, Uganda)	
PP19-977-14	Innovative strategies for active TB case finding in NYSC camp: A study of the WoW and WoK Mobile Diagnostic Units in Nigeria	13:50 - 13:55

	Jerrald Ogogo (Abuja, Nigeria)	
PP19-978-14	Strengthening TB detection and treatment adherence through social contact invitations in Kikuyu and Kabete Sub County, Kiambu County, Kenya Annfreshia Maina (Nairobi, Kenya)	13:55 - 14:00
PP19-979-14	Community outreach for enhanced TB detection and preventive treatment initiation in the National Capital District of Papua New Guinea Catherine Ramoni (National Capital District, Papua New Guinea)	14:00 - 14:05
PP19-980-14	Using spatial network analysis to identify potential locales of community transmission of drug-resistant TB in two high-burden settings in South Africa Rebecca Berhanu (Johannesburg, South Africa)	14:05 - 14:10
	Q&A	14:10 - 14:20
 <i>Paper Posters</i> 13:20 - 14:20		
		M PPB
PP20 - TB pharmacology		
Ivan Pradipta (Bandung, Indonesia)		
PP20-981-14	Paediatric pharmacokinetics of first-line TB drugs in Haitian children under 5 years and accuracy of a finger stick capillary sampling technique Vanessa Rouzier (Port-au-Prince, Haiti)	13:20 - 13:25
PP20-982-14	Evaluation of cycloserine dose regimens in multi-drug-resistant TB participants from India Juan Eduardo Resendiz Galvan (Cape Town, South Africa)	13:25 - 13:30
PP20-983-14	Pyrazinamide in initial regimen for elderly TB Yong-Soo Kwon (Gwangju, Korea, Republic of)	13:30 - 13:35
PP20-984-14	Adverse drug reactions and treatment outcomes in people with drug-resistant TB on short-term treatment regimens in Matabeleland North and Bulawayo Provinces, Zimbabwe (2019-2022) Jannet Usai (Mutare, Zimbabwe)	13:35 - 13:40
PP20-985-14	Is the short regimen safe? Evaluation of the safety and tolerability of linezolid in the treatment of drug-resistant TB Hawa Nakato (Kampala, Uganda)	13:40 - 13:45
PP20-986-14	Enhancing active drug safety monitoring and management (aDSM) for multi-drug-resistant TB: Lessons from the implementation of the Pharmacovigilance Information Management System (PVIMS) Henry Kizito (Kampala, Uganda)	13:45 - 13:50
PP20-987-14	Hepatobiliary disorders, the adverse drug reactions driving missed doses of anti-TB treatment: A retrospective cohort study Eleanor G. Dixon (Edinburgh, United Kingdom)	13:50 - 13:55
PP20-988-14	Pharmacovigilance for HP fixed dose combination (FDC) and 3HP-safety monitoring of generic drugs Mei-Yu Chiou (Taipei city, Taiwan)	13:55 - 14:00
PP20-989-14	Frequency of hepatobiliary disorders in people with TB receiving high-dose rifapentine: Insights from the ORIENT trial safety data Yang Li (Shanghai, China)	14:00 - 14:05
PP20-990-14	Pharmacokinetics of isoniazid and rifampicin and predictors in Ethiopian TB patients	14:05 - 14:10

Tesemma Sileshi (Ambo, Ethiopia)

Q&A

14:10 - 14:20

Paper Posters

13:20 - 14:20

M PPC

PP13 - 3 in 1: TB modeling - VHC - digital health technologies

Rakesh PS (New Delhi, India)

PP13-916-14 **Modelling the epidemiological and economic impact of digital adherence technologies with differentiated care for TB treatment in Ethiopia** 13:20 - 13:25

Lara Goscé (London, United Kingdom)

PP13-917-14 **Estimating the impact of multiple external shocks on the incidence and mortality of TB in Ethiopia: Results from modelling exercise** 13:25 - 13:30

Demelash Abebe (Addis Ababa, Ethiopia)

PP13-918-14 **Prognostic value of health-related quality of life on mortality in people with rifampicin-resistant TB** 13:30 - 13:35

Annelies Van Rie (Antwerp, Belgium)

PP13-919-14 **Impact of interventions for engagement of health and wellness centres on programme output indicators in Parbhani district of Maharashtra, India** 13:35 - 13:40

Kaustav Dasgupta (New Delhi, India)

PP13-920-14 **Wide variation in the proportion of TB-related catastrophic costs among regions of Ethiopia** 13:40 - 13:45

Atakelti Abraha (Addis Ababa, Ethiopia)

PP13-921-14 **Coordination of health partners for their buying and rationalisation of resources to local innovation implementation: The case of CASTTB+ campaign in Uganda** 13:45 - 13:50

Bamuloba Muzamiru (Kampala, Uganda)

PP13-922-14 **Regional patterns of barriers to TB services in mining communities: A case of Shinyanga, Geita and Manyara, Tanzania** 13:50 - 13:55

Meckie Achayo (Dar es Salaam, Tanzania)

PP13-923-14 **Innovative integration: Digital CXR screening data on national LIMS for TB surveillance in Kenya** 13:55 - 14:00

Keziah Gichanga (Nairobi, Kenya)

PP13-924-14 **Strengthening service integration in disease control through artificial intelligence in Nigeria: Implementation strategies and lessons learned** 14:00 - 14:05

Jamiu Olabamiji (Lagos, Nigeria)

PP13-925-14 **Mobile application for TB screening: A game-changer in TB prevention and care** 14:05 - 14:10

Micheal Pedro (Lagos, Nigeria)

Q&A

14:10 - 14:20

Paper Posters

13:20 - 14:20

M PPD

PP14 - Imaging tools for TB diagnosis

Archana Trivedi (New Delhi, India)

PP14-926-14 **CT radiographic findings associated with incident TB among individuals with trace sputum Xpert results during TB screening** 13:20 - 13:25

Mariam Nantale (Kampala, Uganda)

PP14-927-14	Can AI-assisted chest radiography be useful for early TB detection and treatment in resource-limited areas of Punjab, India? Rajesh Bhaskar (Chandigarh, India)	13:25 - 13:30
PP14-928-14	Parallel screening algorithm using WHO symptom screen and portable digital X-ray with artificial intelligence: A strategic approach to optimise TB case finding Eze Chukwu (Abuja, Nigeria)	13:30 - 13:35
PP14-929-14	Revolutionising TB education: TB portals' unmatched repository of annotated clinical images Andrei Gabrielian (Rockville, United States)	13:35 - 13:40
PP14-930-14	Lessons learned from Bangladesh: Child TB screening by using AI-based portable X-ray systems Shahriar Ahmed (Dhaka, Bangladesh)	13:40 - 13:45
PP14-931-14	Improving the diagnostic yield of TB from screening using digital X-ray fitted with computer-aided detection software: Lessons from programmatic implementation in Uganda Aldomoro Burua (Kampala, Uganda)	13:45 - 13:50
PP14-932-14	Artificial intelligence assisted pulmonary TB detection from chest radiographs: A facility-based cross-sectional study at a TB specialised hospital in Ethiopia Tariku Mengesha (Addis Ababa, Ethiopia, Ethiopia)	13:50 - 13:55
PP14-933-14	Applying innovative solutions for TB diagnosis through artificial intelligence in services disruption situation in Ukraine Yana Terleieva (Kyiv, Ukraine)	13:55 - 14:00
	Q&A	14:00 - 14:20
<i>Paper Posters</i>		
13:20 - 14:20		M PPE
PP15 - Moving forward: From industry monitoring to tobacco endgame		
Daniel Ogbuabor (Enugu, Nigeria)		
PP15-934-14	Factors associated with shisha smoking: A cross-sectional telephone-based survey among general population adults in Nigeria Noreen Mdege (York, United Kingdom)	13:20 - 13:26
PP15-935-14	Smoking Cessation Intervention using The Union's "ABC approach" for people with TB in Benin and Burkina Faso: Results from "CesTA_TB" pilot study Attannon Arnauld Fiogbé (Cotonou, Benin)	13:26 - 13:32
PP15-936-14	Effective role of YouTube priority flagger program on online tobacco advertising and promotion monitoring and reporting in Indonesia Wida Arioka (Jakarta, Indonesia)	13:32 - 13:38
PP15-937-14	Smoke-free Kendari City: Evaluating enforcement strategies and compliance in tobacco control Syefira Salsabila (Kendari, Indonesia)	13:38 - 13:44
PP15-938-14	Analysis of "Tobacco Endgame Strategies" in the state of Himachal Pradesh in India Gopal Chauhan (Shimla, India)	13:44 - 13:50
PP15-940-14	India's progress in adopting WHO FCTC Articles 9 and 10: A detailed evaluation Diksha Walia (Chandigarh, India)	13:50 - 13:56
PP15-941-14	Establishing priorities for the effective implementation of Tobacco	13:56 - 14:02

Control Program at national and sub-national level in India

Diksha Walia (Chandigarh, India)

Q&A

14:02 - 14:20

Paper Posters

13:20 - 14:20

M PPF

PP16 - HIV co-morbidities: Services and integrated approaches

Arjan Van Laarhoven (Nijmegen, Netherlands)

PP16-942-14 **TB services uptake and incidence among key populations receiving HIV services in Uganda during 2017-2021** 13:20 - 13:25
Deus Lukoye (Kampala, Uganda)

PP16-943-14 **Integrated TB, cardiovascular disease, and chronic respiratory disease screening in Nasarawa State, Nigeria: Field experiences and lessons learned** 13:25 - 13:30
James Ngbede Ekwu (Karu, Nigeria)

PP16-944-14 **Linking children with TB disease to HIV services in 16 high TB/HIV-burden countries supported by U.S. President's Emergency Plan for AIDS Relief, October 2018-September 2022** 13:30 - 13:35
Kimi Sato (Atlanta, United States)

PP16-945-14 **Implementation of TB services for children living with HIV in PEPFAR-supported programs from 16 high TB/HIV-burden countries in sub-Saharan Africa, 2019-2022** 13:35 - 13:40
Stephanie O'Connor (Atlanta, United States)

PP16-946-14 **Managing multimorbidity: The role of integrated health services in TB screening in Rural Sindh, Pakistan** 13:40 - 13:45
Asadullah Mir (Karachi, Pakistan)

PP16-947-14 **Enhancing access to prevention and care services for TB and co-morbidities for vulnerable populations through an integrated community-based approach in India** 13:45 - 13:50
Aakshi Kalra (Delhi, India)

PP16-948-14 **Investigating alcohol use disorder prevalence among people with presumptive TB, its association with clinical presentation, TB diagnosis and treatment outcomes in adults, in Lusaka, Zambia** 13:50 - 13:55
Nsala Sanjase (Lusaka, Zambia)

PP16-949-14 **Barriers to access counselling for alcohol use among newly-diagnosed people with TB and HIV in India** 13:55 - 14:00
Shatabdi Bagchi (Pune, India)

PP16-950-14 **Implementing integrated TB, mental health and substance use disorder services in Nigeria: Lessons learned so far** 14:00 - 14:05
Chinwe Eze (Enugu, Nigeria)

Q&A

14:05 - 14:20

Paper Posters

13:20 - 14:20

M PPG

PP17 - Voices of TB

Edouard Sansan (ABIDJAN, Cote D'Ivoire)

PP17-951-14 **Project LEAD (Leveraging, Engaging, Advocating to Disrupt TB transmission): A model of comprehensive TB interventions for urban ultra-poor in four metropolitan cities of India** 13:20 - 13:25
Sugata Mukhopadhyay (New Delhi, India)

PP17-952-14 **Addressing gender disparities in TB diagnosis, treatment, and care:** 13:25 - 13:30

	Insights from the KNCV TB LON Project in Nigeria Ezinne Nwokoro (Abuja, Nigeria)	
PP17-953-14	Economic and social consequences of TB care through informal providers in North East Nigeria: A cost estimation study Beatrice Wangari Kirubi (Geneva, Sweden)	13:30 - 13:35
PP17-954-14	Anaemia among persons with TB in tribal district of Odisha: A critical age-gender analysis Ramya Ananthakrishnan (Chennai, India)	13:35 - 13:40
PP17-955-14	Breaking the silence on TB through innovative communication Jason Roque (Manila, Philippines)	13:40 - 13:45
PP17-956-14	Bearing the burden: Community survey to map out-of-pocket expenses among people affected with TB in Karnataka, India Shazia Anjum (New Delhi, 110011, India)	13:45 - 13:50
PP17-957-14	Enhancing TB healthcare in tribal communities: Lesson from India's National TB Programme Sophia Khumukcham (New Delhi, India)	13:50 - 13:55
PP17-958-14	Strengthening TB elimination through public-private partnerships in tribal district, Gadchiroli, India Swarna Ramteke (New Delhi, India)	13:55 - 14:00
PP17-959-14	The role of community leaders (traditional rulers) in increasing community diagnosis of TB in Katsina State Abishai Yakubu Galadima (Katsina, Nigeria)	14:00 - 14:05
PP17-960-14	Improving access to TB diagnosis using the portable digital X-ray machine: A comparison of TB yields in accessible and inaccessible communities in Delta State, Nigeria Eziashi Emmanuel Ajumuka (Asaba, Nigeria)	14:05 - 14:10
	Q&A	14:10 - 14:20
 <i>Paper Posters</i>		
	13:20 - 14:20	M PPH
	PP18 - Information system for TB Aboubacar Magassouba (Conakry, Guinea)	
PP18-961-14	Improving access to TB services through specimen transportation in hard-to-reach communities in Plateau State through the "PICK-ME-UP-TO-JOS" (PUJ) intervention Olatutu Kolapo (Jos, Nigeria)	13:20 - 13:25
PP18-962-14	A comparative study of TB screening methods in Tamil Nadu: AI vs. conventional approach Asha Frederick (Chennai, India)	13:25 - 13:30
PP18-963-14	Trends and patterns in TB research outputs: A bibliometric analysis from 2003 to 2023 in Ethiopia Bianca Goncalves Tasca (The Hague, Netherlands)	13:30 - 13:35
PP18-964-14	Transforming public health: End-to-end AI-driven TB screening in Tamil Nadu Asha Frederick (Chennai, India)	13:35 - 13:40
PP18-965-14	Improving enrollment rate for newly-diagnosed TB cases using an active surveillance system for programme monitoring: A case study of TB LON-3 Project in Lagos Babajide Kadri (Lagos, Nigeria)	13:40 - 13:45
PP18-968-14	Data quality for TB indicators in Uganda: Can Ugandan TB data be	13:45 - 13:50

	trusted? Vincent Kamara (Kampala, Uganda)	
PP18-969-14	Leveraging health information helpline to improve treatment adherence and outcome of person with TB: A pilot from Jharkhand, India Shobha Ekka (Delhi, India)	13:50 - 13:55
PP18-970-14	Enhancing TB case yield through deployment of designated screening staff at major private health facilities in Pakistan Azadar Gillani (Islamabad, Pakistan)	13:55 - 14:00
PP09-880-13	Empowering community-based volunteers: Harnessing tele-mentoring to combat TB in Zambia	14:00 - 14:05
	Q&A	14:05 - 14:20
<i>Paper Posters</i>		
13:20 - 14:20		M PPI
PP11 - New technologies and methods for eliminating TB		
Yacine Mar Diop (Dakar, Senegal)		
PP11-894-14	Baseline PET-CT features predict lung function at 12 months in adolescents treated for pulmonary TB Marieke van der Zalm (Cape Town, South Africa)	13:20 - 13:25
PP11-895-14	Whole genome sequencing analysis uncovers significant regional variation in clustering rates and clonal expansion of M. tuberculosis lineage 4.6.2.2 in Nigeria Opeyemi Alayande (Ibadan, Nigeria)	13:25 - 13:30
PP11-896-14	Biological evaluation of spirocyclic phenol oxazole methyl scaffold as novel mmpL3 anti-tubercular agent Yumi Park (Chungju, Korea, Republic of)	13:30 - 13:35
PP11-898-14	Improving awareness of latent TB and increasing TB prevention treatment by storytelling in Gombong Muhammadiyah Hospital Raden Ismail Hafidh Adinugroho (Jakarta, Indonesia)	13:35 - 13:40
PP11-899-14	Characterisation of adolescents with TB using nationally representative data in Nigeria: An impetus for targeted interventions Ufuoma Aduh (Enugu, Nigeria)	13:40 - 13:45
PP11-900-14	Development of the local TIBULIMS connectivity solution in Kenya for integrated connection of all existing and new TB diagnostic instruments Elvis Muriithi (Nairobi, Kenya)	13:45 - 13:50
PP11-901-14	Lessons learned from multi-country assessment on the development of post-TB lung disability management package for future TB programming Daisy Lekharu (Geneva, Switzerland)	13:50 - 13:55
PP11-902-14	High mortality among people with post-TB lung disease: An analysis of Uganda national level data (2020-2023) Geofrey Amanyanya (Kampala, Uganda)	13:55 - 14:00
PP11-904-14	Prevalence of high blood pressure among persons with presumed and diagnosed TB at two first level hospitals in Lusaka, Zambia Seke Muzazu (Lusaka, Zambia)	14:00 - 14:05
	Q&A	14:05 - 14:20

Paper Posters

13:20 - 14:20

M PPJ

PP12 - TB in pregnancy and young children

Julie Huynh (Ho Chi Minh City, Vietnam)

PP12-905-14	Clinical features and outcomes in pregnant women with active TB: A single centre retrospective study in China Haoxin Xu (Shanghai, China)	13:20 - 13:25
PP12-906-14	Impact on paediatric TB diagnosis of implementing the new WHO Treatment Decision Algorithms in an MSF nutritional centre, Maiduguri, Nigeria Muhammad Bashir Abdullahi (Maiduguri, Nigeria)	13:25 - 13:30
PP12-907-14	Stool specimen testing for diagnosing pulmonary TB among pregnant women and children under five years in rural India: Preliminary results Kajal Taluja (Samastipur, India)	13:30 - 13:35
PP12-908-14	Smaller people, bigger gaps: Is your TB programme 'paeds-proof'? Juli Switala (Cape Town, South Africa)	13:35 - 13:40
PP12-910-14	Parallel use of low-complexity automated nucleic-acid-amplification tests on respiratory samples and stool with/ without urine lipoarabinomannan assays to detect childhood pulmonary TB: A systematic review	13:40 - 13:45
PP12-911-14	Mass school testing for M. tuberculosis infection and disease in an adolescent population: A prospective cohort from eastern China Qiao Liu (Nanjing, China)	13:45 - 13:50
PP12-912-14	An analysis of childhood TB notifications incident rates ratios in Zambia, 2016-2021 Jonathan M. Chama (Lusaka, Zambia)	13:50 - 13:55
PP12-913-14	Maternal and fetal outcomes in pregnancy-associated TB in Uganda: A pilot multi-centre case-controlled study Rose Nakavuma (Kampala, Uganda)	13:55 - 14:00
PP12-914-14	Boosting TB screening and treatment among children attending community care sites in Kinshasa province, DR Congo Stephane Mbuyi (Kinshasa, Congo (Democratic Republic))	14:00 - 14:05
PP12-915-14	"I would cry all the time": The indirect yet complex burden of living in a household affected by TB on children in Cape Town Lieve Vanleeuw (Tampere, Finland)	14:05 - 14:10
	Q&A	14:10 - 14:20

Union Live Session

13:30 - 17:00

UL

UL19 - Union LIVE - Content from across the WCLH 2024*Community Connect*

14:15 - 15:00

AU

CCSA008 - Harmonising research: Collaborative perspectives from community advisory groups and researchers

Nicola James (United Kingdom)

Madhava Sai Sivapuram (India)

Nicola James (United Kingdom)

Introduction 14:15 - 14:21**Community engagement in TB drug trials, impact of strong** 14:21 - 14:27

	partnerships	
	Robyn Waite (Ottawa, Canada)	
	The UNITE4TB community advisory group: Real-world experience on TB drug development and clinical trials	14:27 - 14:33
	Blessina Kumar (New Delhi, India)	
	The Union's Community Advisory Panel (UCAP): Amplifying community voices in a collaborative global platform	14:33 - 14:39
	Zahedul Islam (Ukraine)	
	What can we learn from what exists and what still needs to be 'made' to improve collaborative TB research with affected communities?	14:39 - 14:45
	Sarah Bernays (Australia)	
	Question and answer	14:45 - 15:00
<i>Special Session</i>		
14:20 - 15:50		HB
	SPS03 - North-South collaboration: Reinventing the future direction in ending TB	
	Jeremiah Chakaya (Nairobi, Kenya)	
	Rovina Ruslami (Bandung, Indonesia)	
	Session introduction	14:20 - 14:23
	Challenges in establishing Global South collaboration	14:23 - 14:30
	Willem Hanekom (South Africa)	
	Experience of EDCTP in accelerating research capacity in Global South (What call to Global North)?	14:30 - 14:37
	Michael Makanga (Belgium)	
	Challenges in international collaboration and efforts to solve and improve the collaboration	14:37 - 14:44
	Lucia Rizka Andalucia (Indonesia)	
	What Global North should do - more than funding?	14:44 - 14:51
	Madhukar Pai (Canada)	
	Panel discussion (Chairs + panelists)	14:51 - 15:16
	Charles Wells (Cambridge, Massachusetts, United States)	
	Panel discussion with Q&A from the audience	15:16 - 15:46
	Conclusion and remarks	15:46 - 15:50
<i>Oral Abstract Session</i>		
14:20 - 15:50		FR
	OA19 - Child TB care cascade and treatment	
	Steve Graham (Melbourne, Australia)	
	Nicole Salazar-Austin (Baltimore, United States)	
	Introduction	14:20 - 14:25
OA19-248-14	"Let us scale it up. It works!": Integrating TB, orphans, and vulnerable children services in Uganda	14:25 - 14:34
	Brittany K. Moore (Atlanta, United States)	
OA19-249-14	The effectiveness of innovative integrated case finding among children in Lusaka, Zambia	14:34 - 14:43
	Anne Dorte Hoejrup (Lusaka, Zambia)	

OA19-250-14	Effective screening and diagnostic strategies for paediatric TB in three districts of Malawi Elizabeth Chamwalira (Machinga, Malawi)	14:43 - 14:52
OA19-251-14	Barriers and facilitators of timely TB diagnosis in children and adolescents in Karachi, Pakistan Carole Mitnick (Boston, United States)	14:52 - 15:01
OA19-252-14	Exploring pathways to paediatric TB diagnosis and treatment initiation: Insights from a qualitative study Marieke van der Zalm (Cape Town, South Africa)	15:01 - 15:10
OA19-253-14	A qualitative assessment of adolescent TB care services in Lima, Peru Chelsie Cintron (Providence, United States)	15:10 - 15:19
OA19-254-14	Comprehensive strategy to improve paediatric TB case notifications: A case study in Kigoma, Katavi, Rukwa, and Songwe regions Neema Chillo (Dar Es Salaam, Tanzania)	15:19 - 15:28
OA19-255-14	Growth trajectories of children presenting with presumptive pulmonary TB in the 12 months after treatment in Cape Town, South Africa Marieke van der Zalm (Cape Town, South Africa)	15:28 - 15:37
	Q&A	15:37 - 15:50
<i>Oral Abstract Session</i>		
14:20 - 15:50		BG
OA20 - Health system strengthening strategies for TB prevention and care		
Manu Easow Mathew (New Delhi, India) Anisha Singh (New Delhi, India)		
	Introduction	14:20 - 14:25
OA20-256-14	Utilising DOT expansion strategy to improve TB case finding in a remote location: Experience from Kano State, Nigeria Musa Said Mika'ilu (Kano, Nigeria)	14:25 - 14:34
OA20-257-14	Institutionalising mortality audits at health facilities battling with high TB deaths in Uganda Ignatius Senteza (Kampala, Uganda)	14:34 - 14:43
OA20-258-14	Transitioning towards sustainable TB prevention and care: Bangladesh's path to achieving SDGs and overcoming challenges by 2030 Rupali Sisir Banu (Dhaka, Bangladesh)	14:43 - 14:52
OA20-259-14	Income disparity and healthcare utilisation: Lessons from Indonesia's National Health Insurance Claim Data Abdillah Ahsan (Depok, Indonesia)	14:52 - 15:01
OA20-260-14	Assessing survey instruments for measuring household catastrophic spending due to TB Yin-Jie Huang (Taipei, Taiwan)	15:01 - 15:10
OA20-261-14	Catalysing sustainable TB financing through integration of TB services into health insurance schemes: Effective approaches for low- and middle-income countries Frances Ilika (Washington DC, United States)	15:10 - 15:19
OA20-262-14	Pre-treatment out-of-pocket costs for people with drug-resistant TB in Bandung, Indonesia Silvi Indriani (Bandung, Indonesia)	15:19 - 15:28

OA20-263-14	Journey towards ending TB in Junagadh, Gujarat, India Nirmal Prajapati (Delhi, India)	15:28 - 15:37
	Q&A	15:37 - 15:50
<i>Oral Abstract Session</i>		
14:20 - 15:50		
OC		
OA21 - Values of repurposed drugs and potential markers		
Poonam Puri (New Delhi, India) Patricia Hall-Eidson (Atlanta, United States)		
	Introduction	14:20 - 14:23
OA21-264-14	Linking delamanid and pretomanid minimum inhibitory concentrations with genetic mutations in multi-drug-resistant and extensively-drug-resistant M. tuberculosis isolates in Georgia Ana Tsutsunava (Tbilisi, Georgia)	14:23 - 14:32
OA21-265-14	Pretomanid Resistance Surveillance Program (PAEGIS) 2020 to 2025: An interim report Amit Ravindra Birajdar (Bengaluru, India)	14:32 - 14:41
OA21-266-14	Usefulness of M. tuberculosis-antigen-specific host protein biomarkers as candidates for the diagnosis of spinal TB Bih H. Chendi (Cape Town, South Africa)	14:41 - 14:50
OA21-267-14	Low concordance between bedaquiline drug susceptibility testing with 7H11 solid medium and MGIT methods Elisa Ardizzoni (Antwerp, Belgium)	14:50 - 14:59
OA21-268-14	Comparative analysis of multiplex immunoassays for host biomarker profiling in TB diagnosis and treatment response Candice Snyders (Cape Town, South Africa)	14:59 - 15:08
OA21-269-14	Challenges in the diagnostic cascade of drug-resistant TB in Namibia Olga Shavuka (Windhoek, Namibia)	15:08 - 15:17
OA21-270-14	Potential mutations reducing the binding affinity of MPT64 identified among TB cultures Sanchi Shah (Mumbai, India)	15:17 - 15:26
OA21-271-14	Drug-susceptibility testing for new and repurposed anti-TB drugs: Experience from 3 rounds of Supranational TB Reference Laboratory proficiency panel testing Bouke de Jong (Antwerp, Belgium)	15:26 - 15:35
OA21-272-14	A simplified pyrazinamidase test for M. tuberculosis pyrazinamide drug susceptibility testing Yu-Chen Wang (Taipei, Taiwan)	15:35 - 15:44
	Q&A	15:44 - 15:50
<i>Oral Abstract Session</i>		
14:20 - 15:50		
JKA		
OA22 - Integrating multi-sectoral strategies for TB prevention and care: From research to public impact and government enhancement		
Fernanda Dockhorn (Brasília, Brazil) Kenneth Castro (Atlanta, United States)		
	Introduction	14:20 - 14:25
OA22-273-14	Translating research into policy: Exploring stakeholder perspectives in the Indian Tuberculosis Program	14:25 - 14:35

	Arohi Chauhan (New Delhi, India)	
OA22-274-14	Assessment of governance of TB programmes: Trends and practices in 22 countries Alka Aggarwal Singh (Gurugram, India)	14:35 - 14:45
OA22-276-14	Strengthening TB prevention through multi-sectoral engagement: Lessons from Uganda's collaborative efforts with civil society organisations and private sector Mathius Mwesige (Kampala, Uganda)	14:45 - 14:55
OA22-277-14	Sustaining TB programme interventions amid conflict: Remote phone mentorship experience from Amhara, Ethiopia Kassahun Melkieneh (Addis Ababa, Ethiopia)	14:55 - 15:05
OA22-278-14	Digital drive for TB-free village councils: Charting hotspots and empowering TB Mukht Panchayats (the local governing bodies) in Andhra Pradesh, India G. Mahesh (Hyderabad, India)	15:05 - 15:15
OA22-279-14	Evidence-based advocacy: The gap in public-private mix implementation for TB programmes across seven priority districts in Indonesia Najibah Assadiyah (Jakarta, Indonesia)	15:15 - 15:25
OA22-280-14	Oxygen use and liquid oxygen infrastructure in Vietnam's provincial lung and TB hospitals Hien Nguyen (Hanoi, Vietnam)	15:25 - 15:35
	Q&A	15:35 - 15:50
 <i>Oral Abstract Session</i>		
	14:20 - 15:50	JKB
OA23 - Automation in TB diagnosis		
	Man Mohan Puri (New Delhi, India) Frederick Quinn (Athens, United States)	
	Introduction	14:20 - 14:25
OA23-281-14	QuantIFERON supernatant-based biomarkers predicting active TB progression in people with silicosis Haixin Xu (Shanghai, China)	14:25 - 14:34
OA23-282-14	Understanding stool Xpert Ultra trace results: Evidence from a case-control diagnostic study Anca Vasiliu (Houston, United States)	14:34 - 14:43
OA23-283-14	User perspectives on Molbio Truenat platform and MTB assays for use as a decentralised point-of-care diagnostic test in Mozambique and Tanzania Celso Khosa (Maputo, Mozambique)	14:43 - 14:52
OA23-284-14	Feasibility of deploying rapid molecular anti-TB susceptibility testing using Xpert MTB/XDR assay: A cross-sectional study in three high burden provinces of Zimbabwe, 2022 - 2023 Rutendo Manyati (Harare, Zimbabwe)	14:52 - 15:01
OA23-285-14	Evaluation of the accuracy of Xpert MTB/XDR in detecting isoniazid and fluoroquinolone resistance in children with rifampicin-resistant TB Lichao Fan (Shenyang, China)	15:01 - 15:10
OA23-286-14	A pragmatic, cluster-randomised controlled trial to evaluate the effect of the implementation of Truenat platform/MTB assays at primary health care clinics in Mozambique and Tanzania	15:10 - 15:19

	Celso Khosa (Maputo, Mozambique)	
OA23-287-14	Truenat MTB for detection of pulmonary TB in adolescents and adults: A systematic review of diagnostic test accuracy Leeberk Raja Inbaraj (Chennai, India)	15:19 - 15:28
OA23-288-14	Integrated diagnostic use of GeneXpert machines to scale up laboratory services for HIV and TB programmes in Zimbabwe Patience Musasa (Harare, Zimbabwe)	15:28 - 15:37
	Q&A	15:37 - 15:50
<i>Oral Abstract Session</i>		
14:20 - 15:50		MD
OA24 - Non-sputum based diagnosis		
Daniela Cirillo (Milan, Italy) Digambar Behera (Mohali, India)		
	Introduction	14:20 - 14:25
OA24-289-14	The development of an optimised, cost-effective long-read sequencing pipeline to complete the M. tuberculosis genome Alice Osmaston (London, United Kingdom)	14:25 - 14:36
OA24-290-14	The potential of an electronic nose as a TB screening tool in a high-burden TB country Antonia Saktiawati (Yogyakarta, Indonesia)	14:36 - 14:47
OA24-291-14	A mixed methods evaluation of preferences for tongue swab-based testing among people with presumptive TB in five high-burden countries Victoria Dalay (Cavite, Philippines)	14:47 - 14:58
OA24-292-14	Pooled testing to increase access to rapid molecular diagnostics for TB among people with clinical risk factors of TB in Cameroon Zourriyah Adamou (Bamenda, Cameroon)	14:58 - 15:09
OA24-293-14	Nanopore-based targeted next-generation sequencing (tNGS): A revolutionary technology unmasking mycobacterium species in TB Zeng Yi (Nan Jing, China)	15:09 - 15:20
OA24-294-14	Evaluating stool and sputum-based test accuracy and TB prevalence using Bayesian latent class analysis Abigail Seeger (Houston, United States)	15:20 - 15:31
	Q&A	15:31 - 15:50
<i>Short Oral Abstract Session</i>		
14:20 - 15:50		NS1
SOA06 - From prevention to management of TB		
Rishi Gupta (London, United Kingdom)		
	Introduction	14:20 - 14:25
SOA06-649-14	Prevalence of latent TB infection and the associated factors in correctional institutions in Taiwan, 2019 - 2023 Chi-Fang Feng (Taipei, Taiwan)	14:25 - 14:32
SOA06-650-14	Detection of LTBI and uptake of TB preventive therapy among contacts of people with PTB in a high-burden low-resource setting Obioma Chijioke-Akaniro (Abuja, Nigeria)	14:32 - 14:39
SOA06-651-14	Barriers to integrating LTBI screening with population-level active TB case finding in peri-urban Uganda	14:39 - 14:46

	Tyler Johnson (Baltimore, United States)	
SOA06-652-14	From symptoms to treatment: A narrative study exploring the journey of older adults with TB in the English Midlands, United Kingdom Farah Kidy (Coventry, United Kingdom)	14:46 - 14:53
SOA06-653-14	Understanding barriers to TB service uptake in Kano State: Applying behavior change theory perspectives Abdullahi Yola (Kano, Nigeria)	14:53 - 15:00
SOA06-654-14	Brighter horizons: free chest X-ray services illuminate tuberculosis diagnosis in Kenyan children under 15 Sharon Kitui (Nairobi, Kenya)	15:00 - 15:07
SOA06-655-14	Video-supported treatment of tuberculosis in Tashkent: is it possible to control adverse events? Ruzilya Usmanova (Tashkent, Uzbekistan)	15:07 - 15:14
SOA06-656-14	Tuberculosis in liver transplant recipients: IGRA-based pre-transplant screening performance and active tuberculosis post-transplant Yixuan Yang (Shanghai, China)	15:14 - 15:21
SOA06-657-14	Substance use patterns among people undergoing drug-resistant tuberculosis treatment in South Africa Alanna Bergman (Charlottesville, United States)	15:21 - 15:28
SOA06-658-14	TB preventive treatment follow up and completion matters to end TB Zeki Kılıçaslan (İstanbul, Turkey)	15:28 - 15:35
	Q&A	15:35 - 15:50
<i>Oral Abstract Session</i>		
	14:20 - 15:50	NS2
	OA25 - Harnessing community leadership for achieving target Deborah Ikeh (Abuja, Nigeria) Candy Jacobs (Tableview, South Africa)	
	Introduction	14:20 - 14:25
OA25-297-14	Community engagement in TB elimination: Lessons from the Tribal TB Initiative in Meghalaya, India Agniswar Das (New Delhi, India)	14:25 - 14:34
OA25-298-14	Prevalence of TB multimorbidity among the tribals in India: Findings from a cross-sectional study Sandeepkumar Chauhan (New Delhi, India)	14:34 - 14:43
OA25-299-14	Indigenous community participation in a TB accompaniment program increased the treatment completion rate among The Suku Anak Dalam of Indonesia Christy Abigail Wulandari (Jakarta, Indonesia)	14:43 - 14:52
OA25-300-14	Situation analysis of TB among the tribal population of Karnataka state: A mixed method study Shazia Anjum (New Delhi, 110011, India)	14:52 - 15:01
OA25-301-14	Policy brief to enhance community active case finding and prevention strategies for TB to reduce the burden of TB in Uganda Aldomoro Burua (Kampala, Uganda)	15:01 - 15:10
OA25-302-14	Empowering women to enhance health outcomes in persons with TB: A community engagement initiative in tribal communities of	15:10 - 15:19

	Rajasthan, India Raksha Gupta (Delhi, India)	
OA25-303-14	A hybrid approach to improve community TB contribution: Volunteers and TB survivors augmented health extension workers in Ethiopia Zewdu Gashu Dememew (Addis Ababa, Ethiopia)	15:19 - 15:28
OA25-304-14	Community engagement for TB elimination: Insights from a pilot project in Jharkhand, India Priya Kotwani (New Delhi, India)	15:28 - 15:37
	Q&A	15:37 - 15:50
<i>Oral Abstract Session</i>		
14:20 - 15:50		NS3
	OA26 - Engage private sector for TB prevention and care Panji Fortuna Hadisoemarto (Bandung, Indonesia) Sue McAllister (Dunedin, New Zealand)	
	Introduction	14:20 - 14:25
OA26-305-14	Joining forces: Corporate sector's role in finding the missing people with TB Mohd Shadab (New Delhi, India)	14:25 - 14:34
OA26-306-14	Expanding TB case detection in private health facilities: An intensified intervention in Nigeria Olugbenga Daniel (Ikeja, Nigeria)	14:34 - 14:43
OA26-307-14	District intervention packages to improve TB notification and access to quality TB care in private sector in Indonesia Bobby Simarmata (Jakarta, Indonesia)	14:43 - 14:52
OA26-308-14	Private health facilities: Frontlines in diagnosing TB during conflict in Tigray, Ethiopia Tilaye Tasew Zewde (Addis Ababa, Ethiopia)	14:52 - 15:01
OA26-309-14	Private sector engagement: Integrating TB services into HIV activities while addressing drug use, HIV, and TB in Myanmar Yan Naung Soe (Waimaw, Myanmar)	15:01 - 15:10
OA26-311-14	Patients provider support agencies (PPSA) and its impact on the private sector engagement in TB Elimination Program in Uttar Pradesh, India Bhartesh K. Shetty (Lucknow, India)	15:10 - 15:19
OA26-312-14	Impact of private sector engagement (STEPS) strategy on TB notification and outcome in Kerala, India, 2018-2023 Thaikkattillam Narayanan Anupkumar (New Delhi, India)	15:19 - 15:28
OA26-313-14	Public/private sector engagement for decentralised laboratory services to reduce pre-treatment loss-to-follow-up among persons with drug-resistant TB Ngozi Murphy Okpala (Enugu, Nigeria)	15:28 - 15:37
	Q&A	15:37 - 15:50
<i>Community Connect</i>		
15:00 - 17:00		EG2
	CCWS001 - Setting advocacy priorities: TB communities' action for the global fund replenishment cycle Olya Klymenko (Kyiv, Ukraine) Priyanka Aiyer (India)	

How to close a funding gap?	15:00 - 15:00
Priyanka Aiyer (India)	
The power of more: Lessons on the Global Fund 7th replenishment from TB communities in Asia-Pacific	15:00 - 15:00
Jeff Acaba (Thailand)	
Reflections and triumphs from 7th Global Fund replenishment advocacy campaigns	15:00 - 15:00
Evaline Kibuchi (Kenya)	
Community expectations and advocacy success while shaping the replenishment for TB action	15:00 - 15:00
Yuliia Kalancha (Kyiv, Ukraine)	
Advocacy to donor governments to unlock new funding	15:00 - 15:00
Leigh Raithby (Canada)	
Results report and the road towards the 8th replenishment cycle	15:00 - 15:00
Mohammed Yassin (Geneva, Switzerland)	
<i>Youth4LungHealth</i>	
15:15 - 17:30	MG
Y4LH001 - Youth-led solutions: Engaging the next generation to end TB	
Hannah Monica Dias (Switzerland)	
James Malar (Geneva, Switzerland)	
Kinz Ul Eman (Islamabad, Pakistan)	
Introduction	15:15 - 15:25
Kinz Ul Eman (Islamabad, Pakistan)	
Presentation on youth-led solutions to end TB	15:25 - 16:05
Farai Mavhunga (Switzerland)	
Robyn Waite (Ottawa, Canada)	
Kinz Ul Eman (Islamabad, Pakistan)	
Anna Versfeld (South Africa)	
Hackathon	16:05 - 16:45
Group work and presentation	16:45 - 17:15
Closing remarks from the chairs	17:15 - 17:25
Hannah Monica Dias (Switzerland)	
James Malar (Geneva, Switzerland)	
<i>Community Connect</i>	
15:15 - 16:15	AU
CCSA009 - Targeted next-generation sequencing: Why should communities care?	
Karishma Saran (Switzerland)	
Anita Suresh (Singapore, Singapore)	
Introduction	15:15 - 15:18
Strategies to improve community understanding of tNGS	15:18 - 15:32
Blessina Kumar (New Delhi, India)	
Current status of tNGS implementation and challenges to its uptake	15:32 - 15:46
Smiljka DE LUSSIGNY (Switzerland)	
Experience living through MDR-TB, and how access to tNGS can improve test and treat approaches	15:46 - 16:00
Ani Hernasari (Indonesia)	

	Question and answer	16:00 - 16:15
<i>Community Connect</i>		
15:15 - 16:15		SG
CCSS014 - Empowering TB survivors: Voices, needs, and action		
Vashita Madan (India)		
Vashita Madan (India)		
	Introduction	15:15 - 15:20
	Why we must listen to survivors	15:20 - 15:30
	Chapal Mehra (India)	
	Unheard voice: A personal account of TB treatment and recovery	15:30 - 15:40
	Sandhya Krishnan (India)	
	My journey: Overcoming TB stigma and advocating for change	15:40 - 15:50
	Phumeza Tisile (South Africa)	
	Breaking the silence: How my TB experience inspired me to advocate for better care	15:50 - 16:00
	Manasi Khade (India)	
	Question and answer	16:00 - 16:15
<i>Oral Abstract Session</i>		
16:10 - 17:40		HB
OA27 - Addressing TB myths		
Alanna Bergman (Charlottesville, United States)		
Zahedul Islam (Ukraine)		
	Introduction	16:10 - 16:15
OA27-314-14	Prevalence and predictors of TB stigma in peri-urban settlements in North-central Nigeria	16:15 - 16:24
	Chidiebube Aneke (Karu, Nigeria)	
OA27-315-14	Impact of TB-related stigma on people with TB, their contacts, and the larger society: Insights from Kano State, Nigeria	16:24 - 16:33
	Jane Adizue (Abuja, Nigeria)	
OA27-316-14	Psychological distress of rifampicin-resistant TB diagnosis and treatment on children and their caregivers in South Africa, India, and the Philippines	16:33 - 16:42
	Shatabdi Bagchi (Pune, India)	
OA27-317-14	TB-related stigma in Vietnam: Findings from a nationwide baseline assessment	16:42 - 16:51
	Sara Keller (The Hague, Netherlands)	
OA27-318-14	The national TB stigma assessment in Indonesia: Opportunity to build equitable, rights-based TB care	16:51 - 17:00
	Aris Subakti (Jakarta, Indonesia)	
OA27-319-14	Enhancing sexual health and mitigating stigma in TB care through educational discussions in Conakry	17:00 - 17:09
	Aboubacar Sidiki Magassouba (Conakry, Guinea)	
OA27-320-14	Reducing stigma experience among vulnerable populations with TB: Insights from a community intervention in selected Indian states	17:09 - 17:18
	Subramanian Potty Rajaram (Bengaluru, India)	
OA27-321-14	Stigma in people with multi-drug-resistant TB and HIV in South	17:18 - 17:27

	Africa	
	Amrita Daftary (Toronto, Canada)	
	Q&A	17:27 - 17:40
<i>Symposium</i>		
16:10 - 17:40		FR
	SP15 - TB meningitis - from bench to bedside	
	Fiona Cresswell (Nairobi, Kenya)	
	Reinout van Crevel (Nijmegen, Netherlands)	
SP15-496-14	Introduction	16:10 - 16:15
SP15-497-14	Diagnosis and treatment of adult TB meningitis Sean Wasserman (London, United Kingdom)	16:15 - 16:29
SP15-498-14	Improving diagnosis and outcomes in children with TB meningitis Julie Huynh (Ho Chi Minh City, Vietnam)	16:29 - 16:43
SP15-499-14	TB meningitis in people living with HIV: considerations for diagnosis and management David Meya (Kampala, Uganda)	16:43 - 16:57
SP15-500-14	Clinical trials and pharmacokinetic studies to optimise antimicrobial therapy Rovina Ruslami (Bandung, Indonesia)	16:57 - 17:11
SP15-501-14	Host genotype directed therapy for TB meningitis: new evidence from clinical trials and patient cohorts Thuong Nguyen Thuy Thuong (Ho Chi Minh City, Vietnam)	17:11 - 17:25
SP15-502-14	Q&A	17:25 - 17:40
<i>Symposium</i>		
16:10 - 17:40		BG
	SP16 - Assessing national TB legal environments to facilitate stronger TB responses	
	James Malar (Geneva, Switzerland)	
SP16-503-14	Introduction	16:10 - 16:15
SP16-504-14	Developing the Legal Environment and Human rights Scorecard and piloting it in Kenya Timothy Wafula (Nairobi, Kenya)	16:15 - 16:29
SP16-505-14	Developing a scoring matrix for the legal environment and human rights scorecard Rommy Mom (Abuja, Nigeria)	16:29 - 16:43
SP16-506-14	Implementing the TB legal environment and human rights scorecard in Indonesia Ria Ningsih (Indonesia)	16:43 - 16:57
SP16-507-14	The experience of the TB Legal Environment and Human Rights Scorecard in Moldova Cristina Celan (Chisinau, Moldova)	16:57 - 17:11
SP16-508-14	The importance of strong TB legal environments for ending TB James Malar (Geneva, Switzerland)	17:11 - 17:25
SP16-509-14	Q&A	17:25 - 17:40

Short Oral Abstract Session

16:10 - 17:40

OC

SOA07 - Motivation through communication

Ferdiana Yunita (Central Jakarta, Indonesia)

Archana Trivedi (New Delhi, India)

	Introduction	16:10 - 16:15
SOA07-659-14	Referral of persons with presumptive TB by the community influencers using pictorial referral slips: A pilot from selected tribal districts of India Nisha Sharma (Delhi, India)	16:15 - 16:23
SOA07-660-14	The role of civil society organisations in ensuring the implementation of the UNHLM on TB 2023 Nurliyanti Nurliyanti (South Jakarta, Indonesia)	16:23 - 16:31
SOA07-661-14	Re-imagining TB care: A multi-platform communications initiative to improve understanding of TB and mitigate stigma in Vietnam Tra Vu (Ha Noi, Vietnam)	16:31 - 16:39
SOA07-662-14	The role of Pidgin English in TB awareness creation: A study of KNCV Nigeria's online radio program, THE TB TORI Onyinye Kene-Eneh (Abuja, Nigeria)	16:39 - 16:47
SOA07-663-14	Addressing TB myths through social media campaigns: Lessons from KNCV Nigeria LinkedIn page Onyinye Kene-Eneh (Abuja, Nigeria)	16:47 - 16:55
SOA07-664-14	The impact of the TB community on policy formation and implementation of TB prevention and care measures in Ukraine Olya Klymenko (Kyiv, Ukraine)	16:55 - 17:03
SOA07-665-14	Voices of the community for people-centered TB care services: Findings from the first-round community-led monitoring data in three urban settings of Ethiopia, 2023 Zemedu Trife (Addis Ababa, Ethiopia)	17:03 - 17:11
SOA07-666-14	Detecting asymptomatic TB in contact investigation activities employing CXR-CAD in Yangon, Myanmar Thet Naing Maung (Yangon, Myanmar)	17:11 - 17:19
SOA07-667-14	All for one, but one for all? Combining computer-aided radiography and specimen pooling to optimise TB diagnostic algorithms Andrew James Codlin (Ha Noi, Vietnam)	17:19 - 17:27
	Q&A	17:27 - 17:40

Oral Abstract Session

16:10 - 17:40

JKA

OA28 - Novelty in approaching people with TB

Rina Triasih (Yogyakarta, Indonesia)

	Introduction	16:10 - 16:15
OA28-322-14	Targeting village hotspot sites for active case finding in Vietnam: Comparative results in two rural high-burden provinces Dung Chi Dang (Hanoi, Vietnam)	16:15 - 16:24
OA28-323-14	Integrating TB screening with other primary healthcare services in urban poor communities in the Philippines Julius Lecciones (Makati, Philippines)	16:24 - 16:33
OA28-324-14	Active TB case finding in most at-risk populations at the community level and how it changed after the full-scale war started	16:33 - 16:42

	in Ukraine Evgenia Geliukh (Kyiv, Ukraine)	
OA28-325-14	Role of active case finding and artificial intelligence in significantly increased TB case finding numbers in correctional centers: USAID TB-LON3 project experience in Oyo State Olufemi Ajayi (Abuja, Nigeria)	16:42 - 16:51
OA28-326-14	Uptake, yield and experiences of HIV testing within TB household contact screening programmes: A systematic review and meta-analysis Claire Calderwood (London, United Kingdom)	16:51 - 17:00
OA28-327-14	Enhancing multi-drug-resistant TB case detection in urban Uganda through strengthening access to molecular diagnostic testing for people with presumptive TB Leus Tweenatwine (Kampala, Uganda)	17:00 - 17:09
OA28-328-14	The efficacy of contact tracing and preventive therapy in preventing community transmission in Nigeria Adetokunbo Okungbure (Lagos, Nigeria)	17:09 - 17:18
	Q&A	17:18 - 17:31
<i>Oral Abstract Session</i>		
	16:10 - 17:40	JKB
	OA29 - State of the art TB diagnostics Nazir Ismail (Johannesburg, South Africa) Valeria Rolla (Rio de Janeiro, Brazil)	
	Introduction	16:10 - 16:13
OA29-329-14	The DR Estimator tool: Using state-of-the-art methods to generate clinically actionable outputs for all variants in candidate resistance-conferring genes of M. tuberculosis Miguel de Diego Fuertes (Antwerp, Belgium)	16:13 - 16:22
OA29-330-14	High-sensitivity detection of M. tuberculosis DNA in tongue swab samples Alaina Olson (Seattle, United States)	16:22 - 16:31
OA29-331-14	TB self-testing with multi-non-PAM gRNA derived CRISPR assay Zhen Huang (Shenzhen, China)	16:31 - 16:40
OA29-332-14	Diagnostic accuracy of M. tuberculosis Stool Ultra in detecting TB among adults living with HIV: A multi-centre study George William Kasule (Kampala, Uganda)	16:40 - 16:49
OA29-333-14	Implementation of Xpert MTB/XDR Assay to shorten the delay in drug-resistant TB care cascade of Bangladesh Umme Tasnim Maliha (Dhaka, Bangladesh)	16:49 - 16:58
OA29-334-14	Accuracy in detecting fluoroquinolone-heteroresistant M. tuberculosis mixtures by Xpert MTB/XDR Anzaan Dippenaar (Antwerp, Belgium)	16:58 - 17:07
OA29-335-14	Rapid diagnostic test by Truenat technology for identifying drug-sensitive and drug-resistant TB: A community approach to finding missing people with TB Ashraful Islam (Dhaka, Bangladesh)	17:07 - 17:16
OA29-336-14	Diagnostic accuracy of LiquidArray MTB-XDR VER1.0 for the detection of TB and second-line drug resistance Margaretha de Vos (Geneva, Switzerland)	17:16 - 17:25

OA29-337-14	The second edition of the WHO catalogue of resistance mutations: Achievements, gaps, and future needs Paolo Miotto (Milan, Italy)	17:25 - 17:34
	Q&A	17:34 - 17:40
<i>Oral Abstract Session</i>		
16:10 - 17:40		MD
OA30 - Life after TB: Addressing the problems and needs of TB survivors		
Dominik Zenner (London, United Kingdom) Intan Mauli Dewi (Bandung, Indonesia)		
	Introduction	16:10 - 16:15
OA30-338-14	The association between pulmonary TB disease and long-term all-cause mortality: A retrospective, matched cohort study in Taiwan Yuli Lily Hsieh (Boston, United States)	16:15 - 16:24
OA30-339-14	Risk factors associated with post-TB sequelae: A systematic review and meta-analysis Temesgen Yihunie Akalu (Perth, Australia)	16:24 - 16:33
OA30-340-14	Beyond treatment outcomes: Assessing quality of life among people with multi-drug-resistant TB in Lusaka, Zambia Mary Kagujje (Lusaka, Zambia)	16:33 - 16:42
OA30-341-14	Predicting TB recurrence to help target post-TB screening Samyra Cox (Baltimore, United States)	16:42 - 16:51
OA30-342-14	Prevalence and factors associated with post-TB lung disease among children and adolescents in Kenya: A multi-centre study Mercy Kamene (Nairobi, Kenya)	16:51 - 17:00
OA30-344-14	One-year follow-up outcomes of people with XDR-TB treated with bedaquiline and delamanid +/- carbapenem in Mumbai Vijay Chavan (Mumbai, India)	17:00 - 17:09
OA30-345-14	TB death surveillance and response (TBDSR): A step towards zero deaths due to TB - Lessons learned from West Bengal, India Abhijit Dey (New Delhi, India)	17:09 - 17:18
OA30-346-14	Reducing deaths in elderly with drug-sensitive TB: Lessons from the high altitude region of Ladakh, India Praveen Kumar Yadav (Delhi, India)	17:18 - 17:27
	Q&A	17:27 - 17:40
<i>Oral Abstract Session</i>		
16:10 - 17:40		NS1
OA31 - Safeguards for the caregivers		
Ajoy Kumar Verma (New Delhi, India) Kobto Ghislain Koura (PARIS, France)		
	Introduction	16:10 - 16:15
OA31-347-14	Burden of bacteriologically confirmed pulmonary TB in Uganda's prisons system: Results of a 2023 nationally representative prevalence survey Deus Lukoye (Kampala, Uganda)	16:15 - 16:25
OA31-348-14	TB screening among healthcare workers in Zambia: A key to the attainment of healthcare worker safety 2018-2022 Clara Chola Kasapo (Lusaka, Zambia)	16:25 - 16:35

OA31-349-14	Collaborative strategies for TB elimination: Insights from employer-led model for occupational health interventions in Rajasthan, India Ashutosh Sharma (Delhi, India)	16:35 - 16:45
OA31-350-14	Latent TB infection among healthcare workers in a tertiary care hospital of Puducherry, South India, 2023 Palanivel Chinnakali (Puducherry, India)	16:45 - 16:55
OA31-352-14	TB among healthcare workers in 24 USAID supported high-burden countries for TB Peter R. Kerndt (Washington, United States)	16:55 - 17:05
OA31-353-14	Prevalence of TB among prisoners in incarcerated populations in Indonesia Elly Yuzar (Jakarta, Indonesia)	17:05 - 17:15
OA31-351-14	Prevalence of past and current COVID-19 among people in prison and staff in Uganda - July and August 2023 Deus Lukoye (Kampala, Uganda)	17:15 - 17:25
	Q&A	17:25 - 17:40
<i>Short Oral Abstract Session</i>		
	16:10 - 17:40	NS2
SOA08 - Advanced HIV		
Jyoti Mathad (New York, United States) Leonardo Martinez (Boston, United States)		
	Introduction	16:10 - 16:15
SOA08-668-14	Sepsis in adults living with HIV in Africa: Informing new empiric therapy Eva Otoupalova (Charlottesville, United States)	16:15 - 16:22
SOA08-669-14	The association of NAT2 genetic polymorphisms with TB treatment outcomes and mortality in persons living with HIV in Thailand Ayu Kasamatsu (Tokyo, Japan)	16:22 - 16:29
SOA08-670-14	Cepheid TB host response measurements as prognostic biomarkers in TB meningitis: A prospective cohort study Jayne Ellis (London, Uganda)	16:29 - 16:36
SOA08-671-14	The accuracy of the Bandim TBscore as a screening tool for TB disease among severely ill inpatients with HIV in Ghana Johanna Åhsberg (Odense, Denmark)	16:36 - 16:43
SOA08-672-14	Advanced HIV as an ongoing driver of incident TB in Tongaat, KwaZulu-Natal, South Africa Rubeshan Perumal (Durban, South Africa)	16:43 - 16:50
SOA08-673-14	Secondary prevention of TB: Experience from a cohort of people living with HIV on ART in program settings in Nairobi, Kenya, 2012-2021 Herman Weyenga (Nairobi, Kenya)	16:50 - 16:57
SOA08-674-14	Parallel use of low-complexity automated nucleic acid amplification tests and urine lateral-flow lipoarabinomannan assays to detect TB disease in people with HIV: A systematic review Stephanie Bjerrum (Odense, Denmark)	16:57 - 17:04
SOA08-675-14	Pilot programmatic introduction of lateral flow urine lipoarabinomannan assay for diagnosis of TB in people living with HIV: The Philippines experience Mary Rosary Santiago (Makati, Philippines)	17:04 - 17:11

SOA08-676-14	Diagnostic performance of tNGS and mNGS on TB in a HIV-positive cohort Feili Wei (Beijing, China)	17:11 - 17:18
SOA08-677-14	Immunological predictors of mortality among advanced HIV adults with TB in India Vandana Kulkarni (Pune, India)	17:18 - 17:25
	Q&A	17:25 - 17:40
<i>Late Breaker Oral Abstract Session</i>		
	16:10 - 17:40	NS3
LB03 - The RIT/JATA student late-breaker session		
Carrie Tudor (United States) Norio Yamada (Kiyose, Japan)		
	Introduction	16:10 - 16:15
LB03-1214-14	Barriers to LTBI treatment in project JEET: A prospective observational operations research Vanshika Verma (Rohtak, India)	16:15 - 16:24
LB03-1215-14	Impact of strategic public health interventions to reduce TB incidence in Brazil: A Bayesian Structural Time-Series scenario analysis Klauss Villalva-Serra (Salvador, Brazil)	16:24 - 16:33
LB03-1216-14	TB treatment outcomes following release from prison in Mato Grosso do Sul, Brazil: A retrospective cohort study Yasmine Mabene (Stanford, United States)	16:33 - 16:42
LB03-1217-14	Within-country heterogeneity in patterns of social contact relevant for TB transmission, prevention and care Kate LeGrand (London, United Kingdom)	16:42 - 16:51
LB03-1218-14	Impact of intense exercise on innate bacterial killing capacity of close contacts of people with TB/MDR-TB Saikaew Chuachan (Hatyai, Thailand)	16:51 - 17:00
LB03-1219-14	Extensively-drug-resistant TB: Back to the pre-antibiotic era? A TBnet/ESGMYC multi-country study Ole Skouvig Pedersen (Aarhus, Denmark)	17:00 - 17:09
LB03-1220-14	Characterisation of the Targeted Universal Tuberculosis Testing (TUT) care cascade among people living with HIV in rural and urban districts in South Africa Katlego Motlhaoleng (Pretoria, South Africa)	17:09 - 17:17
LB03-1221-14	RR-TB treatment and the PrEP continuum of care: Opportunities to better integrate HIV prevention efforts into South Africa's TB services Adam Leonard (Baltimore, United States)	17:17 - 17:26
	Q&A	17:26 - 17:40
<i>Community Connect</i>		
	16:30 - 17:30	AU
CCSA010 - "Beyond Cure": Interactive art and overlooked struggles - Engage in the post-TB journey		
Fiona BUDGE (Indonesia) Fiona BUDGE (Indonesia) Trisasi Lestari (Jakarta, Indonesia)		
	Introduction to Session and Artwork	16:30 - 16:35

	“Beyond Cure” interactive art and overlooked struggles: Engage in the post-TB journey	16:35 - 16:45
	Paran Sarimita Winarni (Indonesia)	
	“Beyond Cure” interactive art and overlooked struggles: Engage in the post-TB journey	16:45 - 16:55
	Ray L P (Indonesia)	
	“Beyond Cure” interactive art and overlooked struggles: Engage in the post-TB journey	16:55 - 17:05
	Budi Hermawan (Indonesia)	
	“Beyond Cure” interactive art and overlooked struggles: Engage in the post-TB journey	17:05 - 17:15
	Hanadi Hussien Taj Alsir (Sudan)	
	Question and answer	17:15 - 17:30
<i>Community Connect</i>		
16:30 - 17:30		SG
	CCSS003 - Challenging local funding support for community-based TB initiatives to End TB: Experiences from Indonesia	
	Dini Andriani (Jakarta, Indonesia)	
	Budi Susilo (Indonesia)	
	Dini Andriani (Jakarta, Indonesia)	
	Introduction	16:30 - 16:35
	Mobilising village fund to address TB in remote areas	16:35 - 16:45
	Henry Diatmo (Indonesia)	
	Bridging the gap: Addressing resource shortfalls in community-based TB initiatives	16:45 - 16:55
	Ani Hernasari (Indonesia)	
	Healthy housing to improve quality of life of people affected by TB	16:55 - 17:05
	Ruli Oktavian (Indonesia)	
	Policy gaps and opportunities in mobilising domestic resources for community-based TB initiatives	17:05 - 17:15
	Mohamad Subuh (Indonesia)	
	Question and answer	17:15 - 17:30
<i>Union Live Session</i>		
17:00 - 17:30		UL
	UL20 - Dr Brahmastra Megasakti discusses the role volunteering can play in the fight against TB and Thursday highlights from the conference floor	
<i>Community Connect</i>		
17:30 - 17:45		EG2
	CCLP002 - Singing by Stop TB Tajikistan	
<i>TBScience E-Poster Session</i>		
17:35 - 19:30		M EP7
	TBS-EP04 - Fundamental advances in understanding pathogenesis Part 2	
	Babak Javid (United Kingdom)	
TBS-EP-71	Screening and evaluation of immunomodulatory compounds as host-directed therapy to potentiate antimycobacterial immunity	17:35 - 17:40
	Tamia Lawrence (Durban, South Africa)	

TBS-EP-72	Validation of host protein signatures dually associated with TB pathogenesis in blood and lung Pumla Majozi (Durban, South Africa)	17:40 - 17:45
TBS-EP-73	Novel subunit TB vaccine delivered by flagellin elicit protective humoral and cellular immunological responses in vivo Nkanyezi Masondo (Durban, South Africa)	17:45 - 17:50
TBS-EP-74	Tissue-specific immunophenotyping in a TB mice model reveals different immune responses in lung parenchyma and vasculature José Domínguez-Benítez (Badalona, Spain)	17:50 - 17:55
TBS-EP-75	Role and mechanism of IL-36γ in promoting M1 macrophage differentiation in the anti-TB immune response through the IκBζ pathway Peijun Tang (Soochow, China)	17:55 - 18:00
TBS-EP-76	Single cell RNA-Seq of PBMC reveals that PLHIV with history of TB have distinct immune cell subsets Kathryn Dupnik (New York, United States)	18:00 - 18:05
TBS-EP-77	Breathing new insights: Exploring the lung microbiota in pulmonary TB Charissa Naidoo (Cape Town, South Africa)	18:05 - 18:10
TBS-EP-78	The clinical significance of plasma sCD25 as valuable biomarker for progression and prognosis of TB Yayan Niu (Suzhou, China)	18:10 - 18:15
TBS-EP-79	Efficacy of Diaskintest in diagnosis of TB infection in not at-risk children Anna Abramchenko (Moscow, Russian Federation)	18:15 - 18:20
TBS-EP-80	The impact of COVID-19 and its effects on the individual manifestations of systemic inflammation in people with pulmonary TB Anna Abramchenko (Moscow, Russian Federation)	18:20 - 18:25
TBS-EP-81	The effect of interferon-γ on the efficacy of treatment of people with multi-drug-resistant TB Anna Abramchenko (Moscow, Russian Federation)	18:25 - 18:30
TBS-EP-82	Targeting lung inflammation for TB HDT development Mohlopheni J. Marakalala (Durban, South Africa)	18:30 - 18:35
TBS-EP-83	A robust and standardised progression cascade for compounds targeting host-pathogen interactions in TB	18:35 - 18:40
TBS-EP-84	The likelihood of developing a systemic inflammatory response in extrapulmonary TB Anna Abramchenko (Moscow, Russian Federation)	18:40 - 18:45
TBS-EP-85	Utilising AI-driven drug repurposing to understand TB pathogenesis Nibedita Rath (Bangalore, India)	18:45 - 18:50
TBS-EP-86	The approach of stem cell in TB vaccine Nurindah Saloka Trisnaningrum (Bandung, Indonesia)	18:50 - 18:55
TBS-EP-87	Features of the immune status in people with drug-resistant TB Anna Abramchenko (Moscow, Russian Federation)	18:55 - 19:00
TBS-EP04	Q&A	19:00 - 19:30

<i>Community Connect</i> 17:45 - 18:00		EG2
CCLP003 - "Jingle dance" by Yayasan KNCV Indonesia		
<i>Press Conference</i> 18:00 - 19:30		HB
PR01 - Press Conference		
<i>Side Meeting</i> 18:00 - 19:30		FR
SM17 - NAPs sub section		
<i>Side Meeting</i> 18:00 - 19:00		BG
SM18 - TB B/I sub-section		
<i>Side Meeting</i> 18:00 - 19:00		OC
SM19 - Zoonotic TB sub section		
<i>Side Meeting</i> 18:00 - 19:00		JKA
SM20 - Child Malnutrition and TB WG		
<i>Satellite Session</i> 18:00 - 19:30		JKB
SS11 - Trials and tribulations in TB drug development: A UNITE4TB and PAN-TB perspective		
Jodie Schildkraut (Netherlands)		
Maria Tarcela Gler (Philippines)		
Introduction		18:00 - 18:05
Challenges in TB drug development: A developers' perspective		18:05 - 18:18
David Barros (Spain)		
Challenges in TB drug development: An operational perspective		18:18 - 18:31
Karen Sanders (United Kingdom)		
Challenges in TB drug development: A policy makers' perspective		18:31 - 18:44
Fuad Mirzayev (Geneva, Switzerland)		
Challenges in TB drug development: A partnership perspective - including an update from the PAN-TB trial		18:44 - 18:57
David Holtzman (United States)		
Challenges in TB drug development: A community perspective		18:57 - 19:10
Paul Sommerfeld (United Kingdom)		
Q&A		19:10 - 19:30
<i>Side Meeting</i> 18:00 - 19:00		MD
SM21 - Post -TB Lung Disorders WG		
<i>Side Meeting</i> 18:00 - 19:30		NS1
SM22 - Drug Resistant TB WG		

Friday, 15. November 2024*TBScience Session*

08:00 - 09:00

AU

TBS3A - Disease course heterogeneity

Sarah Fortune (United States)

TBS3A-10	Session introduction	08:00 - 08:05
TBS3A-15	Why TB differentially spares women, and what this can teach us about TB prevention and care William Bishai (United States)	08:05 - 08:20
TBS3A-20	Ancestry-related differences in M. tuberculosis host responses and disease course Sara Suliman (United States)	08:20 - 08:35
TBS3A-25	Basis of TB infection-"resistance" Nelita du Plessis (South Africa)	08:35 - 08:50
TBS3A-30	Q&A	08:50 - 09:00

Meet the Expert Session

08:00 - 09:00

HB

MTE-01 - Finding the missing people with TB

Zahedul Islam (Ukraine)

	Live introduction Zahedul Islam (Ukraine)	08:00 - 08:05
	Finding the missing people with TB Sok Chamreun Choub (Cambodia)	08:05 - 08:20
	Live Q&A	08:20 - 09:00

Meet the Expert Session

08:00 - 09:00

FR

MTE-02 - Treating the person not the disease: Precision medicine and holistic care in TB

Simon Tiberi (London, United Kingdom)

	Live introduction Simon Tiberi (London, United Kingdom)	08:00 - 08:05
	Treating the person not the disease, precision medicine and holistic care in Tuberculosis Onno Akkerman (Groningen, Netherlands)	08:05 - 08:20
	Live Q&A	08:20 - 09:00

Meet the Expert Session

08:00 - 09:00

BG

MTE-03 - Leadership in addressing TB-tobacco co-epidemic

Pinpin Zheng (China)

	Live introduction Pinpin Zheng (China)	08:00 - 08:05
	Leadership in addressing TB-tobacco co-epidemic Tara Singh Bam (Singapore)	08:05 - 08:20
	Live Q&A	08:20 - 09:00

Meet the Expert Session

08:00 - 09:00

OC

MTE-04 - The epidemiology, transmission, diagnosis and management of drug-resistant TB

Palwasha Yousafzai Khan (London, United Kingdom)

Live introduction

08:00 - 08:05

Palwasha Yousafzai Khan (London, United Kingdom)

The epidemiology, transmission, diagnosis and management of DR-TB

08:05 - 08:20

Kogieleum Naidoo (Durban, South Africa)

Live Q&A

08:20 - 09:00

Meet the Expert Session

08:00 - 09:00

NS1

MTE-05 - Access denied: Confronting barriers to care for children with pneumonia

Chishala Chabala (Lusaka, Zambia)

Live introduction

08:00 - 08:05

Chishala Chabala (Lusaka, Zambia)

Access denied: Confronting barriers to care for children with pneumonia (TBC)

08:05 - 08:20

Stephen Howie (New Zealand)

Fiona Langridge (New Zealand)

Sainimere Boladuadua (Auckland, New Zealand)

Live Q&A

08:20 - 09:00

Union Live Session

08:00 - 09:30

UL

UL21 - Messages from our event sponsors*Community Connect*

09:00 - 10:00

SG

CCSS016 - Community leadership is building power and driving #FindAllTB → #TreatAllTB → #PreventAllTB → #EndTB initiative in high TB burden countries

Shobha Shukla (India)

Tariro Kutadza (Zimbabwe)

Shobha Shukla (India)

Opening Remarks

09:00 - 09:09

Dirgh Singh Bam (Nepal)

365 days since the launch of global call to find all TB

09:09 - 09:15

Shobha Shukla (India)

Africa launch of call to find all TB: Experiences and learnings and way forward

09:15 - 09:21

Tariro Kutadza (Zimbabwe)

Screening everyone for TB with ultraportable x-rays and offering point-of-care molecular tests to those with presumptive TB

09:21 - 09:27

Samantha Tinsay (Philippines)

Evidence of screening everyone in high-burden settings: Making an impact to find all TB, treat all and prevent all TB

09:27 - 09:33

Kuldeep Singh Sachdeva (India)

Local actions are critical to find all TB, treat all TB and prevent all TB (and reduce and address risk factors of TB)

09:33 - 09:39

Tara Singh Bam (Singapore)

	Reaching the homeless and migrant people with TB services: making a difference where its needed most	09:39 - 09:45
	Lisbeth Aarup (India)	
	Question and answer	09:45 - 10:00
<i>TBScience Session</i>		
09:05 - 09:50		AU
TBS3B - Mechanisms underlying heterogeneous disease manifestations - Oral Abstracts		
Emily A. Kendall (Baltimore, United States)		
TBS3B-05	Session introduction	09:05 - 09:07
TBS3B-10	The development and multi-country evaluation of a vibroacoustic signature to classify TB severity	09:07 - 09:14
	Tessa Mochizuki (San Francisco, United States)	
TBS3B-15	Characterising the spectrum of TB: A multi-state model analysis of a cohort of household contacts	09:14 - 09:21
	Leyla Larsson (Munich, Germany)	
TBS3B-20	Insights into post-TB lung disease severity from immune characterisation, PET-CT imaging, and lung function testing	09:21 - 09:28
	Stephanus Malherbe (Cape Town, South Africa)	
TBS3B-25	Single gene transcripts for subclinical TB: An individual participant data meta-analysis	09:28 - 09:35
	James Greenan-Barrett (London, United Kingdom)	
TBS3B-30	Q&A	09:35 - 09:50
<i>Oral Abstract Session</i>		
09:20 - 10:50		HB
OA32 - Approaches for identifying TB in children		
Martina Casenghi (Geneva, Switzerland)		
Eric Wobudeya (Kampala, Uganda)		
	Introduction	09:20 - 09:25
OA32-354-15	Treatment-decision algorithms for children evaluated for pulmonary TB: Evaluation of the WHO algorithm and development of the algorithm in Indonesia	09:25 - 09:34
	Rina Triasih (Yogyakarta, Indonesia)	
OA32-355-15	Diagnostic accuracy of Computer-Aided Detection for Tuberculosis® and Xpert Ultra stool testing for pulmonary TB in West African children	09:34 - 09:43
	Sheila Agyeiwaa Owusu (London, United Kingdom)	
OA32-356-15	TB detection in children using the simple one-step stool processing method in three remote zones in Ethiopia	09:43 - 09:52
	Adrian Leung (The Hague, Netherlands)	
OA32-357-15	Exploring opportunities for TB diagnosis in children aged 5-14 years in Nigeria using ultra-portable digital X-ray with computer-aided detection	09:52 - 10:01
	Rupert Eneogu (Abuja, Nigeria)	
OA32-358-15	Finding the missing children: Results from a multi-country study of the diagnostic cascade using WHO treatment decision algorithms for pulmonary TB	10:01 - 10:10
	Helena Huerga (Brussels, Belgium)	
OA32-359-15	Ultra on induced sputum for diagnosis of pulmonary TB in children	10:10 - 10:19

	in a setting with a high burden of HIV or malnutrition Juaneta Luiz (Cape Town, South Africa)	
OA32-360-15	Blinded point-of-care ultrasound to support TB diagnosis in children: A Médecins Sans Frontières cross-sectional study in Malakal, South Sudan Raman Mahajan (Delhi, India)	10:19 - 10:28
OA32-361-15	The performance of WHO-recommended child TB treatment decision algorithms in an individual participant dataset from multi-centre diagnostic accuracy studies in lower-middle-income countries Leyla Larsson (Munich, Germany)	10:28 - 10:37
	Q&A	10:37 - 10:50
<i>Oral Abstract Session</i>		
	09:20 - 10:50	FR
	OA33 - Cost associated with TB Ahmad Fuady (Jakarta, Indonesia) Kritika Dixit (Kathmandu, Nepal)	
	Introduction	09:20 - 09:25
OA33-363-15	Improving AHD care through cost-effective capacity building approaches Makplang Milaham (Maseru, Lesotho)	09:25 - 09:36
OA33-364-15	Identifying barriers to social protection for food insecure people living with HIV and TB in Zimbabwe: Results from a multi-method study Canice Christian (San Francisco, United States)	09:36 - 09:47
OA33-365-15	Baseline assessment of social assistance programs for people affected by TB and their households in Uganda: A situation analysis Grace Nanyunja (Kampala, Uganda)	09:47 - 09:58
OA33-366-15	Dissaving is common among people undergoing TB diagnostic evaluation across four high-burden countries for TB Priya Shete (United States)	09:58 - 10:09
OA33-367-15	Costs, including catastrophic costs, of people with TB with unhealthy alcohol use in Pune, India Minjoo Yang (Seoul, Korea, Republic of)	10:09 - 10:20
OA33-368-15	Financial impact of illness in a cohort of people with TB in Kisumu County, Kenya, during the COVID-19 pandemic, March 2022-January 2023 Julius Oliech (Nairobi, Kenya)	10:20 - 10:31
	Q&A	10:31 - 10:50
<i>Short Oral Abstract Session</i>		
	09:20 - 10:50	BG
	SOA09 - Finding the missing children with TB and the care cascade Finny Fitry Yani (Padang, West Sumatera, Indonesia) Toyin Togun (London, United Kingdom)	
	Introduction	09:20 - 09:25
SOA09-678-15	Impact of integrating TB and orphans and vulnerable children services on TB diagnosis and treatment outcomes in the Rwenzori Region, Uganda Deus Lukoye (Kampala, Uganda)	09:25 - 09:34

SOA09-679-15	A reduction in the burden of childhood TB: The laboratory perspective to a targeted search for missing cases Michael Umoren (Uyo, Nigeria)	09:34 - 09:43
SOA09-680-15	Leveraging on World Health Organization's integrated treatment decision algorithms to optimise child TB detection: A multi-states study in Nigeria Ochuko Urhioke (Abuja, Nigeria)	09:43 - 09:52
SOA09-681-15	TB preventive treatment for children: Opportunities arising from latest WHO recommendations and dosing updates Tiziana Masini (Geneva, Italy)	09:52 - 10:01
SOA09-682-15	Experiences of children with multi-drug-resistant TB across TB care journey in Cape Town, South Africa Abenathi A. Mcinziba (Cape Town, South Africa)	10:01 - 10:10
SOA09-683-15	Incidence of TB in migrant children in Europe: A systematic review and meta-analysis Anca Vasiliu (Houston, United States)	10:10 - 10:19
SOA09-684-15	Diagnostic capacity for childhood TB before the introduction of treatment decision algorithms at decentralised levels of healthcare in Zambia Alan Kachuka (Lusaka, Zambia)	10:19 - 10:28
SOA09-685-15	Innovative, child-friendly solutions for paediatric TB care provision to children and their families affected by TB Olya Klymenko (Kyiv, Ukraine)	10:28 - 10:37
	Q&A	10:37 - 10:50
<i>Oral Abstract Session</i>		
	09:20 - 10:50	OC
OA34 - Strategies bridging education and communication for transformative outcomes		
Trisasi Lestari (Jakarta, Indonesia) Fernando Augusto Dias e Sanches (Rio de Janeiro, Brazil)		
	Introduction	09:20 - 09:25
OA34-369-15	Maximising knowledge retention for TB professionals in Ukraine with retraining Nataliia Lytvynenko (Kyiv, Ukraine)	09:25 - 09:34
OA34-370-15	Leveraging music to promote TB awareness in Kenya Samson Musau (Nairobi, Kenya)	09:34 - 09:43
OA34-371-15	Teachers as TB advocates: A school-based community-driven approach to TB awareness - the CHIRAATH Initiative Anupkumar T. N. (New Delhi, India)	09:43 - 09:52
OA34-372-15	Risk and behavioral change communication: Sensitising primary and secondary school teachers to improve childhood TB detection in Kano state, Nigeria Mustapha Tukur (Kano, Nigeria)	09:52 - 10:01
OA34-373-15	Knowledge, attitude, and practice of TB prevention among female sex workers in the urban area of Aba, South East Nigeria Stanley Chinkata (Umuahia, Nigeria)	10:01 - 10:10
OA34-374-15	TB coaching practice to improve quality of TB care in healthcare facilities: Experience from 28 districts in Indonesia Linda Devega (Jakarta Selatan, Indonesia)	10:10 - 10:19
OA34-375-15	Harnessing potential of youth voices for TB care and prevention:	10:19 - 10:28

	An experience from India Anupama Srinivasan (Chennai, India)	
OA34-376-15	Effectiveness, satisfaction, and cost analysis of a blended learning course for TB case managers I-Wen Chang (Taipei, Taiwan)	10:28 - 10:37
	Q&A	10:37 - 10:50
<i>Oral Abstract Session</i>		
09:20 - 10:50		JKA
OA35 - Tools and technology for TB		
Ya Diul Mukadi (Washington, DC, United States)		
	Introduction	09:20 - 09:25
OA35-377-15	Impact of electronic return of laboratory results on turnaround time through LIMS in resource-limited settings Mufaro Masamha (Harare, Zimbabwe)	09:25 - 09:34
OA35-378-15	TB Watch: An automated monitoring system for targeted field actions towards TB elimination in India Shiv Hiren Joshi (New Delhi, India)	09:34 - 09:43
OA35-379-15	PPM hub: A catalyst for digital TB management towards proactive healthcare in the private sector Nainan Nawaz (Islamabad, Pakistan)	09:43 - 09:52
OA35-380-15	Leveraging connectivity of TB diagnostic instruments with real-time results informing decision-making in Nigeria Segun Adeshina (Abuja, Nigeria)	09:52 - 10:01
OA35-381-15	Advancing towards an integrated, comprehensive, case-based TB surveillance system: A case study from Vietnam Luong Van Quach (Hanoi, Vietnam)	10:01 - 10:10
OA35-382-15	Enhancing data accuracy in India's TB electronic surveillance system: Insights from a nationwide drug-resistant TB data validation study Sandeepkumar Chauhan (New Delhi, India)	10:10 - 10:19
OA35-383-15	Ensuring TB data quality in Ethiopia: Role of digitalising mentorship and registers of people with drug-resistant TB Zewdu Gashu Dememew (Addis Ababa, Ethiopia)	10:19 - 10:28
	Q&A	10:28 - 10:41
<i>Oral Abstract Session</i>		
09:20 - 10:50		JKB
OA36 - Finding TB in key and vulnerable populations		
Sonia Menon (Brussels, Belgium)		
Daria Szkwarko (Providence, United States)		
	Introduction	09:20 - 09:25
OA36-385-15	Enhanced home-based TB contact tracing in rural India, Nagpur, 2021-2022 Radha Munje (Nagpur, India)	09:25 - 09:34
OA36-386-15	Incorporating geospatial analysis for targeted case finding activities for TB in rural communities of Pakistan Asadullah Mir (Karachi, Pakistan)	09:34 - 09:43
OA36-387-15	Can the MATCH framework be used to prioritise the location of	09:43 - 09:52

	active case finding for TB in Vietnam? Christina Mergenthaler (Amsterdam, Netherlands)	
OA36-388-15	Comparison of TB prevalence between contacts of bacteriologically confirmed and clinically diagnosed index people with TB Lilungwe Mutti (Lusaka, Zambia)	09:52 - 10:01
OA36-389-15	Finding the missing children: Experience on enhancing paediatric TB diagnosis in Bombali district, Sierra Leone Jobin Joseph (Makeni, Sierra Leone)	10:01 - 10:10
OA36-390-15	Optimising TB case finding among prisoners through enhanced peer-led approach in Kenya Titus Kiptai (Nairobi, Kenya)	10:10 - 10:19
OA36-391-15	Contact investigators with health background: Changing drug-resistant TB narratives in children and adolescents in a southwestern state, Nigeria Aderonke Agbaje (Abuja FCT, Nigeria)	10:19 - 10:28
OA18-246-14	Improving access to TB diagnosis and care for hard-to-reach trucking population in India	10:28 - 10:37
	Q&A	10:37 - 10:50
<i>Symposium</i>		
	09:20 - 10:50	MD
	SP17 - Bridging the Gap from Policy to Practice for Effective and Ethical Integration of New Shorter MDR/RR-TB Regimens Christophe Perrin (France) Faisal Siraj (Islamabad, Pakistan)	
SP17-510-15	Introduction	09:20 - 09:30
SP17-511-15	Community Perspectives on Integrating New Shorter MDR/RR-TB Treatment Regimens for Equitable Quality Care Paran Sarimita Winarni (East Jakarta, Indonesia)	09:30 - 09:45
SP17-512-15	Addressing Challenges in Laboratory Capacity for TB Drug-Resistance Testing For Effective MDR/RR-TB Management. Debrah Vambe (Houston, Eswatini)	09:45 - 10:00
SP17-513-15	Identifying Opportunities in Tailored Treatment Decisions for MDR/RR-TB Care under Operational Research Conditions. Edwin Hernando Herrera Flores (Lima, Peru)	10:00 - 10:15
SP17-514-15	Insights and Experience in Navigating Patient Management and Adverse Event Monitoring with the Shorter BPAL Regimen. Veriko Mirtskhulava (The Hague, Netherlands)	10:15 - 10:30
SP17-515-15	Q&A	10:30 - 10:50
<i>Oral Abstract Session</i>		
	09:20 - 10:50	NS1
	OA37 - Tobacco and e-cigarette: Feature of use and intervention approaches Sonu Goel (Chandigarh, India) Putu Ayu Swandewi Astuti (Indonesia)	
	Introduction	09:20 - 09:25
OA37-392-15	Gender differences in the determinants of tobacco use in Tanzania: Evidence from a nationwide cross-sectional survey Daniel Ogbuabor (Enugu, Nigeria)	09:25 - 09:36

OA37-393-15	Initiation, cessation and relapse of tobacco smoking among participants in a large longitudinal cohort in rural South Africa Ronel Sewpaul (Cape Town, South Africa)	09:36 - 09:45
OA37-394-15	Prevalence of e-cigarette use, profile of e-cigarette users, and relationship between e-cigarette use and cigarette smoking in South Africa Thomas van Huyssteen (Cape Town, South Africa)	09:45 - 09:54
OA37-395-15	Prioritising hazardous constituents in smokeless tobacco products for tobacco regulation in India Chirag Goel (Chandigarh, India)	09:54 - 10:04
OA37-396-15	From one to endless: A mixed-methods study of loose cigarette purchase and adolescent smoking in Indonesia Gea Melinda (Central Jakarta, Indonesia)	10:04 - 10:13
OA37-398-15	Windows of opportunity to navigate the difference between tax increase and market transaction price on tobacco products in Indonesia Roosita Meilani Dewi (Tangerang Selatan, Indonesia)	10:13 - 10:22
OA37-399-15	Creating a global tobacco control treaty surveillance system Les Hagen (Edmonton, Canada)	10:22 - 10:31
OA37-400-15	The design and effectiveness evaluation of customised smoking cessation messages recommendation system Yuchen Zhao (Shanghai, China)	10:31 - 10:40
	Q&A	10:40 - 10:50
<i>Oral Abstract Session</i>		
	09:20 - 10:50	NS2
	OA38 - Amplifying community voices through advocacy and awareness Jonathan Stillo (Ferndale, United States) Jamilya Ismoilova (Dushanbe, Tajikistan)	
	Introduction	09:20 - 09:25
OA38-401-15	Cross-border collaboration on TB services: Adapting advocacy and sustainability approaches for improved management and long-term collaboration Lethia Bernard (Washington, United States)	09:25 - 09:34
OA38-402-15	Provider-led advocacy and community engagement: Game changer in TB case finding O. Omofaiye (Abuja, Nigeria)	09:34 - 09:43
OA38-403-15	Stop TB country platform enhancing coordination and advocacy efforts in Zimbabwe Melody Mukukundwi (Harare, Zimbabwe)	09:43 - 09:52
OA38-404-15	Leveraging interschool competitions to enhance community TB advocacy, communication, and social mobilisation: An experience from Zambia Hachintu Makomo (Lusaka, Zambia)	09:52 - 10:01
OA38-405-15	An ideal platform for amplifying community voices: The experience of implementing I-monitor ATM+ Kenya App Vincent Onchiri (Nairobi, Kenya)	10:01 - 10:10
OA38-406-15	Unlocking access to life-saving bedaquiline worldwide: Challenges and noteworthy Ukrainian experience for global public campaign Veronika Kochubei (Kyiv, Ukraine)	10:10 - 10:19

OA38-407-15	Ethical challenges in lung transplantation in India: A critical analysis Mahesh Devnani (Chandigarh, India)	10:19 - 10:28
OA38-408-15	TB awareness and knowledge through effective communication: A systematic review of interventions in India Aman Raj (Bhopal, India)	10:28 - 10:37
	Q&A	10:37 - 10:50
<i>Symposium</i>		
09:20 - 10:50		NS3
	SP18 - Children with severe acute malnutrition--progress addressing the burden of TB in this high-risk group Sabine Verkuijl (Geneva, Switzerland) Olivier Marcy (Bordeaux, France)	
SP18-516-15	Introduction	09:20 - 09:25
SP18-517-15	TB diagnosis in children with severe acute malnutrition using the 2022 WHO algorithms in nutrition insecure contexts Jasmine Armour-Marshall (London, United Kingdom)	09:25 - 09:39
SP18-518-15	Burden and outcome of TB in children with severe acute malnutrition hospitalised with acute illness in Sub-Saharan Africa and South-East Asia Mohammad Jobayer Chisti (Dhaka, Bangladesh)	09:39 - 09:53
SP18-519-15	Screening and treatment decision algorithms for TB diagnosis in children below 5 years hospitalised with severe acute malnutrition: A cost-effectiveness analysis Marc d'Elbée (Bordeaux, France)	09:53 - 10:07
SP18-520-15	Pharmacokinetics of first line anti-TB drugs in children with severe acute malnutrition Chishala Chabala (Lusaka, Zambia)	10:07 - 10:21
SP18-521-15	Urine LAM testing for TB diagnosis in children with severe acute malnutrition Bryan Vonasek (East Lansing, United States)	10:21 - 10:35
SP18-522-15	Q&A	10:35 - 10:50
<i>Community Connect</i>		
09:30 - 10:30		EG2
	CCWS004 - Post TB health and wellbeing: Community perspectives and research priorities Ingrid Schoeman (Pretoria, South Africa)	
	The Post-TB CARE (Centre for Assessment & Research Excellence) Brian Allwood (Cape Town, South Africa)	09:30 - 09:30
	Developing pathways to integrated TB and Respiratory Care in Africa Chakaya Muhwa (Kenya)	09:30 - 09:30
	Understanding Post-TB lung disease and novel strategies for prevention, diagnosis and treatment in four African countries. Salome Charalambous (Johannesburg, South Africa)	09:30 - 09:30
	Community feedback discussions Goodman Makanda (South Africa)	09:30 - 09:30
	A roadmap toward integration of PTLT in the continuum of TB care	09:30 - 09:30

Stellah Mpagama (Tanzania)

Union Live Session

09:30 - 10:00

UL

UL22 - Dyuti Sen continues Union LIVE's series exploring the challenges and rewards of volunteering

TBScience Session

10:00 - 11:00

AU

TBS3C - Treatment outcome heterogeneity

Bachti Alisjahbana (Indonesia)

TBS3C-05

Session introduction

10:00 - 10:03

TBS3C-10

Non-drug mechanisms in heterogeneous treatment outcomes: Insights from the H56 trial

10:03 - 10:18

Thomas Scriba (Cape Town, South Africa)

TBS3C-15

Linking clinical and multi-omics data and target host-directed therapy

10:18 - 10:33

Arjan Van Laarhoven (Nijmegen, Netherlands)

TBS3C-20

Mechanisms underlying immune dysregulation in post-TB disease: Too little or too much?

10:33 - 10:48

Intan Mauli Dewi (Bandung, Indonesia)

TBS3C-25

Q&A

10:48 - 11:00

Union Live Session

10:00 - 10:30

UL

UL23 - Union LIVE - Content from across the WCLH 2024

Community Connect

10:15 - 11:00

SG

CCSS017 - Translating UNHLM commitments into reality

Dozia Joseph (New Delhi, India)

Blessina Kumar (New Delhi, India)

Introduction

10:15 - 10:20

Global perspective and WHO's commitments to ending TB

10:20 - 10:25

Farai Mavhunga (Switzerland)

Translating UNHLM commitments into national plans

10:25 - 10:30

Tiffany Tiara Pakasi (South Jakarta, Indonesia)

The role of Stop TB Partnership in achieving UNHLM TB targets

10:30 - 10:35

James Malar (Geneva, Switzerland)

UNHLM commitments: A reality check from the ground

10:35 - 10:40

Carol Mburu (Kenya)

Civil society and community-based organisation perspective on UNHLM targets

10:40 - 10:45

Evaline Kibuchi (Kenya)

Question and answer

10:45 - 11:00

Union Live Session

10:30 - 11:00

UL

UL24 - The latest installment in Union LIVE's Community Connect series and messages from our event sponsors

Union Live Session

11:00 - 11:10

UL

UL25 - David Jackson, Director of Conference and Events, at The Union, discusses the organization of the World Conference on Lung Health - and why host-country selection is central to their successes

Plenary Session

11:10 - 12:10

MG

PL-03 - Addressing the knowledge-to-practice gap for integration of mental health into person-centred TB care

Yves Miel Zuniga (Philippines)

Session introduction

11:10 - 11:16

Introduction - TB and mental health: Why is it important?

11:16 - 11:23

Annika Sweetland (New York, United States)

Comparative Community Based Implementation Models in TB-NCD Programs in Pakistan, Bangladesh and the Philippines

11:23 - 11:35

Uzma Khan (Montreal, Canada)

TB survivor-led research to inform the development of TB stigma interventions in South Africa

11:35 - 11:45

Goodman Makanda (South Africa)

Bending the Curve: Achieving TB and Mental Health Integration to End the Global TB epidemic

11:45 - 11:55

Sok Chamreun Choub (Cambodia)

Panel discussion

11:55 - 12:10

Plenary Session

11:10 - 12:10

EG2

PL003 - Addressing the knowledge-to-practice gap for integration of mental health into person-centred TB care (Broadcasted)

Union Live Session

11:10 - 12:10

UL

ULPL03 - Addressing the knowledge-to-practice gap for integration of mental health into person-centred TB care

Union Live Session

12:10 - 13:00

UL

UL26 - Union LIVE - Content from across the WCLH 2024

E-Posters

12:15 - 13:15

M EP1

EP13 - Public-private mix for TB care

Bertrand Kampoer (YAOUNDE, Cameroon)

EP13-713-15

Deepening the engagement of transport workers to find the missing people with TB

12:15 - 12:20

Ifeanyi Okekearu (Abuja, United Kingdom)

EP13-714-15

Assistance for drug-resistant TB patients with spiritual, psycho-social, and economic approaches to reduce lost to follow-up (LFU)

12:20 - 12:25

	rates at Muhammadiyah Lamongan Hospital Festi Artika (Lamongan, Indonesia)	
EP13-715-15	Critical pathways to novel TB diagnostics adoption in health systems: A realist review Vitri Widyaningsih (Surakarta, Indonesia)	12:25 - 12:30
EP13-716-15	Innovative approaches to enhancing TB detection in the private sector: Implementing a nesting model with patent medicine vendors in Kano, Nigeria Ogoamaka Chukwuogo (Abuja, Nigeria)	12:30 - 12:35
EP13-717-15	Unlocking private sector potential: Engaging in TB preventive treatment management - Insights from India Niraj Kumar Sinha (Chandigarh, India)	12:35 - 12:40
EP13-718-15	Transformative strategies for TB notification enhancement through big chain hospital engagement in Indonesia Merry Samsuri (Jakarta, Indonesia)	12:40 - 12:45
EP13-719-15	Navigating impact of interface agency in catalysing private sector engagement under National TB Elimination Programme, India Vishal Abhishek Laxmalla (New Delhi, India)	12:45 - 12:50
EP13-720-15	Going beyond health sector: Integrating TB prevention services into Uganda's workplace policies and budgets for equitable access Evelyne Tibananuka (Kampala, Uganda)	12:50 - 12:55
EP13-721-15	Sustainable interventions for improvement in External Quality Assurance (EQA) of Truenat MTB/RIF, Telangana State, India Sumalata Chittiboyina (Hyderabad, India)	12:55 - 13:00
EP13-722-15	Exploring advocacy communication social mobilisation through sensitisation in schools to improve TB detection among school children Oluwatimilehin Rotimi-Ojo (Lagos, Nigeria)	13:00 - 13:05
	Q&A	13:05 - 13:15
<i>E-Posters</i>		
12:15 - 13:15		M EP2
	EP14 - Case finding, triaging and access, finding the missing millions Gerard de Vries (Bilthoven, Netherlands)	
EP14-723-15	Boosting systematic screening at the primary health care level in Ukraine for populations at risk for TB Volodymyr Shukatka (Kyiv, Ukraine)	12:15 - 12:20
EP14-724-15	Expanding private sector involvement to enhance TB identification in Pakistan Adeel Tahir (Islamabad, Pakistan)	12:20 - 12:25
EP14-725-15	Decentralised triaging of people with TB under Differentiated Care Model in Jharkhand, India to reduce loss to TB care cascade Anupama Thankamma (Ranchi, India)	12:25 - 12:30
EP14-726-15	Engaging miners and mining communities in finding missing people with TB in Northeast Nigeria Stephen John (Yola, Nigeria)	12:30 - 12:35
EP14-727-15	Statewide triaging at diagnosis for severe illness followed by inpatient care reduces early TB deaths Hemant Deepak Shewade (Chennai, India)	12:35 - 12:40
EP14-728-15	Using patient-pathway analysis to increase access to TB services	12:40 - 12:45

	and inform a differentiated programme response in Nigeria Obioma Chijioke-Akaniro (Abuja, Nigeria)	
EP14-729-15	Innovative endeavor to improve TB notification from private sector by asserting Clinical Establishment Act, 2017 in West Bengal state of India Dhrubojoyoti Deka (Guwahati, India)	12:45 - 12:50
EP14-730-15	Intensifying TB case finding through multi-prong approaches in Cambodia: A review of four years program data Sovannary Tuot (Phnom Penh, Cambodia)	12:50 - 12:55
EP14-731-15	Improving TB case finding among children through intensified multisectoral targeted screening: Lessons from the TB LON3 project in Ogun State Micheal Pedro (Lagos, Nigeria)	12:55 - 13:00
EP14-732-15	Finding the missing people with TB: Lessons learned from using artificial intelligence-enabled chest X-ray system for active TB case search in communities in Lagos, Nigeria Taiwo Osatuyi (Lagos, Nigeria)	13:00 - 13:05
EP14-733-15	TB missing cases in primary health care in Padang Panjang City, Indonesia Rizanda Machmud (Padang, Indonesia)	13:05 - 13:10
	Q&A	13:10 - 13:15
<i>E-Posters</i>		
12:15 - 13:15		M EP3
	EP15 - Improving TB care to make it person centred: Old and new strategies revisited Onno Akkerman (Groningen, Netherlands)	
EP15-734-15	Understanding health-related quality of life among people with TB Agus Fitriangga (Pontianak, Indonesia)	12:15 - 12:20
EP15-735-15	Strategic foundations and preliminary insights: USAID ACCELERATE 2 project's baseline assessment in South Africa's TB landscape Prineetha Naidoo (Durban, South Africa)	12:20 - 12:25
EP15-737-15	Understanding the social protection requirements for people with TB in India Susmita Chatterjee (New Delhi, India)	12:25 - 12:30
EP15-738-15	Retreatment and anti-TB therapy outcomes in Brazil between 2015 and 2022: A nationwide study Beatriz Barreto-Duarte (Salvador, Brazil)	12:30 - 12:35
EP15-739-15	Risk factors for loss to follow-up across twelve rifampicin-resistant TB treatment sites in KwaZulu-Natal and Eastern Cape, South Africa Katherine McNabb (Baltimore, United States)	12:35 - 12:40
EP15-740-15	Differentiating financial assistance for drug-resistant TB affected households to offset income loss during care in Ho Chi Minh City, Vietnam Thanh Thi Nguyen (Ha Noi, Vietnam)	12:40 - 12:45
EP15-741-15	Zero-day ambulatory treatment in drug-resistant TB to enhance enrolment and treatment adherence in Bangladesh Ashraful Hossain (Dhaka, Bangladesh)	12:45 - 12:50
EP15-742-15	Demonstrating the feasibility of differentiated TB care assessment for tailored person care in a high-incidence, low-resource setting	12:50 - 12:55

	district of Bihar, India	
	Bal Krishna Mishra (Patna, India)	
EP15-743-15	Profiling digital technologies used to support the TB care cascade and their implementation across high TB-burden countries: Findings from a systematic realist review	12:55 - 13:00
	Charity Oga-Omenka (Waterloo, Canada)	
	Q&A	13:00 - 13:10
<i>E-Posters</i>		
12:15 - 13:15		M EP4
	EP16 - Treating and preventing drug-resistant TB: Dispatches from the coal face	
	Lorenzo Guglielmetti (Paris, France)	
EP16-744-15	Acceptability of an adult levofloxacin formulation in children on multi-drug-resistant TB preventive treatment: A quantitative analysis	12:15 - 12:20
	Susan Purchase (Cape Town, South Africa)	
EP16-745-15	Patient-reported outcome measurement and reporting for people with tuberculosis: A literature review	12:20 - 12:25
	Masoud Dara (München, Germany)	
EP16-746-15	Effectiveness and safety of the BPAL treatment regimen for multi-drug-resistant TB in Myanmar: Current findings of an operational research study	12:25 - 12:30
	Zaw Myint (Yangon, Myanmar)	
EP16-747-15	Adherence of TB medication among key and vulnerable populations with TB: Experience from a community intervention in selected Indian states	12:30 - 12:35
	Arin Kar (Bengaluru, India)	
EP16-748-15	Adherence during a nine month bedaquiline-based treatment regimen for rifampicin-resistant tuberculosis	12:35 - 12:40
	Johanna Kuhlin (Cape Town, South Africa)	
EP16-749-15	TB treatment monitoring: Assessing the relationship between the method of monitoring and symptoms developed during treatment	12:40 - 12:45
	Adenike McDonald (Athens, United States)	
EP16-750-15	Efficacy and safety of shorter multi-drug-resistant TB regimens: A network meta-analysis	12:45 - 12:50
	Yishak Abraham (Addis Ababa, Ethiopia)	
EP16-751-15	Enabling access to QuantiFERON®-TB Gold and facilitating the introduction of up-to-date TB and drug-resistant TB prevention in Ukraine	12:50 - 12:55
	Volodymyr Shukatka (Kyiv, Ukraine)	
EP16-752-15	Implementing BPALM/BPAL regimen: From operational research to programmatic use - Experience of Ukraine	12:55 - 13:00
	Olesia Medvedieva (Kyiv, Ukraine)	
	Q&A	13:00 - 13:10
<i>E-Posters</i>		
12:15 - 13:15		M EP5
	EP17 - Closing gaps in reaching TB	
	Deborah Ikeh (Abuja, Nigeria)	
EP17-753-15	Enhancing the coverage of molecular diagnostics tests among private sector individuals with TB in Uttar Pradesh, India	12:15 - 12:20

	Bhartesh K. Shetty (Lucknow, India)	
EP17-754-15	Engaging pharmacies in tracking and notifying missed people with TB through Rx Tracker intervention in Pakistan Sameer Ahmed (Islamabad, Pakistan)	12:20 - 12:25
EP17-755-15	Enhancing TB elimination in India: The impact of multisectoral accountability framework and inter-ministerial collaboration on TB detection and notification Mrigen Kumar Deka (Delhi, India)	12:25 - 12:30
EP17-756-15	Improving TB case holding through private sector engagement in Nigeria Olawumi Olarewaju (Abuja, Nigeria)	12:30 - 12:35
EP17-757-15	AHPI-led corporate hospitals' engagement in the Nation's TB elimination efforts Sunil Kumar Khetarpal (Delhi, India)	12:35 - 12:40
EP17-758-15	Enhancing the role of first-line care providers in TB case-finding: Experience from a system strengthening approach in Kano State, Nigeria Chidubem Ogbudebe (Abuja, Nigeria)	12:40 - 12:45
EP17-759-15	Performance-based incentive for private sector engagement: A promising path towards TB elimination in Uttar Pradesh, India Preeti Plavinakuzhiyil Sadanandan (New Delhi, India)	12:45 - 12:50
EP17-761-15	Reducing inequity in access to molecular diagnostic tests among public and private sector individuals with TB in the state of Uttar Pradesh, India Bhartesh K. Shetty (Lucknow, India)	12:50 - 12:55
EP17-762-15	Enhancing private sector engagement for TB elimination in India: A retrospective analysis of the patient-provider support agency intervention Mrigen Kumar Deka (Delhi, India)	12:55 - 13:00
EP17-763-15	Adopt a block campaign: Leveraging the support of corporate social responsibility initiative to boost active TB case finding in Gurugram District of Haryana, India Lakshmi Aravindakshan (New Delhi, India)	13:00 - 13:05
EP17-764-15	Public private partnership in India: What models exist and what works Vijayashree Yellappa (Delhi, India)	13:05 - 13:10
	Q&A	13:10 - 13:15
<i>E-Posters</i>		
12:15 - 13:15		M EP6
EP18 - Access to quality TB care and services		
Chidimma Okoye (Abakaliki, Nigeria)		
EP18-765-15	Zero-TB initiative in Buddhist monasteries: A two-pronged strategy for TB elimination in Ladakh, India Shiv Hiren Joshi (New Delhi, India)	12:15 - 12:20
EP18-766-15	Screening vulnerable populations using artificial intelligence aided portable handheld X-ray machine in Himachal Pradesh, India Aatmika Gopimohan Nair (Delhi, India)	12:20 - 12:25
EP18-767-15	The yield of TB diagnosis using chest X-ray in General Hospital Langtang, Plateau state north-central Nigeria Bot Yohaana Toma (Jos, Nigeria)	12:25 - 12:30

EP18-768-15	Mind the gap and close the gap: Contribution of the TB programme quality efficiency (PQE) on TB notification in DR Congo Romain Kibadi (Kinshasa, Congo (Democratic Republic))	12:30 - 12:35
EP18-769-15	Leveraging, Engaging and Advocating (LEAD) initiative to augment TB care cascade among marginalised urban communities of Delhi, India Praveen Kumar Yadav (Delhi, India)	12:35 - 12:40
EP18-770-15	Assessing the gaps in cascade of TB care in the Greater Accra Region, Ghana Adelaide Sackey (Accra, Ghana)	12:40 - 12:45
EP18-771-15	Determinants of attrition in the treatment cascade for elderly people with multi-drug- or rifampicin-resistant TB in eastern China: A 7-year retrospective cohort study Beibei Che (Shanghai, China)	12:45 - 12:50
EP18-772-15	Pre-treatment evaluation in people with drug-sensitive TB for reducing mortality: A proof of concept study from India Sidharth Sethi (New Delhi, India)	12:50 - 12:55
EP18-773-15	Introducing diagnostics on wheels in prison to screen vulnerable inmates in Bangladesh Ferdous Wahid (Dhaka, Bangladesh)	12:55 - 13:00
EP18-774-15	Using short message service reminders, phone calls and mobile money incentives to enhance TB diagnosis completion among presumptive patients in Uganda: A randomised controlled trial-MILEAGE4TB Esther Buregyeya (Kampala, Uganda)	13:00 - 13:05
	Q&A	13:05 - 13:15
<i>TBScience E-Poster Session</i>		
12:15 - 14:10		M EP7
TBS-EP-05 - Mechanisms underlying heterogeneous disease manifestations Part 1		
DJ Christopher (India)		
TBS-EP-88	The accuracy of a three-gene host response signature to classify TB severity in children Jascent Nakafeero (Kampala, Uganda)	12:15 - 12:20
TBS-EP-89	Identification of genetic variants associated with post-TB lung disease Luming Lin (Munich, Germany)	12:20 - 12:25
TBS-EP-90	Transcriptomic changes associated with lung function impairment after successful TB treatment Olga Baranov (Munich, Germany)	12:25 - 12:30
TBS-EP-91	A multi-country evaluation of the diagnostic performance of Molbio Truenat MTB Ultima, a novel tongue swab molecular test for TB Kingsley Manoj Kumar (Vellore, India)	12:30 - 12:35
TBS-EP-92	Immunometabolic correlates of protection against M. tuberculosis infection among TB household contacts Todia Pediatama Setiabudiawan (Nijmegen, Netherlands)	12:35 - 12:40
TBS-EP-93	Exploring in vivo expressed mycobacterial proteins in the gastric lavage samples of paediatrics pulmonary TB as biomarkers for the development of immunoassay Anjali Kashwal (Chandigarh, India)	12:40 - 12:45
TBS-EP-94	Assessing the activation profile of M. tuberculosis-specific T cells	12:45 - 12:50

	as a surrogate marker for in vivo disease activity in TB household contacts Lwitiho Sudi (Mbeya, Tanzania)	
TBS-EP-95	M. tuberculosis cough aerosol culture status is associated with host inflammatory profiles and clinical characteristics	12:50 - 12:55
TBS-EP-96	Diagnostic accuracy of chest X-ray and sputum screening among household contacts of people with multi-drug-resistant TB in Vietnam H. Manisha Yapa (Sydney, Australia)	12:55 - 13:00
TBS-EP-97	Evaluation of a digital stethoscope for TB diagnosis among symptomatic individuals: A diagnostic accuracy study Helen Cox (Cape Town, South Africa)	13:00 - 13:05
TBS-EP-98	Radiological sequelae in individuals with microbiologically-proven subclinical TB detected in a population-based survey in rural KwaZulu-Natal, South Africa Helgard Claassen (Somkhele, South Africa)	13:05 - 13:10
TBS-EP-99	Transcriptomic responses associated with mortality in HIV-associated TB by longitudinal whole blood analysis Naomi Walker (Liverpool, United Kingdom)	13:10 - 13:15
TBS-EP-100	Host genetic factors related to TB susceptibility and mortality: Genome-wide association studies from Indonesia Reinout van Crevel (Nijmegen, Netherlands)	13:15 - 13:20
TBS-EP-101	TB relapse and reinfection among people with treatment history in Hanoi, Vietnam Nguyen T. L. Hang (Hanoi, Vietnam)	13:20 - 13:25
TBS-EP-102	Hyperferritinaemia associated with bacillary load and mortality in people who have been admitted with HIV-associated TB Linda Boloko (Cape Town, South Africa)	13:25 - 13:30
TBS-EP-103	Comparing TB transmission hotspots: Insights from hotspot identification from residential and activity space data among individuals with newly-diagnosed TB in South Africa Yu Lan (New Haven, United States)	13:30 - 13:35
TBS-EP-104	Risk factors for fatal cases caused by TB of the central nervous system in immune reconstitution inflammatory syndrome and their prediction using logistic regression models Dmyto Butov (Kharkiv, Ukraine)	13:35 - 13:40
TBS-EP-105	Activity space data reveals joint subgrouping of mobility patterns, demographic characteristics, and HIV serostatus among individuals with newly-diagnosed TB in South Africa Dana Bezuidenhout (New York, United States)	13:40 - 13:45
TBS-EP-106	Connecting TB bioarchives to enhance global collaboration and answer fundamental research questions on a large scale Cara Adolph (Dunedin, New Zealand)	13:45 - 13:50
TBS-EP-05	Q&A	13:50 - 14:10
<i>Community Connect</i>		
	12:30 - 13:30	AU
CCF003 - Films and documentaries		
	Mental Health Project by Alliance for Public Health	12:30 - 12:40
	The Twists and Turn of Public Private Mix by Stop TB Indonesia	12:40 - 13:05

	Smoke or Family by Amrit Foundation	13:05 - 13:25
<i>Side Meeting</i>		
12:30 - 13:30		HB
SM23 - Tobacco Control Section		
<i>Side Meeting</i>		
12:30 - 13:30		FR
SM24 - TB Section		
<i>Side Meeting</i>		
12:30 - 13:30		BG
SM25 - Adult and Child Lung Health Section		
<i>Side Meeting</i>		
12:30 - 13:30		OC
SM26 - HIV Section		
<i>Side Meeting</i>		
12:30 - 13:30		JKA
SM27 - TB Education and Training		
<i>Satellite Session</i>		
12:30 - 14:00		JKB
SS12 - Interactive panel discussing active case finding to ensure all communities, urban and rural, receive an accurate diagnosis with minimal disruption		
Akos Somoskovi (United States)		
	Welcome and introductions	12:30 - 12:48
	Perspectives from Diagnostics Innovation partner	12:48 - 13:06
	Adam Penn-Nicholson (Switzerland)	
	Perspectives from an Innovation Hub	13:06 - 13:24
	Anura David (South Africa)	
	Perspectives from a clinical research and care partner	13:24 - 13:42
	Jerry Cangelosi (United States)	
	Perspectives from China CDC	13:42 - 14:00
	Xichao Ou (China)	
<i>Union Live Session</i>		
13:00 - 13:30		UL
UL27 - Messages from our event sponsors		
<i>Paper Posters</i>		
13:20 - 14:20		M PPA
PP21 - Child TB care cascade		
	Riitta Dlodlo (Bulawayo, Zimbabwe)	
PP21-991-15	Involvement of nutritionists in identifying missed paediatric TB cases through active case finding. A case of Chandaria Health Centre, Nairobi Kenya	13:20 - 13:25
	Nicodemus Adera (Nairobi, Kenya)	
PP21-992-15	Childhood TB: NNS and NNT as useful metric for identifying high-	13:25 - 13:30

	yielding intervention Micheal Pedro (Lagos, Nigeria)	
PP21-993-15	Improving childhood TB case finding in Oyo State: Usefulness of focusing attention on paediatric contacts during contact investigation of people with index pulmonary TB Samuel Akingbesote (Abuja, Nigeria)	13:30 - 13:35
PP21-994-15	Enhancing TB case finding among under-15 children in Southwest, Nigeria: Evidence-based from TB-Local Organisation Network Region 3 (TB-LON 3) Project Olugbenga Daniel (Ikeja, Nigeria)	13:35 - 13:40
PP21-995-15	Exploring barriers and facilitators: Implementing Tuberculosis Preventive Therapy (TPT) for under-five children in Myanmar Sandar Oo (Yangon, Myanmar)	13:40 - 13:45
PP21-996-15	Evaluation of TPT initiation among children living with HIV in Zimbabwe 2022 - 2024 Sithabiso Dube (Harare, Zimbabwe)	13:45 - 13:50
PP21-997-15	Scale up childhood TB notification through intensified screening and testing campaign: Insights from Ogun State, Nigeria Musibau Akande Tijani (Abeokuta, Nigeria)	13:50 - 13:55
PP21-998-15	Prioritising children: Decentralised diagnostics and child-friendly approaches transform childhood TB management in Zambia Judith Mzyece (Lusaka, Zambia)	13:55 - 14:00
PP21-999-15	Perceived benefits of community-based TB preventive treatment in children in Uganda: "When she sees other children getting the same medication, she will feel not alone" Elijah Kakande (Kampala, Uganda)	14:00 - 14:05
	Q&A	14:05 - 14:20
<i>Paper Posters</i>		
13:20 - 14:20		M PPB
	PP23 - Strategies for improved child TB identification: Experiences from Nigeria Olivier Marcy (Bordeaux, France)	
PP23-1015-15	National Childhood TB Testing Week in Sokoto State Nigeria: Resolve to innovatively find the missing children with TB Oyama Enang (Abuja, Nigeria)	13:20 - 13:25
PP23-1011-15	Implementation of the WHO treatment decision algorithm doubled childhood TB case finding in the private sector intervention in Lagos state, Nigeria Aderonke Agbaje (Abuja FCT, Nigeria)	13:25 - 13:30
PP23-1012-15	Improving childhood TB diagnosis in rural settings in Nigeria: Utility of a diagnostic algorithm Ogoamaka Chukwuogo (Abuja, Nigeria)	13:30 - 13:35
PP23-1013-15	Implementation of the treatment decision algorithm to improve diagnosis of TB in children in Kaduna State, north-west Nigeria Habiba Jummai (Kaduna, Nigeria)	13:35 - 13:40
PP23-1014-15	Impact of WHO recommended diagnostic algorithm on increased childhood TB case finding in public private mix intervention, Lagos USAID TB LON 3 project experience Babajide Kadri (Lagos, Nigeria)	13:40 - 13:45
PP23-1016-15	The journey of the VEDUTA study: Evaluation of WHO TB treatment decision algorithms in Nigeria	13:45 - 13:50

	Enang Oyama (Abuja, Nigeria)	
PP23-1017-15	Leaving no child behind: Optimising strategies for Childhood TB case finding in Nigeria Austin Ihesie (Abuja, Nigeria)	13:50 - 13:55
PP23-1018-15	Impact of the National TB Testing Week on childhood TB notification in Osun State, South-West Nigeria Charles Ohikhuai (Abuja, Nigeria)	13:55 - 14:00
PP23-1019-15	Improving childhood TB case detection using targeted facility- and community-based intervention during Childhood TB Testing Week in North Central Nigeria Dauda Samuel Hananiya (Minna, Nigeria)	14:00 - 14:05
PP23-1020-15	Improving childhood TB detection through the implementation of a designated childhood TB screening officer: A case study at State Hospital Ikire, Osun State, Nigeria Christian Anyomi (Oshogbo, Nigeria)	14:05 - 14:10
	Q&A	14:10 - 14:20
<i>Paper Posters</i>		
13:20 - 14:20		M PPC
PP24 - Emerging NTM infection		
Gisela Unis (Brasília, DF, Brazil)		
PP24-1021-15	Colony morphology as a prognostic indicator in M. avium complex pulmonary disease Jeongmi Seo (Cheongju, Korea, Republic of)	13:20 - 13:27
PP24-1022-15	Epidemiological characteristics of people with non-tuberculous mycobacterial pulmonary disease in South Korea Jeongmi Seo (Cheongju, Korea, Republic of)	13:27 - 13:34
PP24-1023-15	WQ-3810: A novel fluoroquinolone drug against fluoroquinolone-resistant Mycobacterium avium DNA gyrase Sasini Jayaweera (Sapporo, Japan)	13:34 - 13:41
PP24-1024-15	Non-tuberculous mycobacteria: Diagnostic methods in the Kyrgyz Republic Meerbubu Sydykova (Bishkek, Kyrgyzstan)	13:41 - 13:48
PP24-1025-15	Non-tuberculous mycobacteria among people with microscopy-positive and Xpert-negative in Niger republic Mahamadou Bassirou Souleymane (Niamey, Niger)	13:48 - 13:55
	Q&A	13:55 - 14:06
<i>Paper Posters</i>		
13:20 - 14:20		M PPD
PP25 - COVID-19		
Indira Govender (London, United Kingdom)		
PP25-1026-15	Developing a reproducible quality COVID-19 RDT proficiency testing scheme: A rapid response to quality assured COVID-19 point of care testing Hasfah Ssentamu (Kampala, Uganda)	13:20 - 13:25
PP25-1027-15	Analysis of COVID-19 mortality, incidence, and vaccination incompleteness in the state of São Paulo (2020-2024) Ricardo Alexandre Arcêncio (Ribeirão Preto, Brazil)	13:25 - 13:30
PP25-1028-15	A community-driven digital movement to bolster COVID-19 vaccine	13:30 - 13:35

	uptake in Karachi, Pakistan: An overview of Jeelo Dobara (Live Life Again) Kainat Khurshid (Karachi, Pakistan)	
PP25-1029-15	Lessons learned from Pakistan's COVID-19 response to build resilient health systems and future preparedness Muhammad Adeel Alvi (Lahore, Pakistan)	13:35 - 13:40
PP25-1030-15	Antivirals Introduction in the COVID-19 management in Senegal through Test to Treat (T2T) pilot project implementation Selly Ba (Dakar, Senegal)	13:40 - 13:45
PP25-1031-15	Modelling the economic burden of TB in Myanmar: A comparative study of pre-COVID-19, COVID-19 and post-coup eras (2018-2022) Yu Nandar Aung (Yangon, Myanmar)	13:45 - 13:50
PP25-1032-15	Changes in private healthcare service delivery during the COVID-19 pandemic and potential impacts on TB care Nur Afifah (Bandung, Indonesia)	13:50 - 13:55
PP25-1033-15	SARS-CoV-2 prevalence and TB treatment response in prospective cohort of persons with active TB disease in Kenya Hong-Ha M. Truong (San Francisco, United States)	13:55 - 14:00
PP25-1034-15	Differentiated service delivery for TB services during COVID-19 in Lusaka and Livingstone, Zambia Brittany K. Moore (Atlanta, United States)	14:00 - 14:05
	Q&A	14:05 - 14:20
<i>Paper Posters</i>		
13:20 - 14:20		M PPE
PP26 - Impact of COVID-19 on TB programmes Corinne Merle (Geneva, Switzerland)		
PP26-1035-15	Treatment interruption amongst tuberculosis patients during COVID-19 in West Kalimantan, Indonesia: a retrospective cohort study of 13,924 participants Agus Fitriangga (Pontianak, Indonesia)	13:20 - 13:27
PP26-1036-15	Over rebound of tuberculosis burden in the post-COVID-19 pandemic period of East Java, Indonesia Satiti Palupi (Surabaya, Indonesia)	13:27 - 13:34
PP26-1037-15	Impact of COVID-19 pandemic on the notification and treatment outcome of drug-susceptible TB in Mongolia Ganbaatar Gantungalag (Ulaanbaatar, Mongolia)	13:34 - 13:41
PP26-1038-15	Integration of TB screening into a COVID-19 vaccination campaign to find missing people with TB in Tigray Regional State, Ethiopia Mebrahtu Gebremikael Abraha (Mekelle, Ethiopia)	13:41 - 13:48
PP26-1039-15	Examining factors associated with COVID-19 disruptions to TB services Tejaswini Dharmapuri Vachaspathi (New Haven, United States)	13:48 - 13:55
PP26-1040-15	Navigating challenges: Implementing TB interventions amidst COVID-19 restrictions in Myanmar Myat Kay Khine (Yangon, Myanmar)	13:55 - 14:02
PP26-1041-15	Impact of South Africa's National post-COVID-19 TB Recovery Plan on TB testing, diagnosis, and treatment initiation in Cape Town, South Africa Erika Mohr-Holland (Cape Town, South Africa)	14:02 - 14:09

	Q&A	14:09 - 14:20
<i>Paper Posters</i>		
13:20 - 14:20		
M PPF		
PP27 - Spectrum of lung health across the life course		
Chelsie Cintron (Providence, United States)		
PP27-1042-15	Impact of SARS-CoV-2 viral load on restrictive spirometry patterns in mild COVID-19 recovered middle-aged individuals: A six month prospective study	13:20 - 13:25
	Uzair Abbas (Karachi, Pakistan)	
PP27-1043-15	Pulmonary function test of paediatric patients diagnosed with COVID-19 infection: A meta-analysis	13:25 - 13:30
	Patricia Joy Lunas (Manila, Philippines)	
PP27-1044-15	Grading obstructive lung impairment from unlabeled flow-volume spirometry curves	13:30 - 13:35
	Christoph Killing (Munich, Germany)	
PP27-1045-15	Fractional exhaled nitric oxide (FeNO) levels and adverse outcomes of people with stable post-infectious bronchiectasis in Lung Center of The Philippines	13:35 - 13:40
	Donnah Alvarado (Quezon City, Philippines)	
PP27-1046-15	Is HIV-1 infection a risk factor for lung cancer initiation and progression in Uganda and Tanzania?	13:40 - 13:45
	Grace Soka (Dar Es Salaam, Tanzania)	
PP27-1047-15	Cough peak versus spirometry for the early detection of lung impairment in a cohort of people with pulmonary TB in South Africa and Zambia	13:45 - 13:50
	Denise Evans (Johannesburg, South Africa)	
PP27-1048-15	Longitudinal analysis of prevalence and risk factors of cavitary lung disease in people with drug-resistant TB	13:50 - 13:55
	Kynesha Moopanar (Durban, South Africa)	
PP27-1049-15	Longitudinal changes in prevalence and risk factors for extensive lung disease in people with drug-resistant TB	13:55 - 14:00
	Darshan Chetty (Durban, South Africa)	
PP27-1050-15	Effectiveness evaluation of the group intervention to improve health and well-being of people after COVID-19 in South Africa	14:00 - 14:05
	Salome Charalambous (Johannesburg, South Africa)	
	Q&A	14:05 - 14:20
<i>Paper Posters</i>		
13:20 - 14:20		
M PPG		
PP29 - From screening to treatment: Enhancing the capabilities		
James Johnston (Vancouver, Canada)		
PP29-1062-15	AI-powered chest X-ray screening and point-of-care applications for TB household contact tracing at rural health facilities in Maharashtra	13:20 - 13:27
	Deepak Joshi (Udaipur, India)	
PP29-1063-15	Ultraportable X-ray with CAD: Transitioning from pilot to national scale up in Uzbekistan	13:27 - 13:34
	Shokhsanam Alimjanova (Tashkent, Uzbekistan)	
PP29-1064-15	The potential outlook of artificial intelligence in active TB detection: Achievements demonstrated through the implementation	13:34 - 13:41

	of PDX-CAD in remote communities in Anambra State Chijioke Oke (Awka, Nigeria)	
PP29-1065-15	Evaluation of VinBrain DrAid CAD software performance for TB detection on digital chest X-ray images Andrew James Codlin (Ha Noi, Vietnam)	13:41 - 13:48
PP29-1067-15	Healthcare providers' knowledge, attitudes, and perceptions of using targeted next-generation sequencing on stool to diagnose drug-resistant TB in Eswatini Alexander Kay (Houston, United States)	13:48 - 13:55
PP29-1068-15	Knowledge, attitudes, and practices of artisanal and small-scale miners regarding TB, human immunodeficiency virus, and silicosis in Zimbabwe Florence Moyo (Harare, Zimbabwe)	13:55 - 14:02
	Q&A	14:02 - 14:20
<i>Paper Posters</i>		
13:20 - 14:20		M PPH
PP30 - HIV and comorbidities: Undernutrition		
Madolyn Dauphinais (Boston, United States)		
PP30-1069-15	The TB-HEART study: Determining the burden and natural history of cardiac pathology among persons with pulmonary TB living with and without HIV in Zambia Marcello S. Scopazzini (Lusaka, Zambia)	13:20 - 13:25
PP30-1070-15	Integrated model for TB active case finding in India: Opportunistic screening for BMI as a nutritional-screening biomarker and its association with TB microbiological confirmations Sanya Pawah (New Delhi, India)	13:25 - 13:30
PP30-1071-15	Diabetes among people with TB in Bengaluru is alarming: Time to tackle it efficiently Shilpashree Madhava Kunjathur (Ramanagar, India)	13:30 - 13:35
PP30-1072-15	TB yield from TB-diabetes bidirectional activities in twelve primary healthcare centres in the FCT, Nigeria Enang Enang Oyama (Abuja, Nigeria)	13:35 - 13:40
PP30-1073-15	Prevalence and factors associated with comorbidity diabetes mellitus and TB in Burundi Ciza François (Bujumbura, Burundi)	13:40 - 13:45
PP30-1074-15	Addressing mental health issues in people with drug-resistant TB: Results of pilot intervention during the war in Ukraine Evgenia Geliukh (Kyiv, Ukraine)	13:45 - 13:50
PP30-1075-15	Temporal trends of QFT-Plus test results among participants in a large preventive treatment trial implemented in 3 high HIV- and TB-burden settings Dinis Nguenha (Maputo, Mozambique)	13:50 - 13:55
PP30-1076-15	Preliminary results from piloting integrated TB, mental health, and substance use disorder services in Nigeria Daniel Egbule (Enugu, Nigeria)	13:55 - 14:00
PP30-1077-15	Implementation of bi-directional screening for TB and mental disorders in the TB and mental health programs in Nigeria: Comparative analysis Martin Njoku (Enugu, Nigeria)	14:00 - 14:05
	Q&A	14:05 - 14:20

Paper Posters

13:20 - 14:20

M PPI

PP22 - Lung health over the continuum of care

PP22-1000-15	Achieving excellence in liquid oxygen infrastructure in Vietnam: Learning by doing Hien Nguyen (Hanoi, Vietnam)	13:20 - 13:25
PP22-1001-15	Successfully treated isoniazid-resistant people with TB in Karnataka, India: How are they doing post treatment? Shazia Anjum (New Delhi, 110011, India)	13:25 - 13:30
PP22-1002-15	Prevalence of non-TB cardiopulmonary condition among people with presumptive TB in Nigeria: A call for integrated care Jude Ilozumba (Abuja, Nigeria)	13:30 - 13:35
PP22-1003-15	Implementation of post-TB lung disease screening and pulmonary rehabilitation in Kenya: Experience from Nairobi County, Kenya Elizabeth Mueni (Nairobi, Kenya)	13:35 - 13:40
PP22-1004-15	Post-TB treatment follow-up: A key intervention to enable continuum of TB care in Himachal Pradesh, India	13:40 - 13:45
PP22-1005-15	Results from AI-enabled mobile X-ray for integrated TB, CVDs, and CRDs screening in rural communities in Nigeria Chidimma Okoye (Abakaliki, Nigeria)	13:45 - 13:50
PP22-1006-15	Respiratory health risk assessment of exposure in market wood workers and workshops in Mombele/Kinshasa, the Democratic Republic of the Congo	13:50 - 13:55
PP22-1008-15	The impact of BCG vaccination status on TB meningitis severity in Cape Town Mish-Al Barday (Cape Town, South Africa)	13:55 - 14:00
PP22-1009-15	Unraveling medical practitioner's hesitancy for TB preventive treatment Hardik Solanki (New Delhi, India)	14:00 - 14:05
PP22-1010-15	Development of a software support system for targeted treatment of non-small cell lung cancer utilising genetic mutation analysis data Linh Le Tu (Hanoi, Vietnam)	14:05 - 14:10
	Q&A	14:10 - 14:20

Paper Posters

13:20 - 14:20

M PPJ

PP28 - Community empowerment: Successful TB intervention

Peter Ngo'la Owiti (Makueni, Kenya)

PP28-1051-15	Empowering communities: An approach to tackling TB in Myanmar amidst political and security challenges Aung Ko Ko (Yangon, Myanmar)	13:20 - 13:25
PP28-1052-15	Empowering communities: Unveiling the transformative impact of the Unite to Act Project's Support Hub in Punjab, India with the help of TB champions Niraj Kumar Sinha (Chandigarh, India)	13:25 - 13:30
PP28-1053-15	The contribution of community actors in the fight against TB in Mali Seraphine Kaminsa (Lusaka, Zambia)	13:30 - 13:35
PP28-1054-15	Empowering self-help groups for gender equality in TB elimination	13:35 - 13:40

	efforts: Insights from the breaking the barriers project in India Rehana Begum (Bengaluru, India)	
PP28-1055-15	Power of word of mouth and local community networks as significant communication and mobilisation channels Aheli Basu (Delhi, India)	13:40 - 13:45
PP28-1056-15	Introducing innovative approaches to strengthen community influence on TB programmes in Ukraine Iryna Koroieva (Kyiv, Ukraine)	13:45 - 13:50
PP28-1057-15	TBusco: I'm looking for you - Community positive communication strategy for the active search for new TB cases in the LGBTIQ population Andrés Felipe Cardona Gonzalez (Medellín, Colombia)	13:50 - 13:55
PP28-1058-15	Resilience amidst adversity: Community-based TB care in Myanmar's conflict zones Aungkyaw Htet (Yangon, Myanmar)	13:55 - 14:00
PP28-1059-15	Not just a cough: Linking behavioural insights to mount a digital communications campaign to promote early self-screening for TB Anisha Singh (New Delhi, India)	14:00 - 14:05
PP28-1060-15	Mobilising community stakeholders for effective project development: A case study in TB intervention in Niger State, Nigeria Andrew Agbo (Federal Capital Territory., Nigeria)	14:05 - 14:10
PP28-1061-15	The impact of social protection interventions on treatment and socioeconomic outcomes of TB-affected individuals and households: A systematic review and meta-analysis Talemwa Nalugwa (Kampala, Uganda)	14:10 - 14:15
	Q&A	14:15 - 14:20
	<i>Union Live Session</i> 13:30 - 14:30	UL
	UL28 - Union LIVE - Content from across the WCLH 2024	
	<i>Community Connect</i> 14:15 - 15:15	AU
	CCSA011 - Advocacy across borders: A case study of 1/4/6x24 Campaign's national, regional, and global approach to advocacy Erin McConnell (United States) Jonathan Stillo (Ferndale, United States)	
	Introduction	14:15 - 14:20
	The road ahead: A retrospective of 1/4/6x24 campaign successes and next steps in 2025 and beyond Lindsay Palazuelos (United States)	14:20 - 14:30
	Access to essential TB treatment in EECA: Progress, barriers and next steps - A view from the community Denis Godlevskiy (Russian Federation)	14:30 - 14:40
	Mobilising communities and civil society in Asia-Pacific for 1/4/6x24, post 2023 health HLMs and beyond RD Marte (Philippines)	14:40 - 14:50
	Community voices, government accountability: Ensuring Africa delivers on shorter TB regimens Jacqueline Wambui (Kenya)	14:50 - 15:00

	Question and answer	15:00 - 15:15
<i>Community Connect</i>		
14:15 - 15:00		
SG		
CCSS023 - Leadership in action: Political advocacy for TB prevention and care		
Usman Lodhi (Pakistan)		
Suvanand Sahu (Switzerland)		
Syed Karam Shah (Pakistan)		
	Introduction	14:15 - 14:21
	Engaging political leadership in TB prevention and care: The global experience	14:21 - 14:27
	Suvanand Sahu (Switzerland)	
	Implementing the multi-sectoral accountability framework for TB: From inception to impact	14:27 - 14:33
	Hannah Monica Dias (Switzerland)	
	Securing increase domestic funding: High-level political engagement in Pakistan	14:33 - 14:39
	Razia Kaniz Fatima (Islamabad, Pakistan)	
	Transforming TB care through political advocacy and MAF implementation in Pakistan	14:39 - 14:45
	Kinz Ul Eman (Islamabad, Pakistan)	
	Question and answer	14:45 - 15:00
<i>TBScience E-Poster Session</i>		
14:15 - 16:10		
M EP7		
TBS-EP-06 - Mechanisms underlying heterogeneous disease manifestations Part 2		
Celso Khosa (Maputo, Mozambique)		
TBS-EP-107	Impact of nutritional intervention on cytokine profile of malnourished latent TB individuals in presence and absence of parasitic infection	14:15 - 14:20
	Komal Jain (Puducherry, India)	
TBS-EP-108	Impact of diagnostic machine errors on the timely diagnosis of persons affected with drug-resistant and drug-susceptible TB	14:20 - 14:25
	Arnold Kennedy Tumuhairwe (Kampala, Uganda)	
TBS-EP-109	Challenges in TB diagnosis and treatment delays for deaf individuals in Kampala District: A qualitative study	14:25 - 14:30
	Dennis Mujuni (Kampala, Uganda)	
TBS-EP-110	Exploring challenges and opportunities in TB sample collection instructions for deaf volunteers in Kampala	14:30 - 14:35
	Doreck Ankunda (Kampala, Uganda)	
TBS-EP-111	TREC as a personalised TB predictor in preschool children	14:35 - 14:40
	Anna Abramchenko (Moscow, Russian Federation)	
TBS-EP-112	Effect of diabetes on presentation and treatment outcomes among adults with sputum positive pulmonary TB: A prospective cohort study in Haryana, India	14:40 - 14:45
	Rakesh Kumar (New Delhi, India)	
TBS-EP-113	TB severity factors: A systematic review	14:45 - 14:50
	Robert Akpata (Bordeaux, France)	
TBS-EP-114	Computer-aided detection of chest X-ray as a surrogate marker of disease severity in pulmonary TB	14:50 - 14:55

	Katarina Niward (Linköping, Sweden)	
TBS-EP-115	A role of ethno-geographic factors on the incidence of TB in the region of the South Aral Sea, Uzbekistan Timur Y. Aripov (Tashkent, Uzbekistan)	14:55 - 15:00
TBS-EP-116	The platelet count and platelet to lymphocyte ratio in children with pulmonary TB and latent TB Larissa Gorbach (Minsk, Belarus)	15:00 - 15:05
TBS-EP-117	An assessment of TB diagnosis among people living with HIV with advanced disease (CD4 < 200) admitted at Homabay CTRH in 2022 Okal Nyambaga (Nairobi, Kenya)	15:05 - 15:10
TBS-EP-118	Non-tuberculous mycobacterial infections in people living with HIV Anna Abramchenko (Moscow, Russian Federation)	15:10 - 15:15
TBS-EP-119	Prevalence and risk factors of drug-resistant M. tuberculosis in rural communities of South Africa Maphepele Sara Mashilo (Polokwane, South Africa)	15:15 - 15:20
TBS-EP-120	Factors associated with hospitalisation and mortality of people with pulmonary TB Man Mohan Puri (New Delhi, India)	15:20 - 15:25
TBS-EP-121	Comparison of machine learning algorithms in epidemiological modeling and prediction of TB/multi-drug-resistant TB Mei-Mei Kuan (Taipei, Taiwan)	15:25 - 15:30
TBS-EP-122	Linkages between social determinants, clinical TB manifestations, and treatment outcomes among people with smear-positive pulmonary TB in Almaty and Almaty oblast, Kazakhstan Jamilya Ismoilova (Almaty, Kazakhstan)	15:30 - 15:35
TBS-EP-123	TB in children from family contacts before and during the COVID-19 pandemic Larissa Gorbach (Minsk, Belarus)	15:35 - 15:40
TBS-EP-124	The role of physiotherapy in managing pulmonary cystic fibrosis secondary to pulmonary TB Sheillah T. Nakisanze (Masaka, Uganda)	15:40 - 15:45
TBS-EP-125	The monocyte-to-segmetonuclear neutrophil ratio in children with TB from families with COVID-19 and TB Larissa Gorbach (Minsk, Belarus)	15:45 - 15:50
TBS-EP-06	Q&A	15:50 - 16:05

Special Session

14:20 - 15:50

HB

SPS04 - TB undernutrition: Everybody's concern

Ya Diul Mukadi (Washington, DC, United States)

Subitha Lakshminarayanan (India)

Session introduction

14:20 - 14:25

Experience from a TB survivor

14:25 - 14:35

Naila Hanum Syafira (Indonesia)

Nutrition and TB: What are the knowledge gaps?

14:35 - 14:50

Pranay Sinha (Boston, United States)

Upcoming WHO guidelines on TB and nutrition

14:50 - 15:05

Annabel Baddeley (Geneva, Switzerland)

	Role of donors in nutritional support to end TB	15:05 - 15:15
	Mohammed Yassin (Geneva, Switzerland)	
	Challenges in implementing nutrition support for TB patients: India experience	15:15 - 15:25
	Hemant Deepak Shewade (Chennai, India)	
	Panel discussion with Q&A from the audience	15:25 - 15:50
	Arvind Betigeri (Thailand)	
<i>Oral Abstract Session</i>		
14:20 - 15:50		FR
	OA39 - Optimising finding TB in children	
	Toyin Togun (London, United Kingdom)	
	Norbert Heinrich (Munich, Germany)	
	Introduction	14:20 - 14:25
OA39-409-15	Optimising district selection for implementing child TB treatment-decision algorithms: Insights from a hybrid study in Mozambique and Zambia	14:25 - 14:34
	Natacha Lebrun (Bordeaux, France)	
OA39-410-15	Oral swab testing for the diagnosis of paediatric TB: An interim analysis of diagnostic accuracy in the NOD-pedFEND cohort	14:34 - 14:43
	Nathan Mudrak (Oxford, United Kingdom)	
OA39-411-15	Cross-cutting lessons from the implementation of treatment decision algorithms for children with pulmonary TB: Results from a five-country prospective study	14:43 - 14:52
	Jasmine Armour-Marshall (London, United Kingdom)	
OA39-412-15	“You can save a life if we get algorithms right”: A multi-country qualitative evaluation of new paediatric treatment decision algorithms for TB in children	14:52 - 15:01
	Sofia Payotte (Paris, France)	
OA39-413-15	Impact of PAED surge on paediatrics TB case detection in Katsina State	15:01 - 15:10
	Chika Ali (Abuja, Nigeria)	
OA39-414-15	Improving the diagnosis of TB in children with the implementation of new WHO algorithm in Maradi, Niger	15:10 - 15:19
	Oumarou Farouk Moussa Mamane (Maradi, Niger)	
OA39-415-15	Use of gastric aspiration/sputum induced rooms and GeneXpert increase bacteriologically confirmed TB in children less than 5 years old in Peru	15:19 - 15:28
	Marco Tovar (San Isidro, Peru)	
OA39-416-15	Enhanced diagnosis of pediatric household contacts using child-friendly samples: Programmatic setting experience in India	15:28 - 15:37
	Radha Munje (Nagpur, India)	
	Q&A	15:37 - 15:50
<i>Symposium</i>		
14:20 - 15:50		BG
	SP19 - Social networks of children and adolescents: implications for when and where they are infected with Mycobacterium tuberculosis	
	Helen Jenkins (Boston, United States)	
SP19-523-15	Introduction	14:20 - 14:25

SP19-524-15	Identifying when and where children acquire TB infection: methods and findings from the Socio-spatial Networks and TB infection in Youth (SONET) Study in Rural Uganda. Elijah Kakande (Kampala, Uganda)	14:25 - 14:39
SP19-525-15	Shifting networks of care and exposure risk for children in families affected by MDR-TB in Namibia Graeme Hoddinott (Australia)	14:39 - 14:53
SP19-526-15	Exposure risks and likely transmission pathways among children diagnosed with MDR-TB in South Africa, India, and the Philippines Shatabdi Bagchi (Pune, India)	14:53 - 15:07
SP19-527-15	Studies to identify where TB transmission to children occurs in China Leonardo Martinez (Boston, United States)	15:07 - 15:21
SP19-528-15	Contact rates among children in Guatemala, India, and Mozambique: implications for TB transmission Kristin Nelson (Atlanta, United States)	15:21 - 15:35
SP19-529-15	Q&A	15:35 - 15:50
<i>Oral Abstract Session</i>		
14:20 - 15:50		OC
OA40 - Closing the gaps: Active case finding		
Alena Skrahina (Berlin, Germany) Evgenia Geliukh (Kyiv, Ukraine)		
	Introduction	14:20 - 14:25
OA40-417-15	Digital chest X-ray with computer-aided detection (CAD) in community-based TB case finding in the Philippines Nichel Marquez (Makati City, Philippines)	14:25 - 14:34
OA40-418-15	Artificial intelligence for TB screening to improve active TB case detection among urban slum, rural and pastoralist TB-key affected and vulnerable populations in Ethiopia Tamiru Mebrate (Addis Ababa, Ethiopia)	14:34 - 14:43
OA40-419-15	The impact of targeted advocacy to community leaders in improving active case finding in the community: The Benue WOW Truck experience Joy Emefieh (Abuja, Nigeria)	14:43 - 14:52
OA40-420-15	Community-based active case finding for TB using chest X-rays: Lesson learned and challenges in Indonesia Betty Nababan (Jakarta, Indonesia)	14:52 - 15:01
OA40-421-15	The role of community engagement in promoting access to TB screening services: Lessons learned from Ubumi Bwandi Project in an urban community in Zambia Isaac Mshanga (Lusaka, Zambia)	15:01 - 15:10
OA40-422-15	A view from ground level: The journey of 100,000 Philippine families screened for TB Melinda Kelly Mijares (Manila, Philippines)	15:10 - 15:19
OA40-423-15	Closing the TB case finding gap through artificial intelligence (AI)-aided screening of non-symptomatic population: Katsina State experience Muzbau Oyawale (Katsina, Nigeria)	15:19 - 15:28
OA40-424-15	Innovative and data driven engagement of the community to bridge the gaps in TB notification in Osun state, Nigeria: Experiences	15:28 - 15:37

	from 2020- 2023	
	Amos Omoniyi (Abuja, Nigeria)	
	Q&A	15:37 - 15:50
<i>Oral Abstract Session</i>		
14:20 - 15:50		
		JKA
OA41 - Cutting-edge sequencing technology		
Alaine Umubyeyi Nyaruhirira (Pretoria, South Africa)		
Ajoy Kumar Verma (New Delhi, India)		
	Introduction	14:20 - 14:25
OA41-425-15	TB lineage diversity in Eswatini from nanopore sequencing on stool and correlation with drug-resistant mutations	14:25 - 14:33
	Tara Ness (Houston, United States)	
OA41-426-15	Molecular insight into M. tuberculosis resistance to novel aroylhydrazones gained through in vitro mutagenesis and whole genome sequencing	14:33 - 14:41
	Violeta Valcheva (Sofia, Bulgaria)	
OA41-427-15	Mapping the role of targeted next-generation sequencing in drug-resistant TB diagnostic algorithms	14:41 - 14:49
	Sophia Georghiou (Geneva, Switzerland)	
OA41-428-15	Differentially expressed coding and non-coding RNAs reveal the mechanisms of transcriptome regulation and RNA signatures in clinical strains of M. tuberculosis	14:49 - 14:57
	Nontobeko Mvubu (Durban, South Africa)	
OA41-429-15	The M. tuberculosis complex transcriptome is differentially regulated by non-coding RNAs that can be explored for novel TB biomarkers	14:57 - 15:05
	Asanda Nyide (Durban, South Africa)	
OA41-430-15	A fully-automated molecular diagnostic system for the sensitive detection and quantification of multi-drug-resistant TB	15:05 - 15:13
	Manoj Chugh (Mumbai, India)	
OA41-431-15	Evaluation of the Indigen MTB/DR-TB RT-PCR for rapid screening of TB and detection of rifampicin and isoniazid resistance	15:13 - 15:21
	Dini Budhiarko (Jakarta, Indonesia)	
OA41-432-15	Culture-free whole genome sequencing of M. tuberculosis using ligand-mediated bead enrichment method	15:21 - 15:29
	Renu Verma (Mangalore, India)	
OA24-295-14	Diagnostic performance of a direct-from-sputum next generation sequencing method for prediction of phenotypic resistance to second-line TB drugs	15:29 - 15:37
	Q&A	15:37 - 15:50
<i>Symposium</i>		
14:20 - 15:50		
		JKB
SP20 - Active TB case finding - impactful, fad or fantasy?		
Dennis Falzon (Geneva, Switzerland)		
Anh Innes (Vietnam)		
SP20-530-15	Introduction	14:20 - 14:25
SP20-531-15	WHO's guidance on TB screening: a key tool to ending TB	14:25 - 14:39

	Cecily Miller (Geneva, Switzerland)	
SP20-532-15	What is the potential impact of active case finding - Can it help end TB? Jonathon Campbell (Montreal, Canada)	14:39 - 14:53
SP20-533-15	Indonesia's experience with active case finding - Is it working? Is it affordable? Tiffany Tiara Pakasi (South Jakarta, Indonesia)	14:53 - 15:07
SP20-534-15	Reality check: Survey of active case finding in high incidence and/or high burden countries Dick Menzies (Montreal, Canada)	15:07 - 15:21
SP20-535-15	What will it take for active case finding to have a significant, and lasting impact? Guy Marks (Sydney, Australia)	15:21 - 15:35
SP20-536-15	Q&A	15:35 - 15:50
<i>Short Oral Abstract Session</i>		
14:20 - 15:50		MD
SOA10 - Novel diagnostic methods		
Subha Bhassu (Kuala Lumpur, Malaysia)		
	Introduction	14:20 - 14:25
SOA10-686-15	Democratising M. tuberculosis complex whole genome sequencing: A systematic comparison of automated, user-friendly analysis pipelines with potential for implementation in low-resource settings Ruan Spies (Oxford, United Kingdom)	14:25 - 14:32
SOA10-687-15	Deploying host transcriptional markers for diagnosis of TB Wilber Sabiiti (Fife, Scotland, United Kingdom)	14:32 - 14:39
SOA10-688-15	Detection of M. tuberculosis from exhaled bio-aerosol particles of people with pulmonary TB: A proof-of-concept study Tatsuya Kodama (Kiyose, Japan)	14:39 - 14:46
SOA10-689-15	Evaluation of Truenat isoniazid and fluoroquinolone drug resistance assays in people with rifampicin-resistant TB: A prospective diagnostic accuracy study in Georgia Nino Maghradze (Tbilisi, Georgia)	14:46 - 14:53
SOA10-690-15	A rapid, low-cost lab-in-tube assay for diagnosing TB from respiratory samples to blood Brady Youngquist (New Orleans, United States)	14:53 - 15:00
SOA10-691-15	Nanopore sequencing for TB in Kyrgyzstan: A validation study Gulmira Kalmambetova (Bishkek, Kyrgyzstan)	15:00 - 15:07
SOA10-692-15	Differences in distributions of antimicrobial susceptibility of M. tuberculosis by geographical groups and resistance class Naomi M. Fuller (London, United Kingdom)	15:07 - 15:14
SOA10-693-15	Multi-platform approaches to identify blood-based host protein diagnostic signatures for paediatric TB Melissa Shea Hamilton (London, United Kingdom)	15:14 - 15:21
SOA10-694-15	Individualised whole-genome-sequencing-guided treatment for drug-resistant TB Rubeshan Perumal (Durban, South Africa)	15:21 - 15:28
SOA10-695-15	Unlocking latent TB: Investigating molecular and immunological	15:28 - 15:35

	biomarkers for diagnosis	
	Asif Mohmmmed (New Delhi, India)	
	Q&A	15:35 - 15:50
<i>Oral Abstract Session</i>		
14:20 - 15:50		NS1
OA42 - What you didn't know about Latent TB Infection		
Alberto Matteelli (Brescia, Italy)		
Adrienne Shapiro (Seattle, United States)		
	Introduction	14:20 - 14:25
OA42-433-15	Estimating the global burden of viable M. tuberculosis infection	14:25 - 14:35
	Alvaro Schwalb (London, United Kingdom)	
OA42-434-15	A novel cytokine biomarker for predicting active TB from latent TB: A cohort study	14:35 - 14:45
	Peng Lu (Nanjing, China)	
OA42-435-15	Trajectories of IGRA results over two years in independent cohorts from China, South Africa, Tanzania, and the United States	14:45 - 14:55
	Cheng Chen (Nanjing, China)	
OA42-436-15	Factors associated with completion of short-term treatment for latent TB by international migrants in Manaus - AM, Brazil	14:55 - 15:05
	Yan Alves (Ribeirão Preto, Brazil)	
OA42-437-15	Enhancing TB case detection in Afghanistan: The role of active household contact screening (2018-2023)	15:05 - 15:15
	Pedro Suarez (Virginia, United States)	
OA42-438-15	Duration of effectiveness of TB preventive treatment: An individual-participant meta-analysis	15:15 - 15:25
	Lauren Linde (Boston, United States)	
OA42-439-15	Completion rate and adverse events of latent TB infection treatment in 25,127 subjects with different comorbidities: A 30-year retrospective study	15:25 - 15:35
	Gloria Leonardi (Milan, Italy)	
	Q&A	15:35 - 15:50
<i>Oral Abstract Session</i>		
14:20 - 15:50		NS2
OA43 - Asymptomatic TB: How far and deep should we go? How do we find subclinical TB and what do we do about it?		
Emily A. Kendall (Baltimore, United States)		
Hanif Esmail (London, United Kingdom)		
	Introduction	14:20 - 14:25
OA43-440-15	Analysis of asymptomatic TB from Japan's Nationwide Surveillance, 2017-2022	14:25 - 14:34
	Tomohiko Ukai (Kiyose, Japan)	
OA43-441-15	Occurrence of asymptomatic TB in a community active case finding campaign	14:34 - 14:43
	Nunurai Ruswa (Windhoek, Namibia)	
OA43-442-15	Asymptomatic TB in children with household exposure to M. tuberculosis	14:43 - 14:52
	Humphrey Mulenga (Cape Town, South Africa)	

OA43-443-15	Estimating the risk of incident TB among individuals with Xpert Ultra trace sputum during community-based screening Joowhan Sung (Baltimore, United States)	14:52 - 15:01
OA43-444-15	Low levels of systemic inflammation in symptomatic and asymptomatic TB detected during community-based screening in rural South Africa Lerato Ndlovu (Durban, South Africa)	15:01 - 15:10
OA43-445-15	Unveiling the hidden epidemic: Prevalence of asymptomatic TB in Indonesia's prisons Hetty Widiastuti (Jakarta, Indonesia)	15:10 - 15:19
OA43-446-15	Characteristics of asymptomatic TB cases from the third national TB prevalence survey and their implications to active case detection in Cambodia Khay Mar Aung (Tokyo, Japan)	15:19 - 15:28
OA43-447-15	Prevalence of asymptomatic TB in an infant vaccine trial in South Africa Angelique Kany Kany Luabeya (Cape Town, South Africa)	15:28 - 15:37
	Q&A	15:37 - 15:50

Symposium

14:20 - 15:50

NS3

SP21 - Mitigating bias and improving inference from observational studies and clinical trials of MDR/RR-TB treatment and diagnostics

Molly Franke (Boston, United States)

Mathieu Bastard (Geneva, Switzerland)

SP21-537-15	Introduction	14:20 - 14:30
SP21-538-15	Target trial emulation to estimate the effect of a RR-TB diagnosis by the Xpert MTB/RIF assay on two-year mortality Elise De Vos (Antwerp, Belgium)	14:30 - 14:45
SP21-539-15	Prediction or causality? Conflating concepts in TB observational research Palwasha Yousafzai Khan (London, United Kingdom)	14:45 - 15:00
SP21-540-15	A novel approach to combining data from cutting edge clinical trials of MDR/RR-TB treatments Carole Mitnick (Boston, United States)	15:00 - 15:15
SP21-541-15	Assessing the generalizability of MDR/RR-TB treatment outcomes: from controlled trial environment to real-world settings Uzma Khan (Montreal, Canada)	15:15 - 15:30
SP21-542-15	Q&A	15:30 - 15:50

Union Live Session

14:30 - 15:00

UL

UL29 - Messages from our event sponsors*Community Connect*

15:00 - 17:00

EG2

CCWS002 - Empowering and mobilizing the youth to lead: YOUNITE global

Aman Shukla (India)

	CSO role in building the capacity of youth in TB Austin Obiefuna (Ghana)	15:00 - 15:00
--	--	---------------

	Community network perspective on building youth movement to end TB	15:00 - 15:00
	Timur Abdullaev (Uzbekistan)	
	TB youth champion role in TB elimination	15:00 - 15:00
	Gulshana Verma (India)	
	KVP youth role in TB elimination	15:00 - 15:00
	Amit Singh Gusain (India)	
<i>Union Live Session</i>		
	15:00 - 17:00	UL
UL30 - Union LIVE - Content from across the WCLH 2024		
<i>Community Connect</i>		
	15:15 - 16:15	SG
CCSS018 - Gender and stigma factor in TB care: The lived realities of inequity and moving towards gender-responsive care		
	Vashita Madan (India)	
	Vashita Madan (India)	
	Introduction	15:15 - 15:20
	Unveiling disparities: Gender inequities in the Indian TB care system	15:20 - 15:30
	Ashna Ashesh (India)	
	Voices of resilience: Survivor experiences of gender-based discrimination in TB care	15:30 - 15:40
	Akshata Acharya (India)	
	Breaking barriers: Gender-sensitive healthcare lessons from practice	15:40 - 15:50
	Ruvandhi Nathavitharana (United States)	
	Towards inclusivity: Creating a roadmap for gender-responsive TB care in LMICs	15:50 - 16:00
	Chapal Mehra (India)	
	Question and answer	16:00 - 16:15
<i>Late Breaker Oral Abstract Session</i>		
	16:10 - 17:40	MG
LB04 - The Union-CDC late-breaker session (epidemiology and programmatic)		
	Simon Tiberi (London, United Kingdom)	
	Macarthur Charles (United States)	
	Introduction	16:10 - 16:15
LB04-1222-15	Pharmacokinetics and safety of bedaquiline in infants, children, and adolescents with rifampicin-resistant TB	16:15 - 16:25
	Simon Schaaf (Cape Town, South Africa)	
LB04-1224-15	Field-based performance of TB-specific antigen-based skin tests among healthcare workers in Sevagram, India	16:25 - 16:35
	Rajesh Deshmukh (Mumbai, India)	
LB04-1225-15	Detection of lipoarabinomannan (LAM) from serum in people with and without HIV with active TB disease	16:35 - 16:45
	Daniel Cochrane (Oxford, United Kingdom)	
LB04-1226-15	Optimising TB case finding and preventive therapy among close contacts in Indonesia	16:45 - 16:55

	Tiffany Tiara Pakasi (South Jakarta, Indonesia)	
LB04-1227-15	A cartridge-based assay for improved detection of multi-drug-resistant <i>M. tuberculosis</i> directly from sputum David Alland (Newark, United States)	16:55 - 17:05
LB04-1228-15	Drug resistance profiles of <i>M. tuberculosis</i> using targeted next-generation sequencing: A preliminary study from Indonesia Bony Wiem Lestari (Bandung, Indonesia)	17:05 - 17:15
LB04-1229-15	Expanding Xpert MTB/RIF Ultra® for TB diagnosis among HIV-positive adults admitted to hospitals in Tanzania and Mozambique: A randomised controlled trial (the EXULTANT trial) Alberto Garcia-Basteiro (Barcelona, Spain)	17:15 - 17:25
	Q&A	17:25 - 17:40
<i>Symposium</i>		
16:10 - 17:40		HB
SP22 - Pediatric TB drug dosing: using state of the art modeling to bridge principles to practice		
Tiziana Masini (Geneva, Italy) Rovina Ruslami (Bandung, Indonesia)		
SP22-543-15	Introduction	16:10 - 16:20
SP22-544-15	Principles of paediatric TB drug dosing: allometry and maturation to account for the effects of body size and age in children on pharmacokinetics Anthony Garcia-Prats (Madison, United States)	16:20 - 16:35
SP22-545-15	Evaluating pediatric tuberculosis dosing guidelines: a model-based individual data pooled analysis. Lufina Tzirizani (Cape Town, South Africa)	16:35 - 16:50
SP22-546-15	Harmonizing weight-bands for paediatric dosing Paolo Denti (Cape Town, South Africa)	16:50 - 17:05
SP22-547-15	Pharmacokinetic modelling to inform the optimal dosing of levofloxacin in children for drug-resistant tuberculosis and tuberculosis preventive therapy. Belén Pérez Solans (San Francisco, Spain)	17:05 - 17:20
SP22-548-15	Q&A	17:20 - 17:40
<i>Oral Abstract Session</i>		
16:10 - 17:40		FR
OA44 - Advancements in Pharmacokinetics of anti-TB drugs from bench to bedside		
Rob Aarnoutse (Nijmegen, Netherlands) Vycke Yunivita (Sumedang, Indonesia)		
	Introduction	16:10 - 16:15
OA44-448-15	Using a mouse model to enable quantitative modeling of NC-009 Phase 2 study results and support Phase 3 protocol design for TBAJ-876 development Todd Black (New York, United States)	16:15 - 16:24
OA44-449-15	Exposure-response analysis of bedaquiline as TB preventive therapy in a mouse model of paucibacillary TB Rada Savic (San Francisco, United States)	16:24 - 16:33
OA44-450-15	Clinical predictions for bedaquiline for TB preventive therapy: A translational PKPD modelling study Rada Savic (San Francisco, United States)	16:33 - 16:42

OA44-451-15	Population pharmacokinetics and safety assessment of rifapentine in Chinese children to inform dosing recommendations for latent TB infection Peize Zhang (Shenzhen, China)	16:42 - 16:51
OA44-452-15	Association of low rifampicin and isoniazid plasma levels and poor bacteriological response to the standard anti-TB treatment Rupak Singla (New Delhi, India)	16:51 - 17:00
OA44-453-15	Model-based precision dosing and remedial dosing recommendations for delayed or missed doses of isoniazid in Chinese people with TB Jinmeng Li (Hangzhou, China)	17:00 - 17:09
OA44-454-15	Alterations of the gut microbiota in patients with different plasma drug exposures of anti-TB medication Yue Zhu (Shanghai, China)	17:09 - 17:18
OA44-455-15	Assessing the impact of digital technologies on TB pharmacovigilance in Kyrgyzstan Aizat Kulzhabaeva (Bishkek, Kyrgyzstan)	17:18 - 17:27
	Q&A	17:27 - 17:40
<i>Symposium</i>		
16:10 - 17:40		BG
SP23 - New model for technical support: PeerLINC - peer-to-peer knowledge hub to facilitate country-to-country learning to speed implementation of novel treatments		
Sandeep Juneja (New York, United States) Klara Henderson (Sydney, Australia)		
SP23-549-15	Introduction	16:10 - 16:15
SP23-550-15	Reimagining and simplifying Technical Assistance: the PeerLINC knowledge hub Maria Diachenko (New York, United States)	16:15 - 16:29
SP23-551-15	Importance of deliberate and not incidental Technical Assistance in scaling up new tools Eliud Wandwalo (Geneva, Switzerland)	16:29 - 16:43
SP23-552-15	PeerLINC and Peru: A case study Valentina Antonieta Alarcón Guizado (Lima, Peru)	16:43 - 16:57
SP23-553-15	Perspective of the host country Anna Marie Celina Garfin (Manila, Philippines)	16:57 - 17:11
SP23-554-15	How PeerLINC works Irene Flores (Makati, Metro Manila, Philippines)	17:11 - 17:25
SP23-555-15	Q&A	17:25 - 17:40
<i>Oral Abstract Session</i>		
16:10 - 17:40		OC
OA45 - One step ahead in TB diagnosis		
Yana Terleiva (Kyiv, Ukraine) Adam Penn-Nicholson (Switzerland)		
	Introduction	16:10 - 16:15
OA45-456-15	Streamlining TB diagnostics for complete TB detection efforts: A funnel approach Shalom Balogun (Abuja, Nigeria)	16:15 - 16:24

OA45-457-15	Implementation of the simple-one-step (SOS) method for stool-based GeneXpert testing improves access to molecular diagnosis for children in the Karamoja subregion, north-eastern Uganda Brenda Picho Amon (Kampala, Uganda)	16:24 - 16:33
OA45-458-15	Mainstreaming TB infection testing within National Health Mission (NHM): Integration of IGRA tests with Public Health Laboratories in Telangana, India Gone Srigana (Hyderabad, India)	16:33 - 16:42
OA45-459-15	Leveraging digital technologies to improve turn-around-time tracking and relay of results from GeneXpert testing facilities in a peri-urban district in Uganda Mona Muhammad (Kampala, Uganda)	16:42 - 16:51
OA45-460-15	An unprecedented sample collection and transportation model to overcome challenges in TB detection in Rajasthan, India Raksha Gupta (Delhi, India)	16:51 - 17:00
OA45-461-15	Strengthening equipment maintenance system of NTP Bangladesh by introducing Google sComplain Registration Form: An in-house mechanism to reduce machine downtime Umme Tasnim Maliha (Dhaka, Bangladesh)	17:00 - 17:09
OA45-462-15	Single-cell transcriptome sequencing reveals altered peripheral blood immune cells in people with severe TB Li Wang (Shanghai, China)	17:09 - 17:18
OA45-463-15	Impact of integrating private motorbike riders into the National Specimen Referral System in central Uganda Nelson Modi (Kampala, Uganda)	17:18 - 17:27
	Q&A	17:27 - 17:40
<i>Symposium</i>		
16:10 - 17:40		JKA
	SP24 - Moving from consultation to collaboration: unleashing the power of Social Participation for community empowerment and people-centred care Victoria James (Zimbabwe) Luan Nguyen Quang Vo (Ha Noi, Vietnam)	
SP24-556-15	Introduction	16:10 - 16:15
SP24-557-15	Beyond rhetoric: Social Participation for policy action Lana Syed (Geneva, Switzerland)	16:15 - 16:29
SP24-558-15	Inclusive governance: ensuring equitable representation in decision-making Akramul Islam (Dhaka, Bangladesh)	16:29 - 16:43
SP24-559-15	From consultation to collaboration: fostering genuine engagement in national health responses Yuliia Kalancha (Kyiv, Ukraine)	16:43 - 16:57
SP24-560-15	Documenting and measuring the impact of social participation in TB programming: evolving methods and indicators Handaa Enkh-Amgalan (Berlin, Germany)	16:57 - 17:11
SP24-561-15	Taking a step back to allow others to take one forward Yassen Tcholakov (Montreal, Canada)	17:11 - 17:25
SP24-562-15	Q&A	17:25 - 17:40

Symposium

16:10 - 17:40

JKB

SP25 - Programmatic implementation of targeted next-generation sequencing for drug-resistant TB detection

Anita Suresh (Singapore, Singapore)

Patricia Hall-Eidson (Atlanta, United States)

SP25-563-15	Introduction	16:10 - 16:15
SP25-564-15	Considerations for programmatic implementation of next-generation sequencing for drug-resistant tuberculosis Andrea Cabibbe (Milano, Italy)	16:15 - 16:29
SP25-565-15	Indonesia experience in implementation of next-generation sequencing for detection of drug-resistant tuberculosis Pompini Agustina (Philippines)	16:29 - 16:43
SP25-566-15	Bangladesh experience with programmatic implementation of targeted next-generation sequencing for drug-resistant tuberculosis Mohammad Khaja Mafij Uddin (Dhaka, Bangladesh)	16:43 - 16:57
SP25-567-15	Brazil experience in programmatic implementation of next-generation sequencing for drug-resistant tuberculosis Nicole de Souza (Brasília, Brazil)	16:57 - 17:11
SP25-568-15	The New York State experience in implementing targeted next generation sequencing in tuberculosis programmatic practice Kimberlee Musser (Albany, United States)	17:11 - 17:25
SP25-569-15	Q&A	17:25 - 17:40

Special Session

16:10 - 17:40

MD

SPS05 - Strengthening cross-sector collaboration to improve diagnostics of zoonotic TB

Frederick Quinn (Athens, United States)

Nimalan Arinaminpathy (Switzerland)

	Session introduction	16:10 - 16:15
	Building Resilience: The One Health Joint Plan of Action to control TB in Indonesia Imran Pambudi (Jakarta, Indonesia)	16:15 - 16:30
	Usefulness of Xpert MTB/RIF Ultra for rapid diagnosis of extrapulmonary tuberculosis in Tunisia Imen Bouzouita (Tunisia)	16:30 - 16:45
	End of zoonotic TB in Mexico Alejandro Perera (Mexico)	16:45 - 17:00
	Diagnostic of MTBC species in livestock and wildlife using Next-Generation Sequencing in India Kannan Palaniyandi (Chennai, India)	17:00 - 17:23
	Panel discussion and Q&A from the audience	17:23 - 17:40

Symposium

16:10 - 17:40

NS1

SP26 - Continuing the conversation on equity: checking our blind spots

Amrita Daftary (Toronto, Canada)

Stephen Anguva Shikoli (Nairobi, Kenya)

SP26-570-15	Introduction	16:10 - 16:15
-------------	---------------------	---------------

SP26-571-15	Where is equity in national TB strategies: review of policies from seven countries Nora Engel (Amsterdam, Netherlands)	16:15 - 16:29
SP26-572-15	Beyond incidence and mortality rates: revisiting the metrics for equity Ellen Mitchell (Antwerp, Belgium)	16:29 - 16:43
SP26-573-15	Can economic equity and universal social protection become the business of TB programs? Ahmad Fuady (Jakarta, Indonesia)	16:43 - 16:57
SP26-574-15	Co-design as a first principle for TB interventions Ruvandhi Nathavitharana (United States)	16:57 - 17:11
SP26-575-15	Applying core global health values to TB prevention and care Diego S. Silva (Sydney, Australia)	17:11 - 17:25
SP26-576-15	Q&A	17:25 - 17:40
<i>Oral Abstract Session</i>		
16:10 - 17:40		NS2
OA46 - CAD AI in finding the missing people with TB		
Mustapha Gidado (Den Haag, Netherlands) Raden Rara Diah Handayani (Indonesia)		
	Introduction	16:10 - 16:15
OA46-464-15	Evaluating the performance of Genki CAD software when using photographs of printed X-ray films Andrew James Codlin (Ha Noi, Vietnam)	16:15 - 16:23
OA46-465-15	Diagnostic accuracy of computer-aided detection (CAD) during community-based active case finding for pulmonary TB in South Africa: Is CAD a useful screening test? Alex John Scott (Cape Town, South Africa)	16:23 - 16:31
OA46-466-15	Incorporating standalone CAD4TB enabled chest X-ray diagnosis in private sector intervention: Description of lessons learned from private facilities in Lagos, Nigeria Babajide Kadri (Lagos, Nigeria)	16:31 - 16:39
OA46-467-15	Programmatic roll out of portable digital chest X-rays and computer-aided detection software for systematic TB screening: Implementation lessons from Kenya Brenda Mungai (Nairobi, Kenya)	16:39 - 16:47
OA46-468-15	Implementing facility-based artificial intelligence enabled chest X-ray screening as innovative strategy to improving TB case finding in Lagos, Nigeria Olusola Sokoya (Lagos, Nigeria)	16:47 - 16:55
OA46-469-15	Comparative analysis of TB screening methods: CAD4TB, symptomatic screening, and radiologist assessment in Kenya Samson Muga (Nairobi, Kenya)	16:55 - 17:03
OA46-470-15	Use of CAD-AI to triage ACF campaign participants for clinical consultations and diagnosis of non-bacteriologically confirmed TB in Vietnam Anh Thi Lan Vo (Hanoi, Vietnam)	17:03 - 17:11
OA46-471-15	Finding the unidentified people with TB in Nigeria: Lessons from KNCV Nigeria TB LON Project multi-pronged intervention approach Ogoamaka Chukwuogo (Abuja, Nigeria)	17:11 - 17:19

OA46-472-15	Use of second-party information for tracking a person with TB to reduce loss to follow-up amidst insecurity in Guma LGA Benue state Eze Chukwu (Abuja, Nigeria)	17:19 - 17:27
	Q&A	17:27 - 17:40
<i>Oral Abstract Session</i>		
16:10 - 17:40		NS3
OA47 - Epidemiological models: Trends, predictions and policy implications		
Mmamapudi Kubjane (Johannesburg, South Africa) Kevin Schwartzman (Montreal, Canada)		
	Introduction	16:10 - 16:15
OA47-473-15	Artificial intelligence-based modelling for predicting drug-resistant TB in Uttar Pradesh, India Shiv Hiren Joshi (New Delhi, India)	16:15 - 16:24
OA47-474-15	Fluoroquinolone resistance prevalence and the use of BPaL vs BPaLM in the absence of drug susceptibility testing Chaelin Kim (London, United Kingdom)	16:24 - 16:33
OA47-475-15	Comparative impacts and costs of different strategies for TB active case finding in prisons: A mathematical modelling study Yiran Liu (Stanford, United States)	16:33 - 16:42
OA47-476-15	Epidemiological impact of improving linkage to TB care in South Africa: A modelling study Lauren Brown (Stellenbosch University, South Africa)	16:42 - 16:51
OA47-477-15	Subnational TB burden estimation for Pakistan Alvaro Schwalb (London, United Kingdom)	16:51 - 17:00
OA47-478-15	Social and structural determinants of sex differences in TB prevalence: An ecological analysis of high-burden countries Arianna Colosio (London, United Kingdom)	17:00 - 17:09
OA47-479-15	A novel method to estimate TB incidence using the time from subclinical to symptomatic disease Anne Shapiro (Boston, United States)	17:09 - 17:18
OA47-480-15	Mathematical modelling of subclinical TB in the Philippines Jeremiah Calderon (Makati City, Philippines)	17:18 - 17:27
	Q&A	17:27 - 17:40
<i>Community Connect</i>		
16:30 - 17:30		AU
CCSA014 - Union Leadership and Communities : Dialogue		
	Panel Discussion followed by Question and Answer with The Union leaders from the communities	16:30 - 16:30
Zahedul Islam (Ukraine) Kobto Ghislain Koura (PARIS, France) Guy Marks (Sydney, Australia) David Jackson (United Kingdom) Cassandra Kelly-Cirino (Switzerland)		

Community Connect

16:30 - 17:30

SG

CCSS019 - Climate change and TB: Community-driven solutions from the frontlines

Priyanka Aiyer (India)

Ani Hernasari (Indonesia)

Introduction

16:30 - 16:35

Uniting against TB and climate change: A call to action ahead of the 8th Global Fund Replenishment

16:35 - 16:45

Priyanka Aiyer (India)

Community-led responses to TB and climate change: Insights from Pakistan

16:45 - 16:55

Kinz Ul Eman (Islamabad, Pakistan)

Weathering the storm: Perspectives on climate change from South Africa

16:55 - 17:05

Phumeza Tisile (South Africa)

Innovative approaches to tackling TB and climate challenges: Insights from Indonesia

17:05 - 17:15

Ria Ningsih (Indonesia)

Question and answer

17:15 - 17:30

Union Live Session

17:00 - 17:30

UL

UL31 - Ni Putu Parwatiningsih explores the importance of volunteering in the Union LIVE's themed series and Friday highlights from the conference floor*Community Connect*

17:30 - 17:50

EG2

CCLP004 - Singing by Stop TB Tajikistan*TBScience E-Poster Session*

17:45 - 20:00

M EP7

TBS-EP-07 - Pharmacological considerations for optimising new regimens

Aoubacar Sidiki Magassouba (Conakry, Guinea)

TBS-EP-126

DOLPHIN Kids: Once vs. twice daily dolutegravir with 3 months of weekly isoniazid and rifapentine (3HP) in children with HIV

17:45 - 17:50

Nicole Salazar-Austin (Baltimore, United States)

TBS-EP-127

Exposure analysis of ethionamide and ethionamide sulfoxide from people on TB treatment and determination of a new pharmacodynamic target using hollow fiber studies

17:50 - 17:55

Michel Pieren (Basel, Switzerland)

TBS-EP-128

NAT2 genotype in relation to isoniazid drug exposure and survival among people with tuberculous meningitis in Indonesia

17:55 - 18:00

Reinout van Crevel (Nijmegen, Netherlands)

TBS-EP-129

Dynamic PET facilitated modeling and novel multi-drug-resistant TB antibiotic regimens for tuberculous meningitis

18:00 - 18:05

Sanjay K. Jain (Baltimore, MD, United States)

TBS-EP-135

Computational modelling of bacterial antibiotic target-binding for optimising TB treatment

18:05 - 18:10

Jingyi Liang (Tromso, Norway)

TBS-EP-136

Rifampicin and isoniazid dosage adjustment according to TDM and acetylator status: A single centre prospective observational study

18:10 - 18:15

	Marco Schiuma (Milan, Italy)	
TBS-EP-137	Prediction of poor pulmonary TB treatment outcomes using a combination of host biomarkers Donald Simon (Cape Town, South Africa)	18:15 - 18:20
TBS-EP-138	Effectiveness and safety of the BPaL regimen in people with pre-extensively drug-resistant TB in Ukraine Dmytro Butov (Kharkiv, Ukraine)	18:20 - 18:25
TBS-EP-139	Pharmacogenomic profiling of <i>N-acetyltransferase 2</i> in southern and western Indian TB population Mahadev Rao (Manipal, India)	18:25 - 18:30
TBS-EP-141	A phase 1 PK trial to assess the potential for CYP3A-mediated drug-drug interactions with quabodepistat Axel Leporowski (Princeton, United States)	18:30 - 18:35
TBS-EP-142	Expanding point of care testing for <i>M. tuberculosis</i> through extraction-free processing of sputum specimens Charlotte Ahls (Fishers, United States)	18:35 - 18:40
TBS-EP-143	Apramycin, reconnoitered as the new combination partner for the treatment of TB Shridhar Narayanan (Bangalore, India)	18:40 - 18:45
TBS-EP-144	Anti-TB treatment and relative impact on levels of gamma glutamyl transferase, glutathione, and gamma glutamyl transferase-to-reduced glutathione molar ratio Raymond Eworo (Calabar, Nigeria)	18:45 - 18:50
TBS-EP-145	Development of novel, POC-appropriate sample prep devices for use with tongue swab-based assays Matthew Keller (Bellevue, United States)	18:50 - 18:55
TBS-EP-146	Identification of <i>NAT2</i> and <i>SLCO1B1</i> variants associated with anti-TB drugs in real-world data: All of Us Research Program Mina P. Peyton (Bethesda, MD, United States)	18:55 - 19:00
TBS-EP-147	Efficacy of vitamin D supplementation in accelerating sputum conversion of bacteriologically diagnosed people with TB: A meta-analysis Ayla Niel Castillo (Quezon City, Philippines)	19:00 - 19:05
TBS-EP-148	Treatment outcomes of people with isoniazid mono-resistant <i>M. tuberculosis</i> in Uganda: A retrospective cross-sectional study from 2017 to 2022 Joel Kabugo (Kampala, Uganda)	19:05 - 19:10
TBS-EP-149	Adherence to follow-up laboratory testing guidelines for TB treatment monitoring in Eastern Region, Ghana: Sensitivity analysis of three TB registries Mavis Pearl Kwabla (Hohoe, Ghana)	19:10 - 19:15
TBS-EP-150	Safety of short oral treatment regimens for the treatment of drug-resistant TB Anna Abramchenko (Moscow, Russian Federation)	19:15 - 19:20
TBS-EP-151	Long-term adverse effects of linezolid in the treatment of multi-drug-resistant TB Kazunari Tsuyuguchi (Sakai, Osaka, Japan)	19:20 - 19:25
TBS-EP-153	An assay toolkit for the assessment of anti-TB drugs in the Hollow-Fiber system for TB Ainhua Lucía Quintana (Spain)	19:25 - 19:30

TBS-EP-152	Studying the effectiveness of bedaquiline versus kanamycin-based treatment regimens of multi-drug-resistant TB in terms of occurrence of treatment failure Zuha Jabeen Shaikh (Mumbai, India)	19:30 - 19:35
TBS-EP-130	Intensified treatment of tuberculous meningitis in children: First pharmacokinetic data from the SURE trial Rob Aarnoutse (Nijmegen, Netherlands)	19:35 - 19:40
TBS-EP-07	Q&A	19:40 - 19:50

Satellite Session

18:00 - 19:30

OC

SS13 - Incentivising TB care in the private sector and providing financial support to TB patients: Lessons from NTEP of India

Introduction	18:00 - 18:10
Importance of incentives and enablers in TB elimination Madhukar Pai (Canada)	18:10 - 18:22
Navigating the evolution of Incentives under NTEP: Lessons from India Kavya Sharma (India)	18:22 - 18:34
Reforms to streamline disbursement of incentive schemes under NTEP Raghuram Rao (New Delhi, India)	18:34 - 18:46
Overview: Disbursement status of incentive schemes under NTEP Vijay Kumar Gupta (India)	18:46 - 18:58
On ground challenges in disbursement of benefits to beneficiaries and beneficiary perspective Varsha Rai (India)	18:58 - 19:10
Q&A	19:10 - 19:30

Side Meeting

18:30 - 20:00

JKB

SM28 - American Friends of The Union - fundraising event

Saturday, 16. November 2024*TBScience Session*

08:00 - 09:05

AU

TBS4A - Preclinical and clinical pharmacology of TB drugs

Bern-Thomas Nyang'wa (United Kingdom)

TBS4A-05	Session introduction	08:00 - 08:02
TBS4A-10	BDQ resistance and the next generation of diarylquinoline (TBAJ-587) Todd Black (New York, United States)	08:02 - 08:15
TBS4A-15	Lessons learned about pretomanid Eugene Sun (New York, United States)	08:15 - 08:28
TBS4A-20	Lessons learned about new oxazolidinones (sutezolid, delpazolid) Norbert Heinrich (Munich, Germany)	08:28 - 08:41
TBS4C-15	One size does not fit all: Stratified TB treatment Rada Savic (San Francisco, United States)	08:41 - 08:54
TBS4A-25	Q&A	08:54 - 09:05

Meet the Expert Session

08:00 - 09:00

HB

MTE-06 - Harnessing the power of AI to accelerate TB elimination

Chidimma Okoye (Abakaliki, Nigeria)

	Live introduction Chidimma Okoye (Abakaliki, Nigeria)	08:00 - 08:05
	Harnessing the power of AI to accelerate TB elimination Jacob Creswell (Switzerland)	08:05 - 08:20
	Live Q&A	08:20 - 09:00

Meet the Expert Session

08:00 - 09:00

FR

MTE-07 - The impact of BCG vaccination on the TB burden in livestock

Liliana C. M. Salvador (Tucson, United States)

	Live introduction Liliana C. M. Salvador (Tucson, United States)	08:00 - 08:05
	The impact of BCG vaccination on the TB burden in livestock Abebe Fromsa Merga (Ethiopia)	08:05 - 08:20
	Live Q&A	08:20 - 09:00

Meet the Expert Session

08:00 - 09:00

BG

MTE-08 - Target product profile for TB diagnosis: The process, relevance and challenges

Ajoy Kumar Verma (New Delhi, India)

	Live introduction Ajoy Kumar Verma (New Delhi, India)	08:00 - 08:05
	Target product profile for tuberculosis diagnosis: The process, the relevance and the challenges	08:05 - 08:20

	Daniela Cirillo (Milan, Italy)	
	Live Q&A	08:20 - 09:00
	<i>Meet the Expert Session</i>	
	08:00 - 09:00	OC
	MTE-09 - Population screening and prevention for TB and leprosy: A nursing perspective from the PEARL Project Kiribati	
	Fernando Augusto Dias e Sanches (Rio de Janeiro, Brazil)	
	Live introduction	08:00 - 08:05
	Fernando Augusto Dias e Sanches (Rio de Janeiro, Brazil)	
	Population screening and prevention for TB and leprosy - A nursing perspective from the PEARL Project Kiribati	08:05 - 08:20
	Mareta Hauma (Marshall Islands)	
	Kerrie Shaw (Australia)	
	Niesje Jansen (The Hague, Netherlands)	
	Live Q&A	08:20 - 08:35
	<i>Meet the Expert Session</i>	
	08:00 - 09:00	JKB
	MTE-10 - Pediatric short-course TPT: Pharmacokinetics to implementation	
	Chishala Chabala (Lusaka, Zambia)	
	Live introduction	08:00 - 08:05
	Chishala Chabala (Lusaka, Zambia)	
	Pediatric short-course TPT - pharmacokinetics to implementation	08:05 - 08:20
	Nicole Salazar-Austin (Baltimore, United States)	
	Live Q&A	08:20 - 09:00
	<i>Union Live Session</i>	
	08:00 - 09:00	UL
	UL32 - Messages from our event sponsors	
	<i>Paper Posters</i>	
	08:15 - 09:15	M PPA
	PP31 - Performance of TB and drug-resistant TB detection tools	
	Carel Joseph Peravali (Jakarta, Indonesia)	
	PP31-1078-16 Diagnostic accuracy of tongue swab testing in persons with sputum Xpert Ultra Trace results	08:15 - 08:20
	Adrienne Shapiro (Seattle, United States)	
	PP31-1079-16 Nanopore sequencing for the detection of drug-resistant TB compared to standard-of-care drug susceptibility testing in Kyrgyzstan	08:20 - 08:25
	Aizat Kulzhabaeva (Bishkek, Kyrgyzstan)	
	PP31-1080-16 Multipurpose value of Xpert Ultra on urine: An alternative to sputum and can detect disseminated TB and TB meningitis	08:25 - 08:30
	Nina von Knorring (Johannesburg, South Africa)	
	PP31-1081-16 What proportion of unreported community-based TB is probably infectiousness and can AI-driven computer-aided detection accurately identify cavitory disease as a marker of infectious TB?	08:30 - 08:35
	Alex John Scott (Cape Town, South Africa)	
	PP31-1082-16 Expediting detection of drug resistance TB in routine settings:	08:35 - 08:40

	Lesson learned from the USAID - TIFA supported project, Tanzania Bariki Mtafya (Mbeya, Tanzania)	
PP31-1083-16	Comparison of targeted next-generation sequencing to line probe assays: Findings from the Seq&Treat study Rebecca Colman (Geneva, Switzerland)	08:40 - 08:45
PP31-1084-16	Role of immunohistochemistry with PGRS5 antibody in the diagnosis of cutaneous TB Poonam Puri (Delhi, India)	08:45 - 08:50
PP31-1085-16	Effectiveness of the Xpert XDR assay for rapid triage-and-treatment of drug-resistant TB: Interim results from the TRIAD study Kogieleum Naidoo (Durban, South Africa)	08:50 - 08:55
PP31-1086-16	Fluoroquinolones resistance in Peruvian M. tuberculosis strains by Xpert MTB/XDR and next-generation sequencing: A comparison study Zully M. Puyén (Lima, Peru)	08:55 - 09:00
	Q&A	09:00 - 09:15
<i>Paper Posters</i>		
08:15 - 09:15		M PPB
	PP33 - Game plan for finding the missing people with TB Rizanda Machmud (Padang, Indonesia)	
PP33-1203-16	Impact of TB case finding optimisation and expansion activities on propriety of patent medicine vendors, USAID Tuberculosis Local Organization Network (TBLON3) experience, Southwest Nigeria Aderonke Agbaje (Abuja, Nigeria)	08:15 - 08:20
PP33-1198-16	Is the juice worth the squeeze? Comparing active case finding costs in two districts with varying TB burdens of Ho Chi Minh City, Vietnam Giang Thuy Pham (Ha Noi, Vietnam)	08:20 - 08:25
PP33-1199-16	All roads lead to Rome, some are just shorter - measuring tuberculosis detection yields from four provider types through a public-private-mix intermediary agency in Vietnam Luan Nguyen Quang Vo (Ha Noi, Vietnam)	08:25 - 08:30
PP33-1200-16	Strategic patent medicine vendors engagement: A viable intervention for improving public-private mix TB case finding Olugbenga Daniel (Ikeja, Nigeria)	08:30 - 08:35
PP33-1201-16	The yield of systematic screening for active TB in the outpatient department of two hundred and twenty-two high-burden health facilities in Nigeria Mary Etolue (Abuja, Nigeria)	08:35 - 08:40
PP33-1202-16	Comparative analysis of screening officer-driven intensified case finding and provider-driven intensified case finding supported facilities in Osun State Micheal Pedro (Lagos, Nigeria)	08:40 - 08:45
PP33-1204-16	Evaluation of computer-aided detection powered by artificial intelligence software in detecting TB using radiographs from a TB mass screening program in the Philippines Julius Lecciones (Makati, Philippines)	08:45 - 08:50
PP33-1205-16	Reaching the last mile: Wellness on Keke driven active TB case finding in remote communities in Taraba State Luka Benjamin (Jalingo, Taraba State, Nigeria., Nigeria)	08:50 - 08:55

PP33-1206-16	Wellness on Keke as a game changer in community TB case finding in Kano State Gideon Zephaniah (Kano, Nigeria)	08:55 - 09:00
PP33-1207-16	Illuminating the impact of engaging informal stakeholders in paediatric case finding: A case study of Tsangaya schools in Kano State, Nigeria Husna Baffa (Kano, Nigeria)	09:00 - 09:05
	Q&A	09:05 - 09:15
<i>Paper Posters</i>		
08:15 - 09:15		M PPC
PP34 - Epidemiological, Clinical and Molecular Insights into TB and Co-morbidities		
Helen Ayles (Lusaka, Zambia)		
PP34-1108-16	Utilisation of digital tools to enhance TB screening among people living with HIV in communities for a lasting impact Pauline Chimungu (Harare, Zimbabwe)	08:15 - 08:20
PP34-1109-16	TB molecular diagnostic testing among people living with HIV: Experience from Katavi, Kigoma, Rukwa and Songwe regions Neema Chillo (Dar Es Salaam, Tanzania)	08:20 - 08:25
PP34-1111-16	Delays in treatment initiation affects TB severity in four African countries: A cross-sectional survey Salome Charalambous (Johannesburg, South Africa)	08:25 - 08:30
PP34-1112-16	Mapping drug-resistant TB prevalence in Africa using geospatial analysis Alemneh Liyew (Perth, Australia)	08:30 - 08:35
PP34-1113-16	Analysis of the epidemiological trends of pulmonary TB in China from 2000 to 2019 based on the Joinpoint Regression Model Zhili Li (Beijing, China)	08:35 - 08:40
PP34-1114-16	Unveiling TB transmission dynamics in Indonesia: Insights from a large-scale epidemiological study (2022-2023) Harumi Paramaiswari (Jakarta, Indonesia)	08:40 - 08:45
PP34-1115-16	Molecular epidemiology of TB in area with high burden of HIV in West Siberia, Russia Anna Vyazovaya (St. Petersburg, Russian Federation)	08:45 - 08:50
PP34-1116-16	Tuberculosis prevalence in neighbourhoods in Nairobi, Kenya: Comparing community-based estimates 2015 to 2022 Jane Rahedi Ong'ang'o (Nairobi, Kenya)	08:50 - 08:55
PP34-1180-16	TB transmission in north-eastern states of India: Leads from whole genome sequencing Urvashi B. Singh (New Delhi, India)	08:55 - 09:00
	Q&A	09:00 - 09:15
<i>Paper Posters</i>		
08:15 - 09:15		M PPD
PP36 - Reaching people with TB		
Regina Loprang (Jakarta city (DKI), Indonesia)		
PP36-1128-16	Local outreach-based missed TB case finding among the vulnerable population improves overall TB treatment coverage: Lessons from West Shewa province of Oromia region in Ethiopia Mengistu K. Wakjira (Addis Ababa, Ethiopia)	08:15 - 08:20

PP36-1129-16	WOK intervention to end TB in hard-to-reach areas: The KNCV Imo State experience Israel Chukwunenye (Owerri, Nigeria)	08:20 - 08:25
PP36-1130-16	Efficiency of integrated TB and NCDs screening in Vietnam's border regions Thuc Doan Ngo (Ha Noi, Vietnam)	08:25 - 08:30
PP36-1131-16	Prevalence of TB among special population: A case study of Ilesha and Ife correctional facilities, Osun-State, Nigeria Abiola Riskat Alege (Lagos, Nigeria)	08:30 - 08:35
PP36-1132-16	Enhancing TB notifications in Nigeria: Insights from health facility-based intensified case finding under the USAID TB-LON 3 project Aderonke Agbaje (Abuja FCT, Nigeria)	08:35 - 08:40
PP36-1134-16	Impact of Mobile Medical Vans for TB case detection in out-of-reach populations of Yamunanagar, Haryana, India Lakshmi Aravindakshan (New Delhi, India)	08:40 - 08:45
PP36-1135-16	Dastak Abhiyan: A door-to-door outreach strategy to improve TB detection in Uttar Pradesh, India Preeti Plavinakuzhiyil Sadanandan (New Delhi, India)	08:45 - 08:50
PP36-1136-16	Assessing the effectiveness of contact tracing for people who are clinically diagnosed with TB in Nigeria Emperor Ubochioma (Abuja, Nigeria)	08:50 - 08:55
PP36-1133-16	TB active case finding among special population: TB LON 3 project experience in correctional centres in Oyo and Osun States, Nigeria Abiola Riskat Alege (Lagos, Nigeria)	08:55 - 09:00
	Q&A	09:00 - 09:15
<i>Paper Posters</i>		
08:15 - 09:15		M PPE
PP38 - Managing TB, operational research, outcomes and perspectives Simon Tiberi (London, United Kingdom)		
PP38-1149-16	Sputum-negative pulmonary TB in Shanghai, China: Notification, clinical characteristics and outcomes Zheyuan Wu (Shanghai, China)	08:15 - 08:15
PP38-1150-16	Programmatic experiences of linezolid use for drug-resistant TB in Taiwan Rebecca Chou-Jui Lin (Tao-yuan, Taiwan)	08:15 - 08:15
PP38-1151-16	Clinical audit of the management of drug-resistant TB in hospital in Indonesia Meilina Farikha (Jakarta, Indonesia)	08:15 - 08:15
PP38-1152-16	The role of a shorter treatment regimen in the treatment outcome of multi-drug-resistant TB in Afghanistan Pedro Suarez (Virginia, United States)	08:15 - 08:15
PP38-1153-16	Treatment outcomes of rifampicin- or multi-drug-resistant TB in children and adolescents from an eight-year retrospective cohort in Bandung, Indonesia Fajri Gafar (Montreal, Canada)	08:15 - 08:15
PP38-1154-16	Accelerating implementation of shorter, all-oral regimens for drug-resistant TB: Lessons from BPALM roll out in Eswatini Debrah Vambe (Houston, Eswatini)	08:15 - 08:15
PP38-1155-16	2nd month conversion impact on TB treatment outcomes: Analysis	08:15 - 08:15

	in Indonesian cohort 2017-2023 Lika Apriani (Bandung, Indonesia)	
PP38-1157-16	Recurrence of TB and associated risk factors in Taiwan: A retrospective cohort from 2012 to 2019 Jia-Yih Feng (Taipei, Taiwan)	08:15 - 08:15
PP38-1158-16	Improving paediatric TB management in national TB programmes in sub-Saharan Africa: Role of the Uganda Supranational Reference Laboratory Joanita Namutebi (Kampala, Uganda)	08:15 - 08:15
PP38-1159-16	Mismatch in TB treatment outcome between local and cross-border people with TB in border districts of Zambia: An area of attention in the cross-border efforts Patrick Lungu (Arusha, Tanzania)	08:15 - 08:15
	Q&A	08:15 - 08:30
<i>Paper Posters</i>		
	08:15 - 09:15	M PPF
	PP39 - Increasing uptake and breaking the cycle Alphazazi Soumana (Niamey, Niger)	
PP39-1160-16	Breaking the TB transmission cycle: Strengthening monitoring of TPT uptake among TB contacts in Zimbabwe Kudakwashe Takarinda (Harare, Zimbabwe)	08:15 - 08:20
PP39-1161-16	Systematic follow-up to enhance TB prevention therapy adherence and to evaluate long-term outcomes among recipients in Telangana, South India: A prospective study C. S. Vishnu (New Delhi, India)	08:20 - 08:25
PP39-1162-16	Shift of causes of TB preventive therapy non-completion among people with HIV in Malawi Roblen Chisimba Phiri (Lilongwe, Malawi)	08:25 - 08:30
PP39-1163-16	Overcoming barriers: High acceptance of preventive TB therapy among the tribal population in Chamba District, Himachal Pradesh India, based on accelerated efforts Aashul Heda (Shimla, India)	08:30 - 08:35
PP39-1164-16	Increased uptake of TPT among children under five and PLHIV in three districts in Malawi Mtisunge Nkhono Phiri (Machinga, Malawi)	08:35 - 08:40
PP39-1165-16	Adoption and rapid scale up of short course TB prevention therapy: Lesson learned from three regions in Tanzania Andrew Kigombola (Dar es Salaam, Tanzania)	08:40 - 08:45
PP39-1166-16	TB contact investigation: The gateway to scaling up TB preventive treatment among contacts of people with TB Rupert Eneogu (Abuja, Nigeria)	08:45 - 08:50
PP39-1167-16	Scaling up TB preventive therapy uptake in a southwestern state, Nigeria: Need for a choice-based task-shifting treatment system Samuel Akingbesote (Abuja, Nigeria)	08:50 - 08:55
PP39-1168-16	Completion and correlates of TB preventive therapy in a cohort of people living with HIV in KwaZulu-Natal, South Africa Adrienne Shapiro (Seattle, United States)	08:55 - 09:00
PP39-1169-16	Using cascade analysis to identify opportunities to improve the delivery of TB preventive therapy to close contacts in Uganda Debbie Dada (Kampala, Uganda)	09:00 - 09:05

	Q&A	09:05 - 09:15
<i>Paper Posters</i>		
08:15 - 09:15		M PPG
PP40 - Mpower strategies and industry monitoring		
Les Hagen (Edmonton, Canada)		
PP40-1170-16	Determinants of smoking among women living with HIV in sub-Saharan Africa Daniel Ogbuabor (Enugu, Nigeria)	08:15 - 08:21
PP40-1171-16	Assessing nurses' knowledge and practice of WHO FCTC Article 14 at primary healthcare settings in Bangladesh Jubaida Akhtar (Dhaka, Bangladesh)	08:21 - 08:27
PP40-1172-16	Adaptation needs of an intervention to facilitate tobacco cessation among men attending emergency departments in Nairobi, Kenya Mari Armstrong-Hough (New York, United States)	08:27 - 08:33
PP40-1173-16	The effect of local smoking free policies (SFPs) on youth smoking behavior Hario Megatsari (Surabaya, Indonesia)	08:33 - 08:39
PP40-1174-16	Empowering schools to achieve the status of Tobacco Free Educational Institute: An interventional study from India Ajay Kumar Singh (Solani, India)	08:39 - 08:45
PP40-1175-16	Strengthening tobacco testing laboratories in India: A comprehensive assessment of capacity and capabilities Chirag Goel (Chandigarh, India)	08:45 - 08:51
PP40-1177-16	Message framing for tobacco marketing on Indonesian social media platform: Study analytic from Tobacco Enforcement and Reporting Movement (TERM) data Dianita Sugiyo (Yogyakarta, Indonesia)	08:51 - 08:57
PP40-1178-16	Kiddie pack cigarettes are highly available at the retailers: An urgent call to reduce the alarming increase of adolescent smoking rate in Indonesia	08:57 - 09:03
PP40-1179-16	Tobacco industry interference during the COVID-19 pandemic: A case study in Sri Lanka P.A.S.C Lakmal (Kelaniya, Sri Lanka)	09:03 - 09:09
	Q&A	09:09 - 09:15
<i>Paper Posters</i>		
08:15 - 09:15		M PPH
PP37 - Closing gaps in finding TB		
Ignacio Monedero-Recuero (Paris, France)		
PP37-1137-16	Enhancing TB prevention and care: Challenges and opportunities in cross-border screening of seasonal migrants in Nepal Lok Raj Joshi (Thimi, Bhaktapur, Nepal)	08:15 - 08:20
PP37-1139-16	Contribution of peer supporters in improving TB notification among people living with HIV using community TB screening in Masvingo Province, Zimbabwe Jan-Oct 2023 Gilton Kadziyanhike (Harare, Zimbabwe)	08:20 - 08:25
PP37-1140-16	Finding missing TB cases: USAID Afya Shirikishi Project's experience in providing TB services in hard-to-reach areas in Ukerewe Islands, Tanzania Edward Chilolo (Mwanza, Tanzania)	08:25 - 08:30

PP37-1141-16	Engagement and non-engagement factors in TB active case finding among artisanal small-scale miners and female sex workers in Tanzania: A mixed-methods study Rabia Abeid Khaji (Kahama Municipal Council, Tanzania)	08:30 - 08:35
PP37-1142-16	Should screening for non-TB conditions amongst TB household contacts be a routine service? Consensus findings from a Delphi survey with global TB experts Mikaela Coleman (Bordeaux; Sydney, Australia)	08:35 - 08:40
PP37-1143-16	How to diagnose TB in migrants? A systematic review and decision tree analytical modelling exercise to evaluate properties for single and combined TB screening tests Dominik Zenner (London, United Kingdom)	08:40 - 08:45
PP37-1144-16	Assessment of extrapulmonary TB notifications in five states of Nigeria: Trends and implications for healthcare systems Anthony Meka (Enugu, Nigeria)	08:45 - 08:50
PP37-1145-16	A non-randomised evidence for the effect of community engagement on TB case detection and notification in Nigeria Oluwafunmilayo Omosebi (FCT, Nigeria)	08:50 - 08:55
PP37-1146-16	Tackling TB in Nigeria's marginalised: Tailored interventions amidst economic adversity for improved public health outcomes Chimezie Dimkpa (Bauchi, Nigeria)	08:55 - 09:00
PP37-1147-16	Contamination effects in cluster randomised trials of TB interventions: A review of methods and reporting Kate LeGrand (London, United Kingdom)	09:00 - 09:05
PP37-1148-16	Community-led TB case finding: Reaching a closed community through their peers in Wakiso district, Uganda Lydia Namusisi (Kampala, Uganda)	09:05 - 09:10
	Q&A	09:10 - 09:15
<i>Paper Posters</i>		
08:15 - 09:15		M PPI
PP32 - Digital adherence technologies		
Erik Post (Jakarta, Indonesia)		
PP32-1087-16	Digital technologies for treatment adherence in TB: An assessment of facilitators and barriers to adoption and scale-up in India Sandeepkumar Chauhan (New Delhi, India)	08:15 - 08:20
PP32-1088-16	Evidence on cost-effectiveness in digital approaches to TB treatment Ione Carvalho Pinto (Ribeirão Preto, Brazil)	08:20 - 08:25
PP32-1089-16	Enhancing TB treatment adherence: Insight from participants' experience in a pragmatic randomised control trial using the Tuberculosis Treatment Support Tools Sarah Iribarren (Seattle, United States)	08:25 - 08:30
PP32-1090-16	Examining the challenges of capitalising on mHealth's potential to deliver locally-aligned person-centred MDR-TB care in Vietnam: A qualitative study Duy Trinh-Hoang (Ha Noi, Vietnam)	08:30 - 08:35
PP32-1091-16	Introduction of digital treatment adherence to improve therapeutic outcomes in Eastern DR Congo Olivier Rusumba Bahati (Bukavu, Congo (Democratic Republic))	08:35 - 08:40
PP32-1092-16	Psychometric properties of instruments for TB caregiver burden: A	08:40 - 08:45

	systematic review	
	Dito Aryo Prabowo (Semarang, Indonesia)	
PP32-1094-16	Improving TB treatment adherence in mobile, and homeless people with TB by Humana People to People India (HPPI), a national-level NGO in India	08:45 - 08:50
	Sugata Mukhopadhyay (New Delhi, India)	
PP32-1095-16	Optimising adherence in months 3 and 4 of TB treatment using DAT: A case study at Chandaria Health Centre, Nairobi, Kenya	08:50 - 08:55
	Nicodemus Adera (Nairobi, Kenya)	
PP32-1096-16	The nexus of technology and health: Implementing digital adherence technology in Nairobi County, Kenya - A person-centric approach to drug-susceptible TB management	08:55 - 09:00
PP32-1097-16	The acceptability of digital adherence technology combined with differentiated care and psychosocial intervention among adults with rifampicin-resistant TB in South Africa	09:00 - 09:05
	Tanyaradzwa Dube (Johannesburg, South Africa)	
	Q&A	09:05 - 09:15
<i>Paper Posters</i>		
08:15 - 09:15		M PPJ
PP35 - TB prevention and care, and community engagement		
Hervé Gando (Bangui, Central African Republic)		
PP35-1117-16	Tracking Anti TB Drug (ATT) sales in private health care sector to enhance TB case notification in Uttar Pradesh, India	08:15 - 08:20
	Bhartesh K. Shetty (Lucknow, India)	
PP35-1118-16	Streamlining referrals from private laboratories: Insights from an operational framework for private engagement in Delhi	08:20 - 08:25
	Lakshmi Aravindakshan (New Delhi, India)	
PP35-1119-16	Enhancing TB prevention and care through private sector collaboration in Papua New Guinea (PNG)	08:25 - 08:30
	Graham Low (Port Moresby, Papua New Guinea)	
PP35-1120-16	Engagement of the private sector to enhance the TB prevention cascade in high-burden areas of the Philippines	08:30 - 08:35
	Jeremiah Calderon (Makati City, Philippines)	
PP35-1121-16	Improving quality of TB care in hospitals through the Private Big-Chain Hospitals Engagement Initiative in Indonesia	08:35 - 08:40
	Noerachma Indah Amalia (Jakarta Selatan, Indonesia)	
PP35-1122-16	Multi-sectoral approach to mainstream TB-related activities: Outputs in the state of Uttar Pradesh, India	08:40 - 08:45
	Vinay Singh (Lucknow, India)	
PP35-1123-16	Facilitators and barriers for TB notification by private providers in India: Results from a systematic review and meta-synthesis	08:45 - 08:50
	Rakesh PS (Noida, India)	
PP35-1124-16	Engagement of private healthcare providers in TB notification: Experiences from USAID Afya shirikishi project in Geita, Tanzania	08:50 - 08:55
	Agrey Cosmas (Geita, Tanzania)	
PP35-1125-16	Leveraging intersectoral collaboration and molecular diagnostics for TB elimination in aspirational blocks of India: Insights from the IOCL Initiative	08:55 - 09:00
	Mrigen Kumar Deka (Delhi, India)	

PP35-1126-16	Approaches to ensure access to quality-assured TB medicines after transitioning from Global Fund support Archil Salakaia (Rockville, United States)	09:00 - 09:05
PP35-1127-16	Assessment of inventory management practices of anti-TB drugs during the COVID-19 pandemic in a paediatric healthcare facility in Eswatini Nompumelelo Mzizi (Houston, United States)	09:05 - 09:10
	Q&A	09:10 - 09:15
<i>Community Connect</i>		
09:00 - 10:00		SG
CCSS020 - Experience of CSOs in Moldova, Uzbekistan and Tajikistan in supporting the introduction and roll-out of video-supported treatment (VST)		
Cristina Celan (Chisinau, Moldova)		
Cristina Celan (Chisinau, Moldova)		
Inez de Kruijff-Carter (Netherlands)		
	Introduction	09:00 - 09:05
	VST in the Republic of Moldova: Digital adherence technology for a better programmatic approach on TB people-centred care implementation Svetlana Doltu (Moldova)	09:05 - 09:15
	VST in Uzbekistan: The effective intersectoral cooperation for the benefit of people affected by TB Tatyana Nikitina (Uzbekistan)	09:15 - 09:25
	Video-supported treatment (VST) to enhance treatment adherence in Tajikistan Safarali Naimov (Tajikistan)	09:25 - 09:35
	Ethics considerations in implementing digital adherence technology: A community perspective Oxana Rucsineanu (Moldova)	09:35 - 09:45
	Question and answer	09:45 - 10:00
<i>Union Live Session</i>		
09:00 - 11:20		UL
UL33 - Union LIVE - Content from across the WCLH 2024		
<i>TBScience Session</i>		
09:10 - 09:55		AU
TBS4B - Pharmacological considerations for optimising new regimens - Oral Abstracts		
Sean Wasserman (London, United Kingdom)		
TBS4B-05	Session introduction by Chair	09:10 - 09:12
TBS4B-10	Computational modelling of bacterial antibiotic target-binding for optimising TB treatment Jingyi Liang (Tromso, Norway)	09:12 - 09:20
TBS4B-15	Using long-term evolution models to define drug resistance mechanisms to DDU209, a novel TB drug candidate Lindsay Sonnenkalb (Borstel, Germany)	09:20 - 09:28
TBS4B-20	The clinical-stage drug BTZ-043 fully penetrates murine TB lesions and is effective against M. tuberculosis in the necrotic center Christoph Hölscher (Germany)	09:28 - 09:36

TBS4B-25	A 4-month regimen of quabodepistat, delamanid, and bedaquiline for drug-susceptible pulmonary TB Mohammed Rassool (South Africa)	09:36 - 09:44
TBS4B-30	Q&A	09:44 - 09:55
<i>Oral Abstract Session</i>		
09:30 - 11:00		HB
OA48 - TB prevention and care: Community engagement		
Aboubacar Magassouba (Conakry, Guinea) Farai Mavhunga (Switzerland)		
	Introduction	09:30 - 09:35
OA48-482-16	Strengthening TB case finding through enhancing community TB screening approaches in Zimbabwe Kudakwashe Takarinda (Harare, Zimbabwe)	09:35 - 09:44
OA48-483-16	Empowering communities: A novel approach to active TB case detection in Nigeria Abiola Riskat Alege (Lagos, Nigeria)	09:44 - 09:53
OA48-484-16	Adapting community-based TB care in Myanmar: The role of the Myanmar Medical Association TB Consortium in addressing the TB burden Nyein Thida Thwin (Yangon, Myanmar)	09:53 - 10:02
OA48-485-16	Empowering tribal communities: A comprehensive approach to TB elimination Sophia Khumukcham (New Delhi, India)	10:02 - 10:11
OA48-486-16	Targeted interventions to overcome the challenges for TB among key and vulnerable populations in Bangladesh: A review of special initiatives and barrier mitigation strategies Farhana Nishat Seheli (Dhaka, Bangladesh)	10:11 - 10:20
OA48-487-16	Breaking barriers: Targeting TB in the workplace for men Nkirote Mwirigi (Nairobi, Kenya)	10:20 - 10:29
OA48-488-16	Scaling up targeted TB screening among miners and construction workers in Malawi: A collaborative approach towards TB elimination Kuzani Mbendera (Lilongwe, Malawi)	10:29 - 10:38
OA48-489-16	Enhanced community-based contact investigation improved finding missing people with TB in three districts in Malawi Mtisunge Nkhono Phiri (Machinga, Malawi)	10:38 - 10:47
	Q&A	10:47 - 11:00
<i>Symposium</i>		
09:30 - 11:00		FR
SP27 - Computer-aided detection of TB for children and adolescents - generating data to inform global guidance		
Monde Muyoyeta (Zambia) Sabine Verkuijl (Geneva, Switzerland)		
SP27-577-16	Introduction	09:30 - 09:35
SP27-578-16	Global policy development on computer-aided detection of TB Cecily Miller (Geneva, Switzerland)	09:35 - 09:49
SP27-579-16	Exploring the use of CAD for disease severity stratification in children diagnosed with tuberculosis	09:49 - 10:03

	Megan Palmer (Cape Town, South Africa)	
SP27-580-16	TB Screening of children with portable digital X-Rays in nomadic communities of Nigeria Stephen John (Yola, Nigeria)	10:03 - 10:17
SP27-581-16	Developing paediatric chest X-ray libraries for AI development Rachel Byrne (Liverpool, United Kingdom)	10:17 - 10:31
SP27-582-16	The performance of CAD algorithms to identify TB on paediatric CXRs James Seddon (Cape Town, South Africa)	10:31 - 10:45
SP27-583-16	Q&A	10:45 - 11:00
 <i>Symposium</i>		
09:30 - 11:00		BG
SP28 - National TB prevalence surveys: new survey results and latest insights		
Eveline Klinkenberg (Netherlands) Marina Tadolini (Bologna, Italy)		
SP28-584-16	Introduction	09:30 - 09:35
SP28-585-16	How does WHO use results from national TB prevalence surveys to estimate the burden of TB? Mathieu Bastard (Geneva, Switzerland)	09:35 - 09:49
SP28-586-16	Results from the first national tuberculosis prevalence survey of Timor-Leste, 2022-2023 Constantino Lopes (Dili, East Timor)	09:49 - 10:03
SP28-587-16	Results From the third national tuberculosis prevalence survey of Cambodia, 2023-2024 Huot Chan Yuda (Phnom Penh, Cambodia)	10:03 - 10:17
SP28-588-16	'If not TB, what could it be?': chest X-ray findings from TB prevalence surveys of high-TB-burden countries in Africa Brenda Mungai (Nairobi, Kenya)	10:17 - 10:31
SP28-589-16	Asymptomatic TB: who are these people with TB but with no apparent symptoms? Frank Cobelens (Amsterdam, Netherlands)	10:31 - 10:45
SP28-590-16	Q&A	10:45 - 11:00
 <i>Symposium</i>		
09:30 - 11:00		OC
SP29 - Promoting Equitable Access through Community-based Integrated TB Service Delivery Models of Care		
Uzma Khan (Montreal, Canada) Toufiq Rahman (Geneva, Switzerland)		
SP29-591-16	Introduction	09:30 - 09:40
SP29-592-16	INTEGRATE: Integrating NCDs and TB to Enable Greater Reach of ACF towards TB Elimination in Vietnam Nga Thi Thuy Nguyen (Ha Noi, Vietnam)	09:40 - 09:55
SP29-593-16	Operationalizing a community-driven model to increase access to people-centered care for TB, HIV, and non-communicable diseases (NCDs) in the Democratic Republic of the Congo (DRC). Jessica Farley (Seattle, United States)	09:55 - 10:10
SP29-594-16	Fostering Equitable Care: Community Engagement in Integrated	10:10 - 10:25

	Health Services for TB, Hepatitis C, and Mental Health in Rural Sindh Annum Aftab (Karachi, Pakistan)	
SP29-595-16	Community-Led Approach: Transforming TB, Leprosy, and NCD Care among Key vulnerable populations in Northeast Nigeria Suraj Abdulkarim (Gombe, Nigeria)	10:25 - 10:40
SP29-596-16	Q&A	10:40 - 11:00
<i>Oral Abstract Session</i>		
09:30 - 11:00		JKA
OA49 - Filling in the TB knowledge gaps: Research in action from new drugs to operational research		
Michael Hoelscher (Munich, Germany) Charles Wells (Cambridge, Massachusetts, United States)		
	Introduction	09:30 - 09:35
OA49-490-16	Investigating heteroresistance in M. tuberculosis: Findings from the endTB trial Bouke de Jong (Antwerp, Belgium)	09:35 - 09:45
OA49-491-16	Fourteen-day treatment responses in participants with rifampicin-susceptible pulmonary TB receiving ganfemorole in combination with delamanid or bedaquiline: A phase 2a open-label, randomised trial Simon Tiberi (London, United Kingdom)	09:45 - 09:55
OA49-492-16	High rate of on treatment acquired resistance to WHO group A MDR-TB drugs in people with failure of programmatic MDR-TB treatment in Republic of Moldova Dumitru Chesov (Chisinau, Moldova)	09:55 - 10:05
OA49-493-16	TBAJ-587 CI001: Pharmacokinetics and safety data from a Phase 1 trial of TBAJ-587, a novel 2nd generation diarylquinoline, in healthy participants Eugene Sun (New York, United States)	10:05 - 10:15
OA49-494-16	QT-interval prolongation in children receiving clofazimine and moxifloxacin for treatment of rifampicin-resistance TB: A multi-country study Megan Palmer (Cape Town, South Africa)	10:15 - 10:25
OA49-495-16	Moxifloxacin preventive treatment in children who were exposed to multi-drug-resistant TB Andrey Maryandyshev (Arkhangelsk, Russian Federation)	10:25 - 10:35
OA49-496-16	N-acetylcysteine to reduce kidney and liver injury associated with drug-resistant TB treatment Idu Meadows (Charlottesville, United States)	10:35 - 10:45
	Q&A	10:45 - 11:00
<i>Oral Abstract Session</i>		
09:30 - 11:00		JKB
OA50 - Holistic approach towards curative and preventive measures		
Wayan Gede Artawan Eka Putra (Denpasar, Indonesia) Onno Akkerman (Groningen, Netherlands)		
	Introduction	09:30 - 09:35
OA50-497-16	Impact of an education program for persons with TB and caregivers on treatment outcomes in Madhya Pradesh, India Puja Ambule (New Delhi, India)	09:35 - 09:45

OA50-498-16	Advancing equity and access: The hub and spoke model in TB service delivery within the public-private mix (PPM) initiative in Kano State, Nigeria Husna Baffa (Kano, Nigeria)	09:45 - 09:55
OA50-499-16	District-based public-private mix (DPPM) approach to increase TB case notification and improve quality of TB care at all healthcare facilities in Indonesia R A Della Patrisia Pramesti (Jakarta Selatan, Indonesia)	09:55 - 10:05
OA50-500-16	Engaging Amchis from the traditional Buddhist medical system to augment the TB care cascade in Ladakh, India Praveen Kumar Yadav (Delhi, India)	10:05 - 10:15
OA50-501-16	Integration and decentralisation: PWID-centric solutions in TB-HIV care Ye Htet Kyaw (Yangon, Myanmar)	10:15 - 10:25
OA50-503-16	Patients line list: A tool for data quality improvement and management of people with TB - The Bauchi State experience Habusafwan Ibrahim (Bauchi, Nigeria)	10:25 - 10:35
OA50-504-16	Harnessing leadership across sectors: Strengthening multisectoral collaboration to end TB in India Chandravali Madan (Delhi, India)	10:35 - 10:45
	Q&A	10:45 - 11:00
<i>Oral Abstract Session</i>		
09:30 - 11:00		MD
OA51 - DM theme "Double Trouble": Addressing the epidemiological and treatment challenges of diabetes and TB		
Stellah Mpagama (Tanzania)		
	Introduction	09:30 - 09:35
OA51-505-16	The use of fructosamine and the glycation gap as indicators for TB treatment outcome Chuan-Chin Huang (Boston, United States)	09:35 - 09:44
OA51-506-16	Suboptimal TB treatment outcomes among adults with diabetes in Eswatini: A prospective cohort study Yael Hirsch-Moverman (New York City, United States)	09:44 - 09:53
OA51-507-16	Glycemic control and treatment outcome in rifampicin resistant tuberculosis patients with diabetes mellitus: a prospective cohort study in China Yilin Zhang (Shanghai, China)	09:53 - 10:02
OA51-508-16	Impact of diabetes mellitus on tuberculosis recurrence Jianming Wang (Nanjing, China)	10:02 - 10:11
OA51-509-16	Assessment of post-TB disease outcomes based on glycemic status: a follow-up study in Bangladesh Tasmia Ibrahim (Dhaka, Bangladesh)	10:11 - 10:20
OA51-510-16	Sensitivity and specificity of tuberculosis screening tools in people with diabetes Neha Janrode (London, United Kingdom)	10:20 - 10:29
OA51-511-16	Latent tuberculosis infection in a large adult East African population with diabetes mellitus: prevalence, clinical characteristics, and determinants Phillip Ssekamatte (Kampala, Uganda)	10:29 - 10:38

OA51-512-16	Body Mass Index trajectories and association with tuberculosis risk in a cohort of household contacts in southern Africa Leyla Larsson (Munich, Germany)	10:38 - 10:47
	Q&A	10:47 - 11:00
<i>Symposium</i>		
09:30 - 11:00		NS1
SP30 - Filling the gaps: An update on advancements in maternal TB		
Jyoti Mathad (New York, United States) Sanjaykumar Tambe (India)		
SP30-597-16	Introduction	09:30 - 09:35
SP30-598-16	Immune profiles of TB during pregnancy Beatriz Barreto-Duarte (Salvador, Brazil)	09:35 - 09:49
SP30-599-16	Maternal-TB infant outcomes from the PARTHISA study Mallika Alexander (Pune, India)	09:49 - 10:03
SP30-600-16	Clinical Trials Round-up in Maternal TB Sylvia LaCourse (Seattle, United States)	10:03 - 10:17
SP30-601-16	Measuring TB drug levels in breast milk: results of IMPAACT 2001 Rada Savic (San Francisco, United States)	10:17 - 10:31
SP30-602-16	What a girl wants: Evaluating pregnant participant preferences in TB clinical trials Yael Hirsch-Moverman (New York City, United States)	10:31 - 10:45
SP30-603-16	Q&A	10:45 - 11:00
<i>Symposium</i>		
09:30 - 11:00		NS2
SP31 - Smoking cessation intervention for TB patients: urgent need on translating research finding into policy action		
Kobto Ghislain Koura (PARIS, France) Wenhong Zhang (Shanghai, China)		
SP31-604-16	Introduction	09:30 - 09:40
SP31-605-16	Smoking is independent risk factor for TB recurrence: finding from a longitudinal study in China Lin Yan (Beijing, China)	09:40 - 09:55
SP31-606-16	Effectiveness of smoking cessation intervention with ABC Approach for tuberculosis patients in the Philippines --- a final report Akihiro Ohkado (Kiyose, Tokyo, Japan)	09:55 - 10:10
SP31-607-16	Integration and scale up tobacco cessation within the national and provincial TB programmes in Pakistan Razia Kaniz Fatima (Islamabad, Pakistan)	10:10 - 10:25
SP31-608-16	Integration of smoking cessation Intervention (SCI) into routine care for TB Patients in West Africa: findings from an intervention in Benin and Burkina-Faso Attannon Arnauld Fiogbé (Cotonou, Benin)	10:25 - 10:40
SP31-609-16	Q&A	10:40 - 11:00

Oral Abstract Session

09:30 - 11:00

NS3

OA52 - Lung health and air quality

Andrew Steenhoff (Philadelphia, United States)

Albert Kuate Kuate (Yaounde, Cameroon)

	Introduction	09:30 - 09:35
OA52-513-16	Effects of meteorological factors, air pollutants and their interactions on the incidence of tuberculosis in urban China: a time series analysis Qi Ye (Shenzhen, China)	09:35 - 09:44
OA52-514-16	Long-term effects of coarse particulate matter and modifications by temperature and relative humidity on all-cause mortality in a multidrug-resistant tuberculosis cohort Erjia Ge (Toronto, Canada)	09:44 - 09:53
OA52-515-16	Ambient particulate matter and latent tuberculosis infection: a time-series study among 198,275 students Qiao Liu (Nanjing, China)	09:53 - 10:02
OA52-516-16	Non sporulating molds: lesser known evil in respiratory mycosis Shweta Raina (New Delhi, India)	10:02 - 10:11
OA52-517-16	Accuracy of the novel Phefumla mobile phone reflectance pulse oximeter during hypoxemia in healthy adults Eric D. McCollum (Baltimore, United States)	10:11 - 10:20
OA52-518-16	Implications of alternative reference equations on interpretation of spirometry among members of TB-affected households in three African countries Denise Banze (Maputo, Mozambique)	10:20 - 10:29
OA52-519-16	Results from a feasibility pilot for integrated TB & lung cancer screening in Vietnam Andrew James Codlin (Ha Noi, Vietnam)	10:29 - 10:38
OA52-520-16	Respiratory symptoms after TB treatment: a qualitative study of survivor and provider experiences in Malawi Nora Engel (Amsterdam, Netherlands)	10:38 - 10:47
	Q&A	10:47 - 11:00

Community Connect

09:30 - 10:30

EG2

CCSE002 - Accountability session with The Union Community Advisory Board (UCAP) members

Madhava Sai Sivapuram (India)

	Presentation followed by panel discussion	09:30 - 09:30
	Zahedul Islam (Ukraine)	
	Priyanka Aiyer (India)	
	Kinz Ul Eman (Islamabad, Pakistan)	
	Tariro Kutadza (Zimbabwe)	
	Eva Naznin (Australia)	
	Ajaz Akhtar (Pakistan)	
	Erman Varella (Indonesia)	
	Phumeza Tisile (South Africa)	

TBScience Session

10:00 - 11:00

AU

TBS4C - Tailoring TB treatment

Bachti Alisjahbana (Indonesia)

TBS4C-05	Session introduction	10:00 - 10:03
TBS4C-10	Long-acting drug formulation for TB prevention Eric Nuermberger (United States)	10:03 - 10:16
TBS4C-20	PK and microbiological basis for tailoring TB treatment Rob Aarnoutse (Nijmegen, Netherlands)	10:16 - 10:29
TBS4C-25	How to predict early bactericidal activity using pre-clinical data? Jan-Willem Alffenaar (Sydney, Australia)	10:29 - 10:42
TBS4C-30	Q&A	10:42 - 10:57
TBS4C-35	TBScience closing remarks Bachti Alisjahbana (Indonesia) Willem Hanekom (South Africa)	10:57 - 11:00

Community Connect

10:30 - 11:15

SG

CCSS021 - Designing interventions to address TB stigma and its impact on mental health

Ingrid Schoeman (Pretoria, South Africa)

Erika Mohr-Holland (Cape Town, South Africa)

Phumeza Tisile (South Africa)

Introduction	10:30 - 10:36
Overview of TB-related stigma and its impact on mental health Annika Sweetland (New York, United States)	10:36 - 10:42
Lessons learned from KwaZulu-Natal to improve treatment outcomes through support for people with TB Jacqui Ngozo (South Africa)	10:42 - 10:48
Using mixed methods approaches and human-centred design to co-develop multi-level TB stigma intervention and use motivational interviewing to deliver peer counselling Ruvandhi Nathavitharana (United States)	10:48 - 10:54
Engaging communities to be active participants in stigma intervention research and implementation of peer counselling in Khayelitsha, South Africa Goodman Makanda (South Africa)	10:54 - 11:00
Question and answer	11:00 - 11:15

Plenary Session

11:20 - 12:20

MG

PL-04 - The hidden face of the iceberg: Asymptomatic TB

Edward Nardell (United States)

Session introduction	11:20 - 11:22
The hidden threat of asymptomatic TB Frank Cobelens (Amsterdam, Netherlands)	11:22 - 11:37
Asymptomatic TB: Conceptual Framework Emily A. Kendall (Baltimore, United States)	11:37 - 11:52
WHO Perspectives: Research gaps and evidence needed Dennis Falzon (Geneva, Switzerland)	11:52 - 12:07
Panel discussion with Q&A	12:07 - 12:10

Plenary Session

11:20 - 12:20

EG2

PL004 - The hidden face of the iceberg: Asymptomatic TB (Broadcasted)*Union Live Session*

11:20 - 12:20

UL

ULPL04 - The hidden face of the iceberg: Asymptomatic TB*Union Live Session*

12:20 - 13:00

UL

UL34 - Messages from our event sponsors*Community Connect*

12:30 - 13:15

AU

CCSA012 - Empowering communities to take charge: Building capacity for TB prevention and care

Vimbai Mlambo (Zimbabwe)

Vimbai Mlambo (Zimbabwe)

Introduction

12:30 - 12:33

Principles of community engagement, mobilisation, and advocacy in TB prevention and care

12:33 - 12:42

Dorcas Chikorova (Zimbabwe)

Advocacy and policy change in addressing systemic barriers to TB prevention and care

12:42 - 12:51

Jimmy Wilford (Zimbabwe)

Young people's perspective: TB experiences and challenges

12:51 - 13:00

Elliard Kupfuma (Zimbabwe)

Question and answer

13:00 - 13:15

Community Connect

12:30 - 13:15

SG

CCSS022 - Shattering silos: The cross-disease network

Dozia Joseph (New Delhi, India)

Mike Frick (New York City, United States)

Introduction

12:30 - 12:35

The importance of shattering silos to catalyse transformative change in health advocacy

12:35 - 12:40

Blessina Kumar (New Delhi, India)

Lessons learned as a member of TPT4India and how that has transformed their approach to disease intervention within the PLHIV community

12:40 - 12:45

Rosalynn Lalawmpuii (India)

Lessons learned as a member of TPT4India and how that has transformed their approach to disease intervention within the TB community

12:45 - 12:50

Meera Yadav (India)

Cross Disease Network: Bringing Marginalised Communities Together

12:50 - 12:55

Atul Shendge (India)

The importance of scaling up cross-disease networks to promote health and disease prevention

12:55 - 13:00

Mike Frick (New York City, United States)

	Question and answer	13:00 - 13:15
<i>Oral Abstract Session</i>		
12:40 - 14:10		HB
OA53 - Mycobacteria detection and control under the one health approach		
Shu-Hua Wang (United States) Imran Pambudi (Jakarta, Indonesia)		
	Introduction	12:40 - 12:45
OA53-521-16	Prevalence, distribution, and risk factors of mycobacterium other than tuberculosis among tuberculosis presumptive patients in Karonga district in Malawi Samson Chitsulo (Lilongwe, Malawi)	12:45 - 12:56
OA53-522-16	A mathematical model at the wildlife-livestock-human interface to predict the implications of animal and zoonotic tuberculosis control measures Liliana C. M. Salvador (Tucson, United States)	12:56 - 13:07
OA53-523-16	Are <i>Mycobacterium avium</i> complex in lung diseases from the environment? Prakruti Rao (Charlottesville, United States)	13:07 - 13:18
OA53-524-16	Universal Identification of mycobacterial pathogens at subspecies resolution by the PEP-TORCH algorithm Jia Fan (New Orleans, United States)	13:18 - 13:29
OA53-525-16	Long-term outcomes of people with baseline NTM isolation and drug-resistant tuberculosis from 2015 to 2021 in Ghana, a retrospective observational study Elizabeth Tabitha Abbew (Cape Coast, Ghana)	13:29 - 13:40
OA53-526-16	Isolation and characterization of a mycobacteriophage KIT-AB2023/2766-16 infecting <i>Mycobacterium</i> species GiSu Kang (Cheongju, Korea, Republic of)	13:40 - 13:51
	Q&A	13:51 - 14:10
<i>Symposium</i>		
12:40 - 14:10		FR
SP32 - Social protection to End TB: The role of implementing partners in catalyzing and complementing country efforts for People with TB.		
Beatrice Wangari Kirubi (Geneva, Sweden) Delia Boccia (Italy)		
SP32-610-16	Introduction	12:40 - 12:45
SP32-611-16	Improving TB Prevention Treatment (TPT) uptake through Social protection interventions in Uganda Stella Zawedde-Muyanja (Kampala, Uganda)	12:45 - 12:59
SP32-612-16	Reducing income loss during drug-resistant TB care: A household-based intervention in Vietnam Rachel Forse (Ha Noi, Vietnam)	12:59 - 13:13
SP32-613-16	Saving Lives: Social Protection Initiatives for people affected by Drug-Resistant Tuberculosis Kinz Ul Eman (Islamabad, Pakistan)	13:13 - 13:27
SP32-614-16	Social Protection and TB: the experience of the Bolsa Familia Program	13:27 - 13:41
SP32-615-16	A research toolkit to evaluate the impact of social protection	13:41 - 13:55

	schemes for people affected by TB and their family Corinne Merle (Geneva, Switzerland)	
SP32-616-16	Q&A	13:55 - 14:10
<i>Oral Abstract Session</i>		
12:40 - 14:10		BG
OA54 - Finding unanswered questions and unquestioned answers: The role of epidemiology		
Frank Cobelens (Amsterdam, Netherlands) Palwasha Yousafzai Khan (London, United Kingdom)		
	Introduction	12:40 - 12:43
OA54-527-16	Environmental factors associated with tuberculosis incidence and mortality: a systematic review and meta-analysis Alemneh Liyew (Perth, Australia)	12:43 - 12:52
OA54-528-16	An evaluation of a tuberculosis case finding and treatment outcomes among Afghan migrants living in the refugee's camps of Pakistan Mahboob Ul haq (Islamabad, Pakistan)	12:52 - 13:01
OA54-529-16	Effect of population aging on pulmonary tuberculosis burden in Zhejiang Province, China: a population-based study Yuxiao Ling (Ningbo, China)	13:01 - 13:10
OA54-530-16	Recurrent TB in India: evidence from the country's NTP Jerome Thampi (New Delhi, India)	13:10 - 13:19
OA54-531-16	Rate of isoniazid-monoresistant tuberculosis among person with rifampin-susceptible tuberculosis by GeneXpert MTB/RIF during active case finding in North Lima, Peru Marco Tovar (San Isidro, Peru)	13:19 - 13:28
OA54-532-16	Mixed infections and heteroresistance of multi-drug resistant Mycobacterium tuberculosis in China Yanping Liu (Shenzhen, China)	13:28 - 13:37
OA54-533-16	The use of suboptimal clinical responses to treatment as an indicator for TB treatment failure Chuan-Chin Huang (Boston, United States)	13:37 - 13:46
OA54-534-16	What drives the tuberculosis epidemic in Ethiopia? A paradoxical increase of TB cases amid conflicts and drought Zewdu Gashu Dememew (Addis Ababa, Ethiopia)	13:46 - 13:55
	Q&A	13:55 - 14:10
<i>Oral Abstract Session</i>		
12:40 - 14:10		OC
OA55 - Behind bars, beyond TB: Integration strategies for TB, HIV management and care in prison centres		
Julio Croda (Campo Grande, Brazil) Lika Apriani (Bandung, Indonesia)		
	Introduction	12:40 - 12:45
OA55-542-16	Projected impacts of incarceration policy alternatives on the TB epidemic in Latin America: A mathematical modelling study Yiran Liu (Stanford, United States)	12:45 - 12:55
OA55-535-16	Modeling strategies for implementation of tuberculosis preventive treatment in prisons	12:55 - 13:05

	Ronan Arthur (Stanford, United States)	
OA55-536-16	Enhancing TB care in the penitentiary system of Tajikistan Huriya Hisomova (Dushanbe, Tajikistan)	13:05 - 13:15
OA55-537-16	TB epidemic control in Nigeria correctional facilities: An assessment of TB screening protocol among awaiting trial inmates in Delta State, Nigeria Eziashi Emmanuel Ajumuka (Asaba, Nigeria)	13:15 - 13:25
OA55-538-16	Leveraging the support of government institutions and artificial intelligence in finding missing people with TB: Orphanages and correctional centres in Oyo State Samuel Akingbesote (Abuja, Nigeria)	13:25 - 13:35
OA55-540-16	Risk factors associated with TB in incarcerated individuals in Indonesia Hetty Widiastuti (Jakarta, Indonesia)	13:35 - 13:45
OA55-541-16	Integrated STI, HIV, TB, and Hepatitis (ISHTH): A comprehensive and collaborative disease screening campaign in prisons and closed settings in Punjab, India Rajesh Bhaskar (Chandigarh, India)	13:45 - 13:55
	Q&A	13:55 - 14:10
<i>Symposium</i>		
	12:40 - 14:10	JKA
SP33 - Cost modelling in childhood TB		
Edina Sinanovic (Cape Town, South Africa)		
SP33-617-16	Introduction	12:40 - 12:45
SP33-618-16	Costing in the CATALYST and TB CHAMP studies: introduction to a regimen costing tool in childhood TB Thomas Wilkinson (Cape Town, South Africa)	12:45 - 12:59
SP33-619-16	Leveraging different data sources to estimate the costs of paediatric tuberculosis intervention Nyashadzaishe Mafirakureva (Sheffield, United Kingdom)	12:59 - 13:13
SP33-620-16	Modelling the costs of providing childhood TB services in six high TB incidence countries: Lessons learnt from the TB-Speed Decentralization and TB-Speed SAM studies Marc d'Elbée (Bordeaux, France)	13:13 - 13:27
SP33-621-16	Cost effectiveness analysis of VQUIN trial: Levofloxacin versus placebo for the treatment of latent TB among contacts of patients with MDR-TB in Vietnam Tasnim Hasan (Sydney, Australia)	13:27 - 13:41
SP33-622-16	Cost analysis in a pragmatic cluster-randomized trial of home-based preventive treatment for TB (CHIP-TB) in Ethiopia Akash Malhotra (Seattle, United States)	13:41 - 13:55
SP33-623-16	Q&A	13:55 - 14:10
<i>Symposium</i>		
	12:40 - 14:10	JKB
SP34 - Tuberculosis screening using Computer Aided Detection software enabled digital Chest X-rays: Lessons from field implementation.		
Brenda Mungai (Nairobi, Kenya)		
Zhi Zhen Qin (Dubai, United Arab Emirates)		

SP34-624-16	Introduction	12:40 - 12:45
SP34-625-16	Navigating WHO Guidance on TB Screening and Triage Cecily Miller (Geneva, Switzerland)	12:45 - 12:59
SP34-626-16	Strategic selection of digital X-ray and radiation safety considerations for Ultraportable X-ray use Jarred Halton (Rotterdam, Netherlands)	12:59 - 13:13
SP34-627-16	Programmatic roll out of portable digital chest X-rays and computer aided detection software for systematic tuberculosis (TB) screening: The Kenya Experience Brenda Mungai (Nairobi, Kenya)	13:13 - 13:27
SP34-628-16	Planning for scale up of computer aided detection software enabled portable digital chest X-rays in Nigeria: Lessons learnt Obioma Chijioke-Akaniro (Abuja, Nigeria)	13:27 - 13:41
SP34-629-16	CAD calibration for TB detection in active case finding activities in the Philippines - A practical approach Juno Min (Amsterdam, Netherlands)	13:41 - 13:55
SP34-630-16	Q&A	13:55 - 14:10

Symposium

12:40 - 14:10

MD

SP35 - Assessing the epidemiological impact of strategies to address social and structural determinants: the underutilised role of modelling

Katherine Horton (London, United Kingdom)

Jeremiah Chakaya (Nairobi, Kenya)

SP35-631-16	Introduction	12:40 - 12:45
SP35-632-16	The potential impacts of scaling up the RATIONS trial in South-East Asia Sandip Mandal (New Delhi, India)	12:45 - 12:59
SP35-633-16	Modelling the impact of strategies to increase men's access to care Alexandra Richards (London, United Kingdom)	12:59 - 13:13
SP35-634-16	Modeling the impact of increased diabetes prevalence and mean BMI on tuberculosis control in high burden countries Hsien-Ho Lin (Taipei, Taiwan)	13:13 - 13:27
SP35-635-16	The role of incarceration as a driver of the tuberculosis epidemic in Latin America Yiran Liu (Stanford, United States)	13:27 - 13:41
SP35-636-16	Modelling social and behavioural risk reduction strategies in communities at risk: Findings and key challenges Kevin Schwartzman (Montreal, Canada)	13:41 - 13:55
SP35-637-16	Q&A	13:55 - 14:10

Symposium

12:40 - 14:10

NS1

SP36 - Biomarker studies in the TRUNCATE-TB trial: identifying people who can stop treatment after 8 weeks with low risk of relapse

Nicholas Paton (Singapore, Singapore)

Erlina Burhan (Jakarta, Indonesia)

SP36-638-16	introduction	12:40 - 12:50
SP36-639-16	Bacterial biomarkers	12:50 - 13:05

	Ka Lip Chew (Singapore, Singapore)	
SP36-640-16	RNA transcriptome biomarkers Mahdad Noursadeghi (London, United Kingdom)	13:05 - 13:20
SP36-641-16	Proteome biomarkers Emmanuel Gutierrez (Dasmariñas, Philippines)	13:20 - 13:35
SP36-642-16	Chest X-ray biomarkers Eliana Muis (Makassar, Indonesia)	13:35 - 13:50
SP36-643-16	Q&A	13:50 - 14:10
<i>Oral Abstract Session</i>		
12:40 - 14:10		NS2
OA56 - Understanding Pharmacokinetics for better TB treatment		
Rovina Ruslami (Bandung, Indonesia) Fajri Gafar (Montreal, Canada)		
	Introduction	12:40 - 12:45
OA56-543-16	Population pharmacokinetics of a novel paediatric clofazimine formulation in children with rifampicin-resistant TB Yuanxi Zou (Uppsala, Sweden)	12:45 - 12:54
OA56-544-16	Pharmacokinetics, safety, and tolerability of higher doses of rifampicin in Tanzanian children weighing less than 25kg Arnold Ndaró (Moshi, Tanzania)	12:54 - 13:03
OA56-545-16	Pharmacokinetics and dosing of a novel dispersible moxifloxacin formulation in children with rifampicin-resistant TB Megan Palmer (Cape Town, South Africa)	13:03 - 13:12
OA56-546-16	Pharmacokinetic modelling of rifampicin, isoniazid, pyrazinamide, and linezolid in central nervous system: Insights from a rabbit model of TB meningitis Noha Abdelgawad (Cape Town, South Africa)	13:12 - 13:21
OA56-547-16	Development, validation, and clinical application of a UHPLC-MS/MS method for the determination of 10 anti-TB drugs in human serum Xudong Fan (Hangzhou, China)	13:21 - 13:30
OA56-548-16	The effect of rifampicin on pharmacokinetics of dexamethasone in TB meningitis Jose Miguel Calderin (Cape Town, South Africa)	13:30 - 13:39
OA56-549-16	Cerebrospinal fluid penetration of isoniazid in adults with TB meningitis Jose Miguel Calderin (Cape Town, South Africa)	13:39 - 13:48
OA56-550-16	Pharmacokinetics of bedaquiline in sputa from adults with drug-resistant TB in Haiti Kathleen Walsh (New York, United States)	13:48 - 13:57
	Q&A	13:57 - 14:10
<i>Symposium</i>		
12:40 - 14:10		NS3
SP37 - Mtb infection - what we know, what we don't know and what should we know?		
Rein Houben (London, United Kingdom) Hanif Esmail (London, United Kingdom)		
SP37-644-16	Introduction	12:40 - 12:45

SP37-645-16	Mtb infection: What we know, what we don't know and what should we know? Thomas Scriba (Cape Town, South Africa)	12:45 - 12:59
SP37-646-16	How much Mtb infection do we think is there - updates from a global estimation project Alvaro Schwalb (London, United Kingdom)	12:59 - 13:13
SP37-647-16	What can we learn from the dead? Virginie Rozot (Cape Town, South Africa)	13:13 - 13:27
SP37-648-16	Why do we care - potential and problems of current 'measures' of Mtb infection in policy Thu-Anh Nguyen (Ho Chi Minh city, Vietnam)	13:27 - 13:41
SP37-649-16	What do we need to do - what is the experiment we need to develop a gold standard test run? Anna Coussens (Parkville, Australia)	13:41 - 13:55
SP37-650-16	Q&A	13:55 - 14:10
<i>Union Live Session</i>		
13:00 - 13:30		UL
UL35 - Union LIVE - Content from across the WCLH 2024		
<i>Community Connect</i>		
13:30 - 14:15		AU
CCSA013 - Breaking barriers in TB for a people-centred, rights-based TB response		
Blessina Kumar (New Delhi, India)		
Dozia Joseph (New Delhi, India)		
	Introduction	13:30 - 13:35
	Importance of a people-centred, rights-based approach to TB care Brian Citro (United States)	13:35 - 13:40
	Role of civil society and legal community in breaking barriers in TB care Timothy Wafula (Nairobi, Kenya)	13:40 - 13:45
	Best practices, India: Breaking the barriers in TB care Vikas Panibatla (India)	13:45 - 13:50
	Combatting stigma Blessina Kumar (New Delhi, India)	13:50 - 13:55
	Best practices, Europe: Breaking the barriers in TB care Yuliia Kalancha (Kyiv, Ukraine)	13:55 - 14:00
	Question and answer	14:00 - 14:15
<i>Union Live Session</i>		
13:30 - 15:00		UL
UL36 - Messages from our event sponsors		
<i>Rapporteur</i>		
14:30 - 15:30		MG
RP01 - Rapporteur Session		
	Introduction Carrie Tudor (United States)	14:30 - 14:34

Adult and Child Lung Health (ACLH) Chishala Chabala (Lusaka, Zambia)	14:34 - 14:39
Bacteriology & Immunology (B&I) Ajoy Kumar Verma (New Delhi, India)	14:39 - 14:44
Civil Society Zahedul Islam (Ukraine)	14:44 - 14:49
HIV Palwasha Yousafzai Khan (London, United Kingdom)	14:49 - 14:54
Nurses and Allied Professionals (NAPs) Fernando Augusto Dias e Sanches (Rio de Janeiro, Brazil)	14:54 - 14:59
TBScience Willem Hanekom (South Africa)	14:59 - 15:09
Tobacco Control Pinpin Zheng (China)	15:09 - 15:14
Tuberculosis TB Simon Tiberi (London, United Kingdom)	15:14 - 15:24
Zoonotic TB (ZTB) Liliana C. M. Salvador (Tucson, United States)	15:24 - 15:27
Closing remarks Carrie Tudor (United States)	15:27 - 15:30
<i>Union Live Session</i> 14:30 - 15:30	UL
UL37 - Rapporteur session	
<i>Closing Session</i> 15:40 - 16:40	MG
CS01 - Closing session	
Welcome and In Memoriam Keren Middelkoop (South Africa)	15:40 - 15:46
Princess Chichibu Award - Winner Announcement Seiya Kato (Japan)	15:46 - 15:55
Stephen Lawn TB-HIV Prize - Winners Announcement Anthony D Harries (United Kingdom)	15:55 - 16:05
Christmas Seals - Winners Announcement Cassandra Kelly-Cirino (Switzerland)	16:05 - 16:14
Announcement for #UnionConf2025 Erlina Burhan (Jakarta, Indonesia)	16:14 - 16:19
Closing remarks Nadine Tereza (United Kingdom)	16:19 - 16:21
<i>Closing Session</i> 15:40 - 16:40	EG2
CS02 - Closing session	

Closing Session

15:40 - 16:40

UL

UL39 - Closing session

Union Live Session

17:00 - 17:30

UL

UL38 - David Jackson, Director of Conference and Events, at The Union, looks ahead to the next World Conference on Lung Health